10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION             

Washington, D.C. 20549

FORM 10-K

Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Fiscal Year Ended December 31, 2015

Commission File Number 001-36531

AMSURG CORP.

(Exact Name of Registrant as Specified in Its Charter)

Tennessee	62-1493316
(State or Other Jurisdiction of Incorporation)	(I.R.S. Employer  Identification No.)
1A Burton Hills Boulevard
Nashville, Tennessee	37215
(Address of Principal Executive Offices)	(Zip Code)

Securities registered pursuant to Section 12(b) of the Act:         

Common Stock, no par value

5.250% Mandatory Convertible Preferred Stock, Series A-1, no par value

(Title of class)

Nasdaq Global Select Market

(Name of each exchange on which registered)

Registrant’s telephone number, including area code:  (615) 665-1283

Securities registered pursuant to Section 12(g) of the Act:  None 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes [X]                    No [  ]

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes [   ]                   No [X]

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]                    No [  ]

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X]                    No [  ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  [  ]

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [X]   Accelerated filer [  ]   Non-accelerated filer [  ]   Smaller reporting Company [  ]

(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 

Yes [  ]                     No [X]

As of February 24, 2016, 54,720,648 shares of the Registrant’s common stock were outstanding. The aggregate market value of the shares of common stock of the Registrant held by nonaffiliates on June 30, 2015 (based upon the closing sale price of these shares as reported on the Nasdaq Global Select Market as of June 30, 2015) was approximately $3,318,935,487. This calculation assumes that all shares of common stock beneficially held by executive officers and members of the Board of Directors of the Registrant are owned by “affiliates,” a status which each of the officers and directors individually may disclaim.

Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on May 26, 2016, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Table of Contents to Annual Report on Form 10-K for the Year Ended December 31, 2015

Part I
	Item 1.	Business	1
		Executive Officers of the Registrant	24
	Item 1A.	Risk Factors	25
	Item 1B.	Unresolved Staff Comments	39
	Item 2.	Properties	39
	Item 3.	Legal Proceedings	39
	Item 4.	Mine Safety Disclosures	39
Part II
	Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	40
	Item 6.	Selected Financial Data	41
	Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	43
	Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	61
	Item 8.	Financial Statements and Supplementary Data	62
	Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	101
	Item 9A.	Controls and Procedures	101
	Item 9B.	Other Information	103
Part III
	Item 10.	Directors, Executive Officers and Corporate Governance	104
	Item 11.	Executive Compensation	104
	Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	104
	Item 13.	Certain Relationships and Related Transactions, and Director Independence	104
	Item 14.	Principal Accounting Fees and Services	104
Part IV
	Item 15.	Exhibits and Financial Statement Schedules	105
	Signatures

i

Part I

Item 1.  Business

Company Overview

Founded in 1992, we believe we are a leading, physician-centric surgical center and physician services company with a diversified, complementary business mix. We believe our complementary business segments, ambulatory surgery services and outsourced physician services, well-position our Company to address the healthcare challenges facing physicians, health systems, payors and communities and our scale allows us to leverage administrative and support infrastructure that enable us to effectively recruit and retain physicians and provide services at lower costs.

Through our ambulatory services segment, we acquire, develop and operate ambulatory surgery centers (ASCs, surgery centers, or centers) in partnership with physicians. Through our physician services segment, we provide outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine. We are one of the largest owners and operators of ASCs in the United States based upon total number of facilities, and are a leading provider of outsourced physician services in the specialties we serve. At December 31, 2015, we operated 257 ASCs in 34 states and the District of Columbia in partnership with approximately 2,000 physicians, and provided physician services to more than 450 healthcare facilities in 29 states, employing more than 3,800 physicians and other healthcare professionals.

In July of 2014, we acquired Sheridan Healthcare (Sheridan), a leading national provider of multi-specialty outsourced physician services to hospitals, ASCs and other healthcare facilities. We believe the combination of our ambulatory surgery services and our outsourced physician services allows for a strategy that can accomplish the following:

• improve integration of anesthesia and surgery in the ambulatory episode of care;

• expand relationships with health systems and payors;

• create physician services segment new contract win opportunities at our surgery centers;

• increase revenue opportunities within our gastroenterology and multi-specialty facilities; and

• increase new hospital/ASC joint ventures.

For the year ended December 31, 2015, approximately 48% and 52% of our revenues were generated by our ambulatory services segment and physician services segment, respectively. For information about our reportable segments, please read “Note 20 - Segment Reporting” to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data in this report.

Ambulatory Services

Our surgery centers are typically located adjacent to or in proximity to the medical practices of our partner physicians. We generally own a majority interest, primarily 51%, in the facilities we operate. We also own a minority interest in certain centers in partnerships with leading health systems and physicians and intend to continue to pursue such partnerships.

Our surgery centers primarily provide elective, high volume, lower-risk surgical procedures across multiple specialties, including, among others, gastroenterology, ophthalmology, and orthopaedics. Our ASCs are designed with a cost structure that creates significant savings for patients and payors when compared to surgical services performed in hospital outpatient departments (HOPDs). We acquire, develop and operate ASCs through the formation of strategic partnerships with physicians to better serve the communities in the markets we serve. Since physicians are critical to the delivery of healthcare, we have developed our operating model to encourage physicians to affiliate with us. We believe we attract physicians because we design our facilities and adopt staffing, scheduling and clinical systems and protocols with the goal of increasing physician efficiency. We believe that our focus on physician satisfaction combined with providing safe, high-quality healthcare in a friendly and convenient environment for patients will continue to make our ASCs an attractive alternative to HOPDs for physicians, patients and payors. We believe our facilities, when compared to HOPDs, (1) enhance the quality of care for our patients, (2) provide significant administrative, clinical and efficiency benefits to physicians, and (3) offer a low cost alternative for patients and payors.

1

Item 1.  Business - (continued) Table of Contents

The types of procedures performed at each surgery center depend on the specialty of the practicing physicians that use the surgery center. The procedures most commonly performed at our surgery centers are:

• gastroenterology - colonoscopy and other endoscopy procedures;

• ophthalmology - cataracts and retinal laser surgery; and

• orthopaedic - knee and shoulder arthroscopy and carpal tunnel repair.

The following table presents the number of our surgery centers by specialty and revenue mix for the years ended December 31, 2015, 2014 and 2013.

	Specialty Count			Revenue Mix
	2015	2014	2013	2015		2014		2013
Gastroenterology	151	150	149	51.6	%	51.6	%	50.9	%
Multispecialty	58	51	44	29.3		29.7		30.5
Ophthalmology	39	37	35	13.5		12.1		11.5
Orthopaedic	9	8	8	5.6		6.6		7.1
Total	257	246	236	100.0	%	100.0	%	100.0	%

The following table presents certain information with respect to our ambulatory services segment for the years ended December 31, 2015, 2014 and 2013. An ASC is deemed to be under development when a limited liability company (LLC) or limited partnership (LP) has been formed with the physician partners to develop the ASC.

	2015			2014			2013
Procedures	1,729,262			1,645,350			1,609,761
Centers in operation, end of period (consolidated)	236			237			233
Centers in operation, end of period (unconsolidated)	21			9			3
Average number of continuing centers in operation, during period	238			233			230
New centers added, during period	11			10			6
Centers discontinued, during period	—			6			3
Centers under development, end of period	1			2			—
Centers under letter of intent, end of period	5			5			5
Average revenue per center (in thousands)	$	5,174		$	4,755		$	4,594
Same center revenues increase (consolidated)	6.0		%	0.7		%	0.6		%
Surgical hospitals in operation at end of period (unconsolidated)	1			—			—

Ambulatory Services Industry Overview

For many years, government programs, private insurance companies, managed care organizations and self-insured employers have implemented cost containment measures intended to limit the growth of healthcare expenditures. These cost-containment measures, together with technological advances, have contributed to the significant shift in the delivery of healthcare services away from traditional inpatient hospital settings to more cost-effective alternate sites, including ASCs. ASCs have been widely viewed as a successful way to increase efficiency by improving the quality of, and access to, healthcare and increasing patient satisfaction, while simultaneously reducing costs. According to data issued by the Centers for Medicare and Medicaid Services (CMS) during 2015, there are approximately 5,400 Medicare-certified ASCs. We believe that approximately 65% of those ASCs performed procedures in a single specialty and approximately 35% performed procedures in more than one specialty (multispecialty). Among the single specialty centers, we believe over 2,000 are in our preferred specialties of gastroenterology, ophthalmology, orthopaedic, ear, nose and throat (ENT), and urology, while the remainder are in specialties such as plastic surgery, podiatry and pain management. Of our preferred specialties, we believe approximately 70% of single specialty ASCs and 30% of multi-specialty ASCs are independently owned.

We believe the following factors have contributed to the increased migration of procedures to outpatient surgical facilities:

Cost‑Effective Alternative.Ambulatory surgery is generally less expensive than hospital-based surgery for a number of reasons, including lower facility development costs, more efficient staffing and space utilization, and a specialized operating environment focused on cost containment. Accordingly, charges to patients and payors by ASCs are generally less than hospital charges.

2

Item 1.  Business - (continued) Table of Contents

Physician and Patient Preference.We believe many physicians prefer ASCs because these surgery centers enhance physicians’ productivity by providing them with greater scheduling flexibility, more consistent nurse staffing and faster turnaround time between cases, allowing them to perform more surgeries in a defined period of time. In contrast, HOPDs generally serve a broader group of physicians, including those involved with emergency procedures, which can result in postponed or delayed surgeries for non-emergency procedures. Many patients prefer ASCs as a result of more convenient locations, shorter waiting times and more convenient scheduling and registration than HOPDs.

New Technology.New technology and advances in anesthesia, which have been increasingly accepted by physicians and payors, have significantly expanded the types of surgical procedures that can be performed in ASCs. Lasers, enhanced endoscopic techniques and fiber optics have reduced the trauma and recovery time associated with surgical procedures. Improved anesthesia has also shortened recovery time by reducing post­operative side effects thereby avoiding overnight hospitalization.

Competitive Strengths for our Ambulatory Services

We believe our ambulatory services segment is distinguished by the following competitive strengths:

Market Leading ASC Provider with Broad Geographic Presence.We are one of the largest outpatient surgical facility operators in the United States based upon the total number of facilities. We operate257surgery centers in34states and the District of Columbia. We believe our geographic diversification provides us with a strong competitive position within the highly fragmented ASC industry, and our national scale and position as a large, public company ASC operator makes us an attractive partner for physicians.

Attractive Demographic Trends.We believe we are the market leader in the specialties of gastroenterology and ophthalmology. More gastroenterology and ophthalmology procedures are performed in our surgery centers than any other ASC operator. These specialties in particular have a higher concentration of older patients (50 years and older) than other specialties, such as orthopaedics or ENT. We believe the aging demographics of the United States population will continue to act as a source of growth for gastroenterology and ophthalmology procedures at our ASCs. Additionally, we believe the growing overweight and obese population in the United States will drive procedure growth in gastroenterology, ophthalmology, and orthopaedics. We believe our market strategy is well aligned to respond to these demographic trends.

Diversified Procedure and Payor Mix.At our257ASCs, our physician partners perform a number of different types of surgical procedures. For the year ended December 31, 2015, 52% of our ambulatory services segment revenues were generated at our gastroenterology centers, 29% of our revenues were generated at our multi-specialty centers, which includes our orthopaedic centers, and 14% of our revenues were generated at our ophthalmology centers. For the year ended December 31, 2015, we derived approximately 74% of our ambulatory services segment revenues from commercial and private payors. Over the same period, we derived approximately 26% of our ambulatory services segment revenues from governmental healthcare programs, primarily Medicare. Medicaid represents less than 2% of our ambulatory services segment revenues. Generally, each of our ASCs contracts individually with the payors in its market area. This contracting diversification reduces our risk with respect to the termination of payor contracts. Because of our payor mix and the non-emergent nature of procedures performed in our ASCs, our ambulatory services segment bad debt expense has averaged less than 2% of our ambulatory services segment revenues over the last three years. For information about our classification of bad debt expense for our ambulatory services segment, please read “Note 3 - Accounts Receivable” to our consolidated financial statements included in this report.

While we cannot predict how changes in reimbursement trends will impact our ambulatory services segment, we believe we are well positioned with respect to possible changes in Medicare reimbursement for several reasons:

• Low Cost Provider: The delivery of healthcare will continue to be directed to low cost venues, including ASCs; therefore, we believe governmental healthcare programs will favor ASCs compared to hospitals because of the lower reimbursement rates for the procedures performed in our surgery centers.

• Reimbursement of Procedures Performed in ASCs Comprise a Small Percentage of the Overall Medicare Budget: Reimbursement for procedures performed in ASCs make up less than 1% of the overall Medicare budget, and any future Medicare ASC rate cuts would not likely generate meaningful savings for governmental healthcare programs.

Proven Ability to Identify and Rapidly Integrate Acquisitions.We pursue acquisitions of ASCs through transactions involving single ASCs as well as acquisitions of companies that own and manage multiple ASCs. In the last five years, we have acquired an ownership interest in over 60 ASCs for a combined acquisition price of more than $750 million. A majority of these ASCs were acquired in individual transactions; however, we also pursue the acquisition of companies that own and operate multiple ASCs. We also have a dedicated team responsible for the integration of acquired centers. This team is responsible for converting acquired ASCs to our

3

Item 1.  Business - (continued) Table of Contents

reporting, staffing, clinical quality and other operating systems. Once an acquisition is consummated, the acquired surgery center is generally fully integrated within 60 days.

Focus on clinical excellence. We are focused on achieving the best clinical outcomes for the patients of our ambulatory services. We have adopted a quality strategic plan that is intended to deliver innovative and patient-focused experiences and outcomes through education, leadership development, benchmarking, error prevention initiatives and deployment of best practices. We provide both centralized and field-based quality and clinical resources to our centers. Resources include policies, toolkits, educational offerings and reports that enables the quality focus to remain on the patient at the center level. Resources incorporate quality standards of care and industry best practices, and quality metrics and benchmarking reports are provided to support each center’s quality plan, as well as center compliance with regulatory and accreditation standards. CMS quality reporting is also supported by centralized quality staff.

We are a member of the ASC Quality Collaboration and support national efforts related to ASC quality. Included in that support is participation in new measure development and testing, as well as our centers’ participation in a national patient safety program designed specifically for ambulatory care.

Ambulatory Services Strategy

We believe we are a leader in the acquisition, development and operation of ASCs. The key components of our strategy are to:

• attract and retain physicians that are leaders in their specialty and community;

• increase same-center revenues and profitability at our existing surgery centers;

• expand our national network of ASCs by selectively acquiring both single-specialty ASCs and multi-specialty ASCs, and developing new ASCs in partnership with physicians and health systems; and

• pursue the acquisition of companies that own and operate multiple ASCs.

Attract and Retain Physicians that are Leaders in Their Specialty and Community.Physicians are critical to the delivery of healthcare and are a valuable component of our operating model. At December 31, 2015, we operated 257ASCs with approximately 2,000 physician partners and approximately 1,000 non-partner physicians who utilize our centers. We typically structure partnerships with physicians in a 51% / 49% ownership relationship, whereby we are the majority member. We believe this structure is mutually beneficial to us and our physician partners. Under our partnership structure, AmSurg provides management services, including clinical and regulatory support, financial reporting, performance measurement, group purchasing, contracting, and marketing services. According to Syndics Research Corporation, our net promoter score, as defined by their most recent annual survey to measure overall physician satisfaction, was 86% and exceeded industry benchmarks for physician satisfaction. We believe our focus on physician satisfaction, combined with providing safe, high quality healthcare in a patient friendly and convenient environment helps us attract and retain physician partners.

Increase Same-Center Revenue Growth.We grow revenues in our existing centers primarily through increasing procedure volume by (1) increasing the number of physicians performing procedures at our centers, (2) marketing our centers to referring physicians, payors and patients, and (3) achieving efficiencies in center operations. For the year ended December 31, 2015, we achieved same-center revenue growth of 6%.

Growth in the Number of Physicians Performing Procedures.The most effective way to increase procedure volume and revenues at our ASCs is to increase the number of physicians who use our centers through:

• the physicians affiliated with the ASCs recruiting new physicians to their practices;

• identifying additional physicians to join the partnerships that own the ASCs; and

• recruiting non-partner physicians in the same or other specialties to use the ASCs.

Marketing Our Centers to Referring Physicians, Payors and Patients. We market our ASCs to referring physicians and payors by emphasizing the quality, high patient satisfaction and lower cost at our ASCs. We have a dedicated business development team that is responsible for negotiating contracts on behalf of our centers with third party payors. They are responsible for obtaining new contracts for our ASCs with payors that do not currently contract with us and negotiating increases to reimbursement rates pursuant to existing contracts. We also increase awareness of the benefits of our ASCs with employers and patients through public awareness programs, health fairs and screening programs, including programs designed to educate employers and patients as to the health and cost benefits of our services.

4

Item 1.  Business - (continued) Table of Contents

Achieving Efficiencies in Center Operations:We have dedicated teams with business and clinical expertise that are responsible for implementing best practices within our ASCs. The implementation of these best practices allows the ASCs to improve operating efficiencies through:

• physician scheduling enhancements;

• improved patient flow; and

• improved operating room turnover.

We also enhance the profitability of our ASCs through benefits we receive from economies of scale such as group purchasing, staffing and clinical efficiencies, and cost containment initiatives. We also track center performance relative to certain benchmarks in order to maximize center-level revenues and profitability. The information we gather and collect from our ASCs and ambulatory services segment operations team members allows us to develop best practices and identify those ASCs that could most benefit from improved operating efficiency techniques and cost containment measures.

Expand Our National Network of ASCs.While we have been an active acquirer of ASCs historically, the market remains fragmented, providing many opportunities for additional acquisitions. We target ownership in single-specialty ASCs that perform gastrointestinal endoscopy, ophthalmology and orthopaedic procedures, as well as multi-specialty ASCs that are equipped and staffed to perform surgical procedures in more than one specialty. As of December 31, 2015, approximately 65% of our ambulatory services segment revenues were from single-specialty centers that perform gastroenterology or ophthalmology procedures. These specialties have a higher concentration of older patients than other specialties, such as orthopaedics or ENT. We will also pursue the acquisition of companies that own and operate multiple ASCs when those opportunities arise.

We also plan to continue expanding our network of ASCs through partnerships with hospitals and hospital systems. As a result of recent trends in the healthcare industry, in part influenced by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the Health Reform Law, many hospitals and hospital systems are seeking to enter or improve their operations within the ASC market in order to offer a complete continuum of care as well as to establish better relationships with physicians who have a need to operate in both in-patient and out-patient environments. We believe the relationships we have established with either a hospital or a hospital-owned entity bring both quality and efficiency to such relationships as a result of our deep experience in ASC operations. We also have many markets in which we currently own existing fully developed centers that are located at or near existing hospital systems which could result in a network of expanded providers benefiting the hospital partner, our existing physician partners and the patients we collectively serve. Additionally, we seek to collaborate with our hospital partners on the identification of opportunities for the acquisition or development of new facilities.

We typically look to acquire ASCs that meet the following criteria:

• Diversified Physician Group:ASCs that have eight to ten (or more) physicians. In order to manage succession planning, we look to acquire ASCs where physicians vary in age in order to limit the risk of several physicians exiting the practice in a short period of time.

• Market Leader:ASCs that are market leaders for the procedures performed in that facility.

• Contracts with Payors:ASCs that contract with all or most of the major commercial payors in their market.

• History of Growth:ASCs with a track record of consistent case and revenue growth.

The development staff of our ambulatory services segment identifies existing centers that are potential acquisition candidates and physicians who are potential partners for new center development. We begin our acquisition process with a due diligence review of the target center and its market. We use experienced teams of operations and financial personnel to conduct a review of all aspects of the center’s operations, including the following:

• quality and reputation of the physicians affiliated with the center;

• market position of the center and the physicians affiliated with the center;

• payor and case mix;

• competition and growth opportunities in the market;

• staffing and supply review;

• equipment assessment; and 

• opportunities for operational efficiencies.

In presenting the advantages to physicians of developing a new ASC in partnership with us, our development staff emphasizes the proximity of a surgery center to a physician’s office, the simplified administrative procedures, the ability to schedule consecutive cases without preemption by inpatient or emergency procedures, the rapid turnaround time between cases, the high technical competency of

5

Item 1.  Business - (continued) Table of Contents

the center’s clinical staff and the state-of-the-art surgical equipment. We also focus on our expertise in developing and operating centers, including contracting with vendors and third-party payors. In a development project, we provide services, such as financial feasibility pro forma analysis, site selection, financing for construction, equipment and build out, and architectural oversight. Capital contributed by the physicians and our company plus debt financing provides the funds necessary to construct and equip a new surgery center and initial working capital.

As part of each surgery center acquisition or development transaction, we generally form an LLC or LP, which are referred to herein as “partnerships” where certain states require and enter into an operating agreement or a LP agreement with our physician partners. We generally own 51% of the partnerships. Under these agreements, we receive a percentage of the net income and cash distributions of the entity equal to our percentage ownership interest in the entity and have the right to the same percentage of the proceeds upon a sale or liquidation of the entity. In the LP structure, as the sole general partner, one of our affiliates is generally liable for the debts of the LP. However, the physician partners are generally required to guarantee their pro rata share of any indebtedness or lease agreements to which the limited partnership is a party in proportion to their ownership interest in the LP.

Except in limited instances, we manage each partnership and oversee the business office, contracting, marketing, financial reporting, accreditation, clinical, regulatory and administrative operations of the surgery center. The physician partners provide the center with a medical director and performance improvement chairman and may provide certain other specified services such as billing and collections, transcription and accounts payable processing. In addition, the partnership may lease the services of certain non-physician personnel from entities affiliated with the physician partners, who will provide services at the center. Certain significant aspects of the partnership's governance are overseen by an operating board, which is typically comprised of equal representation by AmSurg and our physician partners. We work closely with our physician partners to increase the likelihood of a successful partnership.

A majority of the operating agreements and LP agreements for our surgery centers provide that, if certain regulatory changes take place, we will be obligated to purchase some or all of the noncontrolling interests of our physician partners. The regulatory changes that could trigger such obligations include changes that: (i) make the referral of Medicare and other patients to our surgery centers by physicians affiliated with us illegal; (ii) create the substantial likelihood that cash distributions from the partnership to the affiliated physicians will be illegal; or (iii) cause the ownership by the physicians of interests in the partnership's to be illegal. There can be no assurance that our existing capital resources would be sufficient for us to meet the obligations, if they arise, to purchase these noncontrolling interests held by physicians. The determination of whether a triggering event has occurred generally would be made by the concurrence of our legal counsel and counsel for the physician partners or, in the absence of such concurrence, by independent counsel having expertise in healthcare law chosen by both parties. Such determination therefore would not be within our control. The triggering of these obligations could have a material adverse effect on our financial condition and results of operations. See “– Government Regulation.”

Ambulatory Services Revenues

Revenues from our ASCs are derived from facility fees charged for surgical procedures performed and, at certain of our surgery centers (primarily centers that perform gastrointestinal endoscopy procedures), charges for anesthesia services provided by medical professionals employed or contracted by our centers. These fees vary depending on the procedure, but usually include all charges for operating room usage, special equipment usage, supplies, recovery room usage, nursing staff and medications. Facility fees do not include professional fees charged by the physicians that perform the surgical procedures. Revenues are recorded at the time of the patient encounter and billings for such procedures are made on or about that same date. At the majority of our centers, it is our policy to collect patient co-payments and deductibles at the time the surgery is performed. Our revenues are recorded net of estimated contractual adjustments from third-party medical service payors.

ASCs depend upon third-party reimbursement programs, including governmental and private insurance programs, to pay for substantially all of the services rendered to patients. We derived approximately 26%, of our ambulatory services segment revenue in the year ended December 31, 2015, and 25% of our revenues in the years ended December 31, 2014 and 2013 from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles. The Medicare program currently pays ASCs in accordance with predetermined fee schedules. Our surgery centers are not required to file cost reports and, accordingly, we have no unsettled amounts from governmental third-party payors.

ASCs are paid under the Medicare program based upon a percentage of the payments to HOPDs pursuant to the hospital outpatient prospective patient system and reimbursement rates for ASCs are updated annually based on changes in the consumer price index (CPI). The Health Reform Law provides for the annual CPI increases applicable to ASCs to be reduced by a productivity adjustment, which is based on historical nationwide productivity gains. In 2013, ASC reimbursement rates increased by 0.6%, which positively impacted our 2013 ambulatory services revenues by approximately $2.5 million and our net earnings per diluted share by $0.02. In

6

Item 1.  Business - (continued) Table of Contents

2014, ASC reimbursement rates increased by 1.2%, which positively impacted our 2014 ambulatory services revenues by approximately $6.5 million and our net earnings per diluted share by $0.05. In 2015, ASC reimbursement rates increased by 1.9%, which positively impacted our 2015 ambulatory services revenues by approximately $9.0 million and our net earnings per diluted share by $0.10. Centers for Medicare and Medicaid Services (CMS) has announced that ASC reimbursement rates will increase by 0.3% for 2016, which we estimate will not have a significant impact our 2016 ambulatory services revenues. There can be no assurance that CMS will not revise the ASC payment system or that any annual CPI increases will be material. 

The Budget Control Act of 2011 (BCA) requires automatic spending reductions of $1.2 trillion for federal fiscal years (FFY) 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs. The percentage reduction for Medicare may not be more than 2% for a FFY, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as “sequestration.” These reductions have been extended through FFY 2025. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress, whether Congress will attempt to restructure or suspend sequestration or the impact sequestration may have on our surgery centers.

CMS is increasing its administrative audit efforts through the nationwide expansion of the recovery audit contractor (RAC) program. RACs are private contractors that have historically conducted post-payment reviews of providers and suppliers that bill Medicare to detect and correct improper payments for services. We maintain policies and procedures to respond to RAC requests and payment denials. Currently, there are significant delays in the assignment of new Medicare appeals to Administrative Law Judges. In April 2015, the Office of Medicare Hearings and Appeals estimated that assignment of requests for hearings could be delayed for up to 28 months. Thus, we may experience a significant delay in appealing any RAC payment denials. The Health Reform Law expands the RAC program’s scope to include Medicaid claims. In addition to RACs, other contractors, such as Medicaid Integrity Contractors, perform payment audits to identify and correct improper payments. We could incur costs associated with appealing any alleged overpayments and be required to repay any alleged overpayments identified by these or other administrative audits.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. CMS has promulgated three national coverage determinations that prevent Medicare from paying for certain serious, preventable medical errors performed in any healthcare facility, such as surgery performed on the wrong patient or the wrong site. Several commercial payors also do not reimburse providers for certain preventable adverse events. CMS established a quality reporting program for ASCs under which ASCs that fail to report on certain required quality measures will receive a 2% reduction in reimbursement. We have implemented programs and procedures at each of our centers to comply with the quality reporting program prescribed by CMS and all of our centers received the full payment update for 2016 based on quality measure reporting. Further, as required by the Health Reform Law, U.S. Department of Health and Human Services (HHS) reported to Congress on its plan for implementing a value-based purchasing program for ASCs that would tie Medicare payments to quality and efficiency measures. As required by the Health Reform Law, HHS studied whether to expand to ASCs its current policy of not paying additional amounts for care provided to treat conditions acquired during an inpatient hospital stay and reported to Congress that it may not be feasible to expand the policy in its current form, but that further exploration of other payment policies aimed at this same goal should be undertaken.

In addition to payment from governmental programs, ASCs derive a significant portion of their revenues from private health insurance plans. These plans include both standard indemnity insurance programs as well as managed care programs, such as preferred provider organizations and health maintenance organizations. The strengthening of managed care systems nationally has resulted in substantial competition among providers of surgery center services that contract with these systems. Further, most of the plans offered through the health insurance exchanges provide for narrow networks that restrict the number of participating providers or tiered networks that impose significantly higher cost sharing obligations on patients who obtain services from providers in a disfavored tier. Exclusion from participation in a managed care network or assignment to a disfavored tier could result in material reductions in patient volume and revenues of our ambulatory services segment. Some of our competitors may have greater financial resources and market penetration than we do. We believe that all payors, both governmental and private, will continue their efforts over the next several years to reduce healthcare costs and that their efforts will generally result in a less stable market for healthcare services. While no assurances can be given concerning the ultimate success of our efforts to contract with healthcare payors, we believe that our position as a low-cost alternative for certain surgical procedures should enable our centers to compete effectively in the evolving healthcare marketplace.

7

Item 1.  Business - (continued) Table of Contents

Ambulatory Services Competition

We encounter competition in our ASC business in three separate areas: competition with other providers for physicians to utilize our surgery centers, patients and managed care contracts; competition with other companies for acquisitions of surgery centers; and competition for joint venture development of new centers.

Competition for Physicians to Utilize Our Surgery Centers, Patients and Managed Care Contracts. We compete with hospitals and other surgery centers in recruiting physicians to utilize our surgery centers, for patients and for the opportunity to contract with payors. In some of the markets in which we operate, there are shortages of physicians in certain specialties. In several of the markets in which we operate, hospitals are recruiting physicians or groups of physicians to become employed by the hospitals, including primary care physicians and physicians in certain specialties. In many cases the hospitals have restricted those physicians’ ability to refer patients to physicians and facilities not affiliated with the hospital. In addition, physicians, hospitals, payors and other providers may form integrated delivery systems that restrict the physicians who may treat certain patients or the facilities at which patients may be treated, and payors may utilize plan structures, such as narrow networks and tiered networks, that further restrict patient facility choice. Competition with hospitals and other surgery centers may limit our ability to contract with payors or negotiate favorable payment rates.

Competition for Acquisitions. There are several companies that compete with us for the acquisition of existing ASCs and companies that own and manage ASCs, including HCA Healthcare Corporation, Surgery Partners Inc., Surgical Care Affiliates, Inc. and United Surgical Partners, Inc., a subsidiary of Tenet Healthcare Corporation. We may also compete with other national healthcare providers or local or regional hospitals under certain circumstances. Some of these competitors may have greater resources than we have. The principal competitive factors that affect our and our competitors’ ability to complete acquisitions are price, experience and reputation, and access to capital.

Competition for Joint Venture Development of Centers. We believe that we do not have a direct corporate competitor in the development of single-specialty ASCs across the specialties of gastroenterology and ophthalmology. There are, however, several publicly and privately held companies that develop multi-specialty surgery centers, and these companies may compete with us in the development of multi-specialty centers. Further, many physicians develop surgery centers without a corporate partner, utilizing consultants who typically perform these services for a fee and who take a small equity interest or no equity interest in the ongoing operations of the surgery center. We also compete with national, regional and local hospital systems for the development of new surgery centers.

Accreditation

Managed care organizations in certain markets will only contract with a facility that is accredited by either the Accreditation Association for Ambulatory Health Care (AAAHC) or The Joint Commission. We believe that undergoing and maintaining voluntary accreditation signifies our commitment to quality. Currently, all of our centers are accredited by AAAHC or The Joint Commission and have received three-year certifications.

8

Item 1.  Business - (continued) Table of Contents

Ambulatory Services Locations

The size of our typical single-specialty ASC is approximately 3,000 to 6,000 square feet. The size of our typical multi-specialty ASC is approximately 8,000 to 12,000 square feet. Each center typically has two to three operating or procedure rooms with areas for reception, preparation, recovery and administration. Each surgery center is specifically tailored to meet the needs of its physician partners. Our surgery centers perform an average of approximately 7,200 procedures per year, though there is a wide range amongcenters from a low of approximately 1,000 procedures per year to a high of approximately 31,000 procedures per year. 

The following table details the location and specialty of our surgery centers as of December 31, 2015:

State Location	Gastroenterology	Multispecialty	Ophthalmology	Orthopaedic	Total
Alabama	—	—	1	—	1
Arizona	7	3	2	2	14
Arkansas	1	1	1	—	3
California	14	12	1	1	28
Colorado	—	1	1	—	2
Connecticut	2	1	2	—	5
Delaware	3	1	—	—	4
Florida	18	11	5	1	35
Idaho	—	1	1	—	2
Illinois	3	—	—	—	3
Indiana	2	—	1	—	3
Kansas	3	—	3	1	7
Kentucky	2	—	2	—	4
Louisiana	4	2	2	—	8
Maryland	13	1	1	—	15
Massachusetts	3	3	—	1	7
Michigan	1	—	1	1	3
Minnesota	—	1	3	—	4
Missouri	3	1	—	2	6
Nevada	1	—	1	—	2
New Hampshire	—	1	—	—	1
New Jersey	7	7	1	—	15
New Mexico	1	—	—	—	1
North Carolina	5	—	—	—	5
Ohio	9	1	2	—	12
Oklahoma	2	—	1	—	3
Oregon	1	3	1	—	5
Pennsylvania	8	2	1	—	11
South Carolina	4	1	1	—	6
Tennessee	8	1	3	—	12
Texas	18	3	1	—	22
Utah	1	—	—	—	1
Washington	5	—	—	—	5
Washington D.C.	1	—	—	—	1
Wyoming	1	—	—	—	1
Total	151	58	39	9	257

9

Item 1.  Business - (continued) Table of Contents

Physician Services

Sheridan is a leading national provider of multi-specialty outsourced physician services to hospitals, ASCs and other healthcare facilities. At December 31, 2015 we provided physician services, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine services, to more than 450 healthcare facilities in 29 states and employed more than 3,800 physicians and other healthcare professionals. Our physician services segment operates with a significant presence in Florida, California, Arizona and New Jersey. We believe our scale and ability to leverage administrative and support infrastructure enable us to effectively recruit and retain physicians and provide physician services at lower costs. Sheridan has grown organically through same-contract revenue growth and new contract wins, as well as through acquisitions of complementary medical practice groups.

The following table presents the revenue mix from our primary physician services specialties for the year ended December 31, 2015 and for the period from July 16, 2014 through December 31, 2014.

	Revenue Mix
	Year Ended December 31, 2015		Period from July 16, 2014 - December 31, 2014 (1)
Anesthesiology services	71.0	%	75.0	%
Radiology services	12.4		6.5
Children's services	7.3		7.8
Emergency medicine services	5.9		6.3
Office based and other	3.4		4.4
Total	100.0	%	100.0	%

(1) On July 16, 2014, we completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

Anesthesiology services

We are one of the two largest and most experienced providers of outsourced anesthesia services in the United States. We have many long standing customer relationships, some of which have a history of over 50 years of continuously provided anesthesia services. During 2015, our approximately 2,900 anesthesia professionals serviced over 1.25 million anesthetic cases at more than 320 facilities. Our anesthesia care teams provide anesthesiology services to hospitals, ASCs and other healthcare facilities in 19 states. These teams are comprised of board-certified or board-eligible physicians and allied health professionals which include certified registered nurse anesthetists (CRNAs) and Anesthesia Assistants. Our anesthesiologists are a key part of the effective management and productivity of hospital surgery departments, ASCs and other healthcare facilities. Anesthesiology services involve the selection and delivery of drugs in order to induce a state of unconsciousness or numbness, in preparation for medical and surgical procedures, as well as for pain management purposes. Anesthesia services are provided by anesthesiologists, as well as other healthcare professionals, who are typically CRNAs. They are responsible for selecting the correct anesthesia drug and dosage for each patient and, typically, for administering the anesthesia and monitoring the patient.

Radiology services

We are a leading provider of radiology services, including diagnostic, interventional and teleradiology services, to hospitals, imaging centers and physician group practices in the United States. In 2015, our radiologists interpreted approximately 3.5 million studies. All of our radiologists are fellowship-trained or board-certified, locally licensed physicians based in the United States. Many of our radiologists provide their services at healthcare facilities where they interpret all modalities of radiology images and can consult directly with attending physicians, providing prompt, accurate interpretations, which promotes the professional development of our radiologists as they interact constantly with the physicians at our clients’ facilities. The practice of radiology involves the interpretation of images of the human body to aid in the diagnosis and treatment of diseases, conditions and injuries. Diagnostic radiologists correlate findings from imaging procedures with clinical information and other medical examinations to make diagnoses or recommend further examinations or treatments in consultation with the patient’s attending physician. Interventional radiology, which is also referred to as vascular and interventional radiology, is a sub-specialty of radiology that utilizes minimally-invasive image-guided procedures to diagnose and treat diseases in nearly every organ system. Teleradiology is the process whereby digital radiologic images are sent from one point to another, which allows hospitals to have 24/7 access to full-time radiology support even when access to on-site radiologists may be limited. We provide teleradiology services from remote reading facilities staffed by

10

Item 1.  Business - (continued) Table of Contents

radiologists from our affiliated practice groups to improve the productivity of our radiologists and expand access to 24/7 diagnoses and interpretations (also known as “studies”) and increase availability of sub-specialty consultations.

Children’s services

We are one of the largest providers of children’s services in the United States. In 2015, we supported over 80 children’s services programs in 14 states with approximately 250,000 patient days. We principally provide neonatal management services, specializing in acute inpatient care and treatment of infants. We continue to increasingly expand our provision of children’s services in pediatric hospitalist, pediatric intensivist and pediatric emergency medicine subspecialties. Our children’s services teams, led by dedicated on-site medical directors, consist of physicians and Advanced Registered Nurse Practitioners (ARNPs) who collaborate with community obstetricians, pediatricians, hospital nursing staff and hospital administration. These teams staff the neonatal intensive care units (NICUs) at our clients’ facilities. We also provide specialists in pediatric intensivist services in pediatric emergency department settings and pediatric intensivist care units in hospitals. Additionally, our children's services staff administers our universal newborn hearing screening program called Healthy Hearing.

Neonatologists are pediatricians that have additional training and certifications to care for premature or newborn infants with low birth weight or other potential medical complications. Our neonatologists are staffed in NICUs and are responsible for daily rounds, ongoing newborn care, and coverage of all neonatal and pediatric emergencies, including C-sections and deliveries. We also employ perinatologists that are obstetricians that have additional training and certifications to care for women with high risk or complicated pregnancies and their unborn babies.

Emergency medicine services

We are a leading provider of emergency medicine services to hospitals. These services are performed by physicians with emergency department specializations and other healthcare professionals such as ARNP's and Physician Assistants. In 2015, we had annual volume of approximately 315,000 visits in six states. We continue to provide high-quality care that is also cost-effective, supporting our clients’ facilities as well as their communities.

Emergency medicine services involve the immediate diagnosis and treatment of patients. The emergency department is one of the most challenging areas to manage given the immediate and often acute nature of patients’ conditions and the required treatment. Emergency departments are an essential access point for medical services and are a primary source of patient admissions. Consequentially, hospitals require efficient and effectively operated emergency departments, often turning to providers of outsourced physician services with greater experience and resources.

Other services

We operate a small group of office-based medical practices in South Florida and Texas that primarily focus on women’s health and provide services in the areas of gynecology and obstetrics. We maintain and operate our office-based practices in communities where the practices support and integrate with our facilities-based specialties, providing additional value to our healthcare facility clients through coordination of care.

We provide management services to our joint ventures, affiliated physician group practices and other office-based practices and specialties. Under our management services agreements, we typically manage all aspects of the practice other than the provision of medical services except in jurisdictions where we are permitted to also provide clinical management services. In exchange for these services, we are paid a management fee.

Key Constituents

We are dedicated to achieving the best outcomes for our patients. Sheridan has been able to successfully and profitably grow its business by delivering strong and consistent value to two key constituents.

Clients, Including Hospitals, ASCs and Other Healthcare Facilities. Our physicians usually lead the daily operations of their specialty departments and integrate themselves into the clinical leadership at our clients’ facilities. This integration allows us to collaborate with hospitals, ASCs and other healthcare facilities to improve their operations. We believe our national scale and footprint enable us to provide better coordination of care, better physician coverage, stronger recruiting services, more professional and experienced management and improved patient throughput and outcomes as compared to smaller independent physician groups or directly affiliated facility practices with which we compete.

11

Item 1.  Business - (continued) Table of Contents

Physicians and Other Healthcare Professionals. We employ approximately 3,800 healthcare professionals nationwide, including approximately 2,000 physicians. We provide clinical resources and handle administrative support functions for our healthcare professionals, allowing them to focus on providing quality medical care. We employ approximately 1,800 non-clinical support staff to manage these administrative functions, including client and payor contracting, billing and reimbursement, employee benefits, technology support, regulatory compliance, professional liability and other administrative activities associated with supporting a modern-day physician group practice. Our healthcare professionals receive competitive compensation, job stability and the opportunity for upward career mobility on our physician management teams. We believe that the level of clinical autonomy, attractive compensation and infrastructure support we provide to our healthcare professionals makes us a more attractive alternative in comparison to smaller provider groups.

Physician Services Industry Overview

The growing complexity of the healthcare delivery system has led many healthcare facilities to increasingly outsource medical coverage and administrative functions to improve productivity, increase the overall quality of care and reduce administrative costs. We believe the primary clinical areas we serve, which include anesthesiology, radiology, children’s services and emergency medicine, are specialties that are extremely important lines of service for the overall provision of care. The market for outsourced services in our specialties tends to be highly fragmented and is predominantly served by small group practices.

We believe our physician services segment is well-positioned to benefit from certain industry trends including the following:

Shift towards national providers of physician outsourcing.Hospitals, ASCs and other healthcare facilities are increasingly utilizing national providers of outsourced healthcare professionals as a means of reducing operating expenses; achieving targeted physician coverage levels, including by addressing difficulties in hiring and retaining physicians; and increasing operational efficiency to improve patient flow, reduce wait times, coordinate care, shorten lengths of stay and reduce readmission rates, all of which lead to lower costs and promote improved patient care. Historically, hospitals, ASCs and other healthcare facilities have relied on local practice groups to provide outsourced physician services, but an increasing number have been turning to national outsourced physician groups to meet their increasingly complex needs. We are a direct beneficiary of this continuing shift from smaller local groups to larger national provider organizations.

Consolidation of healthcare providers.Historically, healthcare has predominantly been provided through smaller, fragmented local provider groups. However, due to changes in reimbursement, increasing regulatory compliance requirements and growing client demands for quality measurement and cost efficiencies, hospitals, ASCs and other healthcare facilities, in some instances, are increasingly consolidating with one another, provider groups are consolidating into larger groups and individual physicians are seeking larger partners. A significant portion of our growth has come from consolidation with regional provider groups, other acquisitions of smaller physician group practices and new contract wins, all of which have in part been driven by these industry consolidation trends.

Opportunities created by healthcare reform. We believe the Health Reform Law and other measures of healthcare reform should increase the number of people with access to health insurance over time. These measures are expected to reduce the number of uninsured and underinsured, which we believe will in turn lead to increased demand for healthcare services. The Health Reform Law also increases the obligation of healthcare providers to provide coordinated care and holds provider accountable for showing measurable patient outcomes. As a national provider group, we believe that we are in a favorable position to serve the expected growth in patient populations and to meet our clients’ needs for increased coordination and outcomes measurement.

Increased competition for specialty physicians. With a growing and aging population in the United States, demands for specialty physician services are increasingly outpacing the supply of qualified practitioners. We believe there will be a shortage of physicians occurring in the next ten years, including shortages in anesthesiology, radiology, children's services and emergency medicine. This growing shortage has led to increasing challenges in recruiting and retaining specialty physicians among hospitals, ASCs and other healthcare facilities, which we believe we can service in part by utilizing other healthcare professionals, such as CRNAs, ARNPs and physician assistants. Given our expertise in recruiting healthcare professionals in our specialty fields and the attractiveness of our business model to such specialists, we believe we are well-positioned to continue to recruit and retain healthcare professionals and, thus, meet increasing demands for their services in the years to come.

12

Item 1.  Business - (continued) Table of Contents

Competitive Strengths of our Physician Services

We believe the following competitive strengths position our physician services segment favorably to capitalize on healthcare industry trends:

Leading multi-specialty provider with national scale. We are one of the largest providers of multispecialty outsourced healthcare services in the United States. Our multi-specialty offering positions us well to adapt to the particular needs of our clients by providing attractive economic solutions. Further, when a client contracts with us for more than one of our specialties, it helps alleviate their administrative burden of managing multiple physician group relationships. Our infrastructure not only improves productivity and quality of care while reducing the cost of care, but also provides operating leverage to drive economies of scale as we continue to expand. We believe our scale also enables us to achieve more favorable managed care contract terms and to efficiently manage the operations and billing and collections processes. While we have a national footprint serving more than 450 healthcare facilities in 29 states, we also have a strong local presence. Our local presence fosters our community-based relationships with healthcare facilities and administrators, which we believe results in high retention with both our clients and our physicians.

Proven ability to grow organically and through acquisitions.Sheridan has historically grown physician services segment revenue through (1) strong same-contract growth driven by increases in payment rates and patient volume, (2) new contract wins and (3) acquisitions. We have driven substantial new contract growth by bidding and competing for new contracts and providing existing clients with high-quality service. We believe our expertise in effectively managing and deploying physician resources, negotiating more favorable contracts with payors, providing high quality outcomes and delivering service more efficiently has contributed significantly to the organic growth of our physician services segment. In addition, given that the market for outsourced physician services is highly fragmented and predominantly served by small provider groups, we believe there is significant opportunity for further growth through new contract wins from smaller provider groups and through select, targeted acquisitions. Our physician services segment infrastructure allows us to successfully integrate new contract wins and newly acquired physician group practices while achieving economies of scale.

Focus on clinical excellence. Our physician services segment is focused on achieving the best clinical outcomes for our patients through the application of rigorous recruiting and credentialing standards, the promotion of a physician-led leadership structure and the monitoring of our clinical quality measures.

• We are certified by the National Committee for Quality Assurance, a leading nationally recognized independent organization that evaluates the quality and credentials of physician organizations.

• Through extensive clinical and leadership development programs, we train our healthcare professionals to continually enhance their skills. Our healthcare professionals are supported through our specialty-specific networks, which are led by our physician senior leadership. We provide internally developed continuing medical education accredited courses to our healthcare professionals, including instructor-led and on-line education sessions.

• We have developed and implemented quality measurement systems which track multiple key indicators which assist our professionals in systematically monitoring, examining and analyzing outcomes and processes. These quality measurement systems are supplemented by our active peer review infrastructure designed to ensure the development and implementation of actionable items that will improve patient outcomes.

Our ability to deliver high levels of client service and patient care is a direct result of this focus, and helps us to attract and retain clients.

Proven ability to recruit and retain healthcare professionals. Sheridan has over 50 years’ experience of recruiting, credentialing and retaining qualified physicians and other healthcare professionals. We offer our physicians and other healthcare professionals the clinical autonomy of working in a group practice with the financial and administrative support of a large, national organization. This support allows them to focus on patients and quality of care, while we handle the demanding administrative burdens of a modern healthcare practice. We also offer our healthcare professionals scheduling and location flexibility, employment stability and competitive compensation.

Recurring diversified revenue stream from long-standing client base. Our physician services segment revenue is highly diversified across the broad base of medical services that we provide. Net revenue from our physician services segment in 2015 was derived from approximately 5.3 million patient encounters across more than 450 healthcare facilities. Many of our client relationships exceed 15 years, and our original physician services client has been with Sheridan for more than 50 years. In addition, our physician services segment has a well-diversified payor mix. For the year ended December 31, 2015, we estimate approximately 70% of our physician services net revenue was derived from commercial and managed care contracts, approximately 18% was from Medicare, Medicaid and approximately 12% was from other services and self-pay. Most of our significant managed care payors are under multi-year

13

Item 1.  Business - (continued) Table of Contents

contracts, which typically include contractual annual rate escalators. Importantly, although our strategy is to participate with all relevant payors, payment for our services is not contingent on us having a contract with any given payor; if we perform services for a patient who carries insurance from a payor with whom we have not contracted, we still bill and generally collect for those services.

Physician Services Strategy

We intend to capitalize on our competitive strengths and favorable industry trends to grow the revenue and profitability of our physician services segment by:

Delivering distinctive service to our existing client base to drive strong same-contract growth. The foundation of our physician services segment business lies in how we service our existing base of healthcare facilities. To ensure that we maintain and further strengthen these client relationships, we pursue the following key strategies:

• expand our national physician services capabilities through increases in our internal physician recruiting, credentialing and onboarding organizations, further development of our provider quality metrics capabilities and investment in reimbursement technologies;

• work with our clients to develop increased operating room efficiencies through the application of best

practice information regarding physician staffing and procedural turnaround; and

• further advance our relationships with national managed care plans to facilitate favorable contract terms

and more efficient reimbursement.

Organically expanding through new contract wins.The market for outsourced physician services is highly fragmented and predominantly served by smaller local and regional provider groups. Such fragmentation creates significant opportunities for organic growth, as we believe that we can provide better solutions for hospitals, ASCs and other healthcare facilities than those that are offered by smaller provider groups. Our differentiated capabilities and market presence has enabled us to win contracts with both new and existing clients, and we expect to continue to capitalize on these trends within our industry. Within our existing client base, there is a significant opportunity to win new contracts by cross-selling additional specialties, as we currently provide two or more lines of service at only one in five clients. We have significantly invested in expanding the breadth and focus of our physician services segment business development functions. We believe our expanded efforts and dedicated internal resources will position us well to continue to win new contracts.

Executing acquisitions to augment our organic growth.As the physician services industry continues to consolidate, we believe we will have the opportunity to augment the organic growth of our physician services segment through opportunistic acquisitions of regional and local providers. We will target strategic “platform” practices to catalyze future growth in new markets and “in-market” practices in geographies where we have an established presence. In the last five years, Sheridan has successfully acquired and integrated 22 physician group practices for a combined acquisition price of approximately $1.2 billion, adding more than 1,200 physicians and healthcare professionals.

Enhancing profitability by achieving further operating efficiencies. We believe that we can improve the operating efficiency of our physician services segment as we grow. Our infrastructure is designed to achieve economies of scale by enhancing profitability with revenue growth without compromising the quality of operations or clinical care. We believe our processes related to managed care contracting, billing, coding, collection and compliance have driven a track record of strong revenue cycle management. We have made a significant investment in infrastructure including management information systems that we believe will continue to enable us to improve the clinical results and key client metrics while reducing the cost of providing patient care.

Physician Services Revenues

Our physician services segment revenue primarily consists of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities we serve. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors.

We record revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors.

We also recognize revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

14

Item 1.  Business - (continued) Table of Contents

Our provision for uncollectibles includes the estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. We record net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

Many of our most significant managed care payor contracts in our physician services segment are for a term of three to five years, terminable only for cause. They often provide for annual increases in reimbursement rates. These contracts may be national or state-wide and are most often applicable to all lines of service. Most other payor contracts are terminable without cause with short term notice. We participate with most large managed care payors.

Our physician services segment performs substantially all of the billing for our affiliated physicians and employs a billing staff of approximately 600 employees. Additionally, we have invested in several applications that provide the foundation for the day-to-day operations of our physician services segment, including facilities-based billing and office-based billing.

We derive approximately 18% of our physician services segment net revenue from services rendered to beneficiaries of Medicare, Medicaid and other government-sponsored healthcare programs. For the year ended December 31, 2015, we received approximately 13% and 5% of our physician services segment net revenue from Medicare and Medicaid, respectively. In addition, these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, all of which may materially increase or decrease the payments we receive for our services as well as affect the cost of providing services. In recent years, Congress has consistently attempted to curb federal spending on such programs, including through sequestration, which is mandated by the BCA, and requires automatic spending reductions through FFY 2025. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress, whether Congress will attempt to restructure or suspend sequestration or the impact sequestration may have on our physician practices.

Reimbursement to our physician services segment typically is conditioned on our providing accurate procedure and diagnosis codes and properly documenting both the service itself and the medical necessity for the service. Incorrect or incomplete documentation and billing information, or the incorrect selection of codes for the level of service provided, could result in non-payment for services rendered or lead to allegations of billing fraud. Moreover, third-party payors may disallow, in whole or in part, requests for reimbursement based on determinations that certain amounts are not reimbursable, were for services provided that were not medically necessary, lacked sufficient supporting documentation, or were disallowed for a number of other reasons.

Retroactive adjustments, recoupments or refund demands may change amounts realized from third party payors and retroactive adjustments to amounts previously reimbursed can and do occur on a regular basis as a result of reviews and audits. Additional factors that could complicate our physician services segment billing include:

• disputes between payors as to which party is responsible for payment;

• the difficulty of adherence to specific compliance requirements, diagnosis coding and various other procedures mandated by the government; and

• failure to obtain proper physician credentialing and documentation in order to bill governmental payors.

Due to the nature of our business and our participation in the Medicare and Medicaid programs, we are involved from time to time in regulatory reviews, audits or investigations by government agencies of matters such as compliance with billing regulations and rules. We may be required to repay these agencies if a determination is made that we were incorrectly reimbursed, or we may lose eligibility for certain programs in the event of certain types of non-compliance. Delays and uncertainties in the reimbursement process adversely affect our level of accounts receivable, increase the overall cost of collection, and may adversely affect our working capital.

Medicare Physician Fee Schedule (MPFS). Medicare pays for all physician services based upon the MPFS which contains a list of uniform rates. The payment rates under the MPFS are determined based on: (i) national uniform relative value units for the services provided, (ii) a geographic adjustment factor, and (iii) a conversion factor. Payment rates under the MPFS are updated annually. Historically, a sustainable growth rate (SGR) formula tied to the U.S. gross domestic product (GDP) was used to calculate these annual updates. However, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) repealed the SGR formula while establishing annual fee updates through calendar year 2019 and outlining a new method for determining updates thereafter. Also, MACRA incentivizes the development of, and participation in, alternative payment models. A new merit-based incentive payment system will consolidate and replace several existing incentive programs beginning in 2019. There can be no assurance that Congress will not make further changes to physician payment methodology.

15

Item 1.  Business - (continued) Table of Contents

Physician Services Competition

The markets in which we compete are highly fragmented. We consider our primary competitors to be local physician group practices. On a regional and national basis, we compete with companies such as Envision Healthcare Holdings, Inc. (formerly Emcare), Mednax Inc., and Team Health Holdings, Inc.

Physician Services Locations

As of December 31, 2015 we served a diverse group of more than 450 healthcare facilities in 29 states with a concentration in Florida, New Jersey, Arizona and California. During the year ended December 31, 2015, Florida, New Jersey, Arizona and California accounted for approximately 85% of our physician services segment net revenue. There is limited concentration among existing clients, with the largest client accounting for less than 10% of our physician services segment net revenue; however, some of our clients are affiliated with one another or owned and operated by the same entity. Our physician services segment has contracts in the states of Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Minnesota, Missouri, North Carolina, New Jersey, New Mexico, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Vermont, Washington and West Virginia.

Government Regulation

The healthcare industry is subject to extensive regulation by a number of governmental entities at the federal, state and local level. Government regulation affects our business activities by controlling our growth, requiring licensure and certification for our facilities, regulating the use of our properties and controlling reimbursement to us for the services we provide.

Health Reform.The Health Reform Law represents significant change across the healthcare industry. The Health Reform Law contains a number of provisions designed to reduce Medicare program spending, including the annual productivity adjustment previously discussed, that reduces payment updates to ASCs and various initiatives that may reduce payments for physician services. However, the Health Reform Law also expands coverage of previously uninsured individuals through a combination of public program expansion and private sector health insurance reforms. For example, the Health Reform Law has expanded eligibility under existing Medicaid programs in states that have not opted out of the expansion, created financial penalties on certain individuals who fail to carry insurance coverage, established affordability credits for those not enrolled in an employer-sponsored health plan, resulted in the establishment of federal and state health insurance exchanges and allowed states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid. The Health Reform Law also required a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates, and increased dependent coverage.

We believe that health insurance market reforms under the Health Reform Law that expand insurance coverage have resulted in an increased volume for certain procedures at our centers or the facilities we serve. Medicare now covers and many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies. States that provide Medicaid coverage of these preventive services without cost-sharing receive a one percentage point increase in their federal medical assistance percentage for these services. Our centers or the facilities we serve have also benefited from increased numbers of individuals with insurance. However, there can be no assurance the increased volume we have experienced will continue to occur. In addition, other aspects of the Health Reform Law could have a negative impact on our ambulatory services segment. For example, the Health Reform Law established a Medicare Shared Savings Program, which created Accountable Care Organizations (ACOs) to allow groups of providers, hospitals and suppliers to come together voluntarily to provide coordinated high quality care to Medicare patients. The formation of ACOs or other coordinated care models could make competing for patients more difficult and negatively impact our centers and the medical practices of our physician partners.

Within our physician services segment, we derive a significant portion of our revenue from payments made by government healthcare programs, including Medicare and Medicaid. CMS has implemented, or is implementing, a number of programs and requirements intended to transform Medicare from a passive volume-based payment system to an active purchaser of quality goods and services. These efforts directly impact hospitals, but may also affect the level of utilization of and payments received for our physician staffing services. These programs include financially rewarding hospitals that meet quality performance standards established by CMS, penalizing hospitals that do not meet those performance standards or experience “excess readmissions” for certain conditions, denying reimbursement for treatment of hospital acquired conditions (HACs) and reducing payments to hospitals with high rates of HACs. In addition, hospitals may be penalized for non-compliance with the admission and medical review criteria for inpatient services commonly known as the “two midnight rule.” The ultimate impact of these initiatives is not certain, but may lead to hospitals increasingly tying payments for our physician services to obtaining certain quality measures or negotiations to reduce payment rates

16

Item 1.  Business - (continued) Table of Contents

for our physician services segment. Our physician services segment may also experience increased competition from ACOs and other coordinated care models.

It is unclear what the ultimate resulting impact of the Health Reform Law will be on the number of uninsured individuals or what the payment terms will be for individuals covered by the Medicaid expansion or who purchase coverage through health insurance exchanges. Further, the Health Reform Law remains subject to legislative efforts to repeal or modify the law, further delay and a number of court challenges to its constitutionality and interpretation. For example, the excise tax on high-cost employer-sponsored health insurance plans, commonly known as the Cadillac tax, has been delayed for two years and, therefore, will not take effect until 2020. Because of the many variables involved, including the law’s complexity, lack of comprehensive implementing definitive regulations or interpretive guidance, gradual or partially delayed implementation, court challenges, the possibility of amendments, repeal, or further implementation delays, uncertainty regarding how individuals and employers will respond to the choices afforded them by the law, we are unable to predict the net effect of the Health Reform Law. In addition, efforts to reform the healthcare industry continue to attract attention at both the federal and state levels.

Certification. We depend on third-party programs, including governmental and private health insurance programs, to reimburse us for services rendered to patients in our ASCs and by our outsourced physicians in various care settings. In order to receive Medicare reimbursement, each surgery center must meet the applicable conditions for coverage set forth by HHS relating to the type of facility, its equipment, personnel and standard of medical care, as well as its compliance with state and local laws and regulations, all of which are subject to change from time to time. ASCs undergo periodic on-site Medicare certification surveys. Each of our existing surgery centers is certified as a Medicare provider. Our outsourced physicians participate in Medicare, but are not subject to certification surveys or on-site inspections. While we intend for our outsourced physicians and centers to participate in Medicare and other government reimbursement programs, there can be no assurance that our physicians or centers will continue to qualify for participation.

Medicare-Medicaid Fraud and Abuse Provisions. The federal Anti-Kickback Statute prohibits healthcare providers and others from knowingly and willfully soliciting, receiving, offering or paying, directly or indirectly, any remuneration (including any kickback, bribe or rebate) in return for, or to induce, referrals or orders for services or items covered by a federal healthcare program. The Anti-Kickback Statute is very broad in scope, and many of its provisions have not been uniformly or definitively interpreted by case law or regulations. Courts have found a violation of the Anti-Kickback Statute if just one purpose of the remuneration is to generate referrals, even if there are other lawful purposes. Furthermore, the Health Reform Law provides that knowledge of the law or intent to violate the law is not required to establish a violation of the Anti-Kickback Statute.

Violations may result in criminal penalties or fines of up to $25,000 or imprisonment for up to five years, or both. Violations of the Anti-Kickback Statute may also result in substantial civil penalties, including penalties of up to $50,000 for each violation, plus three times the amount claimed, and exclusion from participation in the Medicare and Medicaid programs. Exclusion from these programs would result in significant reduction in revenues and would have a material adverse effect on our business. The Health Reform Law provides that submission of a claim for services or items generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim and may be subject to additional penalties under the federal False Claims Act (FCA). The Bipartisan Budget Act of 2015 requires civil monetary penalties, including those for violations of the Anti-Kickback Statute and those imposed under the FCA, to increase by up to 150% by August 1, 2016, and to increase annually thereafter based on updates to the Consumer Price Index.

Congress and HHS have published safe harbors that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute. Failure to meet the requirements of a safe harbor does not necessarily render the conduct or business arrangement illegal under the Anti-Kickback Statute. However, such conduct and business arrangements may lead to increased scrutiny by governmental enforcement authorities. In addition, the HHS Office of Inspector General (OIG) is authorized to issue advisory opinions regarding the interpretation and applicability of the federal Anti-Kickback Statute, including whether an activity constitutes grounds for the imposition of civil or criminal sanctions. Although advisory opinions are not binding on any entity other than the parties who submitted the requests, advisory opinions provide some guidance as to how the OIG would analyze a particular arrangement.

HHS has published regulations for safe harbors that relate to investment interests in general and to investments in certain types of ASCs. The limited partnerships and limited liability companies that own our surgery centers do not meet all of the criteria of a safe harbor. However, a business arrangement that does not substantially comply with a safe harbor is not necessarily illegal under the Anti-Kickback Statute.

17

Item 1.  Business - (continued) Table of Contents

We believe that our surgery centers and the related limited partnerships and limited liability companies are in compliance with the current requirements of applicable federal and state law because, among other factors:

• the limited partnerships and limited liability companies exist to effect legitimate business purposes, including the ownership, operation and continued improvement of high quality, cost-effective and efficient services to the patients served;

• the limited partnerships and limited liability companies function as an extension of the practices of physicians who are affiliated with the surgery centers and the surgical procedures are performed personally by these physicians without referring the patients outside of their practice;

• our physician partners have a substantial investment at risk in the limited partnerships and limited liability companies;

• terms of the investment do not take into account the volume of the physician partners’ past or anticipated future services provided to patients of the centers;

• the physician partners are not required or encouraged as a condition of the investment to treat Medicare or Medicaid patients at the centers or to influence others to refer such patients to the centers for treatment;

• the limited partnerships, the limited liability companies, our subsidiaries and our affiliates do not loan any funds to or guarantee any debt on behalf of the physician partners with respect to their investment; and

• distributions by the limited partnerships and limited liability companies are allocated uniformly in proportion to ownership interests.

The safe harbor regulations also set forth a safe harbor for personal services and management contracts. Certain of our limited partnerships and limited liability companies have entered into ancillary services agreements with our physician partners’ group practices, pursuant to which the practice may provide the center with billing and collections, transcription, payables processing, payroll and other ancillary services. The consideration payable by a limited partnership or limited liability company for certain of these services may be based on the volume of services provided by the practice, which is measured by the limited partnership’s or limited liability company’s revenues. Although these relationships do not meet all of the criteria of the personal services and management contracts safe harbor, we believe that the ancillary services agreements are in compliance with the current requirements of applicable federal and state law because, among other factors, we believe the fees payable to the physician practices are equal to the fair market value of the services provided.

In addition, certain of our limited partnerships and limited liability companies have entered into certain arrangements for professional services, including arrangements for anesthesia services. The OIG has issued advisory opinions in which it concluded that proposed arrangements between anesthesia groups and facilities, including, physician-owned ASCs could result in prohibited remuneration under the federal Anti-Kickback Statute. We believe our arrangements for anesthesia services are unlike those described in the OIG advisory opinions and are in compliance with the requirements of the federal Anti-Kickback Statute.

In connection with our outsourced physician services, we have a variety of financial relationships with physicians, hospitals, ASCs, and other healthcare services, including joint venture arrangements. These financial relationships do not meet all of the criteria of the personal services and management contracts safe harbor, but we believe that the arrangements are in compliance with the current requirements of applicable federal and state law because, among other factors, we believe the fees payable under the arrangements are consistent with fair market value of the services provided.

We believe we have structured our relationships with physicians and other providers to comply with the Anti-Kickback Statute, but we cannot assure you that a federal or state agency charged with enforcement of the Anti-Kickback Statute and similar laws might not assert a contrary position or that new federal or state laws might not be enacted that would cause these arrangements to become illegal, or result in the imposition of penalties on us or certain of our facilities. Even the assertion of a violation could have a material adverse effect upon us.

Many of the states in which we operate have adopted laws that prohibit payments to physicians in exchange for referrals similar to the federal Anti-Kickback Statute, some of which apply regardless of the source of payment for care. These statutes typically provide criminal and civil penalties as well as loss of licensure.

In addition to the Anti-Kickback Statute, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides for criminal penalties for healthcare fraud offenses that apply to all health benefit programs, including the payment of inducements to Medicare and Medicaid beneficiaries in order to influence those beneficiaries to order or receive services from a particular provider or practitioner. Federal enforcement officials have numerous enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program and an incentive program under which individuals can receive up to $1,000 for providing information on Medicare fraud and abuse that leads to the recovery of at least $100 of Medicare funds. In addition, federal enforcement officials have the ability to exclude from Medicare and Medicaid any investors, officers and managing employees associated with business entities that have committed healthcare fraud.

18

Item 1.  Business - (continued) Table of Contents

Evolving interpretations of current, or the adoption of new, federal or state laws or regulations could affect many of our arrangements. Law enforcement authorities, including the OIG, the courts and Congress, are increasing their scrutiny of arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to exchange remuneration for patient care referrals or opportunities. Investigators also have demonstrated a willingness to look behind the formalities of a business transaction to determine the underlying purposes of payments between healthcare providers and potential referral sources.

Prohibition on Certain Self-Referrals and Physician Ownership of Healthcare Facilities. The federal physician self-referral law, commonly referred to as the Stark Law, prohibits a physician from making a referral for a designated health service to an entity if the physician or a member of the physician’s immediate family has a financial relationship with the entity, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, refunding amounts received for services provided pursuant to prohibited referrals, civil money penalties of up to $15,000 per prohibited service provided and exclusion from the federal healthcare programs. The Bipartisan Budget Act of 2015 requires these penalties to increase by up to 150% in 2016, and annually thereafter as described above. Failure to refund amounts received as a result of a prohibited referral on a timely basis may constitute a false or fraudulent claim and may result in civil penalties and additional penalties under the FCA. The Stark Law applies to referrals involving the following services under the definition of “designated health services”: clinical laboratory services; physical therapy services; occupational therapy services; radiology and imaging services; radiation therapy services and supplies; durable medical equipment and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics and prosthetic devices and supplies; home health services; outpatient prescription drugs; and inpatient and outpatient hospital services. Through a series of rulemakings, CMS has issued final regulations interpreting the Stark Law. While the regulations help clarify the requirements of the exceptions to the Stark Law, it is difficult to determine how the government will interpret many of these exceptions for enforcement purposes.

A number of provisions of the Stark Law implemented regulations to limit how the Stark Law affects ASCs. Under these regulations, services that would otherwise constitute a designated health service, but that are paid by Medicare as a part of the surgery center payment rate, are not a designated health service for purposes of the Stark Law. The so-called ASC exemption to the Stark Law also applies to any radiology and imaging procedures that are integral to a covered ASC surgical procedure and that are performed immediately before, during, or immediately following the surgical procedure (that is, on the same day). Similarly, CMS has excluded from the Stark Law definition of “outpatient prescription drugs” any drugs that are “covered as ancillary services” under the revised ASC payment system. These drugs include those furnished during the immediate postoperative recovery period to a patient to reduce suffering from nausea or pain. CMS cautioned, however, that only those radiology, imaging and outpatient prescription drug items and services that are integral to an ASC procedure and performed on the same day as the covered surgical procedure will qualify for the ASC exemption. The Stark Law prohibition continues to prohibit a physician-owned ASC from furnishing outpatient prescription drugs for use in a patient’s home. In addition, there is a Stark Law exception covering implants, prosthetics, implanted prosthetic devices and implanted durable medical equipment provided in a surgery center setting under certain circumstances. Because of these exemptions, we believe the Stark Law does not prohibit physician ownership or investment interests in our surgery centers to which they refer patients.

With respect to our outsourced physician services, we contract with hospitals and other providers of designated health services. Our physician practices also provide services, such as imaging and laboratory services, that constitute designated health services. Thus, we are required to structure our financial relationships involving providers of designated health services in a manner that complies with a Stark Law exception. There are a number of exceptions that may apply to our outsourced physician services, including the exceptions for bona fide employment relationships, indirect compensation arrangements and in-office ancillary services. We attempt to structure our relationships to meet an exception to the Stark Law when required, but the regulations implementing the exceptions are detailed and complex, and we cannot guarantee that every relationship complies fully with the Stark Law.

Several states in which we operate have self-referral statutes similar to the Stark Law. Often these state laws are broad in scope and may apply regardless of the source of payment for care. Little precedent exists for the interpretation or enforcement of these state laws. We believe that physician ownership of surgery centers is not prohibited by these state self-referral statutes.

The Stark Law and similar state statutes are subject to different interpretations. Violations of the Stark Law and any state self-referral laws may result in substantial civil or criminal penalties, including large civil monetary penalties and exclusion from participation in the Medicare and Medicaid programs. Exclusion of our surgery centers or physician groups from these programs could result in significant loss of revenues and could have a material adverse effect on us. We can give no assurances that further judicial or agency interpretations of existing laws or further legislative restrictions on physician ownership or investment in, or financial relationships with, healthcare entities will not be issued that could have a material adverse effect on us.

19

Item 1.  Business - (continued) Table of Contents

The Federal False Claims Act and Similar Federal and State Laws. We are subject to state and federal laws that govern the submission of claims for reimbursement. These laws generally prohibit an individual or entity from knowingly and willfully presenting a claim (or causing a claim to be presented) for payment from Medicare, Medicaid or other third-party payors that is false or fraudulent. Penalties under these statutes include substantial civil and criminal fines, exclusion from the Medicare program, and imprisonment. The standard for “knowing and willful” often includes conduct that amounts to a reckless disregard for whether accurate information is presented by claims processors. One of the most prominent of these laws is the federal FCA, which may be enforced by the federal government directly, or by a qui tam plaintiff (or whistleblower) on the government’s behalf. There are many potential bases for liability under the FCA, including knowingly and improperly avoiding repayment of an overpayment received from the government and the knowing failure to report and return an overpayment within 60 days of identifying the overpayment. The Health Reform Law expanded the scope of the federal FCA to cover payments in connection to the exchanges created under the Health Reform Law, if those payments include any federal funds. When a private plaintiff brings a qui tam action under the FCA, the defendant often will not be made aware of the lawsuit until the government commences its own investigation or makes a determination whether it will intervene. The Health Reform Law provides that submission of claims for services or items generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. In some cases, qui tam plaintiffs and the federal government have taken the position, and some courts have held, that providers who allegedly have violated other statutes, such as the Stark Law, have thereby submitted false claims under the FCA. When a defendant is determined by a court of law to be liable under the FCA, the defendant may be required to pay three times the amount of the alleged false claim, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false claim. These penalties will increase by up to 150% by August 1, 2016, and will increase annually thereafter, as described above. The private plaintiff may receive a share of any settlement or judgment. We believe that we have procedures in place to ensure the accurate completion of claims forms and requests for payment. However, the laws and regulations defining proper Medicare or Medicaid billing are complex and have not been subjected to extensive judicial or agency interpretation. Billing errors can occur despite our best efforts to prevent or correct them, and we cannot assure you that the government will regard such errors as inadvertent and not in violation of the FCA or related statutes.

Every entity that receives at least $5.0 million annually in Medicaid payments must have written policies for all employees, contractors or agents, providing detailed information about false claims, false statements and whistleblower protections under certain federal laws, including the federal FCA, and similar state laws. A number of states, including states in which we operate, have adopted their own false claims provisions as well as their own qui tam provisions whereby a private party may file a civil lawsuit in state court. States that enact false claims laws that are comparable to the federal FCA are entitled to an increased share of FCA recoveries.

Healthcare Industry Investigations. Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral relationships and billing practices. The Health Reform Law includes additional federal funding of $350 million over 10 years to fight healthcare fraud, waste and abuse, including $30 million for FFY 2016. From time to time, the OIG and the Department of Justice have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Some of our activities could become the subject of governmental investigations or inquiries. For example, we have significant Medicare billings and we have joint venture arrangements involving physician investors. In addition, our executives and managers, many of whom have worked at other healthcare companies that are or may become the subject of federal and state investigations and private litigation, could be included in governmental investigations or named as defendants in private litigation. We are not aware of any governmental investigations involving any of our facilities, our executives or our managers. A future adverse investigation of us, our executives or our managers could result in significant expense to us, as well as adverse publicity.

Privacy and Security Requirements. There are currently numerous legislative and regulatory initiatives at the state and federal levels addressing the privacy and security of patient health and other identifying information. The privacy and security regulations promulgated pursuant to HIPAA extensively regulate the use and disclosure of individually identifiable protected health information and require “covered entities,” including healthcare providers, to implement administrative, physical and technical safeguards to protect the security of such information. Violations of the regulations may result in criminal penalties and civil penalties of up to $50,000 per violation and a maximum civil penalty of $1.5 million in a calendar year for violations of the same requirement. HHS enforces HIPAA and is required to perform compliance audits. State attorneys general are also authorized to bring civil actions seeking either injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents. A covered entity may be subject to penalties as a result of a business associate (an entity that handles identifiable health information on behalf of a covered entity) violating HIPAA if the business associate is found to be an agent of the covered entity. Business associates are also directly subject to certain provisions of the HIPAA security and privacy regulations and may be penalized for violations of the regulations. Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay, but not to exceed 60 days following discovery of the breach by the covered entity or its agents. Notification must also be made to HHS and, in certain situations involving large breaches, to the media. There is a presumption that all non-permitted uses or disclosures of unsecured protected health information are breaches unless the covered

20

Item 1.  Business - (continued) Table of Contents

entity or business associate establishes that there is a low probability the information has been compromised.

In addition, there are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our facilities remain subject to any federal or state laws that encompass privacy concerns or the reporting of security breaches that are more restrictive than the regulations issued under HIPAA. These laws vary and could impose additional penalties. For example, various state laws and regulations may require us to notify affected individuals in the event of a data breach involving certain individually identifiable health or financial information. In some cases, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to data breaches.

HIPAA Administrative Simplification Requirements. Pursuant to HIPAA, HHS has adopted regulations establishing electronic data transmission standards that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically. HIPAA also requires that each provider use a National Provider Identifier. In addition, CMS requires the use of standard code sets to report certain medical diagnoses and procedures. As of October 1, 2015, the use of the ICD-10 code set is mandatory for all healthcare providers covered by HIPAA. Transitioning to the ICD-10 coding system involved significant administrative changes, including modifying our payment systems and processes. In addition to these upfront transition costs, any difficulty or delays in payors and other providers transitioning to this significantly more detailed code set could disrupt or delay payment due to technical or coding errors or other implementation issues. Further, the transition to the more detailed ICD-10 coding system could result in decreased reimbursement if the use of ICD-10 codes results in conditions being reclassified with lower levels of reimbursement than assigned under the previous system, however, we believe that the cost of compliance with these regulations has not had and is not expected to have a material adverse effect on our business, financial position or results of operations.

Obligations to Buy Out Physician Partners. Under many of our agreements with physician partners of our surgery centers, we are obligated to purchase the interests of the physicians at an amount as specified in the limited partnership and operating agreements in the event that their continued ownership of interests in the limited partnerships and limited liability companies becomes prohibited by the statutes or regulations described above. The determination of such a prohibition generally is required to be made by our counsel in concurrence with counsel of the physician partners or, if they cannot concur, by a nationally recognized law firm with expertise in healthcare law jointly selected by us and the physician partners. The interest we are required to purchase will not exceed the minimum interest required as a result of the change in the law or regulation causing such prohibition.

Certificates of Need (CONs) and State Licensing. CON statutes and regulations control the development of certain facilities and services, such as ASCs in certain states. CON statutes and regulations generally provide that, prior to the expansion of existing centers, the construction of new health care facilities, the acquisition of major items of equipment or the introduction of certain new services, approval must be obtained from the designated state health planning agency. In giving approval, a designated state health planning agency must determine that a need exists for expanded or additional facilities or services. Our development of ASCs focuses on states that do not require CONs. Acquisitions of existing surgery centers usually do not require CON approval.

State licensing of ASCs, is generally a prerequisite to the operation of each of our centers and to participation in federally funded programs, such as Medicare and Medicaid. Once a center becomes licensed and operational, it must continue to comply with federal, state and local licensing and certification requirements, as well as local building and safety codes. In addition, every state imposes licensing requirements on individual physicians, such as those who provide services in our ASCs or through our outsourced physician services, and many states impose licensing requirements on facilities and services operated and owned by physicians. Physician practices are also subject to federal, state and local laws dealing with issues such as occupational safety, employment, medical leave, insurance regulations, civil rights and discrimination and medical waste and other environmental issues.

Corporate Practice of Medicine. The laws of several states in which we operate or may operate in the future do not permit business corporations to practice medicine, exercise control over physicians who practice medicine or engage in various business practices, such as employing physicians and certain non-physician practitioners. Similarly, many states prohibit fee-splitting arrangements with physicians where professional fees of physicians are shared with other persons or entities. The physicians who perform procedures at the surgery centers or who perform contracted physician services are individually licensed to practice medicine. In most instances within our surgery center line of business, the physicians and physician group practices are not affiliated with us other than through the physicians’ ownership in the limited partnerships and limited liability companies that own the surgery centers and through the service agreements we have with some physicians. We directly employ nearly all of the physicians who provide outsourced services. The laws in many states regarding the corporate practice of medicine have been subjected to limited judicial and regulatory interpretation, and interpretation and enforcement of these laws vary significantly from state to state. Therefore, we cannot provide assurances that our activities, if challenged, will be found to be in compliance with these laws.

21

Item 1.  Business - (continued) Table of Contents

Employees

As of December 31, 2015, we and our affiliated entities employed approximately 12,400 persons, approximately 9,000 of whom were full-time employees and 3,400 of whom were part-time employees. Of those employees, we lease the services of approximately 900 full-time employees and 500 part-time employees from entities affiliated with our physician partners. We employ approximately 1,700 corporate employees or other employees performing support functions, primarily based at our headquarters in Nashville, Tennessee and in Sunrise, Florida. In addition, none of these employees are represented by a union. We believe our relationships with our employees to be good.

Environmental Matters

We are subject to federal, state and local laws and regulations relating to hazardous materials, pollution and the protection of the environment. Such regulations include those governing emissions to air, discharges to water, storage, treatment and disposal of wastes, including medical waste, remediation of contaminated sites, and protection of worker health and safety. These laws and regulations frequently change and have become increasingly stringent over time. Non-compliance with these laws and regulations may result in significant fines or penalties or limitations on our operations or claims for remediation costs, as well as alleged personal injury or property damages. Certain environmental laws and regulations impose strict, and under certain circumstances joint and several, liability for investigation and remediation of the release of regulated substances into the environment. Such liability can be imposed on current or former owners or operators of contaminated sites, or on persons who dispose or arrange for disposal of wastes at a contaminated site.

Support Infrastructure and Technology

To support our clinical staff and client facilities, we maintain an infrastructure that provides clinical, administrative and business support services to physicians, other healthcare professionals and administrative staff. These support services include but are not limited to:

• non-clinical operation management;

• physician and allied care recruiting;

• revenue cycle management;

• compliance, education and oversight;

• managed care contracting with third-party payors;

• information technology;

• human resources;

• risk management;

• quality improvement; and

• credentialing.

These support services are critical to the success of our physician partners and employed healthcare professionals. We have a support staff that assists in the efforts to obtain accreditation at each of our ASCs. Personnel located at our corporate headquarters primarily provide these services, but we also have regional offices where we have substantial operations. These services allow us to leverage our operational excellence and existing infrastructure to provide services to our clients, employees and physician partners. Our infrastructure has enabled us to integrate newly developed or acquired ASCs or physician group practices while achieving significant economies of scale.

We have invested in and developed management information systems that support our current operations and that management believes will support our projected growth. We purchase hardware and software that has been customized for us, as well as develop our own technology in both our clinical and administrative areas, which we believe may provide a competitive advantage over local, regional and emerging national providers. There are several applications currently in use and under development that provide the foundation for our day-to-day operations, including:

• Billing services- Billing systems that perform facilities-based revenue cycle management for each of the specialties in which we provide physician services, as well as for many of our ASCs.

• Enterprise management- Enterprise-wide reporting systems that are used for all essential accounting and finance functions, which include both integrated human resource and payroll functions.

• Recruitment and business development- A third-party database used by our business development departments and our physician recruitment subsidiary, Tiva Healthcare. This application is primarily used to develop a database of medical professionals that can be targeted in the recruitment process and also to manage other aspects of the recruitment and hiring process.

22

Item 1.  Business - (continued) Table of Contents

• Web-based applications- Our web-based comprehensive neonatal clinical electronic health record system, which is used in each of the facilities where we provide NICU and newborn nursery services to gather all pertinent clinical data from our patients to determine outcomes. Our web-based portal providing physician partners with access to financial information, financial and quality benchmarking reports along with best practices from the ambulatory services segment community of centers and peer, physician-to-physician, insights on latest technologies and therapies.

Insurance and Legal Proceedings

From time to time, we may be named a party to other legal claims and proceedings in the ordinary course of business. We are not aware of any claims or proceedings against us or our subsidiaries that we believe will have a material financial impact on our consolidated financial condition, results of operations or cash flows.

Our ambulatory services segment maintains professional and general liability insurance that, subject to certain deductibles, provides coverage on a claims-made basis of generally $1.0 million per incident and $3.0 million in annual aggregate coverage per surgery center, including the facility and employed staff. In addition, physicians who provide professional services in our surgery centers are generally required to maintain separate malpractice coverage with similar minimum coverage limits. We also maintain insurance for general liability, director and officer liability, business interruption and property damage, as well as an additional umbrella liability insurance policy in the aggregate amount of $25.0 million. Coverage under certain of these policies is contingent upon the policy being in effect when a claim is made regardless of when the events which caused the claim occurred.

Given the nature of the services provided, our physician services segment is subject to professional and general liability claims and related lawsuits in the ordinary course of business. We maintain professional insurance for our physician services segment with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of our professional liability loss risks are being provided by a third-party insurer which is fully reinsured by our wholly-owned captive insurance subsidiary. In addition, our wholly-owned captive insurance subsidiary provides stop loss coverage for the self-insured employee health program for employees of our physician services segment. The assets, liabilities and results of operations of our wholly-owned captive insurance subsidiary are included in our consolidated financial statements. The liabilities for self-insurance include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. 

Our reserves for professional liability claims are based upon periodic actuarial calculations. Our reserves for losses and related expenses represent estimates involving actuarial and statistical projections, at a given point in time, of our expectation of the ultimate resolution plus administration costs of the losses that we have incurred. Our reserves are based on historical claims, demographic factors, industry trends, severity and exposure factors and other actuarial assumptions calculated by an independent actuarial firm. The independent actuarial firm performs studies of projected ultimate losses on an annual basis and provides semi-annual updates to those projections. We refer to these actuarial estimates as part of our process by which we determine appropriate reserves. Liabilities for claims incurred but not reported are not discounted. The estimation of professional liabilities is inherently complex and subjective, as these claims are typically resolved over an extended period of time, often as long as ten years or more. We periodically reevaluate our accruals for professional liabilities, and our actual results may vary significantly from our estimates as the key assumptions used in our actuarial valuations are subject to constant adjustment as a result of changes in our actual loss history and the movement of projected emergence patterns as claims develop.

Antitrust

The federal government and most states have enacted antitrust laws that prohibit certain types of conduct deemed to be anti-competitive. These laws prohibit price fixing, market allocation, bid-rigging, concerted refusal to deal, market monopolization, price discrimination, tying arrangements, acquisitions of competitors and other practices that have, or may have, an adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. Antitrust enforcement in the health care industry is currently a priority of the Federal Trade Commission and the Department of Justice. We believe we are in compliance with such federal and state laws, but courts or regulatory authorities may reach a determination in the future that could adversely affect our operations.

Seasonality

Historically, the impact of seasonal effects on our revenues and operating results have been dampened due to growth from acquisitions as well as our geographic diversification. Without giving effect to these growth and diversification factors and with the exception of emergency medicine and children's services, our net revenue would fluctuate based on the number of business days in each calendar quarter, because the majority of medical services provided by our anesthesiology, office-based practices and ambulatory surgery centers consist of scheduled procedures and office visits that occur during business hours. Our net revenue would also be impacted by

23

Item 1.  Business - (continued) Table of Contents

unpredictable weather events such as snowstorms or hurricanes that reduce the number of days of operations as well as the number of patients. Revenue in the fourth quarter could also be impacted by an increased utilization of services as patients try to utilize their healthcare benefits before they expire at year-end. In addition, we incur a significantly higher payroll tax expense during the first and second quarters due to a significant number of our employees exceeding the level of taxable wages for social security contributions during the second half of the year.

Available Information

We file reports with the Securities and Exchange Commission (SEC) including annual reports on Form 10-K, quarterly reports on Form 10-Q and other reports from time to time.  The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E., Room 1580, Washington, DC 20549.  The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  We are an electronic filer and the SEC maintains an Internet site at http://www.sec.gov that contains the reports, proxy and information statements and other information filed electronically. Our website address is:  http://www.amsurg.com.  We make available free of charge through our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC.  In addition we use our Facebook page (https://www.facebook.com/AMSURG) and Twitter account (https://twitter.com/amsurgcorp) as channels of distribution of company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings and public conference calls and webcasts. The information provided on our website and social media channels is not part of this report, and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this annual report on Form 10-K.

Executive Officers of the Registrant

The following table sets forth certain information regarding the persons serving as our executive officers.  Our executive officers serve at the pleasure of the Board of Directors.

Name	Age	Experience
Christopher A. Holden	51	Chief Executive Officer and Director since October 2007; Senior Vice President and a Division President of Triad Hospitals Inc. from May 1999 to July 2007.
Claire M. Gulmi	62	Executive Vice President since February 2006; Chief Financial Officer since September 1994; Director since May 2004; Senior Vice President from March 1997 to February 2006; Secretary since December 1997; Vice President from September 1994 through March 1997.
Robert J. Coward	51	President - Physician Services Division and Chief Development Officer since November 2014; President and Chief Operating Officer of Sheridan Healthcare from January 2010 to July 2014; Chief Financial Officer and Senior Vice President of Operations of Sheridan Healthcare from January 2000 to December 2009.
Phillip A. Clendenin	51	President - Ambulatory Services Division since November 2014; Executive Vice President-Operations since February 2013; Senior Vice President of Corporate Services from March 2009 to February 2013; Chief Executive Officer of River Region Health System, a hospital located in Vicksburg, Mississippi, from July 2001 to July 2008; Chief Executive Officer of Greenview Regional Hospital, a hospital located in Bowling Green, Kentucky, from November 1997 to June 2001.
Kevin D. Eastridge	50	Senior Vice President of Finance since July 2008; Vice President of Finance from April 1998 to July 2008; Chief Accounting Officer since July 2004; Controller from March 1997 to June 2004.

24

Item 1A.   Risk Factors Table of Contents

The following factors affect our business and the industry in which we operate. The risks and uncertainties described below are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also have an adverse effect on us. If any of the matters discussed in the following risk factors were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially adversely affected.

Risk Related to Our Overall Business

Our physician services segment operates in a different line of business from our historical operations, and we may face challenges managing our physician services segment as a new business and may not realize anticipated benefits. As a result of the Sheridan acquisition, we are now significantly engaged in the outsourced physician services business, which is a new line of business for us. We may not have the expertise, experience, and resources necessary to successfully operate both our ambulatory services segment and physician services segment. The administration of our physician services segment will require implementation of appropriate operations, management, and financial reporting systems and controls. We may experience difficulties in effectively implementing these and other systems. The management of our physician services segment will require the focused attention of our management team, including a significant commitment of its time and resources. The need for management to focus on these matters could have a material and adverse impact on our revenues and operating results. If our physician services segment operations are less profitable than we currently anticipate or we do not have the experience, the appropriate expertise, or the resources to operate all businesses in the combined company, our results of operations and financial condition may be materially and adversely affected.

We have been and could become the subject of federal and state investigations and compliance reviews.Health care companies are subject to numerous investigations by various governmental agencies. Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral and billing practices. Further, the federal FCA permits private parties to bring qui tam or “whistleblower” lawsuits against companies. Some states have adopted similar state whistleblower and false claims provisions.

From time to time, the OIG and the Department of Justice have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Some of our activities could become the subject of governmental investigations or inquiries.  For example, we have significant Medicare billings and we have joint venture arrangements involving physician investors. In addition, our executives and managers, some of whom have worked at other healthcare companies that are or may become the subject of federal and state investigations and private litigation, could be included in governmental investigations or named as defendants in private litigation. Governmental agencies and their agents conduct audits of health care providers, and private payers may conduct similar audits, investigations and monitoring activities. An investigation or audit of us, our executives or our managers could result in significant expense to us, adverse publicity, and divert management’s attention from our business, regardless of the outcome, and could result in significant penalties. Depending on nature of the conduct and whether the underlying conduct under investigation or audit could be considered systemic, the resolution of any review could have a material adverse effect on our financial position, results of operations and liquidity.

We are unable to predict the impact of the Health Reform Law. The Health Reform Law represents significant change across the healthcare industry. The Health Reform Law expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms, which we believe has resulted in an increased volume for certain procedures and in patients seeking care from us. The law also contains requirements and incentives that increase coverage, without cost-sharing, of certain preventive services performed at our centers, including screening colonoscopies. However, the impact of the increased volume in patients and procedures or additional coverage of our services by third-party payors could be offset by other provisions of the law. The Health Reform Law provides for reductions in reimbursement under the Medicare program, including an annual payment update, such as the annual productivity adjustment that reduces payments to ASCs and reductions in payments to hospitals, which could indirectly impact our physician services business. Further, ACOs or other coordinated care models may increase competition for patients and negatively impact our centers and medical practices. In addition, the law requires CMS to implement a number of programs and requirements intended to transform Medicare from a passive volume-based payment system to an active purchaser of quality goods and services. These efforts directly impact hospitals, but may also potentially reduce the level of utilization by, and payments received from, hospitals for our physician services business. We are unable to predict the net effect of the reductions in Medicare spending, potential increases in revenues from a rise in procedure volume and individuals with health insurance, and an increase in other models care delivery and service providers.

Further, the Health Reform Law remains subject to legislative efforts to repeal, modify or delay the law, and a number of court challenges to its constitutionality and interpretation. In addition, while most of the provisions of the Health Reform Law are in effect, certain delays have occurred. For example, the excise tax on high-cost employer-sponsored health insurance plans, commonly known as the “Cadillac Tax”, has been delayed for two years and, therefore, will not take effect until 2020.

25

Item 1A.   Risk Factors - (continued) Table of Contents

Because of the many variables involved, including the law’s complexity, lack of comprehensive implementing definitive regulations or interpretive guidance, gradual or partially delayed implementation, court challenges, the possibility of amendments, repeal, or further implementation delays, uncertainty regarding how individuals and employers will respond to the choices afforded them by the law, and numerous other provisions in the law that may affect us, we cannot predict the full impact of the Health Reform Law on us at this time.

Treatment methodologies and governmental or commercial health insurance controls designed to reduce the number of surgical procedures may reduce our revenue and profitability. Controls imposed by Medicare and Medicaid, employer-sponsored healthcare plans and commercial health insurance payors designed to reduce surgical volumes, in some instances referred to as “utilization review,” could adversely affect our facilities and medical practices. Although we are unable to predict the effect these changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees may reduce our revenue and profitability. Additionally, trends in treatment protocols and commercial health insurance plan design, such as plans that shift increased costs and accountability for care to patients, could reduce our surgical volumes in favor of lower intensity and lower cost treatment methodologies, each of which could, in turn, have a material adverse effect on our business, prospects, results of operations and financial condition.

If we fail to implement our business strategy, our financial performance and our growth could be materially and adversely affected. Our future financial performance and success are dependent in large part upon our ability to implement our business strategy successfully. Our business strategy includes several initiatives, including maintaining our existing relationships with our physician partners at our surgery centers, our physician services segment clients and our employed healthcare professionals; acquiring additional surgery centers and physician practices; winning contracts with new physician services clients; pursuing joint ventures with local and regional health systems; capitalizing on organic growth opportunities in both our ambulatory services segment and physician services segment; and enhancing operational efficiencies. We may not be able to implement our business strategy successfully or achieve the anticipated benefits of our business strategy. Implementation of our business strategy could also be affected by a number of factors beyond our control, such as increased competition, regulatory developments, general economic conditions or increased operating costs or expenses. In addition, to the extent we have misjudged the nature and extent of industry trends or our competition, we may have difficulty in achieving our strategic objectives. If we are unable to execute our strategy, our long-term growth, profitability, and ability to service our debt will be adversely affected. Even if we are able to implement some or all of the initiatives of our business strategy successfully, our operating results may not improve to the extent we anticipate, or at all.

Our success depends on our ability to manage growth effectively. Even if we are successful in obtaining new business, failure to manage our growth could adversely affect our financial condition. We may experience extended periods of very rapid growth, and if we are not able to manage our growth effectively, our business and financial condition could materially suffer. Our growth may significantly strain our managerial, operational and financial resources and systems. To manage our growth effectively, we will have to continue to implement and improve our operational, financial and management controls, reporting systems and procedures. In addition, we must effectively expand, train and manage our employees. We will be unable to manage our businesses effectively if we are unable to alleviate the strain on resources caused by growth in a timely and successful manner.

We may make acquisitions which could divert the attention of management and may not be integrated successfully into our existing business. A portion of our growth has resulted from, and is expected to continue to result from, the acquisition of surgery centers, physician groups and other healthcare providers and businesses. We may continue to pursue acquisitions to increase our presence in existing markets, enter new geographic markets and expand the scope of services we provide. We have evaluated and expect to continue to evaluate possible acquisition targets on an ongoing basis, and such acquisition targets may be of significant size and involve operations in multiple jurisdictions. We cannot assure you that we will identify suitable acquisition candidates, acquisitions will be completed on acceptable terms, our due diligence process will uncover all potential liabilities or issues affecting our integration process, we will not incur break-up, termination or similar fees and expenses and/or we will obtain all necessary or expected consents from third parties. We cannot assure you that we will be able to integrate successfully the operations of any acquired business into our existing business. In particular, we may experience challenges relating to the retention of physicians and other healthcare professionals of our acquired businesses or the integration of such healthcare professionals. Furthermore, acquisitions into new geographic markets and services may require us to comply with new and unfamiliar legal and regulatory requirements, which could impose substantial obligations on us and our management, cause us to expend additional time and resources, and increase our exposure to penalties or fines for non-compliance with such requirements. The acquisition and integration of another business could divert management attention from other business activities. This diversion, together with other difficulties we may incur in integrating an acquired business and managing the cost of acquisitions could adversely affect our business, financial condition and results of operations.

26

Item 1A.   Risk Factors - (continued) Table of Contents

Our substantial indebtedness could adversely affect our ability to raise additional capital to fund our growth strategy, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent of any variable rate debt, and prevent us from meeting our obligations under our indebtedness. As of December 31, 2015, our total indebtedness was approximately $2.4 billion, of which approximately $1.0 billion is exposed to variable rates and an additional $325.0 million available for borrowings under our senior secured revolving credit facility which is also subject to a variable rate. Our substantial indebtedness could have adverse consequences, including:

• increasing our vulnerability to adverse economic, industry, or competitive developments;

• requiring a substantial portion of our cash flows from operations to be dedicated to the payment of principal and interest on our indebtedness, therefore reducing our ability to use our cash flows to fund acquisitions of additional surgery centers and physician practice groups, capital expenditures, and future business opportunities;

• exposing us to the risk of increased interest rates to the extent of any future borrowings, including borrowings under our senior secured credit facility, at variable rates of interest;

• making it more difficult for us to satisfy our obligations with respect to our indebtedness, including our senior secured credit facility, our 2020 senior notes and our 2022 senior notes, and any failure to comply with the obligations of any of our debt instruments, including restrictive covenants and borrowing conditions, could result in an event of default under our senior secured credit facility, the indentures governing the notes and the agreements governing other indebtedness;

• limiting our ability to obtain additional financing for working capital, capital expenditures, debt service requirements, acquisitions, and general corporate or other purposes; and

• limiting our flexibility in planning for, or reacting to, changes in our business or market conditions and placing us at a competitive disadvantage compared to our competitors who are less leveraged and who, therefore, may be able to take advantage of opportunities that our leverage may prevent us from exploiting.

Despite our indebtedness level, we and our subsidiaries will still be able to incur significant additional amounts of debt, including secured debt, which could further exacerbate the risks associated with our substantial indebtedness. We and our subsidiaries may be able to incur substantial additional indebtedness in the future. Although our senior secured credit facility and the indentures governing our senior notes contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of significant qualifications and exceptions, and under certain circumstances, the amount of indebtedness that could be incurred in compliance with these restrictions could be substantial. If new debt is added to our and our subsidiaries’ existing debt levels, the related risks that we now face would increase. In addition, our senior secured credit facility and the indentures governing our senior notes will not prevent us from incurring obligations that do not constitute prohibited indebtedness thereunder.

Servicing our debt requires a significant amount of cash. Our ability to generate sufficient cash depends on numerous factors beyond our control, and we may be unable to generate sufficient cash flow to service our debt obligations. Our ability to make scheduled payments on or to refinance our debt obligations depends on our financial condition and operating performance, which is subject to prevailing economic and competitive conditions and to certain financial, business, and other factors beyond our control. We may not be able to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay investments and capital expenditures, or to sell assets, seek additional capital, or restructure or refinance our indebtedness. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. The terms of existing or future debt instruments, including the senior secured credit facility, the indentures governing our senior notes, may restrict us from adopting some of these alternatives. In addition, any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in a reduction of our credit rating, which could harm our ability to incur additional indebtedness. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations.

Restrictive covenants in our senior secured credit facility and the indentures governing our senior notes may restrict our ability to pursue our business strategies, and failure to comply with any of these restrictions could result in acceleration of our debt. The operating and financial restrictions and covenants in our senior secured credit facility and the indentures governing our senior notes may adversely affect our ability to finance future operations or capital needs or to engage in other business activities. Such agreements limit our ability, among other things, to:

• incur additional indebtedness or issue certain preferred equity;

• pay dividends on, repurchase or make distributions in respect of our common stock, prepay, redeem, or repurchase certain debt or make other restricted payments;

27

Item 1A.   Risk Factors - (continued) Table of Contents

• make certain investments;

• create certain liens;

• enter into agreements restricting our subsidiaries’ ability to pay dividends, loan money, or transfer assets to us;

• consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;

• enter into certain transactions with our affiliates; and

• designate our subsidiaries as unrestricted subsidiaries.

A breach of any of these covenants could result in a default under one or more of these agreements, including as a result of cross default provisions and, in the case of the senior secured credit facility, permit the lenders to cease making loans to us. Upon the occurrence of an event of default under the senior secured credit facility or the indentures governing our senior notes, the creditors thereunder could elect to declare all amounts outstanding to be immediately due and payable and, in the case of our revolving credit facility, which is a part of the senior secured credit facility, terminate all commitments to extend further credit. Such action by our creditors could cause cross defaults under the indentures governing our senior notes.

If our operating performance declines, we may be required to obtain waivers from the lenders under the senior secured credit facility, from the holders of our senior notes or from the holders of other obligations, to avoid defaults thereunder. If we are not able to obtain such waivers, our creditors could exercise their rights upon default, and we could be forced into bankruptcy or liquidation.

Furthermore, if we were unable to repay the amounts due and payable under our secured obligations, the creditors thereunder could proceed against the collateral granted to them to secure our obligations thereunder. We have pledged a significant portion of our assets, including our ownership interests in certain of our directly owned subsidiaries, as collateral under our senior secured credit facility. If the creditors under our senior secured credit facility accelerate the repayment of our debt obligations, we cannot assure you that we will have sufficient assets to repay our senior secured credit facility, our senior notes and our other indebtedness, or will have the ability to borrow sufficient funds to refinance such indebtedness. Even if we were able to obtain new financing, it may not be on commercially reasonable terms, or terms that are acceptable to us.

We are a holding company and rely on our operating subsidiaries to provide us with funds necessary to meet our financial obligations. We are a holding company, and our principal assets are the ownership interests in our subsidiaries that own substantially all of our operating assets. As a result, we are dependent on dividends and other payments from our subsidiaries to generate the funds necessary to meet our financial obligations. Our subsidiaries are legally distinct from us and may be prohibited or restricted from paying dividends or otherwise making funds available to us under certain conditions. If we are unable to obtain funds from our subsidiaries, we may be unable to meet our financial obligations.

If we fail to comply with applicable laws and regulations, we could suffer penalties or be required to make significant changes to our operations. The health care industry is heavily regulated and we are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to among other things:

• billing and coding for services, including documentation of care, appropriate treatment of overpayments and credit balances, and the submission of false statements or claims;

• relationships and arrangements with physicians and other referral sources and referral recipients, including self-referral restrictions, prohibitions on kickbacks and other non-permitted forms of remuneration and prohibitions on the payment of inducements to Medicare and Medicaid beneficiaries in order to influence their selection of a provider;

• licensure, certification, enrollment in government programs and CON approval, including requirements affecting the operation, establishment and addition of services and facilities;

• the necessity, appropriateness, and adequacy of medical care, equipment, and personnel and conditions of coverage and payment for services;

• quality of care and data reporting;

• restrictions on ownership of surgery centers;

• operating policies and procedures;

• qualifications, training and supervision of medical and support personnel;

• fee-splitting and the corporate practice of medicine;

• screening, stabilization and transfer of individuals who have emergency medical conditions;

• workplace health and safety;

• debt collection practices;

• anti-competitive conduct;

• confidentiality, maintenance, data breach, identity theft and security issues associated with health-related and other personal information and medical records; and

• environmental protection.

28

Item 1A.   Risk Factors - (continued) Table of Contents

Because of the breadth of these laws and the narrowness of available exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws. For example, failure to bill properly for services or return overpayments and violations of other statutes, such as the federal Anti-Kickback Statute or the federal Stark Law, may be the basis for actions under the FCA or similar state laws. Criminal penalties may be imposed for healthcare fraud offenses involving not just federal healthcare programs but also private health benefit programs.

Enforcement actions under some statutes, including the FCA, may be brought by the government as well as by a private person under a qui tam or “whistleblower” lawsuit. Federal enforcement officials have numerous enforcement mechanisms to combat fraud and abuse, including bringing civil actions under the Civil Monetary Penalty Law, which has a lower burden of proof than criminal statutes. 

If we fail to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including fines, damages, recoupment of overpayments, loss of licenses needed to operate, and loss of enrollment and approvals necessary to participate in Medicare, Medicaid and other government sponsored and third-party healthcare programs. Federal enforcement officials have the ability to exclude from Medicare and Medicaid any investors, officers and managing employees associated with business entities that have committed healthcare fraud. 

Many of these laws and regulations have not been fully interpreted by regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or require us to make changes in our operations, facilities, equipment, personnel, services, capital expenditure programs or operating expenses to comply with the evolving rules. Any enforcement action against us, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

The laws and regulations governing the provision of healthcare services are frequently subject to change and may change significantly in the future. We cannot assure you that current or future legislative initiatives, government regulation or judicial or regulatory interpretations thereof will not have a material adverse effect on us. We cannot assure you that a review of our business by judicial, regulatory or accreditation authorities will not subject us to fines or penalties, require us to expend significant amounts, reduce the demand for our services or otherwise adversely affect our operations.

Our relationships with referral sources and recipients, including healthcare providers, facilities and patients, are subject to the federal Anti-Kickback Statute and similar state laws.The federal Anti-Kickback Statute prohibits healthcare providers and others from knowingly and willfully soliciting, receiving, offering or paying, directly or indirectly, any remuneration in return for, or to induce, referrals or orders for services or items covered by a federal healthcare program. In addition, many of the states in which we operate also have adopted laws, similar to the federal Anti-Kickback Statute, that prohibit payments to physicians in exchange for referrals, some of which apply regardless of the source of payment for care. The federal Anti-Kickback Statute and similar state laws are broad in scope and many of their provisions have not been uniformly or definitively interpreted by case law or regulations.  Courts have found a violation of the federal Anti-Kickback Statute if just one purpose of the remuneration is to generate referrals, even if there are other lawful purposes. Furthermore, the Health Reform Law provides that knowledge of the law or intent to violate the law is not required to establish a violation of the federal Anti-Kickback Statute. Congress and HHS have established narrow safe harbor provisions that outline practices deemed protected from prosecution under the federal Anti-Kickback Statute. While we endeavor to comply with applicable safe harbors, certain of our current arrangements, including the ownership structures of our surgery centers, do not satisfy all of the requirements of a safe harbor. Failure to qualify for a safe harbor does not mean the arrangement necessarily violates the federal Anti-Kickback Statute, but may subject the arrangement to greater scrutiny. Violations of the federal Anti-Kickback Statute and similar state laws may result in substantial civil or criminal penalties, exclusion from participation in the Medicare and Medicaid programs and loss of licensure, which could have a material adverse effect on our business.

If regulations or regulatory interpretations change, we may be obligated to buy out interests of physicians who are minority owners of our surgery centers. A majority of our limited partnership and operating agreements provide that if certain regulations or regulatory interpretations change, we will be obligated to purchase some or all of the noncontrolling interests of our physician partners. The regulatory changes that could trigger such obligations include changes that:

• make the referral of Medicare and other patients to our surgery centers by physicians affiliated with us illegal;

• create the substantial likelihood that cash distributions from the limited partnerships or limited liability companies to the affiliated physicians will be illegal; or

• cause the ownership by the physicians of interests in the limited partnerships or limited liability companies to be illegal.

The cost of repurchasing these noncontrolling interests would be substantial if a triggering event were to result in simultaneous

29

Item 1A.   Risk Factors - (continued) Table of Contents

purchase obligations at a substantial number or at all of our surgery centers. The purchase price to be paid in such event would be determined as specified in each of the limited partnership and operating agreements, which also provide for the payment terms, generally over four years. There can be no assurance, however, that our existing capital resources would be sufficient for us to meet the obligations, if they arise, to purchase these noncontrolling interests held by physicians. The determination of whether a triggering event has occurred generally would be made by the concurrence of our legal counsel and counsel for the physician partners or, in the absence of such concurrence, by a nationally recognized law firm having an expertise in healthcare law jointly selected by both parties. Such determinations therefore would not be within our control. The triggering of these obligations could have a material adverse effect on our financial condition and results of operations. We believe physician ownership of ASCs as structured within our limited partnerships and limited liability companies is in compliance with applicable law, but from time to time, the issue of physician ownership in ASCs is considered by some state legislatures and federal and state regulatory agencies. We can give no assurances that legislative or regulatory changes will not occur that would have an adverse impact on us.

If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could result in a material adverse effect on our reported financial results. We have acquired entities that do not have any publicly traded debt or equity and therefore are not required to conform to the rules and regulations of the SEC, especially as it relates to internal control structure. As such, upon acquisition by us, such entities may not have had in place all the necessary controls as required by the Public Company Accounting Oversight Board. The integration of acquired entities into our internal control over financial reporting has required and will continue to require significant time and resources from our management and other personnel and will increase our compliance costs. We are required to include our assessment of the effectiveness of the internal controls over financial reporting of entities we acquire in our overall assessment. We plan to complete the evaluation and integration of internal controls over financial reporting and report our assessment within the required time frame. Failure to maintain an effective internal control environment could have a material adverse effect on our ability to accurately report our financial results, the market’s perception of our business and our stock price.

We depend on numerous complex information systems and processes, and any failure to successfully maintain them or implement new systems and processes could materially harm our business. We depend on complex, integrated information systems and procedures for operational, billing and financial information. We may experience unanticipated delays, complications and expenses in implementing, upgrading, integrating and operating our systems, which involve a variety of different processes. Any interruptions in operations during periods of implementation or upgrade would adversely affect our ability to properly allocate resources and process billing information in a timely manner, which could result in delayed cash flow. Additionally, unanticipated complications or disruptions in our systems or processes could delay or adversely affect our ability to report our required financial information in a timely and accurate manner, or we may not have the necessary resources to further enhance our information systems or implement new systems where necessary to handle our volume and changing needs. We also use the development and implementation of sophisticated and specialized technology to improve our profitability. The failure to successfully develop, implement and maintain operational, financial and billing information systems could have an adverse effect on our ability to obtain new business, retain existing business and maintain or increase our profit margins.

The transition to the ICD-10 coding system could adversely affect our operations. Health plans and providers, including our surgery centers and professionals, transitioned to the new ICD-10 coding system as of October 1, 2015. This coding system greatly expands the number and detail of billing codes used for third-party claims. Transition to the new ICD-10 system required significant investment in coding technology and software as well as the training of staff involved in the coding and billing process. In addition to these upfront costs of transitioning to ICD-10, it is possible that we could experience disruption or delays in payment due to technical or coding errors, processing and claims submission backlogs or other implementation issues involving our systems or the systems and implementation efforts of health plans and their business partners. Further, the extent to which the transition to the more detailed ICD-10 coding system could result in decreased reimbursement, because the use of ICD-10 codes results in conditions being reclassified to payment groupings with lower levels of reimbursement than assigned under the previous system, is unknown at this time.

If we are unable to effectively manage information security risks, or the security measures protecting our information technology systems are breached, we could suffer a loss of confidential data, which may subject us to liability, or a disruption of our operations. We rely on our information systems to securely transmit, store, and manage confidential data. A failure in or breach of our operational or information security systems as a result of cyber-attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information, damage our reputation, increase our costs or lead to liability under privacy and security laws, litigation, governmental inquiries, fines and financial losses. Information security risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health information, business and financial information. Outside parties may also attempt to fraudulently induce employees to take actions, such as releasing confidential or sensitive information or making fraudulent payments, through electronic spamming, phishing or other tactics. As a result, we must continue to focus on cyber security and the continued

30

Item 1A.   Risk Factors - (continued) Table of Contents

development and enhancement of the controls and processes designed to protect our systems, computers, software, data and networks from attack, damage or unauthorized access, and we must continue to focus on any security risks in connection with the transition and integration of information systems as we pursue our growth and acquisition strategy. Although we believe that we have appropriate information security procedures and other safeguards in place, there can be no assurance that we will not be subject to a cyber-attack. We continue to prioritize the security of our information technology systems and the continued development and enhancement of our controls, processes and practices designed to protect our systems, computers, software, data and networks from cyber-attack, damage or unauthorized access. As cyber threats continue to evolve due to the proliferation of new technologies and the increased activities by perpetrators of such attacks, we may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities or breaches.

Disruptions in our disaster recovery systems or management continuity planning could limit our ability to operate our business effectively. Our information technology systems facilitate our ability to conduct our business. While we have disaster recovery systems and business continuity plans in place, any disruptions in our disaster recovery systems or the failure of these systems to operate as expected could, depending on the magnitude of the problem, adversely affect our operating results by limiting our capacity to effectively monitor and control our operations. Despite our implementation of a variety of security measures, our technology systems could be subject to physical or electronic break-ins, and similar disruptions from unauthorized tampering or weather related disruptions where our headquarters is located. In addition, in the event that a significant number of our management personnel were unavailable in the event of a disaster, our ability to effectively conduct business could be adversely affected.

Shortages of products, equipment and medical supplies and quality control issues with such products, equipment and medical supplies could disrupt our operations and adversely affect our operations and profitability. Our operations depend significantly upon our and our clients’ ability to obtain sufficient products, drugs, equipment and medical supplies on a timely basis. If we or our clients are unable to obtain such necessary products, or if we or our clients fail to properly manage existing inventory levels, we may be unable to perform certain surgeries or provide certain medical services, which could adversely affect our operations. In addition, as a result of shortages, we could suffer, among other things, operational disruptions, disruptions in cash flows, increased costs and reductions in profitability. At times, supply shortages have occurred in our industry, and such shortages may be expected to recur from time to time.

Medical supplies and services may be subject to supplier product quality control incidents and recalls. In addition to contributing to materials shortages, product quality can affect patient care and safety. National suppliers in our industry have experienced material quality control incidents in the past, which may occur again in the future for reasons beyond our control, and such incidents can negatively impact case volume, product costs and our reputation. In addition, we may have to incur costs to resolve quality control incidents related to medical supplies and services regardless of whether they were caused by us. Our inability to obtain the necessary amount and quality of products, equipment and medical supplies due to a quality control incident or recall could have a material adverse effect on our business, prospects, results of operations and financial condition.

We may become involved in litigation which could harm the value of our business. From time-to-time we are involved in lawsuits, claims, audits and investigations, including those arising out of services provided, personal injury claims, professional liability claims, billing and marketing practices, employment disputes and contractual claims. We may become subject to future lawsuits, claims, audits and investigations that could result in substantial costs and divert our attention and resources and adversely affect our business condition. In addition, since our current growth strategy includes acquisitions, among other things, we may become exposed to legal claims for the activities of an acquired business prior to the acquisition. These lawsuits, claims, audits or investigations, regardless of their merit or outcome, may also adversely affect our reputation and ability to expand our business.

In addition, from time to time we have received, and expect to continue to receive, correspondence from former employees terminated by us who threaten to bring claims against us alleging that we have violated one or more labor and employment regulations. In certain instances former employees have brought claims against us and we expect that we will encounter similar actions against us in the future. An adverse outcome in any such litigation could require us to pay contractual damages, compensatory damages, punitive damages, attorneys’ fees and costs.

We may be subject to liability claims for damages and other expenses not covered by insurance that could reduce our earnings and cash flows. Our operations and how we manage the Company may subject us, as well as our officers and directors to whom we owe certain defense and indemnity obligations, to litigation and liability for damages. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including claims related to adverse patient events, contractual disputes, professional and general liability, and directors’ and officers’ duties. We currently maintain insurance coverage for those risks we deem are appropriate. However, a successful claim, including a professional liability, malpractice or negligence claim which is in excess of any applicable insurance coverage, could have a material adverse effect on our earnings and cash flows.

31

Item 1A.   Risk Factors - (continued) Table of Contents

In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our earnings and cash flows could be materially and adversely affected by any of the following:

• the collapse or insolvency of our insurance carriers;

• further increases in premiums and deductibles;

• increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; or

• an inability to obtain one or more types of insurance on acceptable terms, if at all.

If antitrust enforcement authorities conclude that our market share in any particular market is too concentrated, that our or our clients’ commercial payor contract negotiating practices are illegal, or that we otherwise violate antitrust laws, we could be subject to enforcement actions that could have a material adverse effect on our business, prospects, results of operations and financial condition. The federal government and most states have enacted antitrust laws that prohibit certain types of conduct deemed to be anti-competitive. These laws prohibit price fixing, concerted refusal to deal, market monopolization, price discrimination, tying arrangements, acquisitions of competitors and other practices that have, or may have, an adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. Antitrust enforcement in the healthcare industry is currently a priority of the Federal Trade Commission. We believe we are in compliance in all material respects with federal and state antitrust laws, but courts or regulatory authorities may reach a determination in the future that could have a material adverse effect on our business, prospects, results of operations and financial condition.

We may write-off intangible assets, such as goodwill. As a result of purchase accounting for our various acquisition transactions, our balance sheet at December 31, 2015 contained intangible assets designated as either goodwill or intangibles totaling approximately $4.0 billion in goodwill and approximately $1.6 billion in intangibles. Additional acquisitions that result in the recognition of additional intangible assets would cause an increase in these intangible assets. On an ongoing basis, we evaluate whether facts and circumstances indicate any impairment of the value of intangible assets. As circumstances change, we cannot assure you that the value of these intangible assets will be realized by us. If we determine that a significant impairment has occurred, we will be required to write-off the impaired portion of intangible assets, which could have a material adverse effect on our results of operations in the period in which the write-off occurs.

Risks Related to Our Ambulatory Services Business

If payments from third-party payors, including government healthcare programs, decrease or do not increase as our costs increase, the operating margins and profitability of our surgery centers would be adversely affected. Our surgery centers depend on private and governmental third-party sources of payment for the services provided to patients. We derived approximately 26% of our ambulatory services segment revenues in 2015 from U.S. government healthcare programs, primarily Medicare. The amount our surgery centers receive for their services may be adversely affected by market and cost factors as well as other factors over which we have no control, including future changes to the Medicare and Medicaid payment systems and the cost containment and utilization decisions of third-party payors. Although the Health Reform Law expands coverage of preventive care and the number of individuals with healthcare coverage, the law also provides for reductions to Medicare and Medicaid program spending. It is impossible to predict how the various components of the Health Reform Law, some of which are not currently in effect, will affect our ambulatory services segment and the businesses of our physician partners. Several states are also considering healthcare reform measures. This focus on healthcare reform at the federal and state levels may increase the likelihood of significant changes affecting government healthcare programs in the future.

Managed care plans have increased their market share in many areas in which we operate surgery centers, which has resulted in substantial competition among healthcare providers for inclusion in managed care contracting. The trend toward increased consolidation among managed care plans may further limit the ability of healthcare providers to negotiate favorable payment rates. In addition, managed care payors may lower reimbursement rates in response to increased obligations on payors imposed by the Health Reform Law or future reductions in Medicare reimbursement rates. Further, payors may utilize plan structures, such as narrow networks or tiered networks that limit patient provider choices or impose significantly higher cost sharing obligations when care is obtained from providers in a disfavored tier. We can give you no assurances that future changes to reimbursement rates by government healthcare programs, cost containment measures by private third-party payors, including fixed fee schedules and capitated payment arrangements, or other factors affecting payments for healthcare services will not adversely affect our future ambulatory services segment revenues, operating margins or profitability.

Our ambulatory services business may be adversely affected by changes to the medical practices of our physician partners or if we fail to maintain good relationships with the physician partners who use our surgery centers.Our ambulatory services business depends on, among other things, the efforts and success of the physician partners who perform procedures at our surgery centers and

32

Item 1A.   Risk Factors - (continued) Table of Contents

the strength of our relationship with these physicians. The medical practices of our physician partners may be negatively impacted by general economic conditions, changes in payment rates or systems by payors (including Medicare), actions taken by referring physicians, other providers and payors, and other factors impacting their practices. Adverse economic conditions, including high unemployment rates, could cause patients of our physician partners and our ASCs to cancel or delay procedures. Our physician partners that use our ASCs are not required to use our surgery centers and may perform procedures at other facilities. From time to time, we have had and may have future disputes with physicians who use or own interests in our surgery centers. The revenues and profitability of our ambulatory services segment may be adversely affected if a key physician or group of physicians stops using or reduces their use of our surgery centers as a result of changes in their physician practice, changes in payment rates or systems, or a disagreement with us. In addition, if the physicians who use our surgery centers do not provide quality medical care or follow required professional guidelines at our facilities or there is damage to the reputation of a physician or group of physicians who use our surgery centers, our business and reputation could be damaged.

If we are unable to increase procedure volume at our existing surgery centers, the operating margins and profitability of our ambulatory services segment could be adversely affected. Our growth strategy for our ambulatory services segment includes increasing our revenues and earnings primarily by increasing the number of procedures performed at our surgery centers. We seek to increase procedure volume at our surgery centers by increasing the number of physicians performing procedures at our centers, obtaining new or more favorable managed care contracts, improving patient flow at our centers, increasing the capacity at our centers, promoting screening programs and increasing patient and physician awareness of our centers. Procedure volume at our centers may be adversely impacted by economic conditions, high unemployment rates, natural disasters and physicians who no longer utilize our centers and other factors that may cause patients to delay or cancel procedures. We can give you no assurances that we will be successful at increasing or maintaining procedure volumes, revenues and operating margins at our centers.

If we are unable to effectively compete for physician partners, managed care contracts, patients and strategic relationships, our ambulatory services segment would be adversely affected. We compete with other healthcare providers, primarily hospitals and other surgery centers, in recruiting physicians to utilize our surgery centers, for patients and in contracting with managed care payors.  In some of the markets in which we operate, there are shortages of physicians in the targeted specialties of our surgery centers.  In several of the markets in which we operate, hospitals are recruiting physicians or groups of physicians to become employed by the hospitals, including primary care physicians and physicians in the targeted specialties of our surgery centers, and restricting those physicians’ ability to refer patients to physicians and facilities not affiliated with the hospital. In addition, physicians, hospitals, payors and other providers may form integrated delivery systems or utilize plan structures that restrict the physicians who may treat certain patients or the facilities at which patients may be treated. These restrictions may impact our surgery centers and the medical practices of our physician partners. Some of our competitors may have greater resources than we do, including financial, marketing, staff and capital resources, have or may develop new technologies or services that are attractive to physicians or patients, or have established relationships with physicians and payors.

We compete with public and private companies in the development and acquisition of ASCs. Further, many physician groups develop ASCs without a corporate partner. We can give you no assurances that we will be able to compete effectively in any of these areas or that our results of operations will not be adversely impacted.

Our surgery centers may be negatively impacted by weather and other factors beyond our control.The results of operations of our ambulatory services segment may be adversely impacted by adverse weather conditions, including hurricanes and widespread winter storms, or other factors beyond our control that cause disruption of patient scheduling, displacement of our patients, employees and physician partners, or force certain of our surgery centers to close temporarily. In certain geographic areas, we have a large concentration of surgery centers that may be simultaneously affected by adverse weather conditions or events. The future financial and operating results of our surgery centers may be adversely affected by weather and other factors that disrupt the operation of our surgery centers.

We are liable for the debts and other obligations of the limited partnerships that own and operate certain of our surgery centers.   In the limited partnerships in which one of our affiliates is the general partner, our affiliate is liable for 100% of the debts and other obligations of the limited partnership; however, the physician partners are generally required to guarantee their pro rata share of any indebtedness or lease agreements to which the limited partnership is a party in proportion to their ownership interest in the limited partnership. We also have primary liability for the bank debt that may be incurred for the benefit of the limited liability companies, and in turn, lend funds to these limited liability companies, although the physician members also guarantee this debt. There can be no assurance that a third-party lender or lessor would seek performance of the guarantees rather than seek repayment from us of any obligation of the limited partnership or limited liability company if there is a default, or that the physician partners or members would have sufficient assets to satisfy their guarantee obligations.

33

Item 1A.   Risk Factors - (continued) Table of Contents

We have a legal responsibility to the minority owners of the entities through which we own our surgery centers, which may conflict with our interests and prevent us from acting solely in our own best interests. As the owner of majority interests in the limited partnerships and limited liability companies that own our surgery centers, we owe a fiduciary duty to the noncontrolling interest holders in these entities and may encounter conflicts between our interests and that of the minority holders. In these cases, our representatives on the governing board of each partnership or joint venture are obligated to exercise reasonable, good faith judgment to resolve the conflicts and may not be free to act solely in our own best interests. In our role as manager of the limited partnership or limited liability company, we generally exercise our discretion in managing the business of the surgery center. Disputes may arise between us and the physician partners regarding a particular business decision or the interpretation of the provisions of the limited partnership agreement or limited liability company operating agreement. The agreements provide for arbitration as a dispute resolution process in some circumstances. We cannot assure you that any dispute will be resolved or that any dispute resolution will be on terms satisfactory to us.

Risks Related to Our Physician Services Business

Our physician services segment bears the risk of changes in patient volume and patient mix. Our physician services segment bears the risk of changes in patient volume and the mix of patients for whom we provide services: uninsured and underinsured patients, patients covered by government healthcare programs and beneficiaries of commercial and employer insurance programs. A substantial decrease in patient volume, an increase in the number of uninsured or underinsured patients or an increase in the number of patients covered by government healthcare programs, as opposed to commercial plans that have higher reimbursement levels, could reduce the profitability of our physician services segment and adversely impact future growth.

Our physician services segment has several significant client relationships that result in concentration of revenue. Although we negotiate and enter into separate contracts with facilities to which we deliver physician services, many facilities are affiliated with one another or owned and operated by the same entity. As a result, although no single contract represents more than 10% of our physician services segment revenue, we have several significant client relationships with groups of affiliated facilities that result in concentration of revenue. The loss or reduction of business from any of our significant client relationships could materially adversely affect the revenues and results of operations of our physician services segment.

Our physician services segment revenue would be adversely affected if our contracts are canceled or not renewed or if we are not able to enter into additional contracts under terms that are acceptable to us. Substantially all of our physician services are provided under contracts with facilities, many of which have a limited duration. Many of our contracts, including contracts with several of our significant client relationships, are terminable upon notice of as little as 30 days. Furthermore, certain of our physician services contracts expire during each fiscal year. Any of those contracts may not be renewed or, if renewed, may contain terms that are not as favorable to us as our current contracts. We cannot assure you that we will be successful in retaining our existing physician services contracts or that any loss of contracts would not have a material adverse effect on the business, financial condition and results of operations of our physician services segment.

Our physician services segment is subject to potential decreases in our reimbursement rates, revenue and profit margin. We provide physician services through fee for service payor arrangements. Under these arrangements, we collect fees directly or through our affiliated physicians or through the entities where the physician services are provided. These arrangements accounted for approximately 90% of our physician services net revenue for the fiscal year ended December 31, 2015. Under these arrangements, we assume the risks related to changes in third party reimbursement rates.

We are dependent on the reimbursements by third-party payors, such as managed care payors and governmental payors, for the physician services we provide. There are significant private and public sector pressures to restrain healthcare costs and to restrict reimbursement rates for medical services and we believe that such pressures will continue. Both private insurers and government-sponsored programs have taken and may continue to take steps to control costs, eligibility for and use and delivery of healthcare services. During the past several years, major payors of healthcare, such as federal and state governments, insurance companies and employers, have undertaken initiatives to monitor healthcare costs, increase the cost sharing of individual patients and revise payment methodologies. Federal and state governments have also undertaken legislative and regulatory efforts to contain or reduce reimbursement rates for medical services for insurers and patients. As part of their efforts to contain healthcare costs, purchasers increasingly are demanding discounted or global fee structures or the assumption by healthcare providers of all or a portion of the financial risk through shared risk, capitation and care management arrangements, often in exchange for exclusive or preferred participation in their benefit plans. We expect efforts to impose greater discounts and more stringent cost controls by government and other payors to continue, thereby reducing the payments we receive for our physician services. Further, the ability of commercial payors to control healthcare costs may be enhanced by the increasing consolidation of insurance and managed care companies, which may reduce our ability to negotiate favorable contracts with such payors. We cannot assure you that we will be able to offset reduced operating margins through cost reductions, increased volume, the introduction of additional procedures or otherwise, and to the extent

34

Item 1A.   Risk Factors - (continued) Table of Contents

we are not able to do so, such reductions in reimbursements could materially adversely affect our revenues, financial condition and results of operations.

Failure to timely or accurately bill for services could have a negative impact on our physician services segment net revenue, bad debt expense and cash flow. Billing for physician-related services is complex. The current practice of providing medical services in advance of payment or, in many cases, prior to assessment of ability to pay for such services, may have significant negative impact on our physician services segment net revenue, bad debt expense and cash flow. We bill numerous and varied payors, such as self-pay patients, managed care payors and Medicare and Medicaid. These different payors typically have different billing requirements that must be satisfied prior to receiving payment for services rendered. Reimbursement is typically conditioned on our documenting medical necessity and correctly applying diagnosis codes. Incorrect or incomplete documentation and billing information could result in non-payment for services rendered.

Additional factors that could complicate our physician services segment billing include:

• disputes between payors as to which party is responsible for payment;

• failure of information systems and processes to submit and collect claims in a timely manner;

• variation in coverage for similar services among various payors;

• the difficulty of adherence to specific compliance requirements, diagnosis coding and other procedures mandated by various payors; and

• failure to obtain proper physician credentialing and documentation in order to bill various payors.

To the extent that the complexity associated with billing for our physician services segment causes delays in our cash collections, we may experience increased carrying costs associated with the aging of our accounts receivable as well as increased potential for bad debt expense.

Laws and regulations that regulate payments for medical services made by government healthcare programs could cause our physician services segment revenues to decrease. We derive a significant portion of our physician services segment net fee-for-service revenue from payments made to us by government healthcare programs such as Medicare and Medicaid. During the year ended December 31, 2015, Medicare and Medicaid represented approximately 13% and 5%, respectively, of our physician services segment net revenue. Further, the reimbursement rates of the Medicare program are increasingly used by certain private payors as benchmarks to establish their reimbursement rates and any adjustment in Medicare reimbursement rates may impact our reimbursement rates from such private payors as well. Government healthcare programs are subject to, among other things, statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating payments or reimbursements, all of which could materially increase or decrease payments we receive from these government programs for our physician services in the future. Any change in reimbursement policies, practices, interpretations, regulations or legislation that places limitations on reimbursement amounts or practices could significantly affect hospitals, and consequently affect our operations unless we are able to renegotiate satisfactory contractual arrangements with our hospital clients. Reductions in amounts paid by government programs for physician services or changes in methods or regulations governing payment could cause our physician services segment revenues and profits to decline.

Physician services are reimbursed under the MPFS, which is updated annually. The CHIP Reauthorization Act of 2015 (MACRA) changed the method for updating the MPFS, effectively eliminating a scheduled payment reduction. The law provides for a 0.5% update to the MPFS for each calendar year through 2019.

Other changes to the Medicare program intended to implement Medicare’s new “pay for performance” initiatives may require us to make investments to receive maximum Medicare reimbursement for our physician services segment. These initiatives include the Medicare Physician Quality Reporting System which provides additional Medicare compensation to physicians who implement and report certain quality measures. MACRA requires the establishment of the Merit-Based Incentive Payment System beginning in 2019, under which physicians will receive payment incentives or reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of electronic health records.

In addition, we cannot assure you that federal, state and local governments will not impose reductions in fee schedules or mandate global fees or rate regulations applicable to our physician services segment in the future. Many states are continuing to collect less revenue than they did in prior years, and as a result may face ongoing budget shortfalls and underfunded pension and other liabilities. Deteriorating financial conditions in the states where we operate could lead to reduced or delayed funding for Medicaid programs, and we may experience reduced or delayed reimbursement for physician services provided. Any such reductions could have a material adverse effect on the business, financial condition or results of operations.

35

Item 1A.   Risk Factors - (continued) Table of Contents

If we are unable to timely enroll our physician services segment providers in the Medicare and Medicaid programs, the collections and revenue of our physician services segment will be harmed. We are required to enroll our physician services segment providers who are not otherwise already enrolled with Medicare and Medicaid in order to bill these programs for the physician services they provide. With respect to Medicare, providers can retrospectively bill Medicare for services provided 30 days prior to the effective date of the enrollment. In addition, the enrollment rules provide that the effective date of the enrollment will be the later of the date on which the enrollment application was filed and approved by the Medicare contractor, or the date on which the provider began providing services. If we are unable to properly enroll physicians and other applicable healthcare professionals within the 30 days after the provider begins providing services, we will be precluded from billing Medicare for any services which were provided to a Medicare beneficiary more than 30 days prior to the effective date of the enrollment. With respect to Medicaid, new enrollment rules and whether a state will allow providers to retrospectively bill Medicaid for services provided prior to submitting an enrollment application varies by state. Failure to timely enroll providers could reduce our physician services segment net revenue and have a material adverse effect on the business, financial condition or results of operations of our physician services segment.

In addition, the Health Reform Law added additional enrollment requirements for Medicare and Medicaid. Those statutory requirements have been further enhanced through implementing regulations and increased enforcement scrutiny. Every enrolled provider must revalidate its enrollment at regular intervals and must update the Medicare contractors and many state Medicaid programs with significant changes on a timely basis. If we fail to provide sufficient documentation as required to maintain our enrollment, Medicare and Medicaid could deny continued future enrollment or revoke our enrollment and billing privileges.

We have partnerships with certain healthcare providers, including risk-based partnerships under the Health Reform Law. If this strategy is not successful, our physician services segment business could be adversely affected. We have strategic business partnerships with hospital systems to take advantage of commercial opportunities in our facility-based physician services business. However, joint venture and strategic partnership models may expose us to commercial risks that may be different from our other business models, including that the success of the joint venture or partnership may be only partially under our operational and legal

control and the opportunity cost of not pursuing the specific venture independently or with other partners. In addition, under certain joint venture or strategic partnership arrangements, the hospital system partner has the option to acquire our stake in the venture on a predetermined financial formula, which, if exercised, could lead to the loss of our associated revenue and profits which might not be offset fully by the immediate proceeds of the sale of our stake. Additionally, under certain joint venture partnership arrangements, the hospital system partner has the right of first refusal should we desire to acquire an unrelated provider who derives 40% or more of their revenues from services provided to that hospital system or its affiliates. Furthermore, joint ventures may raise fraud and abuse issues. For example, the OIG has taken the position that certain contractual joint ventures between a party which makes referrals and a party which receives referrals for a specific type of service may violate the Anti-Kickback Statute if one purpose of the arrangement is to encourage referrals.

In addition, we may take advantage of various opportunities afforded by the Health Reform Law to enter into risk-based partnerships designed to encourage healthcare providers to assume financial accountability for outcomes and work together to better coordinate care for patients, both in the hospital and after discharge. Advancing such initiatives can be time consuming and expensive, and there can be no assurance that our efforts in these areas would ultimately be successful. In addition, if we succeed in our efforts to enter into these risk-based partnerships but fail to deliver quality care at a cost consistent with our expectations, we may be subject to significant financial penalties depending on the program, and an unsuccessful implementation of such initiatives could materially and adversely affect the business, financial condition or results of operations of our physician services segment.

The high level of competition in our segments of the market for medical services could adversely affect our contract and revenue base for our physician services segment. The market for providing outsourced physician staffing and related management services to hospitals and clinics is highly competitive. Such competition could adversely affect our ability to obtain new facility contracts, retain existing contracts and increase or maintain profit margins. We compete with national and regional enterprises, some of which may have greater financial and other resources available, greater access to physicians or greater access to potential clients. We also compete against local physician groups and self-operated facility-based physician services departments that also provide staffing and scheduling services. Many of these competitors provide healthcare services that are similar in scope to the services we provide. Moreover, in certain regions, some of our competitors have already established a significant network of physician groups and it may be more difficult for us to compete in such areas.

Our physician services segment may not be able to successfully recruit and retain physicians, nurses and other clinical providers with the qualifications and attributes desired by us and our clients. Our ability to recruit and retain qualified physicians and other healthcare professionals to work in our physician services segment is critical for delivery of clinical services under our contracts. Our clients increasingly demand a greater degree of specialized skills and higher training and experience levels for the healthcare professionals providing services under their contracts with us. Moreover, because of the scope of the geographic diversity of our physician services segment operations, we must recruit healthcare professionals, and particularly physicians, to staff a broad spectrum

36

Item 1A.   Risk Factors - (continued) Table of Contents

of contracts. We have had difficulty in the past recruiting physicians to staff contracts in some regions of the country and at some less economically advantaged hospitals due to limits on compensation, facility and equipment availability, reduced back-up staffing by other specialists, local cost of living and lifestyle preferences. In some instances, we may not be able to recruit physicians and healthcare professionals quickly enough to permanently staff all openings. Further, we compete with other providers of physician services for such qualified physicians and other healthcare professionals and must offer competitive wages and benefits. The anticipated expansion of new patients covered by health insurance resulting from implementation of the Health Reform Law may further constrain the markets for qualified physicians to staff our physician services segment operations. If we raise wages in response to wages increases of our competitors and are unable to negotiate for increased fees from our clients, such increases may adversely affect the business, financial condition and results of operations of our physician services segment. In addition, our ability to recruit physicians is closely regulated and limitations imposed by various federal and state statutes may create additional challenges in recruiting and retaining physicians. The physician population of each of our specialties is subject to unique supply and demand dynamics, including the demographics of the physician population and graduation rates for residency and fellowship programs. Our future success in retaining and winning new physician services contracts depends in part on our ability to recruit and retain physicians and other healthcare professionals to maintain and expand our physician services segment operations.

We may not accurately assess the costs we will incur under new contracts. Our new physician services contracts with hospitals and other health care facilities and health systems increasingly involve a competitive bidding process. As a result, it is critical for us to accurately assess the costs to be incurred in providing physician services in order to price new contracts accurately so that we may realize adequate profit margins and otherwise meet financial and strategic objectives. Increasing pressures from third-party payors to restrict or reduce reimbursement rates as well as pressures from healthcare facilities to eliminate or reduce contractual subsidies and income guarantees at a time when the costs of providing medical services continue to increase make assessing the costs associated with new contracts, as well as maintenance of existing contracts, more difficult. In addition, servicing new physician services contracts, particularly those in new geographic locations, could prove more costly, and could require more management time, than we anticipate. Our failure to accurately predict costs or to negotiate adequate profit margins could adversely affect the business, financial condition and results of operations of our physician services segment.

The margins in our physician services segment business may be negatively impacted by cross-selling to existing clients or selling bundled services to new clients. One of our growth strategies for our physician services business involves the continuation and expansion of our efforts to sell complementary physician services across our multi-specialty practice and related management services businesses. There can be no assurance that we will be successful in our cross-selling efforts. As part of our cross-selling efforts, we may need to offer a bundled package of physician services at a lower price point in general than individual services and such efforts may result in downward price pressure on our services. Such price pressure may have a negative impact on our operating margins. In addition, if a complementary service offered as part of a bundled package underperforms as compared to the other physician services included in such package, we could face reputational harm which could negatively impact our relationships with our clients and ultimately our results of operations.

Some jurisdictions preclude us from employing non-compete agreements with our physicians, and other non-compete agreements and restrictive covenants applicable to our physicians and other clinical employees may not be enforceable. Our physician services segment has contracts with physicians and other health professionals in many states. Some of our physician services contracts, as well as many of our physician services contracts with hospitals, include provisions preventing these physicians and other health professionals from competing with us both during and after the term of our contract with them. The law governing non-compete agreements and other forms of restrictive covenants varies from state to state. Some jurisdictions prohibit us from using non-compete covenants with our professional staff. Other states are reluctant to strictly enforce non-compete agreements and restrictive covenants applicable to physicians and other healthcare professionals. There can be no assurance that our non-compete agreements related to affiliated physicians and other health professionals will be found enforceable if challenged in certain states. In such event, we would be unable to prevent former affiliated physicians and other health professionals from competing with us, potentially resulting in the loss of some of our hospital contracts and other business. Additionally, certain facilities have the right to employ or engage our providers after the termination or expiration of our contract with those facilities and cause us not to enforce our non-compete provisions related to those providers.

Unfavorable changes in regulatory, economic and other conditions could occur in the states where our operations are concentrated. During the year ended December 31, 2015, Florida, New Jersey, California and Arizona accounted for approximately 85% of our physician services segment net revenue. This concentration increases the risk that, should our physician services segment programs in these states be adversely affected by changes in law or regulatory, economic and other conditions, our physician services segment revenue and profitability could materially decline. Furthermore, a natural disaster or other catastrophic event could affect us more significantly than other companies with less geographic concentration.

37

Item 1A.   Risk Factors - (continued) Table of Contents

Our physician services business could be subject to professional liability lawsuits, some of which we may not be fully insured against or reserved for. Physicians, hospitals and other participants in the healthcare industry are subject to lawsuits alleging medical malpractice and related legal theories. Many of these lawsuits involve large claims and substantial defense costs. We maintain professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of our professional liability loss risks are being provided by a third-party insurer which is fully reinsured by our wholly-owned captive. In addition, our wholly-owned captive provides stop loss coverage for our self-insured employee health program related to our physician services segment. The assets, liabilities and results of operations of our wholly-owned captive insurance company subsidiary are included in our consolidated financial statements. The liabilities for self-insurance include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. We also obtain professional liability insurance on a claims-made basis from third party insurers for certain of our owned practices and employed physicians.

Our reserves for professional liability claims are based upon periodic actuarial calculations. Our reserves for losses and related expenses represent estimates involving actuarial and statistical projections, at a given point in time, of our expectation of the ultimate resolution plus administration costs of the losses that we have incurred. Our reserves are based on historical claims, demographic factors, industry trends, severity and exposure factors and other actuarial assumptions calculated by an independent actuarial firm. The independent actuarial firm performs studies of projected ultimate losses on an annual basis. We refer to these actuarial estimates as part of our process by which we determine appropriate reserves. Liabilities for claims incurred but not reported are not discounted. The estimation of professional liabilities is inherently complex and subjective, as these claims are typically resolved over an extended period of time, often as long as ten years or more. Our reserves could be significantly affected if current and future occurrences differ from historical claim trends and expectations. We periodically reevaluate our reserves for professional liabilities, and our actual results may vary significantly from our estimates as the key assumptions used in our actuarial valuations are subject to constant adjustment as a result of changes in our actual loss history and the movement of projected emergence patterns as claims develop. While we monitor claims closely when we estimate reserves, the complexity of claims and the wide range of potential outcomes may hamper timely adjustments to the assumptions we use in these estimates. Actual losses and related expenses may deviate, individually and in the aggregate, from the reserve estimates reflected in our combined consolidated financial statements. If we determine that our estimated reserves are inadequate, we will be required to increase reserves at the time of the determination, which would result in a reduction in the net income of our physician services segment in the period in which the deficiency is determined.

Our captive insurance company is subject to government regulation, and legislative or regulatory action may make our captive insurance company arrangement less feasible or otherwise reduce our profitability. We own a captive insurance company located in a foreign country. Insurance companies are subject to government regulation, the primary purpose of which is generally to protect policyholders and not necessarily to protect creditors and investors. The nature and extent of such regulation typically involve such items as: standards of solvency and minimum amounts of statutory capital surplus that must be maintained, regulation of reinsurance, methods of accounting and filing of annual and other reports with respect to financial condition and other matters. Such regulation may increase our costs of regulatory compliance, restrict our ability to access cash held in our captive insurance company and otherwise impede our ability to take actions we deem advisable.

Insurance regulators and other regulatory agencies regularly reexamine existing laws and regulations applicable to insurance companies and their products. Changes in these laws and regulations, or in interpretations thereof, are often made for the benefit of the consumer at the expense of the insurer and could materially and adversely affect our business, results of operations or financial condition. The use of captive insurance companies in particular has come under scrutiny by insurance regulators in the United States. Any regulatory action that prohibits or limits our use of or materially increases our cost of using our captive reinsurance company, either retroactively or prospectively, could have a material adverse effect on the financial condition or results of operations of our physician services segment.

38

Item 1B. Unresolved Staff Comments

Not applicable.

Item 2.    Properties

Our principal executive offices, which also house our ambulatory services segment's operations, are located in Nashville, Tennessee and contain approximately 110,000 square feet of office space, which we lease from a third-party pursuant to an agreement with an initial term expiring in February 2030. Our physician services segment operates from offices located in Sunrise, Florida and contains an aggregate of approximately 130,000 square feet of office space, which we lease from a third-party pursuant to an agreement in which the initial term expires in February 2024. We also lease office space for our regional offices in Tempe, Arizona; Miami, Florida; Conshohocken, Pennsylvania; Nashville, Tennessee and Dallas, Texas which include offices for both our regional operations and our central billing services. Our affiliated limited partnerships and limited liability companies lease space for their surgery centers ranging from 1,000 to 25,000 square feet, with expected remaining lease terms ranging from 1 to 20 years. 

On January 16, 2015, we entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which we intend to be the future headquarters of our physician services operations. We took possession of the space in the fourth quarter of 2015 to begin tenant improvements on approximately 167,000 square feet of space, which we intend to occupy during the third quarter of 2016. In addition, we plan to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which we will occupy during the fourth quarter of 2016. Annual rent expense is expected to be approximately $2.9 million. The initial term of this lease agreement expires in February 2029.

Item 3.    Legal Proceedings

On November 1, 2013, the United States District Court for the Eastern District of California in Sacramento issued an order unsealing a qui tam lawsuit filed against the Company, Gastroenterology Associates Endoscopy Center, LLC (GAEC), an entity that owns and operates an ambulatory surgery center located in Redding, California in which the Company owns a majority ownership interest, and certain other defendants. The lawsuit was filed in August 2012 by two CRNAs who provided services as independent contractors to GAEC during the period from September 2010 through December 2010. GAEC terminated its contracts with the plaintiffs in December 2010. In the lawsuit, the plaintiffs assert claims pursuant to the Federal False Claims Act and the California False Claims Act relating to the alleged failure by GAEC to comply with applicable Federal and state regulatory requirements relating to pre-procedure medical histories and physical assessments. The lawsuit also asserts a claim for retaliatory discharge. According to the order entered by the District Court, both the United States and the State of California declined to intervene in the case. The plaintiffs filed an amended complaint in January 2014. The Company filed a motion to dismiss the case in March 2014, and the court issued an order denying the motion in December 2014. The Company believes the claims in the lawsuit have no merit, and intends to vigorously defend the lawsuit.

Item 4.    Mine Safety Disclosures

Not applicable.

39

PART II

Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock trades under the symbol “AMSG” on the Nasdaq Global Select Market.  The following table sets forth the high and low sales prices per share for the common stock for each of the quarters in 2014 and 2015, as reported on the Nasdaq Global Select Market:

	1st		2nd		3rd		4th
	Quarter		Quarter		Quarter		Quarter
2014:
High	$	47.75	$	52.81	$	54.48	$	55.65
Low	$	40.05	$	40.00	$	45.19	$	47.68
2015:
High	$	65.03	$	72.85	$	87.42	$	87.29
Low	$	52.42	$	60.43	$	54.11	$	58.37

At February 17, 2016, there were approximately 41,320 holders of our common stock, including approximately 260 shareholders of record.  We have never declared or paid a cash dividend on our common stock.  We intend to retain our earnings to finance the growth and development of our business and do not expect to declare or pay any cash dividends on our common stock in the foreseeable future.  The declaration of dividends is within the discretion of our Board of Directors, subject to certain covenants which limit, but may not restrict, our ability to pay dividends.

40

Item 6.   Selected Financial Data Table of Contents

The following tables summarize selected financial data and should be read in conjunction with our related consolidated financial statements and notes thereto. The 2015 columns in the tables below include results of operations for Sheridan Healthcare (Sheridan) and its consolidated subsidiaries for the entire year while the 2014 columns in the tables below include only include the results of operations for Sheridan and its consolidated subsidiaries effective July 16, 2014. Certain prior year amounts below have been reclassified to reflect the impact of discontinued operations.

	Year Ended December 31,
	2015			2014			2013		2012		2011
	(In thousands, except per share and operating data)
Consolidated Statement of Earnings Data:
Net revenue (1)	$	2,566,884		$	1,621,949		$	1,057,196	$	899,245	$	748,447
Operating expenses	2,002,225			1,238,034			729,912		627,268		517,903
Net gain on deconsolidations (2)	36,694			3,411			2,237		—		—
Equity in earnings of unconsolidated affiliates	16,152			7,038			3,151		1,564		613
Operating income	617,505			394,364			332,672		273,541		231,157
Interest expense, net	121,586			83,285			29,525		16,950		15,311
Debt extinguishment costs	—			16,887			—		—		—
Earnings from continuing operations before income taxes	495,919			294,192			303,147		256,591		215,846
Income tax expense	113,790			48,103			48,654		40,893		33,457
Net earnings from continuing operations	382,129			246,089			254,493		215,698		182,389
Net earnings (loss) from discontinued operations	(1,013		)	(1,296		)	7,051		7,945		7,725
Net earnings	381,116			244,793			261,544		223,643		190,114
Less net earnings attributable to noncontrolling interests	218,169			191,092			188,841		161,080		140,117
Net earnings attributable to AmSurg Corp. shareholders	162,947			53,701			72,703		62,563		49,997
Preferred stock dividends	(9,056		)	(4,503		)	—		—		—
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	49,198		$	72,703	$	62,563	$	49,997
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of tax	$	154,892		$	50,777		$	71,009	$	60,037	$	47,760
Earnings (loss) from discontinued operations, net of tax	(1,001		)	(1,579		)	1,694		2,526		2,237
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	49,198		$	72,703	$	62,563	$	49,997
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations	$	3.22		$	1.29		$	2.27	$	1.95	$	1.57
Net earnings	$	3.20		$	1.25		$	2.32	$	2.03	$	1.64
Diluted earnings per share attributable to AmSurg Corp. common shareholders (3):
Net earnings from continuing operations	$	3.18		$	1.28		$	2.22	$	1.90	$	1.53
Net earnings	$	3.16		$	1.24		$	2.28	$	1.98	$	1.60
Weighted average number of shares and share equivalents outstanding:
Basic	48,058			39,311			31,338		30,773		30,452
Diluted (3)	51,612			39,625			31,954		31,608		31,211

41

Item 6.   Selected Financial Data - (continued) Table of Contents

	Year Ended December 31,
	2015			2014			2013			2012			2011
	(In thousands, except operating data)
Consolidated Balance Sheet and Cash Flow Data:
Cash and cash equivalents	$	106,660		$	208,079		$	50,840		$	46,398		$	40,718
Working capital (4)	149,481			278,140			121,155			107,768			109,561
Total assets	6,546,482			5,501,062			2,177,944			2,044,586			1,573,018
Long-term debt and other long-term liabilities	2,501,313			2,321,629			608,801			646,677			476,094
Non-redeemable and redeemable noncontrolling interests (5)	647,016			602,783			539,056			486,360			302,858
AmSurg Corp. shareholders’ equity	2,293,463			1,679,547			764,197			689,488			616,245
Cash flows provided by operating activities	537,959			412,371			332,824			295,652			243,423
Cash flows used in investing activities	(1,016,825		)	(2,225,135		)	(98,738		)	(298,943		)	(254,367		)
Cash flows provided by (used in) financing activities	377,447			1,970,003			(229,644		)	8,971			17,515
Other Ambulatory Services Operating Data:
Continuing centers at end of year	257			246			236			231			215
Procedures performed during year	1,729,262			1,645,350			1,609,761			1,478,888			1,321,618
Same center revenues increase (consolidated)	6.0		%	0.7		%	0.6		%	2.5		%	0.7		%

(1) Comparability of revenue is impacted by the acquisition of Sheridan on July 16, 2014 and other acquisitions. See Note 4 to the “Consolidated Financial Statements” included in Item 8 of this Form 10-K for the impact of acquisitions on net revenue.

(2) The net gain on deconsolidations is driven by the number of entities in which we sold or contributed a portion of our equity interests into new unconsolidated investments. See Note 5 to the “Consolidated Financial Statements” included in Item 8 of this Form 10-K.

(3) See Note 15 to the “Consolidated Financial Statements” included in Item 8 of this Form 10-K for a reconciliation of amounts used in diluted earnings per share.

(4) Working capital has been impacted at December 31, 2015 and 2014 by the adoption of Financial Accounting Standards Board's (FASB) Accounting Standards Update (ASU) 2015-17 “Balance Sheet Classification of Deferred Taxes,” which required all deferred tax assets and liabilities to be classified as non-current. See Note 1 to the "Consolidated Financial Statements", included in Item 8 of this Form 10-K.

(5) See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies.”

42

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations Table of Contents

Forward-Looking Statements

This report contains certain forward-looking statements (all statements other than statements with respect to historical fact) within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve known and unknown risks and uncertainties including, without limitation, those described in Item 1A. Risk Factors, some of which are beyond our control. Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate. Therefore, there can be no assurance that the forward-looking statements included in this report will prove to be accurate. Actual results could differ materially and adversely from those contemplated by any forward-looking statement. In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. We undertake no obligation to publicly release any revisions to any forward-looking statements in this discussion to reflect events and circumstances occurring after the date hereof or to reflect unanticipated events. Forward-looking statements and our liquidity, financial condition and results of operations may be affected by the risks set forth in Item 1A. Risk Factors or by other unknown risks and uncertainties.

Executive Overview

We are one of the largest owners and operators of ASCs in the United States based upon total number of facilities, and are a leading provider of outsourced physician services. Through our ambulatory services segment, we acquire, develop and operate ambulatory surgery centers (ASCs, surgery centers, or centers) in partnership with physicians. Through our physician services segment, we provide outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine.

Our operations consist primarily of two major segments, ambulatory services and physician services.

Ambulatory Services Overview

We acquire, develop and operate surgery centers in partnership primarily with physicians.  Our surgery centers are typically located adjacent to or in close proximity to the medical practices of our partner physicians. At December 31, 2015, we operated 257 ASCs in 34 states and the District of Columbia in partnership with approximately 2,000 physicians. We generally own a majority interest, primarily 51%, in the surgery centers we operate. We also own a minority interest in certain surgery centers in partnerships with leading health systems and physicians and intend to continue to pursue such partnerships.

Physician Services Overview

At December 31, 2015, we delivered physician services, primarily in the areas of anesthesiology, radiology, children’s services and emergency medical services, to more than 450 healthcare facilities in 29 states, with a significant presence in Florida, New Jersey, Arizona and California. At December 31, 2015, we employed more than 3,800 physicians and other healthcare professionals in our physician services business. We receive reimbursement from third-party payors for fee for service medical services rendered by our affiliated healthcare professionals and employees to the patients who receive medical treatment at these facilities. In addition to this primary form of reimbursement, in certain cases, we also receive contract revenue directly from the facilities where we perform our services through a variety of payment arrangements that are established to supplement payments from third-party payors. We also provide physician services and manage office-based practices in the areas of gynecology, obstetrics and perinatology.

Operating Environment

Our ASCs and physician practices depend upon third-party reimbursement programs, including governmental and private insurance programs, to pay for substantially all of the services rendered to patients. For the year ended December 31, 2015, we derived approximately 26% and 18%, respectively, of our ambulatory services and physician services net revenue from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles. The Medicare program currently reimburses physician services and ASCs in accordance with predetermined fee schedules. We are not required to file cost reports for our centers or physician services and, accordingly, we have no unsettled amounts from governmental third-party payors.

ASCs are paid under the Medicare program based upon a percentage of the payments to hospital outpatient departments pursuant to the hospital outpatient prospective patient system and reimbursement rates for ASCs are increased annually based on increases in the consumer price index (CPI). The Patient Protection and Affordable Care Act, as amended by the Health Care and Education

43

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Reconciliation Act of 2010 (together, the Health Reform Law), provide for the annual CPI increases applicable to ASCs to be reduced by a productivity adjustment, which is based on historical nationwide productivity gains. In 2013, ASC reimbursement rates increased by 0.6%, which positively impacted our 2013 ambulatory services revenues by approximately $2.5 million and our net earnings per diluted share by $0.02. In 2014, ASC reimbursement rates increased by 1.2%, which positively impacted our 2014 ambulatory services revenues by approximately $6.5 million and our net earnings per diluted share by $0.05. In 2015, ASC reimbursement rates increased by 1.9%, which positively impacted our 2015 ambulatory services revenues by approximately $9.0 million and our net earnings per diluted share by $0.10. Centers for Medicare and Medicaid Services (CMS) has announced that ASC reimbursement rates will increase by 0.3% for 2016, which we estimate will not have a significant impact our 2016 ambulatory services revenues. There can be no assurance that CMS will not revise the ASC payment system or that any annual CPI increases will be material. 

Physician services are paid under the Medicare program based upon the Medicare Physician Fee Schedule (MPFS), under which CMS has assigned a national relative value unit (RVU) to most medical procedures and services that reflects the various resources required by a physician to provide the services relative to all other services. Each RVU is calculated based on a combination of work required in terms of time and intensity of effort for the service, practice expense (overhead) attributable to the service and malpractice insurance expense attributable to the service. These three elements are each modified by a geographic adjustment factor to account for local practice costs and then aggregated. Historically, the aggregated amount was multiplied by a conversion factor calculated by the sustainable growth rate (SGR) to arrive at the payment amount for each service. In April 2015, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) repealed the SGR physician payment methodology. Instead of tying payments to the SGR, MACRA provides for a 0.5% payment update for each calendar year through 2019. In addition, MACRA requires the establishment of the Merit-Based Incentive Payment System (MIPS) beginning in 2019, under which physicians will receive performance-based payment incentives or payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of electronic health records. MIPS will consolidate certain existing physician incentive programs, including payments to physicians for the meaningful use of electronic health records. MACRA also requires CMS beginning in 2019 to provide incentive payments for physicians and other eligible professionals that participate in alternative payment models, such as accountable care organizations.

In November 2012, CMS adopted a rule under the Health Reform Law that generally allows physicians in certain specialties who provide eligible primary care services to be paid at the Medicare reimbursement rates in effect in calendar years 2013 and 2014 instead of state-established Medicaid reimbursement rates (Medicaid-Medicare Parity). Generally, state Medicaid reimbursement rates are lower than federally established Medicare rates. Legislation was passed in certain states to extend Medicaid-Medicare Parity for calendar year 2015. Accordingly, our 2015 Medicaid program revenues were reduced by approximately $3.2 million compared to a full fiscal 2014. We do not expect further reduction in reimbursement rates in 2016 in those states which previously extended Medicaid-Medicare Parity.

The Budget Control Act of 2011 (BCA) requires automatic spending reductions of $1.2 trillion for federal fiscal years (FFY) 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs. The percentage reduction for Medicare may not be more than 2% for a FFY, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as “sequestration.” Sequestration began on March 1, 2013, and CMS imposed a 2% reduction on Medicare claims as of April 1, 2013. These reductions have been extended through FFY 2025. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress, whether Congress will attempt to restructure or suspend sequestration or the impact sequestration may have on our business.

The Health Reform Law represents significant change across the healthcare industry and contains a number of provisions designed to reduce Medicare program spending. However, the Health Reform Law also expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms. For example, the Health Reform Law has expanded eligibility under existing Medicaid programs in states that have not opted out of the expansion, created financial penalties on individuals who fail to carry insurance coverage, established affordability credits for those not enrolled in an employer-sponsored health plan, resulted in the establishment of, or participation in, a health insurance exchange for each state and allowed states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid. The Health Reform Law also required a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates and increased dependent coverage.

Many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies. Medicare now covers these preventive services without cost-sharing, and states that provide Medicaid coverage of these preventive services without cost-sharing receive a one percentage point increase in their federal medical assistance percentage for these services.

44

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

We believe health insurance market reforms that expand insurance coverage have resulted in an increased volume of certain procedures at our centers. Most of the provisions of the Health Reform Law that are reducing the number of uninsured individuals are in effect. Including, as of January 1, 2016, the employer mandate, which requires firms with 50 or more full-time employees to offer health insurance or pay fines. Because of the many variables involved, including the law’s complexity, lack of implementing definitive regulations or interpretive guidance, gradual or partially delayed implementation, court challenges, amendments, repeal, or further implementation delays, we are unable to predict the net effect of the reductions in Medicare spending, the expected increases in revenues from increased procedure volumes, and numerous other provisions in the law that may affect us. We are further unable to foresee how individuals and employers will respond to the choices afforded them by the Health Reform Law. Thus, we cannot predict the full impact of the Health Reform Law on us at this time.

Recent Accounting Pronouncements

See Note 1 in the Notes to the Consolidated Financial Statements.

Critical Accounting Policies

Our accounting policies are described in the notes of our consolidated financial statements. We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. We consider the following policies to be most critical in understanding the judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Principles of Consolidation

Ambulatory Services

The consolidated financial statements include our accounts, our subsidiaries' accounts, and the accounts of the consolidated limited liability companies (LLCs) and limited partnerships (LPs). Consolidation of such LLCs and LPs is necessary as our wholly-owned subsidiaries have primarily 51% or more of the financial interest, are generally the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LLCs and LPs, and have control of the entities. The responsibilities of our noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances are eliminated. We also have an ownership interest of less than 51% in 23 of our LLCs and LPs, 2 of which we consolidate as we have substantive participation rights and 21 of which we do not consolidate as our rights are limited to protective rights only.

We identify and present ownership interests in subsidiaries held by noncontrolling parties in our consolidated financial statements within the equity section but separate from our equity. However, in instances in which certain redemption features that are not solely within our control are present, classification of noncontrolling interests outside of permanent equity is required. The amounts of consolidated net income attributable to us and to the noncontrolling interests are identified and presented on the face of the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Lastly, the cash flow impact of certain transactions with noncontrolling interests is classified within financing activities.

Upon the occurrence of various fundamental regulatory changes, we would be obligated under the terms of our partnership and operating agreements to purchase the noncontrolling interests related to a majority of our partnerships. We believe that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015, and the occurrence of such regulatory changes is outside of our control. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of our equity and are classified as noncontrolling interests – redeemable on our consolidated balance sheets.

Center profits and losses are allocated to our partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of our center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of our consolidated partnerships are generally determined on a pre-tax basis. Total net earnings attributable to noncontrolling interests are

45

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

presented after net earnings. However, we consider the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which we must determine our tax expense. In addition, distributions from the partnerships are made to both our wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

Our consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan currently has management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by us, except in the case of gross negligence, fraud or bankruptcy by us. The professional corporation structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at our sole discretion. The nominee shareholder is generally a medical doctor who is generally one of our senior corporate employees. We have a contractual right to transfer the ownership of the PCs at any time to any person we designate as the nominee shareholder. We have the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. We have exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of our wholly-owned affiliates. Based on the provisions of these agreements, we have determined that the PCs are variable interest entities and that we are the primary beneficiary as defined in the Financial Accounting Standards Board's Accounting Standards Codification 810 “Consolidations.”

In both our ambulatory services segment and physician services segment, the investments in unconsolidated affiliates in which we exert significant influence but do not control or otherwise consolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates in our consolidated balance sheets. Our share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in our consolidated statement of earnings. We monitor each investment for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the company and record a reduction in carrying value when necessary.

Revenue Recognition

Ambulatory Services

Our ambulatory services revenues, net of adjustments, are derived from facility fees charged for surgical procedures performed in our centers and, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), charges for anesthesia services provided by medical professionals employed or contracted by our centers.  These fees vary depending on the procedure, but usually include all charges for operating room usage, special equipment usage, supplies, recovery room usage, nursing staff and medications.  Facility fees do not include professional fees charged by the physicians that perform the surgical procedures.  Revenues are recorded at the time of the patient encounter and billings for such procedures are made on or about that same date. At the majority of our centers, it is our policy to collect patient co-payments and deductibles at the time the surgery is performed. Our revenues are recorded net of estimated contractual adjustments from third-party medical service payors. Our billing and accounting systems provide us historical trends of the centers’ cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly for each of our centers as revenues are recognized. Our ability to accurately estimate contractual adjustments is dependent upon and supported by the fact that our centers perform and bill for limited types of procedures, the range of reimbursement for those procedures within each surgery center specialty is very narrow and payments are typically received within 15 to 45 days of billing. These estimates are not, however, established from billing system generated contractual adjustments based on fee schedules for the patient’s insurance plan for each patient encounter.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2015, 2014 and 2013, we derived approximately 26%, 25% and 25%, respectively, of our ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

Physician Services

Physician services revenue primarily consists of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities we serve. Contract revenue represents income earned from our hospital customers to supplement payments from third-party payors.

46

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Fee for service revenue is billed to patients for services provided, and we receive payments for these services from patients or their third-party payors. Payments for services provided are generally less than our billed charges. We recognize fee for service revenue, net of contractual adjustments and provision for uncollectibles, at the time services are provided by healthcare providers. Services provided but not yet billed are estimated and recognized in the period services are provided. We record revenue net of an allowance for contractual adjustments, which represents the net revenue we expect to collect from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries).

Our provision for uncollectibles includes our estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. We record net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

We also recognize revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

Estimating physician services net revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability, at times, of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. In the period services are provided, we estimate gross charges based on billed services plus an estimate for unbilled services based on pending case data collected, we estimate contractual allowances based on our contracted rates and historical or actual cash collections (net of recoveries), when available, and we estimate our provision for uncollectibles based on historical cash collections (net of recoveries) from uninsured patients. The relationship between gross charges and the allowances for both contractual adjustments and provision for uncollectibles is significantly influenced by payor mix, as collections on gross charges may vary significantly depending on whether and with whom the patients we provide services to in the period are insured, and the contractual relationships with their payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. We periodically assess the estimates of unbilled revenue, contractual adjustments, provision for uncollectibles and payor mix for a period of at least one year following the date of service by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statement of earnings in the period that the assessment is made.

We derived approximately 18% of our physician services segment net revenue from services rendered to beneficiaries of Medicare, Medicaid and other government-sponsored healthcare programs during the year ended December 31, 2015. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

Allowance for Contractual Adjustments, Provision for Uncollectibles and Bad Debt Expense

We manage accounts receivable by regularly reviewing our accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Assessment of actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. We routinely test our analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, for each facility or contract, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by us to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. We may also supplement our allowance for doubtful accounts policy for our physician services division using a hindsight calculation that utilizes write-off data for all payor classes during the previous periods to estimate the allowance for doubtful accounts at a point in time. Material changes in estimate may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by us. Significant changes in payor mix, specialty mix, acuity, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on our estimates and significantly affect our results of operations and cash flows.

47

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Due to the nature of our ambulatory services segment operations, we are required to separate the presentation of the bad debt expense on the consolidated statement of earnings. We record the portion of our bad debts associated with our physician services segment as a component of net revenue in our consolidated statement of earnings, and the remaining portion, which is associated with our ambulatory services segment, is recorded as a component of other operating expenses in our consolidated statement of earnings. The bifurcation is a result of our ability to assess the ultimate collection of the patient service revenue associated with our ambulatory services segment before services are provided. Our ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Our ability to accurately estimate contractual adjustments is dependent upon and supported by the fact that our surgery centers perform and bill for limited types of procedures, that the range of reimbursement for those procedures within each surgery center specialty is very narrow and that payments are typically received within 15 to 45 days of billing. In addition, our surgery centers are not required to file cost reports, and therefore, we have no risk of unsettled amounts from governmental third-party payors. Except in certain limited instances, these estimates are not, however, established from billing system-generated contractual adjustments based on fee schedules for the patient’s insurance plan for each patient encounter.

While we believe that our allowances for contractual adjustments, provision for uncollectibles and bad debt expense are adequate, if the actual contractual adjustments and write-offs are in excess of our estimates, our results of operations may be overstated. During the years ended December 31, 2015, 2014 and 2013, we had no significant adjustments to our allowances for contractual adjustments, provisions for uncollectibles and bad debt expense related to prior periods. At December 31, 2015 and 2014, our allowances for doubtful accounts was $167.4 million and $113.4 million, respectively and the increase is primarily a result of operations from acquisitions completed during the year ended December 31, 2015.

Business Combinations

We record tangible and intangible assets acquired and liabilities assumed in business combinations under the acquisition method of accounting. Amounts paid for each acquisition are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. We then allocate the purchase price in excess of net tangible assets acquired to identifiable intangible assets based on detailed valuations that use information and assumptions provided by management. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired and liabilities assumed to goodwill. If the fair value of the assets acquired exceeds our purchase price, the excess is recognized as a gain. Significant management judgments and assumptions are required in determining the fair value of acquired assets and liabilities, particularly acquired intangible assets. The valuation of purchased intangible assets is based upon estimates of the future performance and cash flows from the acquired business. Each asset is measured at fair value from the perspective of a market participant. If different assumptions are used, it could materially impact the purchase price allocation and adversely affect our results of operations and financial condition.

Intangible Assets

Goodwill is evaluated annually for impairment during our fourth quarter or earlier upon the occurrence of certain events or substantive changes in circumstances. The first step of the two-step process involves a comparison of the estimated fair value of a reporting unit to its carrying amount, including goodwill. In performing the first step, we determine the fair value of a reporting unit using a discounted cash flow (DCF) analysis. The cash flows are projected based on a year-by-year assessment that considers historical results, estimated market conditions, internal projections, and relevant publicly available statistics. The cash flows projected are then used as the basis for projecting cash flows for the remaining years in our model. Determining fair value requires the exercise of significant judgment, including judgments about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The significant judgments are typically based upon Level 3 inputs, generally defined as unobservable inputs representing our own assumptions. The cash flows employed in the DCF analysis are based on our most recent budgets and business plans and, when applicable, various growth rates are assumed for years beyond the current business plan period. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of the respective reporting units. The discount rate is mainly based on judgment of the specific risk inherent within the reporting unit. The variables within the discount rate, many of which are outside of our control, provide our best estimate of all assumptions applied within the model.

If the carrying amount of a reporting unit exceeds its estimated fair value, then the second step of the goodwill impairment test must be performed. The second step of the goodwill impairment test compares the implied fair value of the reporting unit's goodwill with its carrying amount to measure the amount of impairment loss, if any. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination (i.e., the estimated fair value of the reporting unit is allocated to all of the assets and liabilities of that reporting unit, including any unrecognized intangible assets, as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid). If the carrying amount of the reporting unit's goodwill exceeds the implied fair value of the reporting unit's goodwill, an impairment loss is recognized in an amount equal to that excess.

48

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

As of December 31, 2015, the ambulatory services segment and the physician services segment each had approximately $2.0 billion of goodwill. Each segment represents a reporting unit that was evaluated during our annual impairment test as required as of October 1, 2015. Our analysis determined that it is not necessary to recognize impairment in our indefinite lived intangibles as the fair value of our reporting units are substantially in excess of their carrying value. To perform this evaluation, we obtain valuations at the reporting unit level prepared by third party valuation specialists which utilize a combination of the income, market and cost approaches to determine an estimated fair value.

In order for the estimated fair values to decrease below the carrying values for all of our reporting units, we would need to experience a significant decrease in future profitability projections coupled with a significant increase in the weighted average cost of capital, both of which we believe is unlikely to occur during the year ended December 31, 2016.

We test our finite-lived intangibles, other than goodwill, for impairment whenever events or circumstances indicate that it is more likely than not that the carrying amount may not be recoverable. Our policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. To determine whether it is more likely than not that the carrying amount may not be recoverable, we assessed various factors including, but not limited to, our financial performance, any contemplated strategic changes to our lines of business, or any changes to the macroeconomic environment in which we operate. During the year ended December 31, 2015, there were no events or circumstances that indicated a potential impairment in our finite-lived intangibles.

We evaluate our indefinite lived intangibles, which consist primarily of the Sheridan trade name, for impairment at least on an annual basis. Impairment of the carrying value will also be evaluated more frequently if certain indicators are encountered. Indefinite lived intangibles are required to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including indefinite lived intangibles. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles of the reporting unit are not considered to be impaired. During the year ended December 31, 2015, there were no events or circumstances that indicated a potential impairment in our indefinite lived intangibles.

Accrued Professional Liabilities

Given the nature of the services provided, we are subject to professional and general liability claims and related lawsuits in the ordinary course of business. We maintain professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of our professional liability loss risks are being provided by a third-party insurer which is fully reinsured by our wholly-owned captive. In addition, our wholly-owned captive provides stop loss coverage for our self-insured employee health program related to our physician services division. The assets, liabilities and results of operations of our wholly-owned captive insurance company subsidiary are included in our consolidated financial statements.

The liabilities for self-insurance include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. We also obtain professional liability insurance on a claims-made basis from third party insurers for certain of our owned practices and employed physicians.

Our reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. Our reserves for losses and related expenses represent estimates involving actuarial and statistical projections, at a given point in time, of our expectation of the ultimate resolution plus administration costs of the losses that we have incurred. Our reserves are based on historical claims, demographic factors, industry trends, severity and exposure factors and other actuarial assumptions calculated by an independent actuarial firm. The independent actuarial firm performs studies of projected ultimate losses on an annual basis. We refer to these actuarial estimates as part of our process by which we determine appropriate reserves. Liabilities for claims incurred but not reported are not discounted. The estimation of professional liabilities is inherently complex and subjective, as these claims are typically resolved over an extended period of time, often as long as ten years or more. We periodically reevaluate our accruals for professional liabilities, and our actual results may vary significantly from our estimates if future claims differ from expected trends. The key assumptions used in our actuarial valuations are subject to constant adjustment as a result of changes in our actual loss history and the movement of projected emergence patterns as claims develop.

49

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Results of Operations

Our consolidated statements of earnings include the results of both our ambulatory services segment and our physician services segment. Our consolidated revenues consist of both facility fees charged for surgical procedures performed in our ASCs and fee for service revenue, contract revenue and other revenue derived principally from the provision of physician services to patients of the healthcare facilities we serve through our physician services segment. Additionally, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), we charge for anesthesia services provided by medical professionals employed or contracted by our centers. As it relates to our ambulatory services segment, we generally own a controlling interest, primarily 51%, in our centers, and our consolidated statements of earnings include 100% of the results of operations of each of our consolidated entities, reduced by the noncontrolling partners’ share of the net earnings or loss of the surgery centers. The noncontrolling ownership interest in each LP or LLC is generally held directly or indirectly by physicians who perform procedures at the center. We generally own 100% of the entities included in our physician services segment with the exception of our affiliated professional corporations which we consolidate as they are variable interest entities and we are the primary beneficiary. On a consolidated basis, our share of the profits and losses of non-consolidated entities is reported in equity in earnings of unconsolidated affiliates in our consolidated statements of earnings.

Our revenues are influenced by national surgery trends, hospital specific factors, and other factors affecting patient needs for medical services. National surgery trends can change based on changes in patient utilization, population growth and demographics, weather related disruptions, as well as general economic factors. Hospital-specific elements include changes in local availability of alternative sites of care to the patient, changes in surgeon utilization of the facility, construction and regulations that affect patient flow through the hospital. We believe patient utilization can be affected by changes in the portion of medical costs for which the patients themselves bear financial responsibility, by general economic conditions, and by other factors.

Our ambulatory services revenues are directly related to the number of procedures performed at our centers. Our overall growth in ASC procedure volume is impacted directly by the number of centers in operation and the procedure volume at existing centers. We increase our number of centers through acquisitions, joint venture partnerships and developments. Procedure growth at an existing center may result from additional contracts entered into with third-party payors, increased numbers of procedures performed by our physician partners, additional physicians utilizing the center and/or scheduling and operating efficiencies gained at the surgery center.

Our physician services revenues consist of fee for service revenue, contract revenue and other revenue. Fee for service revenue is primarily generated through the provision of anesthesiology, radiology, children's services and emergency medical services at the facilities we serve. Contract revenue reflects payments received or receivable directly from certain of the facilities where we provide medical services to supplement payments from third-party payors. We also earn other revenue for certain ancillary services performed.

Expenses associated with our ambulatory services segment relate directly and indirectly to procedures performed and include: clinical and administrative salaries and benefits, supply cost and other operating expenses such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense. The majority of our salary and benefits cost is associated directly with the number of centers we own and manage and tends to grow in proportion to the growth in our number of centers in operation. We also incur operating expenses resulting from our corporate oversight which includes salaries and benefits of our operators and administrative support infrastructure. Our centers also incur costs that are more fixed in nature, such as lease expense, legal fees, property taxes, utilities and depreciation and amortization.

Salaries and benefits expense is a significant component of the total expenses associated with our physician services segment and includes compensation and benefits for our employed physicians and other professional providers as well as the salaries and benefits of our administrative support staff. Other operating expenses of our physician services segment includes professional liability costs, costs of business development and marketing, information technology, dues and licenses, occupancy costs and other administrative functions that are indirectly related to the operations of our physician group practices. Our professional liability costs include provisions for paid and estimated losses for actual claims and estimates of claims likely to be incurred in the period, based on our past loss experience and actuarial analysis provided by a third party, as well as actual direct costs, including investigation and defense costs, and other costs related to provider professional liability. We plan to continue to expand our investment in administrative support initiatives as a result of our planned future growth from new contracts and acquisitions.

Our depreciation expense primarily relates to charges for equipment and leasehold improvements. Amortization expense primarily relates to intangible assets recorded for customer relationships, computer software, and other technologies arising from acquisitions that we have made.

Our interest expense results primarily from our borrowings used to fund acquisition and development activity, as well as interest incurred on capital leases and the amortization of deferred financing costs.

50

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

The effective tax rate on pre-tax earnings as presented is approximately 23% for the year ended December 31, 2015. However, after removing the earnings attributable to non-controlling interest, our adjusted effective tax rate generally increases to approximately 40%. We file a consolidated federal income tax return and numerous state income tax returns with varying tax rates which reflects the blending of these rates.

Profits and losses are allocated to our noncontrolling partners, all of which relate to our ambulatory services segment, in proportion to their individual ownership percentages and reflected in the aggregate as total net earnings attributable to noncontrolling interests. The noncontrolling partners are typically organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each noncontrolling partner shares in the pre-tax earnings or loss of the entity of which it is a partner. Accordingly, net earnings attributable to the noncontrolling interests in each of our LPs and LLCs are generally determined on a pre-tax basis, and pre-tax earnings are presented before net earnings attributable to noncontrolling interests have been subtracted.

Consolidated Operations

The following table shows certain statement of earnings items expressed as a percentage of revenues for the years ended December 31, 2015, 2014 and 2013. The operating results of Sheridan are included in our operating results effective July 16, 2014.

	2015		2014		2013
Net revenue	100.0	%	100.0	%	100.0	%
Operating expenses:
Salaries and benefits	51.2		42.8		31.0
Supply cost	7.2		10.1		14.5
Other operating expenses	15.5		17.6		20.5
Transaction costs	0.3		2.1		—
Depreciation and amortization	3.8		3.7		3.1
Total operating expenses	78.0		76.3		69.0
Net gain on deconsolidations	1.4		0.2		0.2
Equity in earnings of unconsolidated affiliates	0.6		0.4		0.3
Operating income	24.1		24.3		31.5
Interest expense	4.7		5.1		2.8
Debt extinguishment costs	—		1.0		—
Earnings from continuing operations before income taxes	19.3		18.1		28.7
Income tax expense	4.4		3.0		4.6
Net earnings from continuing operations	14.9		15.2		24.1
Net earnings (loss) from discontinued operations	—		(0.1	)	0.7
Net earnings	14.8		15.1		24.7
Net earnings attributable to noncontrolling interests	8.5		11.8		17.9
Net earnings attributable to AmSurg Corp. shareholders	6.3	%	3.3	%	6.9	%

51

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Year Ended December 31, 2015 Compared to Year Ended December 31, 2014

We experienced significant changes in our consolidated operations primarily due to the following factors:

• our operating results for the year ended December 31, 2015 include the operating results of Sheridan for a full fiscal year. Our prior year results only include Sheridan from July 16 through December 31, 2014;

• we incurred additional interest expense associated with the debt financing consummated in July of 2014 to complete the acquisition of Sheridan;

• we completed acquisitions in both our ambulatory services and physician services segments; and

• we experienced a positive increase in our same center and same contract organic growth during the current year.

Net revenue increased $944.9 million, or 58.3%, to $2.6 billion in 2015 from $1.6 billion in 2014. Our consolidated net revenue was impacted during 2015 primarily due to the following:

• an increase of $824.8 million associated with the acquisition of Sheridan and subsequent acquisitions in our physician services segment; and

• an increase of $120.1 million associated with our ambulatory services segment.

Operating income increased $223.1 million, or 56.6%, to $617.5 million during the year ended December 31, 2015, from $394.4 million in 2014. Our operating income was impacted during the year ended December 31, 2015 primarily due to the following:

• an increase of $100.1 million associated with the acquisition of Sheridan and subsequent acquisitions in our physician services segment; and

• an increase of $123.1 million associated with results from our ambulatory services segment which includes a $39.8 million increase in the net gain on deconsolidations.

Net interest expense increased to $121.6 million in the year ended December 31, 2015 from $83.3 million in 2014, primarily due to having the full year impact of the increased indebtedness which resulted due to the financings consummated during 2014 to complete the acquisition of Sheridan. In addition, during 2014 we recorded $12.8 million in interest expense in the accompanying statements of earnings related to fees paid to obtain a commitment for bridge financing in order to effect the Sheridan transaction. During 2014, we were able to obtain permanent financing and therefore expensed the commitment fee. See “- Liquidity and Capital Resources.” for additional information.

On July 3, 2014, we redeemed our senior secured notes due 2020 (the Senior Secured Notes) and terminated our obligation under our revolving credit facility utilizing proceeds received from our common and preferred stock offerings. As a result, we recognized debt extinguishment costs of $16.9 million, which included an early termination fee of approximately $12.4 million to the holders of the Senior Secured Notes and the write-off of net deferred loan costs of approximately $4.5 million primarily related to the existing revolving credit facility.

We recognized income tax expense of $113.8 million for the year ended December 31, 2015, compared to $48.1 million in the year ended December 31, 2014. Our increase in tax expense for the year ended December 31, 2015 is due to having a full twelve months of operating activity from our physician services segment as compared to approximately six months in the prior year and due to the reduction in transaction cost in the current year, which were higher in the prior year due the acquisition of Sheridan. Our effective tax rate during the year ended December 31, 2015 was approximately 23% of earnings from continuing operations. This differs from the federal statutory income tax rate of 35% primarily due to the exclusion of the noncontrolling interests’ share of pre-tax earnings and the impact of state income taxes. However, after removing the earnings attributable to non-controlling interest, our adjusted effective tax rate generally increases to approximately 40%. For the year ended December 31, 2015, our adjusted effective tax rate was approximately 41%.

Noncontrolling interests in net earnings for the year ended December 31, 2015 increased $27.1 million from the year ended December 31, 2014, primarily as a result of noncontrolling interests in earnings at surgery centers recently added to operations. Due to the inclusion of Sheridan's revenue in the years ended December 31, 2015 and 2014, noncontrolling interests in earnings as a percentage of revenues decreased to 8.5% during 2015 from 11.8% during 2014.

52

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Year Ended December 31, 2014 Compared to Year Ended December 31, 2013

We experienced significant changes in our consolidated operations primarily due to the following factors:

• operating results of Sheridan for the period from July 16, 2014 through December 31, 2014;

• transaction costs associated with the acquisition of Sheridan;

• additional interest expense and related charges associated with the new debt financing required to complete the acquisition of Sheridan; and

• acquisitions of ASCs and growth in same-center results.

Net revenue increased $564.8 million, or 53.4%, to $1.622 billion in 2014 from $1.057 billion in 2013. Our consolidated net revenue was impacted during 2014 primarily due to the following:

• an increase of $512.0 million associated with the acquisition of Sheridan on July 16, 2014; and

• an increase of $52.7 million associated with our ambulatory services segment.

Operating income increased $61.7 million, or 18.5%, to $394.4 million during the year ended December 31, 2014, from $332.7 million in 2013. Our operating income was impacted during the year ended December 31, 2014 primarily due to the following:

• an increase of $76.7 million associated with the acquisition of Sheridan on July 16, 2014; and

• a decrease of operating income due to transaction costs primarily associated with the acquisition of Sheridan of $33.9 million for the year ended December 31, 2014.

Interest expense increased to $83.3 million in the year ended December 31, 2014 from $29.5 million in 2013, primarily due to increased indebtedness as a result of the financings associated with the acquisition of Sheridan during the year ended December 31, 2014. 

On July 3, 2014, we redeemed our Senior Secured Notes and terminated our obligation under our existing revolving credit facility utilizing proceeds received from our common and preferred stock offerings. As a result, we recognized debt extinguishment costs of $16.9 million, which included an early termination fee of approximately $12.4 million to the holders of the Senior Secured Notes and the write-off of net deferred loan costs of approximately $4.5 million primarily related to the existing revolving credit facility.

We recognized income tax expense of $48.1 million for the year ended December 31, 2014, compared to $48.7 million in the year ended December 31, 2013. Our reduction in tax expense for the year ended December 31, 2014 is due to the fact we recorded a loss attributable to the recognition of certain of the Sheridan transaction costs in which the tax benefit substantially offset the tax expense derived from our physician services segment. Our effective tax rate during the year ended December 31, 2014 was approximately 16% of earnings from continuing operations. However, after removing the earnings attributable to non-controlling interest, our adjusted effective tax rate generally increases to approximately 40%. For the year ended December 31, 2014, our effective tax rate was 46% which differs from our historical percentage of approximately 40% due to the non-deductibility for tax purposes of certain transaction costs as well as other deferred tax adjustments resulting from the Sheridan transaction and from the impact of gains and losses from the deconsolidation and disposals of certain of our centers which were recognized during the year.

Noncontrolling interests in net earnings for the year ended December 31, 2014 increased $2.3 million from the year ended December 31, 2013, primarily as a result of noncontrolling interests in earnings at surgery centers recently added to operations. All of the results of operations related to noncontrolling interests relate to our ownership of ambulatory services. Due to the inclusion of Sheridan's revenue in 2014, noncontrolling interests in earnings of surgery centers as a percentage of revenues decreased to 11.8% in the year ended December 31, 2014 from 17.9% in 2013.

53

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Ambulatory Services Operations

The following table presents the number of procedures performed at our continuing centers and changes in the number of ASCs in operation, under development and under letter of intent for the years ended December 31, 2015, 2014 and 2013. An ASC is deemed to be under development when a LLC or LP has been formed with the physician partners to develop the ASC.

	2015			2014			2013
Procedures	1,729,262			1,645,350			1,609,761
Centers in operation, end of period (consolidated)	236			237			233
Centers in operation, end of period (unconsolidated)	21			9			3
Average number of continuing centers in operation, during period	238			233			230
New centers added, during period	11			10			6
Centers discontinued, during period	—			6			3
Centers under development, end of period	1			2			—
Centers under letter of intent, end of period	5			5			5
Average revenue per consolidated center (in thousands)	$	5,174		$	4,755		$	4,594
Same center revenues increase (consolidated)	6.0		%	0.7		%	0.6		%
Surgical hospitals in operation at end of period (unconsolidated)	1			—			—

Of the continuing centers in operation at December 31, 2015, 151 centers performed gastrointestinal endoscopy procedures, 58 centers performed procedures in multiple specialties, 39 centers performed ophthalmology procedures and 9 centers performed orthopaedic procedures. In addition, during the year ended December 31, 2015, we acquired a non-controlling interest in a surgical hospital. The results of operations of the surgical hospital are included in our consolidated statement of earnings as a component of equity in earnings of unconsolidated affiliates.

A significant measurement of how much our ambulatory services revenues grow from year to year for existing centers is the change in our same-center revenue. We define our same-center group each year as those centers that contain full year-to-date operations in both comparable reporting periods, including the expansion of the number of operating centers associated with a LLC or LP. Ambulatory services revenues at our 2015 same-center group, comprising 221 centers and constituting approximately 94% of our total number of consolidated centers, increased by 6.0% during the year ended December 31, 2015 compared to 2014.

The following table presents selected statement of earnings data expressed in dollars (in thousands) and as a percentage of net revenue for our ambulatory services segment.

	December 31,
	2015				2014				2013
Net revenue	$	1,230,050	100.0	%	$	1,109,935	100.0	%	$	1,057,196	100.0	%
Operating expenses:
Salaries and benefits	372,149		30.3		341,906		30.8		327,585		31.0
Supply cost	181,783		14.8		163,004		14.7		153,126		14.5
Other operating expenses	247,525		20.1		230,307		20.7		216,501		20.5
Transaction costs	1,762		0.1		29,004		2.6		300		—
Depreciation and amortization	35,835		2.9		34,667		3.1		32,400		3.1
Total operating expenses	839,054		68.2		798,888		72.0		729,912		69.0
Net gain on deconsolidations	43,251		3.5		3,411		0.3		2,237		0.2
Equity in earnings of unconsolidated affiliates	6,466		0.5		3,199		0.3		3,151		0.3
Operating income	$	440,713	35.8	%	$	317,657	28.6	%	$	332,672	31.5	%

54

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Year Ended December 31, 2015 Compared to Year Ended December 31, 2014

The number of procedures performed in our ASCs increased by 83,912, or 5.1%, to 1,729,262 in 2015 from 1,645,350 in 2014. Ambulatory services revenues increased $120.1 million, or 10.8%, to $1.2 billion, in the year ended December 31, 2015 from $1.1 billion in 2014. Our ambulatory services revenues were impacted during the year ended December 31, 2015 primarily due to the following:

• centers acquired in 2014, which contributed $37.7 million of additional revenues in the year ended December 31, 2015 due to having a full period of operations in 2015;

• centers acquired or opened in 2015, which generated $45.3 million in revenues during the year ended December 31, 2015;

• revenue growth of $60.4 million for the year ended December 31, 2015 recognized by our 2015 same-center group, reflecting a 6.0% increase in our 2015 same-center group attributable to a 2.0% increase in procedures and a 4.0% increase in revenue per procedure; and

• reduced revenue recognized during the year ended December 31, 2015 of $23.7 million resulting from the deconsolidation of centers which we sold all or a portion of our ownership interest in that were previously consolidated in 2014. Our share of the results of operations from the deconsolidated centers are reflected in equity in earnings of unconsolidated affiliates in our consolidated statements of earnings.

Salaries and benefits increased by $30.2 million, or 8.8%, to $372.1 million in the year ended December 31, 2015 from $341.9 million in 2014. The increase was primarily a result of staffing at newly acquired and developed centers, as well as the additional staffing required at existing centers. Salaries and benefits declined as a percentage of revenue primarily due to the increase in our same center revenue during the year ended December 31, 2015.

Supply cost increased $18.8 million, or 11.5%, to $181.8 million in the year ended December 31, 2015 from $163.0 million in the year ended December 31, 2014. The increase was primarily due the additional supply cost of centers acquired or opened in 2015.

Other operating expenses increased $17.2 million, or 7.5%, to $247.5 million in the year ended December 31, 2015 from $230.3 million in the year ended December 31, 2014. The additional expense in 2015 resulted primarily from:

• an increase of $9.9 million in other operating expenses at our 2015 same-center group in the year ended December 31, 2015;

• centers acquired during 2014, which resulted in an increase of $7.2 million in other operating expenses in the year ended December 31, 2015;

• centers acquired or opened during 2015, which resulted in an increase of $6.9 million in other operating expenses in the year ended December 31, 2015; and

• reduced operating expense during the year ended December 31, 2015 of $4.5 million resulting from the deconsolidation of centers that were consolidated in 2014.

Depreciation and amortization expense increased $1.2 million, or 3.4%, in the year ended December 31, 2015, primarily as a result of centers acquired or opened during 2014 and 2015.

Equity in earnings of unconsolidated affiliates was $6.5 million in the year ended December 31, 2015 compared to $3.2 million in 2014. The increase during the year ended December 31, 2015, is due to the consummation of five separate equity method investments. As a result of these investment transactions, we contributed our controlling interest in nine centers in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and us. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, we obtained a non-controlling interest in three additional centers and one surgical hospital which were contributed by the health systems.

55

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Year Ended December 31, 2014 Compared to Year Ended December 31, 2013

The number of procedures performed in our ASCs increased by 35,589, or 2.2%, to 1,645,350 in 2014 from 1,609,761 in 2013. Ambulatory services revenues increased $52.7 million, or 5.0%, to $1.110 billion, in the year ended December 31, 2014 from $1.057 billion in 2013. Our ambulatory services revenues were impacted during the year ended December 31, 2014 primarily due to the following:

• centers acquired or opened in 2013, which contributed $32.7 million of additional revenues in the year ended December 31, 2014, respectively, due to having a full period of operations in 2014;

• centers acquired in 2014, which generated $23.5 million in revenues during the year ended December 31, 2014;

• centers that were deconsolidated during the year ended December 31, 2014 which generated $9.5 million in the comparative period (our share of the results of operations from the deconsolidated centers are now reflected in equity in earnings in unconsolidated affiliates in our consolidated statement of earnings); and

• revenue growth of $7.3 million for the year ended December 31, 2014 recognized by our 2014 same-center group, reflecting a 0.7% increase in our 2014 same-center group.

Salaries and benefits increased by 4.4% to $341.9 million in the year ended December 31, 2014 from $327.6 million in 2013. The increase was a result of staffing at newly acquired and developed centers, as well as the additional staffing required at existing centers.

Supply cost increased $9.9 million, or 6.5%, to $163.0 million in the year ended December 31, 2014 from $153.1 million in the year ended December 31, 2013. The increase was primarily due the additional supply cost of centers acquired in 2014, which were mainly multi-specialty centers, as well as those centers acquired in 2013 that now have a full period of supplies costs as compared to the prior year.

Other operating expenses increased $13.8 million, or 6.4%, to $230.3 million in the year ended December 31, 2014 from $216.5 million in the year ended December 31, 2013. The additional expense in the 2014 periods resulted primarily from:

• an increase of $7.6 million in other operating expenses at our 2014 same-center group in the year ended December 31, 2014;

• centers acquired or opened during 2013, which resulted in an increase of $4.8 million in other operating expenses in the year ended December 31, 2014; and

• centers acquired or opened during 2014, which resulted in an increase of $3.9 million in other operating expenses in the year ended December 31, 2014.

During the year ended December 31, 2014, we recognized in operating expenses transaction costs primarily associated with the acquisition of Sheridan of $29.0 million.

Depreciation and amortization expense increased $2.3 million, or 7.0%, in the year ended December 31, 2014, primarily as a result of centers acquired during 2013 and 2014.

Equity in earnings of unconsolidated affiliates was $3.2 million during each of the years ended December 31, 2014 and 2013. During the year ended December 31, 2014, we entered into four separate equity method investments. As a result of these investment transactions, we contributed our controlling interest in four of our centers and received net cash of $1.2 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and us. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, we obtained a non-controlling interest in one additional centers which was contributed by a health system.

56

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Physician Services Operations

We utilize certain measures for our physician services operations to monitor our net revenue growth, which includes same contract revenue, new contract revenue and acquired contract revenue. Our same contract revenue reflects revenue received from services provided through contracts in existence in both comparable reporting periods. Our new contract revenue reflects revenue from contracts that have not been in effect for both the entire current and comparable periods less the amount of revenue relating to contracts terminated during such periods. Acquired contract revenue reflects the revenue from acquisitions that were completed during the periods. The following table presents the percentage change related to our net revenue growth and same contract revenue growth during the year ended December 31, 2015.

	2015
Contribution to Net Revenue Growth:
Same contract	7.5	%
New contract	2.0
Acquired contract and other	14.9
Total net revenue growth	24.4	%
Same contract revenue growth	9.9	%

During the year ended December 31, 2015, our total growth in net revenue resulted primarily from physician practices acquired in 2015, which contributed approximately $173.7 million. In addition, we experienced an increase in net revenue as a result of same contract growth, which is reflective of an increase in patient encounters and increased revenue per patient encounter, which in part is due to the continuing positive payer mix shift from serving a higher percentage of insured patients, increased acuity, and positive contracting efforts.

We evaluate our physician services revenue net of contractual adjustments and provisions for uncollectible charges. Payors generally receive discounts from standard charges, which we refer to as contractual adjustments. In addition, patients our physicians serve may be personally responsible for the payment of the medical services they receive. Our contracts with hospitals and other facilities typically require us to provide care to all patients who present at our locations. While we seek to bill for all medical services we provide, a portion of our medical services are delivered to patients that have no insurance and from whom we cannot collect full compensation. As a result, we establish a provision for uncollectible charges. Our net revenue from our physician services operations represents gross billings after provisions for contractual allowances and uncollectibles.

The following table presents selected statement of earnings data expressed in dollars (in thousands) and as a percentage of net revenue for our physician services segment.

	Year Ended December 31, 2015					July 16, 2014 - December 31, 2014 (1)
Net revenue	$	1,336,834		100.0	%	$	512,014	100.0	%
Operating expenses:
Salaries and benefits	942,243			70.5		352,670		68.9
Supply cost	2,439			0.2		1,292		0.3
Other operating expenses	150,269			11.2		54,621		10.7
Transaction costs	6,562			0.5		4,886		1.0
Depreciation and amortization	61,658			4.6		25,677		5.0
Total operating expenses	1,163,171			87.0		439,146		85.8
Loss on deconsolidation	(6,557		)	(0.5	)	—		—
Equity in earnings of unconsolidated affiliates	9,686			0.7		3,839		0.7
Operating income	$	176,792		13.2	%	$	76,707	15.0	%

(1) On July 16, 2014, we completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

57

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Year Ended December 31, 2015 Compared to the Period from July 16 through December 31, 2014

Included in total operating expenses above for the year ended December 31, 2015 is approximately $979.2 million incurred for direct practice expenses, which primarily includes salaries and benefits costs of our physicians and other professional medical personnel. During the period July 16, 2014 through December 31, 2014, direct practice expenses was $372.6 million. As a percentage of physician services revenue, direct practice expense was 73.2% for the year ended December 31, 2015 compared to 72.8% for the period July 16, 2014 through December 31, 2014. Direct practice expense is generally higher in the first quarter due to the concentration of additional payroll taxes and other employee benefits which is not included in prior year's results since the acquisition date was after the first quarter. During the year ended December 31, 2015, we recognized approximately $8.8 million in other operating expenses associated with the net change in fair value of contingent consideration which related to acquisitions completed during the year ended December 31, 2014.

During the year ended December 31, 2015, we incurred approximately $6.6 million of transaction costs associated with our acquisition of physician practices compared to $4.9 million incurred during the prior year period.

Depreciation and amortization for our physician services segment includes approximately $59.1 million of amortization for the year ended December 31, 2015 resulting primarily from amortizable intangible assets related to our customer relationships with hospitals. During the period July 16, 2014 through December 31, 2014 depreciation and amortization for our physician services segment included approximately $24.6 million of amortization. The increase in amortization associated with customer relationships with hospitals during the year ended December 31, 2015 compared to the prior year period is a result of acquisitions completed subsequent to the Sheridan transaction.

We recognized a loss on deconsolidation of $6.6 million during the year ended December 31, 2015 as a result of the deconsolidation of certain contracts which we contributed to one of our unconsolidated investments.

Equity in earnings of unconsolidated affiliates increased to $9.7 million in the year ended December 31, 2015 compared to $3.8 million for the year ended December 31, 2014 primarily due to the growth in operations of our investments in unconsolidated affiliates and due to the additional contracts contributed to and established within these investments during the year.

Liquidity and Capital Resources

Cash and cash equivalents at December 31, 2015 and December 31, 2014 were $106.7 million and $208.1 million, respectively. Our net change in cash is primarily due to the following:

• an increase in net earnings of $136.3 million over the prior year primarily due to having a full year of physician services operations and due to the reduction of transaction costs which were incurred in 2014 to complete the acquisition of Sheridan;

• completed ambulatory services and physician services acquisitions totaling $962.7 million (net of cash acquired);

• net proceeds from a common stock equity offering of $447.7 million;

• net borrowings on the revolving credit agreement of $175.0 million;

• interest payments of $112.7 million compared to $38.1 million in 2014; and

• income tax payments of $74.6 million compared to $19.2 million in 2014.

At December 31, 2015, we had working capital of $149.5 million, compared to $278.1 million at December 31, 2014. The decrease is primarily due to the cash paid for acquisitions completed during the year ended December 31, 2015, an increase in accrued salaries and benefits primarily resulting from increased profit sharing incentives and partially offset by net accounts receivable recorded for current year acquisitions. Operating activities for the year ended December 31, 2015 generated $538.0 million in cash flow from operations, compared to $412.4 million for the year ended December 31, 2014. Additionally, net cash flow provided by operating activities, net of distributions to noncontrolling interests, for the year ended December 31, 2015 was $323.1 million, compared to $222.3 million for the year ended December 31, 2014. The increase in operating cash flow resulted primarily from the additional earnings from our physician services segment, which is included from July 16, 2014 (the date of acquisition) through December 31, 2014 and an increase in net earnings from our ambulatory services segment. For our ambulatory services segment, positive operating cash flows of individual centers are the sole source of cash used to make distributions to our wholly-owned subsidiaries, as well as to our physician partners, which we are obligated to make on a monthly basis in accordance with each partnership’s partnership or operating agreement.

The principal source of our operating cash flow is the collection of accounts receivable from governmental payors, commercial payors and individuals. We bill for services as delivered, usually within a few days following the date the service is rendered for our ambulatory services segment and within five to ten days following the date the service is rendered for our physician services segment.

58

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Generally, unpaid amounts that are 30 to 45 days past due are rebilled based on a standard set of procedures. If amounts remain uncollected after 60 days, we proceed with a series of late-notice notifications until amounts are either collected, contractually written off in accordance with contracted rates or determined to be uncollectible, typically after 90 to 120 days. Receivables determined to be uncollectible are written off and such amounts are applied to our estimate of allowance for bad debts as previously established in accordance with our policy for bad debt expense. The amount of actual write-offs of account balances for each of our subsidiaries is continuously compared to established allowances for bad debt to ensure that such allowances are adequate. At December 31, 2015 and 2014, our ambulatory services segment net accounts receivable represented 38 and 37 days of revenue outstanding, respectively. At December 31, 2015 and 2014, our physician services segment net accounts receivable represented 44 and 41 days of revenue outstanding, respectively.

During the year ended December 31, 2015, we had total acquisition and capital expenditures of $1.0 billion, which included:

• $831.4 million for the acquisition of physician practices;

• $131.3 million for the acquisition of interests in surgery centers; and

• $62.5 million for new or replacement property, including $2.3 million in new capital leases.

At December 31, 2015, we had unfunded construction and equipment purchase commitments for our new physician services headquarters and for surgery centers under development or under renovation of approximately $18.3 million, which we intend to fund through additional borrowings of long-term debt and operating cash flow.

As of December 31, 2015 we had $27.4 million of restricted cash and marketable securities which is restricted for the purpose of satisfying the obligations of our wholly-owned captive insurance company. Approximately $13.5 million is reflected as a component of total current assets in the accompanying consolidated balance sheets which is expected to be utilized to satisfy the claims payments estimated to occur in the next 12 months.

During the year ended December 31, 2015, we received approximately $2.6 million from the exercise of stock options under our employee stock incentive plans and the tax benefit received from the exercise of those options and restricted stock vested was approximately $4.0 million.

During the year ended December 31, 2015, we repurchased 67,000 shares of our common stock by withholding a portion of employee restricted stock that vested, with a value of approximately $3.7 million, to cover payroll withholding taxes in accordance with the restricted stock agreements. During the year ended December 31, 2014, we repurchased 100,720 shares of our common stock by withholding a portion of employee restricted stock that vested, with a value of approximately $4.6 million, to cover payroll withholding taxes in accordance with the restricted stock agreements.

During December 2015, we issued 5,835,000 shares of its common stock in a public offering, at $80.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $19.1 million. Proceeds were used to repay a portion of our revolving credit facility, to fund a portion of the acquisitions completed during the year ended 2015 and for general corporate purposes.

For the year ended December 31, 2015, we had net proceeds from long-term borrowings of $167.5 million. At December 31, 2015, we had available $325.0 million under our revolving credit agreement, $250.0 million outstanding pursuant to our 5.625% senior unsecured notes due 2020 (the 2020 Senior Unsecured Notes), $1.1 billion outstanding pursuant to our 5.625% Senior Unsecured Notes due 2022 (the 2022 Senior Unsecured Notes) and $857.0 million outstanding pursuant to our term loan.

On July 16, 2014, we completed the acquisition of Sheridan in a cash and stock transaction valued at approximately $2.35 billion. To fund the transaction, we completed offerings of common stock and mandatory convertible preferred stock on July 2, 2014, which resulted in the issuance of 9,775,000 shares of common stock and 1,725,000 shares of mandatory convertible preferred stock. Proceeds from the common stock offering and mandatory preferred stock offering, net of estimated transaction fees, were approximately $421.3 million and $166.6 million, respectively. In addition, on July 16, 2014, we entered into a new senior secured credit facility comprised of an $870.0 million term loan and a $300.0 million revolving credit facility and completed a private offering of $1.1 billion aggregate principal amount of our 2022 Senior Unsecured Notes. As a result of these transactions, the obligations related to our previously existing revolving credit facility and Senior Secured Notes were satisfied and terminated.

Our $870.0 million term loan matures on July 16, 2021 and bears interest equal to, at our option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on December 31, 2015). The new revolving credit facility, which matures on July 16, 2019, permits us to borrow up to $500.0 million, as amended, at an interest rate equal to, at our option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a

59

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

combination thereof; and provides for a fee of 0.375% of unused commitments. In accordance with the terms of the senior secured credit facility, principal payments are required quarterly in installments of an amount equal to 0.25% of the aggregate initial principal amount of the term loan. We have the option to increase borrowings under our senior secured credit facility beyond the initial term under both the term loan and revolver as long as certain financial covenants are met and lender approval is obtained. On October 21, 2015, we exercised the accordion feature of our revolving credit facility and increased our borrowing capacity by $200.0 million to $500.0 million.

During 2014, we completed a private offering of $1.1 billion aggregate principal amount in 2022 Senior Unsecured Notes. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15 through the maturity date on July 15, 2022. At December 31, 2015, we had approximately $28.5 million in accrued interest associated with the 2022 Senior Unsecured Notes reflected in other accrued liabilities, which was paid in January 2016.

The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends began to accrue from the date of issuance and, to the extent lawful and declared by our board of directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at our election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. On July 1, 2017, all outstanding shares of our mandatory convertible preferred stock will convert into common stock. During the year ended December 31, 2015, our Board of Directors has declared four dividend payments each totaling $1.3125 per share in cash, or $2.3 million each, totaling $9.1 million. All declarations have been funded to the paying agent at December 31, 2015 except those declared on November 19, 2015, which were funded to the paying agent to be paid on January 1, 2016 to shareholders of record as of December 15, 2015. During the year ended December 31, 2014, our Board of Directors declared dividends totaling $4.5 million.

During 2012, we completed a private offering of $250.0 million in 2020 Senior Unsecured Notes. Interest accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30th and November 30th, through the maturity date on November 30, 2020. At December 31, 2015, we had approximately $1.2 million in accrued interest associated with the 2020 Senior Unsecured Notes reflected in other accrued liabilities which will be paid in May 2016. The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit our ability to enter into or guarantee additional borrowing, sell preferred stock, pay dividends and repurchase stock, in each case subject to certain exceptions.

As of December 31, 2015, we were in compliance with all covenants contained in our credit agreement, the indenture governing our 2020 Senior Unsecured Notes, and the indenture governing our 2022 Senior Unsecured Notes.

The following schedule summarizes our contractual obligations by period as of December 31, 2015 (in thousands):

	Payments Due by Period
			Less than						More than
	Total		1 Year		1-3 Years		3-5 Years		5 Years
Long-term debt, including interest (1)	$	3,066,523	$	130,037	$	253,259	$	658,247	$	2,024,980
Capital lease obligations, including interest	25,224		3,021		5,278		3,934		12,991
Operating leases, including renewal option periods (2)	599,166		55,636		109,372		102,412		331,746
Liability for unrecognized tax benefits	3,426		—		3,426		—		—
Contingent consideration	5,509		5,509		—		—		—
Construction in progress commitments	18,290		18,290		—		—		—
Total contractual obligations	$	3,718,138	$	212,493	$	371,335	$	764,593	$	2,369,717

(1) Our long-term debt may increase based on future acquisition activity. We intend to either use our operating cash flow to repay our long-term debt or refinance such obligations as they come due.

(2) Operating lease obligations do not include common area maintenance, insurance or tax payments for which we were also obligated.

On January 16, 2015, we entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which we intend to be the future headquarters of our physician services operations. We took possession of the space in the fourth quarter of 2015 to begin tenant improvements on approximately 167,000 square feet of space, which we intend to occupy during the third quarter of 2016. In addition, we plan to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which we intend to occupy during the fourth quarter of 2016. Annual rent expense is expected to be approximately

60

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

$2.9 million. The initial term of this lease agreement expires in February 2029. Our rent obligation does not require cash payments until September 2016.

Based upon our current operations and anticipated growth, we believe our operating cash flow, borrowing capacity and ability to access capital markets will provide adequate resources to meet our working capital and capital expenditure requirements for the next 12 to 18 months. In addition to acquiring and developing ASCs and physician practices, we may from time to time consider other acquisitions or strategic joint ventures involving other companies, multiple-center chains, networks of ASCs or physician practices. Such acquisitions, joint ventures or other opportunities may require an amendment to our current debt agreements or additional external financing, which may include sales of equity securities. We cannot assure you that any required financing will be available, or will be available on terms acceptable to us.

Item 7A.      Quantitative and Qualitative Disclosures About Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates. Our variable debt instruments are primarily indexed to the prime rate or LIBOR. Interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements. Based upon our indebtedness at December 31, 2015, a 100 basis point interest rate change would impact our net earnings and cash flow by approximately $6.2 million annually. Although there can be no assurances that interest rates will not change significantly, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2016.

The table below provides information as of December 31, 2015 about our long-term debt obligations based on maturity dates that are sensitive to changes in interest rates, including principal cash flows and related weighted average interest rates by expected maturity dates (in thousands, except percentage data):

																					Fair Value at
	Years Ended December 31,																				December 31,
	2016			2017			2018			2019			2020			Thereafter			Total		2015
Fixed rate	$	11,098		$	8,995		$	5,768		$	3,193		$	252,311		$	1,110,848		$	1,392,213	$	1,387,088
Average interest rate	3.6		%	3.6		%	3.9		%	4.4		%	5.6		%	5.6		%
Variable rate	$	9,279		$	9,022		$	9,030		$	183,813		$	8,700		$	813,450		$	1,033,294	$	1,033,294
Average interest rate	3.5		%	3.5		%	3.5		%	3.4		%	3.5		%	3.5		%

61

Item 8.   Financial Statements and Supplementary Data Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

AmSurg Corp.

Nashville, Tennessee

We have audited the accompanying consolidated balance sheets of AmSurg Corp. and subsidiaries (the “Company”) as of December 31, 2015 and 2014, and the related consolidated statements of earnings, changes in equity, and cash flows for each of the three years in the period ended December 31, 2015. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of AmSurg Corp. and subsidiaries as of December 31, 2015 and 2014, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2015, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company's internal control over financial reporting as of December 31, 2015, based on the criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2016 expressed an unqualified opinion on the Company's internal control over financial reporting.

/s/  DELOITTE & TOUCHE LLP

Nashville, Tennessee

February 25, 2016

62

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

AmSurg Corp. Consolidated Balance Sheets (In thousands)
	December 31,		December 31,
	2015		2014
Assets
Current assets:
Cash and cash equivalents	$	106,660	$	208,079
Restricted cash and marketable securities	13,506		10,219
Accounts receivable, net of allowance of $167,411 and $113,357, respectively	337,330		233,053
Supplies inventory	21,406		19,974
Prepaid and other current assets	75,771		92,900
Total current assets	554,673		564,225
Property and equipment, net	189,168		180,448
Investments in unconsolidated affiliates	169,170		75,475
Goodwill	3,970,210		3,381,149
Intangible assets, net	1,641,811		1,273,879
Other assets	21,450		25,886
Total assets	$	6,546,482	$	5,501,062
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	20,377	$	18,826
Accounts payable	32,561		29,585
Accrued salaries and benefits	202,537		140,044
Accrued interest	30,480		29,644
Other accrued liabilities	119,237		67,986
Total current liabilities	405,192		286,085
Long-term debt	2,405,130		2,232,186
Deferred income taxes	699,498		611,018
Other long-term liabilities	96,183		89,443
Commitments and contingencies
Noncontrolling interests – redeemable	175,732		184,099
Equity:
Preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632		166,632
Common stock, no par value, 120,000 and 70,000 shares authorized, respectively, 54,294 and 48,113 shares issued and outstanding, respectively	1,345,418		885,393
Retained earnings	781,413		627,522
Total AmSurg Corp. equity	2,293,463		1,679,547
Noncontrolling interests – non-redeemable	471,284		418,684
Total equity	2,764,747		2,098,231
Total liabilities and equity	$	6,546,482	$	5,501,062

See accompanying notes to the consolidated financial statements.

63

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

AmSurg Corp. Consolidated Statements of Earnings (In thousands, except earnings per share)
	Year Ended December 31,
	2015			2014			2013
Revenues	$	2,832,958		$	1,738,950		$	1,057,196
Provision for uncollectibles	(266,074		)	(117,001		)	—
Net revenue	2,566,884			1,621,949			1,057,196
Operating expenses:
Salaries and benefits	1,314,392			694,576			327,585
Supply cost	184,222			164,296			153,126
Other operating expenses	397,794			284,928			216,501
Transaction costs	8,324			33,890			300
Depreciation and amortization	97,493			60,344			32,400
Total operating expenses	2,002,225			1,238,034			729,912
Net gain on deconsolidations	36,694			3,411			2,237
Equity in earnings of unconsolidated affiliates	16,152			7,038			3,151
Operating income	617,505			394,364			332,672
Interest expense, net	121,586			83,285			29,525
Debt extinguishment costs	—			16,887			—
Earnings from continuing operations before income taxes	495,919			294,192			303,147
Income tax expense	113,790			48,103			48,654
Net earnings from continuing operations	382,129			246,089			254,493
Net earnings (loss) from discontinued operations	(1,013		)	(1,296		)	7,051
Net earnings	381,116			244,793			261,544
Less net earnings attributable to noncontrolling interests	218,169			191,092			188,841
Net earnings attributable to AmSurg Corp. shareholders	162,947			53,701			72,703
Preferred stock dividends	(9,056		)	(4,503		)	—
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	49,198		$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	154,892		$	50,777		$	71,009
Earnings (loss) from discontinued operations, net of income tax	(1,001		)	(1,579		)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	49,198		$	72,703
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations	$	3.22		$	1.29		$	2.27
Net earnings (loss) from discontinued operations	(0.02		)	(0.04		)	0.05
Net earnings	$	3.20		$	1.25		$	2.32
Diluted earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations	$	3.18		$	1.28		$	2.22
Net earnings (loss) from discontinued operations	(0.02		)	(0.04		)	0.05
Net earnings	$	3.16		$	1.24		$	2.28
Weighted average number of shares and share equivalents outstanding:
Basic	48,058			39,311			31,338
Diluted	51,612			39,625			31,954

See accompanying notes to the consolidated financial statements.

64

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

AmSurg Corp. Consolidated Statements of Changes in Equity (In thousands)
	AmSurg Corp. Shareholders																	Noncontrolling
												Noncontrolling						Interests –
												Interests –			Total			Redeemable
	Common Stock					Preferred Stock			Retained			Non-			Equity			(Temporary
	Shares		Amount			Shares	Amount		Earnings			Redeemable			(Permanent)			Equity)
Balance at January 1, 2013	31,941		$	183,867		—	$	—	$	505,621		$	310,978		$	1,000,466		$	175,382
Net earnings	—		—			—	—		72,703			49,789			122,492			139,052
Issuance of restricted common stock	292		—			—	—		—			—			—			—
Cancellation of restricted common stock	(16	)	—			—	—		—			—			—			—
Stock options exercised	1,393		33,349			—	—		—			—			33,349			—
Stock repurchased	(1,257	)	(45,964		)	—	—		—			—			(45,964		)	—
Share-based compensation	—		8,321			—	—		—			—			8,321			—
Tax benefit related to exercise of share-based awards	—		7,247			—	—		—			—			7,247			—
Acquisitions and other transactions impacting noncontrolling interests	—		679			—	—		—			48,115			48,794			(319		)
Distributions to noncontrolling interests, net of capital contributions	—		—			—	—		—			(49,533		)	(49,533		)	(134,298		)
Disposals and other transactions impacting noncontrolling interests	—		(1,626		)	—	—		—			2,010			384			(2,120		)
Balance at December 31, 2013	32,353		$	185,873		—	$	—	$	578,324		$	361,359		$	1,125,556		$	177,697
Net earnings	—		—			—	—		53,701			56,048			109,749			135,044
Issuance of stock	15,490		693,289			1,725	166,632		—			—			859,921			—
Issuance of restricted stock	272		—			—	—		—			—			—			—
Cancellation of restricted stock	(12	)	—			—	—		—			—			—			—
Stock options exercised	111		2,630			—	—		—			—			2,630			—
Stock repurchased	(101	)	(4,615		)	—	—		—			—			(4,615		)	—
Share-based compensation	—		10,104			—	—		—			—			10,104			—
Tax benefit related to exercise of share-based awards	—		3,177			—	—		—			—			3,177			—
Dividends paid on preferred stock	—		—			—	—		(4,503		)	—			(4,503		)	—
Acquisitions and other transactions impacting noncontrolling interests	—		744			—	—		—			54,725			55,469			6,482
Distributions to noncontrolling interests, net of capital contributions	—		—			—	—		—			(56,439		)	(56,439		)	(133,594		)
Disposals and other transactions impacting noncontrolling interests	—		(5,809		)	—	—		—			2,991			(2,818		)	(1,530		)
Balance at December 31, 2014	48,113		$	885,393		1,725	$	166,632	$	627,522		$	418,684		$	2,098,231		$	184,099
Net earnings	—		—			—	—		162,947			67,568			230,515			150,601
Issuance of stock	5,835		447,720			—	—		—			—			447,720			—
Issuance of restricted stock	314		—			—	—		—			—			—			—
Cancellation of restricted stock	(14	)	—			—	—		—			—			—			—
Stock options exercised	113		2,584			—	—		—			—			2,584			—
Stock repurchased	(67	)	(3,684		)	—	—		—			—			(3,684		)	—
Share-based compensation	—		15,009			—	—		—			—			15,009			—
Tax benefit related to exercise of share-based awards	—		4,001			—	—		—			—			4,001			—
Dividends paid on preferred stock	—		—			—	—		(9,056		)	—			(9,056		)	—
Acquisitions and other transactions impacting noncontrolling interests	—		1,019			—	—		—			81,863			82,882			(725		)
Distributions to noncontrolling interests, net of capital contributions	—		—			—	—		—			(66,294		)	(66,294		)	(147,182		)
Disposals and other transactions impacting noncontrolling interests	—		(6,624		)	—	—		—			(30,537		)	(37,161		)	(11,061		)
Balance at December 31, 2015	54,294		$	1,345,418		1,725	$	166,632	$	781,413		$	471,284		$	2,764,747		$	175,732

See accompanying notes to the consolidated financial statements.

65

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

AmSurg Corp. Consolidated Statements of Cash Flows (In thousands)
	Year Ended December 31,
	2015			2014			2013
Cash flows from operating activities:
Net earnings	$	381,116		$	244,793		$	261,544
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	97,493			60,344			32,400
Amortization of deferred loan costs	8,362			17,715			1,977
Provision for uncollectibles	287,427			139,274			21,947
Net (gain) loss on sale of long-lived assets	(12		)	2,843			(1,468		)
Net gain on deconsolidations	(36,694		)	(3,411		)	(2,237		)
Share-based compensation	15,009			10,104			8,321
Excess tax benefit from share-based compensation	(4,001		)	(3,177		)	(7,247		)
Deferred income taxes	19,037			30,780			38,363
Equity in earnings of unconsolidated affiliates	(16,152		)	(7,038		)	(3,151		)
Debt extinguishment costs	—			4,536			—
Net change in fair value of contingent consideration	8,804			—			—
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(326,234		)	(137,663		)	(23,244		)
Supplies inventory	(342		)	(206		)	132
Prepaid and other current assets	25,880			(9,091		)	(5,308		)
Accounts payable	3,131			(8,440		)	441
Accrued expenses and other liabilities	66,600			66,175			6,693
Other, net	8,535			4,833			3,661
Net cash flows provided by operating activities	537,959			412,371			332,824
Cash flows from investing activities:
Acquisitions and related expenses	(962,689		)	(2,184,058		)	(73,594		)
Acquisition of property and equipment	(60,305		)	(40,217		)	(28,856		)
Proceeds from sale of interests in surgery centers	7,114			7,069			3,553
Purchases of marketable securities	(3,984		)	(6,474		)	—
Maturities of marketable securities	4,233			3,486			—
Other	(1,194		)	(4,941		)	159
Net cash flows used in investing activities	(1,016,825		)	(2,225,135		)	(98,738		)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	560,133			2,048,958			162,204
Repayment on long-term borrowings and revolving credit facility	(392,586		)	(408,475		)	(202,083		)
Distributions to noncontrolling interests	(214,899		)	(190,097		)	(184,149		)
Proceeds from preferred stock offering	—			172,500			—
Proceeds from common stock offering	466,777			439,875			—
Proceeds from issuance of common stock upon exercise of stock options	2,584			2,630			33,349
Repurchase of common stock	(3,684		)	(4,615		)	(45,964		)
Payments of equity issuance costs	(19,058		)	(24,494		)	—
Financing costs incurred	(1,111		)	(65,811		)	(1,322		)
Other	(20,709		)	(468		)	8,321
Net cash flows provided by (used in) financing activities	377,447			1,970,003			(229,644		)
Net increase (decrease) in cash and cash equivalents	(101,419		)	157,239			4,442
Cash and cash equivalents, beginning of period	208,079			50,840			46,398
Cash and cash equivalents, end of period	$	106,660		$	208,079		$	50,840
Supplemental cash flow information:
Interest payments	$	112,678		$	38,129		$	28,378
Income tax payments, net of refunds	$	74,602		$	19,224		$	7,756

See accompanying notes to the consolidated financial statements.

66

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

AmSurg Corp.

Notes to the Consolidated Financial Statements

(1) Summary of Accounting Policies

Below are a summary of the Company's policies that are not otherwise found within other notes.

a.     Principles of Consolidation

Ambulatory Services

AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics. All LLCs and LPs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively. The Company does not have an ownership interest in a partnership greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in 23 partnerships, 2 of which it consolidates as the Company has substantive participation rights and 21 of which it does not consolidate as the Company’s rights are limited to protective rights only. Consolidation of certain less than wholly owned partnerships is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the partnership, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the partnership, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. 

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LLCs or LPs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of

67

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan has certain management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is generally a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned affiliates. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “Consolidations.”

b.    Cash and Cash Equivalents

Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value.

c.    Restricted Cash and Marketable Securities

As of December 31, 2015 and 2014, the Company had $27.4 million and $30.3 million, respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $13.9 million and $20.1 million as of December 31, 2015 and 2014, respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of December 31, 2015 and 2014, the Company had $2.7 million and $3.0 million, respectively, included in restricted cash and marketable securities at cost, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.

d.    Supplies Inventory

Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.

e.    Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2015 and 2014, with the exception of contingent purchase price payables and the retained interests of investments in unconsolidated affiliates (further discussed in note 4 and note 5, respectively), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended

68

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

December 31, 2015. The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value.

f.    Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

g.    Reclassifications

Certain amounts in the consolidated financial statements and these notes have been reclassified for the retrospective adoption of the Financial Accounting Standards Board's (FASB) Accounting Standards Update (ASU) 2015-17 “Balance Sheet Classification of Deferred Taxes”. See below for further explanation.

h.    Recent Accounting Pronouncements

In April 2014, the FASB issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted. From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. The guidance in ASU 2014-09 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein.

The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015, including interim periods therein. The Company does not believe this ASU will impact the Company's consolidated financial position, results of operations or cash flows. However, the Company continues to evaluate the disclosures required under this ASU and has not yet determined the impact, if any.

In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. Upon adoption, the Company will reclassify debt issuance costs which are currently presented as a component of intangible assets in the accompanying consolidated balance sheets to long-term debt, except those debt issuance costs associated with the Company's revolving credit facility. The Company expects the adoption of this standard will not have a significant impact on the Company's

69

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

consolidated financial position and will have no impact on the results of operations or cash flows.

In September 2015, the FASB issued ASU 2015-16 “Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments” which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment, including the effect on earnings of any amounts it would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after December 31, 2015 with early adoption permitted. The Company adopted this standard as of September 2015. The adoption of this ASU did not have a material effect on the Company's consolidated financial position, results of operations or cash flows as of December 31, 2015.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes” which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and non-current. The guidance is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted and companies may adopt the guidance prospectively or retrospectively. The Company adopted this standard retrospectively as of December 31, 2015 and as a result, reclassified $22.5 million from prepaid and other current assets to noncurrent deferred income taxes at December 31, 2014 in the accompanying consolidated balance sheets.

(2)  Revenue Recognition

Ambulatory Services

Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2015, 2014 and 2013, the Company derived approximately 26%, 25% and 25%, respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.

Physician Services

Physician services revenues primarily consist of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors.

The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors.

The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

70

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Net revenue for the physician services segment consists of the following major payors (in thousands):

	Year Ended December 31, 2015					Period from July 16, 2014 - December 31, 2014 (1)
Medicare	$	172,783		12.9	%	$	61,378		12.0	%
Medicaid	69,607			5.2		28,224			5.5
Commercial and managed care	1,007,902			75.4		382,343			74.7
Self-pay	222,830			16.7		102,727			20.1
Net fee for service revenue	1,473,122			110.2		574,672			112.3
Contract and other revenue	129,786			9.7		54,343			10.6
Provision for uncollectibles	(266,074		)	(19.9	)	(117,001		)	(22.9	)
Net revenue for physician services	$	1,336,834		100.0	%	$	512,014		100.0	%

(1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

(3) Accounts Receivable

The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Assessment of actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company routinely tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, for each facility or contract, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company may also supplement its allowance for doubtful accounts policy for its physician services using a hindsight calculation that utilizes write-off data for all payor classes during the previous periods to estimate the allowance for doubtful accounts at a point in time. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, specialty mix, acuity, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.

Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statement of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statement of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statement of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for the ambulatory services segment is included in other operating expenses and was approximately $21.4 million, $21.9 million and $21.7 million for the years ended December 31, 2015, 2014 and 2013, respectively. Bad debt expense related to physician services was $266.1 million for the year ended December 31, 2015 and $117.0 million during the period from July 16, 2014 through December 31, 2014.

At December 31, 2015 and 2014 allowances for doubtful accounts were $167.4 million and $113.4 million, respectively. The increase in the allowance for doubtful accounts is primarily a result of operations from acquisitions completed during the year ended December 31, 2015. At December 31, 2015 and 2014, approximately 80% and 73%, respectively, of the Company’s allowance for doubtful accounts was related to fee for service patient receivables associated with the Company's physician services segment. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors and by the geographic dispersion of the Company’s operations.

71

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

(4)  Acquisitions

The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Ambulatory Services Acquisitions

During 2015 and 2014, the Company, through a wholly-owned subsidiary, acquired a controlling interest in seven and eight surgery centers, respectively. Of the centers acquired during 2014, three were acquired as part of the Sheridan transaction and five were individually acquired in separate transactions. The aggregate amount paid for the centers and for settlement of purchase price payable obligations during December 31, 2015 and 2014 was approximately $131.3 million and $50.9 million, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility. The acquisitions completed during the year ended December 31, 2015 consist of the following:

Acquired Operations	Location	Date Acquired	Specialty
River Drive Surgery & Laser Center, LLC	Elmwood Park, NJ	February 2015	Ophthalmology
Campus Surgery Center, LLC	Daly City, CA	June 2015	Multi-Specialty
Waverly Surgery Center, LLC	Palo Alto, CA	June 2015	Multi-Specialty
Surgical Center at Millburn, LLC	Millburn-East Willow, NJ	July 2015	Multi-Specialty
Eye Surgery Center of Western Ohio, LLC	Lima, OH	August 2015	Ophthalmology
Surgical Specialty Center of Northeastern PA, LLC	Forty Fort, PA	October 2015	Multi-Specialty
South Portland Surgical Center, LLC	Tualatin, OR	November 2015	Multi-Specialty

Physician Services Acquisitions

The Company completed the acquisition of nine physician practices in 2015 and two physician practices in 2014 following the acquisition of Sheridan. During 2015 and 2014, the total consideration consisted of cash of $831.4 million and $19.0 million, respectively, which was funded at closing through available cash, current year operating cash flow and borrowings through the Company's credit facility. The acquisitions completed during the year ended December 31, 2015 consist of the following:

Acquired Operations	Location	Date Acquired	Specialty
Ambulatory Anesthesia Care, PC	Mountainside, NJ	January 2015	Anesthesia
Sheridan Radiology Management Services, Inc.	Beachwood, OH	January 2015	Radiology
Radiology Associates of Hollywood, P.A.	Pembroke Pines, FL	March 2015	Radiology
Halifax Anesthesiology Associates, P.A.	Daytona Beach, FL	April 2015	Anesthesia
Coastal Anesthesiology Consultants, P.A.	St. Augustine, FL	July 2015	Anesthesia
Bay Area Anesthesia, LLC	Tampa, FL	August 2015	Anesthesia
Valley Anesthesia Consultants, Ltd.	Phoenix, AZ	November 2015	Anesthesia
Chandler Emergency Medical Group, LLC	Phoenix, AZ	December 2015	Emergency
Northside Anesthesiology Consultants, LLC	Atlanta, GA	December 2015	Anesthesia

As a result of certain acquisitions completed during the year ended December 31, 2014, the Company has agreed to pay as additional consideration, amounts which are contingent on the acquired entities achieving future performance metrics. As of December 31, 2015 and December 31, 2014, the Company had accrued $5.5 million and $20.7 million, respectively, as a component of accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets which represents management's estimate of the fair values of the contingent consideration. During the year ended December 31, 2015, the Company made a payment of $28.7 million, of which $15.7 million was to settle the amount recorded at the acquisition date and represents a financing outflow in the consolidated statement of cash flows. As of December 31, 2015, the Company estimates it may have to pay between $5.0 million and $6.0 million

72

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

in future contingent payments for acquisitions made prior to December 31, 2014 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisitions over each respective measurement period. During the year ended December 31, 2015, the Company recorded a net increase of $10.0 million based on results of operations of the associated acquisitions, of which $8.8 million is included in other operating expenses in the accompanying consolidated statements of earnings. Additionally, the Company recorded an increase in the contingent liability of $3.5 million during the year ended December 31, 2015 as a result of the acquisition accounting associated with the purchase of Sheridan. The acquisitions completed during the year ended December 31, 2015 did not contain provisions for contingent consideration.

The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the payments of the additional consideration varies by agreement but is expected to occur within one to three years from the respective date of acquisition.

Sheridan Acquisition

On July 16, 2014 (the “acquisition date”), the Company completed the acquisition of Sheridan in a cash and stock transaction. At closing, the Company paid approximately $2.1 billion in cash and issued 5,713,909 shares of its common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The shares issued to Sheridan were valued at approximately $272.0 million based on the closing price of the Company's common stock on July 16, 2014. The acquisition of Sheridan enhances the growth profile and diversity of the Company focusing on complementary specialties across the healthcare continuum.

To fund the transaction, the Company completed offerings of common stock and mandatory convertible preferred stock resulting in the issuance of 9,775,000 shares of common stock and 1,725,000 shares of mandatory convertible preferred stock. Proceeds from the common stock offering and mandatory preferred stock offering, net of transaction fees, were approximately $421.3 million and $166.6 million, respectively. In addition, on July 16, 2014, the Company entered into a new senior secured credit facility, which includes an $870.0 million term loan and a $300.0 million revolving credit facility, and completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022.

Fees and expenses associated with the Sheridan transaction, which includes fees incurred related to the Company's equity issuances and debt financings, was approximately $139.1 million during the year ended December 31, 2014. Approximately $53.0 million was capitalized as deferred financing costs, $24.5 million was related to the equity offerings and recorded as a reduction to equity, $31.9 million was expensed as transaction costs, $12.8 million was amortized through interest expense and $16.9 million was recorded as debt extinguishment costs during the year ended December 31, 2014.

73

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Purchase Price Allocations

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2015 and 2014, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 

	2015			2014
	Individual			Individual
	Acquisitions (1)			Acquisitions			Sheridan
Accounts receivable	$	62,216		$	1,816		$	130,260
Other current assets	21,477			1,075			105,757
Property and equipment	15,484			3,294			20,185
Goodwill	682,458			101,865			1,534,656
Intangible assets	420,414			14,207			1,200,028
Other long-term assets	342			—			50,304
Accounts payable	(3,641		)	(2,519		)	(5,862		)
Other accrued liabilities	(45,386		)	(626		)	(118,548		)
Deferred income taxes	(88,728		)	—			(432,792		)
Other long-term liabilities	(4,958		)	(8,588		)	(69,456		)
Long-term debt	(6,046		)	(717		)	(4,594		)
Total fair value	1,053,632			109,807			2,409,938
Less: Fair value attributable to noncontrolling interests	85,443			39,371			24,365
Acquisition date fair value of total consideration transferred	$	968,189		$	70,436		$	2,385,573

(1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2015.

During 2015, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2014. During 2015, factors became known to the Company that resulted in changes to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to Sheridan and resulted in a net decrease to goodwill of $8.3 million, an increase to other accrued expenses, a decrease to other current assets and a decrease to deferred income taxes.

The total fair value of acquisitions completed by the Company include amounts allocated to goodwill, which result from the acquisitions' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. Additionally, the Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests associated with acquisitions completed in the last twelve months. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the amortizable intangible assets recognized. The amount allocated to the deferred income tax liability is subject to change as a result of the final allocation of purchase price to amortizable intangibles. The Company expects to finalize the purchase price allocation for its most recent acquisitions as soon as practical.

During the year ended December 31, 2015, the Company incurred approximately $8.3 million of transaction costs associated with its acquisition of surgery centers and physician practices. During the year ended December 31, 2014, the Company incurred approximately $33.9 million of transaction costs primarily associated with the acquisition of Sheridan. Such costs excluded those amounts that were either capitalized or expensed as part of the financing transactions associated with acquisitions.

74

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Revenues and net earnings included in the years ended December 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands):

	2015		2014
	Individual		Individual
	Acquisitions		Acquisitions		Sheridan
Net revenue	$	179,113	$	20,844	517,213
Net earnings	26,901		5,155		26,776
Less: Net earnings attributable to noncontrolling interests	7,448		2,859		459
Net earnings attributable to AmSurg Corp. common shareholders	$	19,453	$	2,296	$	26,317

The unaudited consolidated pro forma results for the years ended December 31, 2015 and 2014, assuming all 2015 acquisitions had been consummated on January 1, 2014, all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands):

	2015		2014
Net revenue	$	2,858,544	$	2,680,273
Net earnings	401,950		322,653
Amounts attributable to AmSurg Corp. common shareholders:
Net earnings	170,453		104,548
Net earnings per common share:
Basic	$	3.55	$	2.21
Diluted	$	3.48	$	2.20

(5) Investments in Unconsolidated Affiliates

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination are generally based on a combination of multiple valuation methods which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

As of December 31, 2015 and 2014, the Company has recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $169.2 million and $75.5 million, respectively. The Company's net earnings from these investments during the years ended December 31, 2015, 2014 and 2013 were approximately $16.2 million, $7.0 million and $3.2 million, respectively.

During the year ended December 31, 2015, the Company's ambulatory services segment entered into five separate equity method investments. As a result of these investment transactions, the Company contributed its controlling interest in nine centers and received net cash of $8.5 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and the Company. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, the Company obtained a non-controlling interest in three additional centers and one surgical hospital which were contributed by the health systems.

During the year ended December 31, 2015, the Company's physician services segment contributed three contracts into an entity jointly owned by the Company and a health system.

During the year ended December 31, 2014, the Company's ambulatory services segment entered into four separate equity method investments. As a result of these investment transactions, the Company contributed its controlling interest in four of its centers and received net cash of $1.2 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly

75

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

owned by a health system and the Company. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, the Company obtained a non-controlling interest in one additional centers which was contributed by a health system.

During the year ended December 31, 2013, the Company's ambulatory services segment entered into one equity method investment. As a result of this investment transaction, the Company contributed cash of $0.3 million and its controlling interest in one center in exchange for a noncontrolling interests in the new investment. This investment is jointly owned by a health system and the Company. The newly formed investment (including the contributed center) are controlled by the health system. Also, as part of this transaction, the Company obtained a non-controlling interest in one additional center which was contributed by the health system.

As a result of these transactions, for the years ended December 31, 2015 and 2014, the Company recorded the fair value of the Company's investment in these entities of approximately $83.1 million and $56.4 million, respectively, in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates.

In each of these transactions, the gain or loss on deconsolidation, which is primarily non-cash in nature, is determined based on the difference between the fair value of the Company’s interest, which is based on estimates of the expected future earnings, in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers or contracts immediately prior to each transaction. In certain cases, the Company evaluated likely scenarios which were weighted by a range of expected probabilities of 10% to 50% which were primarily based on third party valuations received by the Company. Accordingly, the Company recognized a net gain on deconsolidations in the accompanying consolidated statements of earnings of approximately $36.7 million, $3.4 million, and $2.2 million during the years ended December 31, 2015, 2014 and 2013.

Included in the Company’s investments in unconsolidated affiliates are certain investments which the Company has determined meet the definition of a variable interest entity. The Company has a variable interest in these investments through its equity interests; however, the Company is not the primary beneficiary of these entities as it only holds 50% of the voting rights and does not have the power to direct the activities that most significantly impact the entities' economic performance as a result of the Company’s shared control. As a result, the Company has accounted for these investments under the equity method of accounting. The Company's investment in these entities was $89.6 million and $53.2 million as of December 31, 2015 and 2014, respectively, and are reflected in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates. During the year ended December 31, 2015, the Company contributed four centers which were previously controlled into an entity deemed by the Company to meet the definition of a variable interest entity which resulted in the Company’s recording the fair value of its retained noncontrolling interest of approximately $27.1 million as a component of investments in unconsolidated affiliates in the accompanying consolidated balance sheets. During the year ended December 31, 2014, as part of the acquisition of Sheridan, the Company acquired an interest in an entity deemed to be a variable interest entity and recorded the estimated fair value of the investment of $49.4 million on the acquisition date. The Company’s ownership interest in these investments ranges from 49% to 51% and under the terms of the operating agreements, the Company earns billing and management fees and receives its share of earnings distributions from each entity. The Company has no other material obligations or guarantees related to these entities.

The Company has recorded its share of the earnings of these investments of $11.0 million and $3.4 million as a component of equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings during 2015 and 2014, respectively. In addition, the Company recognized management and billing fees totaling $14.3 million and $4.7 million during 2015 and 2014, respectively, which are included in net revenue in the accompanying consolidated statement of earnings. Additionally, the Company has recorded receivables from these entities in the amount of $2.3 million and $3.5 million as of December 31, 2015 and 2014, respectively. These receivables are included in other current assets in the accompanying consolidated balance sheets.

76

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

(6)  Discontinued Operations

During the years ended December 31, 2014 and 2013, the Company discontinued the operations of certain centers in its ambulatory services segment due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. For centers discontinued in 2014 and prior, the results of operations of those centers have been classified as discontinued operations in all periods presented. As of January 1, 2015, the Company adopted ASU 2014-08 which raised the threshold for a disposal to qualify as a discontinued operation. As a result, the Company expects that any future disposals of its centers will no longer meet the definition to be accounted for as discontinued operations, and any gain or loss from such disposals will be included in continuing operations. The Company did not dispose of any centers during the year ended December 31, 2015, but continues to have operating activity associated with centers previously classified as discontinued operations.

Results of operations and associated gain (loss) on discontinued centers for the years ended December 31, 2015, 2014 and 2013 are as follows (in thousands):

	2015			2014			2013
Revenues	$	—		$	9,545		$	25,373
Earnings before income taxes	—			893			5,607
Results of discontinued operations, net of tax:
Earnings (loss) from operations of discontinued interests in surgery centers	(1,013		)	710			4,449
Gain (loss) on disposal of discontinued interests in surgery centers	—			(2,006		)	2,602
Net earnings (loss) from discontinued operations	(1,013		)	(1,296		)	7,051
Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests	(12		)	283			5,357
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$	(1,001	)	$	(1,579	)	$	1,694

Cash proceeds from centers discontinued for the years ended December 31, 2014 and 2013 were $7.1 million and $3.6 million, respectively. There were no cash proceeds during 2015.

(7) Prepaid and Other Current Assets

The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Income taxes receivable	$	7,908	$	28,694
Prepaid expenses	18,900		18,682
Deferred compensation plan assets	16,623		17,320
Other	32,340		28,204
Total prepaid and other current assets	$	75,771	$	92,900

(8)  Property and Equipment

Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment is recognized over useful lives of three to ten years.

77

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Property and equipment at December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Building and improvements	$	177,253		$	170,420
Movable equipment	237,312			215,444
Construction in progress	8,676			11,940
	423,241			397,804
Less accumulated depreciation	(234,073		)	(217,356		)
Property and equipment, net	$	189,168		$	180,448

At December 31, 2015, the Company and its partnerships had unfunded construction and equipment purchases of approximately $18.3 million in order to complete construction in progress primarily associated with the construction of the Company's new physician services headquarters. Depreciation expense for continuing and discontinued operations for the years ended December 31, 2015, 2014 and 2013 was $35.4 million, $33.2 million and $29.8 million, respectively.

(9)  Goodwill and Intangible Assets

The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in the Company's physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2015, and determined that its indefinite lived intangibles were not impaired. The Company's finite-lived intangibles includes its customer relationship with hospitals. The Company tests its finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2015, there were no events or circumstances that indicated a potential impairment in the Company's finite-lived intangibles.

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands):

	2015			2014
Balance, beginning of year	$	3,381,149		$	1,758,970
Goodwill acquired, including post acquisition adjustments	674,476			1,636,521
Goodwill disposed, including impact of deconsolidation transactions	(85,415		)	(14,342		)
Balance, end of year	$	3,970,210		$	3,381,149

As of December 31, 2015, the ambulatory services segment and the physician services segment each had approximately $2.0 billion of goodwill compared to $1.9 billion for ambulatory services and $1.5 billion for physician services, respectively, at December 31, 2014. During the year ended December 31, 2015, goodwill increased $123.4 million for the ambulatory services segment primarily due to the acquisition of seven centers, net of nine deconsolidations. During the year ended December 31, 2015, goodwill increased by $465.7 million for the physician services segment primarily due to the acquisition of nine physician practices, net of three deconsolidations. For the years ended December 31, 2015 and 2014 approximately $295.7 million and $64.5 million, respectively, of goodwill recorded was deductible for tax purposes.

Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements. Customer relationships with hospitals are initially recorded at their estimated fair value and amortized on a straight-line basis over 20 years. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years.

78

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015							2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,379,977	$	(74,490	)	$	1,305,487	$	971,645	$	(22,145	)	$	949,500
Deferred financing costs	60,664		(13,490		)	47,174		59,574		(5,151		)	54,423
Capitalized software	71,462		(28,125		)	43,337		50,387		(19,197		)	31,190
Agreements, contracts and other	11,267		(2,449		)	8,818		3,523		(2,752		)	771
Total amortizable intangible assets	1,523,370		(118,554		)	1,404,816		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	8,995		—			8,995		9,995		—			9,995
Total non-amortizable intangible assets	236,995		—			236,995		237,995		—			237,995
Total intangible assets	$	1,760,365	$	(118,554	)	$	1,641,811	$	1,323,124	$	(49,245	)	$	1,273,879

Amortization of intangible assets for the years ended December 31, 2015, 2014 and 2013 was $70.5 million, $32.5 million and $2.2 million, respectively. Included in the 2014 amount above is also $12.8 million that was charged to interest expenses related to a write-off of a commitment fee for bridge financing, which the Company had secured in order to complete the acquisition of Sheridan but did not require upon obtaining permanent financing. Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2015 is $90.3 million, $89.1 million, $87.8 million, $84.8 million, $81.6 million and $971.2 million, respectively. The Company expects to recognize amortization of all intangible assets over a weighted average period of 17.8 years with no expected residual values.

(10) Other Accrued Liabilities

The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Accrued professional liabilities	$	14,362	$	11,983
Contingent purchase price payable	5,509		12,213
Current income taxes payable	7,892		—
Refunds payable	48,415		17,752
Other	43,059		26,038
Total other accrued liabilities	$	119,237	$	67,986

(11) Accrued Professional Liabilities

The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted.

79

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

At December 31, 2015, the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands):

	2015		2014
Estimated losses under self-insured programs	$	30,748	$	25,337
Incurred but not reported losses	36,166		28,448
Total accrued professional liabilities	66,914		53,785
Less estimated losses payable within one year	14,362		11,983
Total	$	52,552	$	41,802

The changes to the Company's estimated losses under self-insured programs as of December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Balance, beginning of year	$	53,785		$	1,171
Assumed liabilities through acquisitions	13,317			53,512
Provision related to current period reserves	15,943			5,423
Payments for current period reserves	(4,475		)	(1,595		)
Benefit related to changes in prior period reserves	(425		)	(661		)
Payments for prior period reserves	(8,863		)	(6,055		)
Other, net	(2,368		)	1,990
Balance, end of year	$	66,914		$	53,785

(12)Long-term Debt

Long-term debt at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015		2014
Revolving credit agreement	$	175,000	$	—
Term Loan	856,950		865,650
Senior Unsecured Notes due 2020 (5.625%)	250,000		250,000
Senior Unsecured Notes due 2022 (5.625%)	1,100,000		1,100,000
Other debt at an average interest rate of 3.4%, due through 2022	24,944		20,156
Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021	18,613		15,206
	2,425,507		2,251,012
Less current portion	20,377		18,826
Long-term debt	$	2,405,130	$	2,232,186

Principal payments required on the Company’s long-term debt and capital leases in the five years and thereafter subsequent to December 31, 2015 are $20.4 million, $18.0 million, $14.8 million, $187.0 million, $261.0 million, and $1.9 billion. The fair value of the Company's fixed rate long-term debt and variable rate long-term debt approximated its carrying values of $1.4 billion and $1.0 billion at December 31, 2015, respectively.  With the exception of the Company’s 2020 and 2022 Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s 2020 and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

a.     Term Loan and Credit Facility

On July 16, 2014, the Company entered into a credit facility that is comprised of an $870.0 million term loan and a $300.0 million revolving credit facility. On October 21, 2015, the Company exercised the accordion feature of its revolving credit facility and increased the Company's borrowing capacity by $200.0 million to $500.0 million. As of December 31, 2015, the Company had available $325.0 million under the revolving credit facility.

80

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on December 31, 2015). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually.

The revolving credit facility matures on July 16, 2019 and permits the Company to borrow at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a combination thereof; and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the senior secured credit facility by an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s less than wholly-owned subsidiaries. As of December 31, 2015, the Company was in compliance with the covenants contained in the term loan and credit facility.

Prior to entering into the Company's credit facility, the Company maintained a revolving credit facility which had a maturity of June 2018. On July 3, 2014, the Company utilized proceeds received from its common and preferred stock offerings to repay its outstanding obligation under the existing revolving credit facility. As a result of the early termination, the Company recognized approximately $4.5 million as debt extinguishment costs in the accompanying statements of earnings during the year ended December 31, 2014 related to the write-off of net deferred loan costs.

b.     Senior Unsecured Notes

2020 Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (2020 Senior Unsecured Notes). On May 31, 2013, the Company completed an offer to exchange the outstanding 2020 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended (Securities Act). The net proceeds from the issuance of the 2020 Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The 2020 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.

The Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:  

Period	Redemption Price
2015	104.219	%
2016	102.813	%
2017	101.406	%
2018 and thereafter	100.000	%

The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at December 31, 2015.

2022 Senior Unsecured Notes

On July 16, 2014, the Company completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (2022 Senior Unsecured Notes). On February 19, 2015, the Company completed an offer to exchange the outstanding 2022 Senior Unsecured Notes, for an equal amount of such notes that are registered under the Securities Act. The 2022 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, beginning on January 15, 2015, and ending on the maturity date of July 15, 2022.

81

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:

Period	Redemption Price
2017	104.219	%
2018	102.813	%
2019	101.406	%
2020 and thereafter	100.000	%

The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at December 31, 2015.

c.     Senior Secured Notes

During 2010, the Company issued $75.0 million principal amount of senior secured notes due 2020 (Senior Secured Notes) pursuant to a note purchase agreement. The Senior Secured Notes had a maturity date of May 28, 2020. On July 16, 2014, the Company redeemed the Senior Secured Notes utilizing proceeds received from its common and preferred stock offerings. As a result of the early extinguishment, the Company paid an early termination fee of approximately $12.4 million to the holders of the Senior Secured Notes, which is recognized as a component of debt extinguishment costs during the year ended December 31, 2014 in the accompanying statements of earnings.

d.     Other debt

Certain partnerships included in the Company’s consolidated financial statements have loans with local lending institutions, included above in other debt, which are collateralized by certain assets of the surgery centers with a book value of approximately $41.7 million. The Company and the partners have guaranteed payment of the loans in proportion to the relative partnership interests.

(13) Other Long-term Liabilities

The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Accrued professional liabilities	$	52,552	$	41,802
Contingent purchase price payable	—		8,470
Deferred rent	18,958		16,814
Tax-effected unrecognized benefits	3,426		8,353
Other	21,247		14,004
Other long-term liabilities	$	96,183	$	89,443

(14)  Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

82

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012.

Total income taxes expense (benefit) for the years ended December 31, 2015, 2014 and 2013 was included within the following sections of the consolidated financial statements as follows (in thousands):

	2015			2014			2013
Earnings from continuing operations	$	113,790		$	48,103		$	48,654
Discontinued operations	(694		)	(643		)	9
Shareholders’ equity	(2,227		)	(3,177		)	(7,381		)
Total	$	110,869		$	44,283		$	41,282

Income tax expense from continuing operations for the years ended December 31, 2015, 2014 and 2013 was comprised of the following (in thousands):

	2015		2014		2013
Current:
Federal	$	83,228	$	8,640	$	7,895
State	14,268		4,396		3,598
Deferred:
Federal	11,715		27,505		31,509
State	4,579		7,562		5,652
Income tax expense	$	113,790	$	48,103	$	48,654

Income tax expense from continuing operations for the years ended December 31, 2015, 2014 and 2013 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):

	2015			2014			2013
Statutory federal income tax	$	173,572		$	102,967		$	106,101
Less federal income tax assumed directly by noncontrolling interests	(76,364		)	(66,783		)	(64,219		)
State income taxes, net of federal income tax benefit	11,604			6,616			5,539
Increase in valuation allowances	317			4,662			924
Interest related to unrecognized tax benefits	(548		)	(161		)	(155		)
Other	5,209			802			464
Income tax expense	$	113,790		$	48,103		$	48,654

The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Decreases in interest and penalty obligations of $0.2 million, $0.1 million and $0.2 million were recognized in the consolidated statement of earnings for the years ended December 31, 2015, 2014 and 2013, respectively, resulting in a total recognition of interest and penalty obligations of approximately $0.8 million and $1.2 million in the consolidated balance sheet at December 31, 2015 and 2014, respectively.

83

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

The Company primarily has unrecognized tax benefits that represent an amortization deduction which is temporary in nature. A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2015, 2014 and 2013 is as follows (in thousands):

	2015			2014			2013
Balance at beginning of year	$	7,336		$	6,330		$	9,235
Additions for tax positions of current year	—			204			46
Increases (decreases) for tax positions taken during a prior period	(1,006		)	1,069			—
Lapse of statute of limitations	(3,178		)	(267		)	(2,951		)
Balance at end of year	$	3,152		$	7,336		$	6,330

The Company believes that the total amount of increases in unrecognized tax benefits within the next 12 months is not considered significant. The total amount of unrecognized tax benefits that would affect the Company’s effective tax rate if recognized is approximately $0.1 million.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Deferred tax assets:
Allowance for uncollectible accounts	$	3,276		$	1,096
Accrued assets and other	36,600			27,537
Share-based compensation	10,710			7,719
Interest on unrecognized tax benefits	113			245
Accrued liabilities and other	4,080			3,931
Medical malpractice	19,035			16,240
Operating and capital loss carryforwards	29,718			22,709
Valuation allowances	(21,814		)	(17,457		)
Total deferred tax assets	81,718			62,020
Deferred tax liabilities:
Prepaid expenses	1,789			2,435
Property and equipment, principally due to differences in depreciation	16,787			15,235
Goodwill, intangible assets and other, principally due to differences in amortization	762,640			655,358
Total deferred tax liabilities	781,216			673,028
Net deferred tax liabilities	$	699,498		$	611,008

The Company has provided valuation allowances on its gross deferred tax assets to the extent that management does not believe that it is more likely than not that such asset will be realized. Capital loss carryforwards began to expire in 2014, and state net operating losses began to expire in 2015.

(15)  Shareholders’ Equity

a. Common Stock

During December 2015, the Company issued 5,835,000 shares of its common stock in a public offering, at $80.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $19.1 million. Proceeds were used to repay a portion of the Company's revolving credit facility, to fund a portion of the acquisitions completed during the year ended 2015 and for general corporate purposes.

On July 2, 2014, the Company issued 9,775,000 shares of its common stock in a public offering, at $45.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $18.5 million. Proceeds from the issuance were used to satisfy certain debt obligations with the remaining amount utilized to fund a portion of the Sheridan acquisition. In addition, on July 16, 2014, the Company issued 5,713,909 shares of its common stock directly to the former owners of Sheridan as part of the total consideration for the Sheridan acquisition. The Company registered these shares with the SEC in October of 2014. The former owners of Sheridan subsequently sold their shares in November of 2014.

84

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

During 2013, under a board authorized stock repurchase program, the Company purchased 1,154,378 shares of the Company's common stock for approximately $42.7 million, at an average price of $36.93 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company's stock incentive plans. The stock repurchase program expired during 2014.

In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vested to cover payroll withholding taxes in accordance with the restricted stock agreements. During 2015 and 2014, the Company repurchased 67,000 shares and 100,720 shares, respectively, of common stock for approximately $3.7 million and $4.6 million, respectively.

b. Preferred Stock

On July 2, 2014, the Company issued 1,725,000 shares of its mandatory convertible preferred stock in a public offering, at $100.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $5.9 million.

The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate from the date of issuance and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100, plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount.

During the year ended December 31, 2015, the Company's Board of Directors declared four dividends each totaling $1.3125 per share in cash, or $2.3 million, for the Company's mandatory convertible preferred stock. All dividends declared during 2015 have been paid except those dividends declared on November 19, 2015, which were funded to the paying agent to be paid on January 1, 2016 to the shareholders of record as of December 15, 2015.

On August 29, 2014, the Company's Board of Directors declared its first dividend of $1.2979 per share in cash, or $2.2 million and on November 25, 2014, the Company's Board of Directors declared a dividend for $1.3125 per share, or $2.3 million for the Company's mandatory convertible preferred stock.

c. Stock Incentive Plans

Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards. 

Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $4.0 million, $3.2 million and $7.2 million for the years ended December 31, 2015, 2014 and 2013, respectively.

The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to

85

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock.

In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan. The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At December 31, 2015, 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 900,039 shares were available for future equity grants. Restricted stock granted to outside directors vests on the first anniversary of the date of grant. Restricted stock granted to employees vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date. Under Company policy, shares held by outside directors and senior management are subject to certain holding requirements and restrictions.

The Company has not issued options subsequent to 2008, and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity for the years ended December 31, 2015, 2014 and 2013 was as follows (in thousands):

	2015		2014		2013
Share-based compensation expense	$	15,009	$	10,104	$	8,321
Fair value of shares vested	13,220		15,126		11,742
Cash received from option exercises	2,584		2,630		33,349
Tax benefit from option exercises	4,001		3,177		7,247

As of December 31, 2015, the Company had total unrecognized compensation cost of approximately $16.6 million related to non-vested awards, which the Company expects to recognize through 2019 and over a weighted average period of 1.1 years. During the years ended December 31, 2015, 2014 and 2013, there were no options that were anti-dilutive.

A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2015, is as follows:

			Weighted
	Number		Average
	of Shares		Grant Price
Non-vested shares at January 1, 2013	828,686		$	22.50
Shares granted	291,863		31.66
Shares vested	(360,337	)	21.55
Shares forfeited	(16,343	)	23.11
Non-vested shares at December 31, 2013	743,869		$	26.54
Shares granted	272,780		43.12
Shares vested	(336,160	)	25.69
Shares forfeited	(12,380	)	38.94
Non-vested shares at December 31, 2014	668,109		$	33.51
Shares granted	313,498		56.19
Shares vested	(233,831	)	28.19
Shares forfeited	(13,675	)	42.15
Non-vested shares at December 31, 2015	734,101		$	44.73

In addition to the non-vested restricted shares, during the year ended December 31, 2015, the Company granted 68,533 performance-based restricted stock units (RSUs) to certain of its officers and physician employees. The fair value of the Company's common stock on the grant date of these RSUs was $55.40. The RSUs will vest ratably over a three year period from the grant date. The conversion of the RSUs to restricted stock is contingent on the Company’s achievement of a specified one-year financial performance goal for the year ended December 31, 2015 and, if achieved, would occur during the first quarter of 2016. If the financial performance goal is not achieved, the RSUs will be forfeited. The number of RSUs that will ultimately be received by the holders range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At December 31, 2015, the financial performance goal was achieved at a level that will result in the conversion of the RSUs to restricted stock at 150%.

86

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

A summary of stock option activity for the three years ended December 31, 2015 is summarized as follows:

					Weighted
			Weighted		Average
			Average		Remaining
	Number		Exercise		Contractual
	of Shares		Price		Term (in years)
Outstanding at January 1, 2013	1,662,830		$	23.82	2.9
Options exercised with total intrinsic value of $33.3 million	(1,392,366	)	23.95
Outstanding at December 31, 2013	270,464		$	23.16	2.5
Options exercised with total intrinsic value of $2.6 million	(111,743	)	23.53
Outstanding at December 31, 2014	158,721		$	22.89	1.7
Options exercised with total intrinsic value of $4.9 million	(113,220	)	22.81
Options terminated	(11,750	)	23.42
Outstanding, Vested and Exercisable at December 31, 2015 with an aggregate intrinsic value of $1.8 million	33,751		$	22.98	1.1

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at December 31, 2015 exercised their options at the Company’s closing stock price on December 31, 2015.

d. Earnings per Share

Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.

87

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

	Earnings		Shares	Per Share
	(Numerator)		(Denominator)	Amount
For the year ended December 31, 2015:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	154,892	48,058	$	3.22
Preferred stock dividends	9,056		—
Effect of dilutive securities, options and non-vested shares	—		3,554
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	163,948	51,612	$	3.18
For the year ended December 31, 2014:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	50,777	39,311	$	1.29
Effect of dilutive securities, options and non-vested shares	—		314
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	50,777	39,625	$	1.28
For the year ended December 31, 2013:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	71,009	31,338	$	2.27
Effect of dilutive securities, options and non-vested shares	—		616
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	71,009	31,954	$	2.22

(16)  Leases

The Company has entered into various building and equipment capital and operating leases in operation and under development and for office space, expiring at various dates through 2037. Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2015 were as follows (in thousands):

Year Ended December 31,	Capital Leases		Operating Leases
2016	$	3,021	$	55,636
2017	2,776		55,857
2018	2,502		53,515
2019	2,068		52,034
2020	1,866		50,378
Thereafter	12,991		331,746
Total minimum rentals	25,224		$	599,166
Less amounts representing interest at rates ranging from 1.7% to 13.4%	6,611
Capital lease obligations	$	18,613

At December 31, 2015, buildings and equipment with a cost of approximately $23.4 million and accumulated depreciation of approximately $5.6 million were held under capital leases. The Company and the partners in the partnerships have guaranteed payment of certain of these leases. Rental expense for operating leases for the years ended December 31, 2015, 2014 and 2013 was approximately $74.6 million, $66.1 million and $52.6 million, respectively.

88

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

(17)  Related Party Transactions

Certain surgery centers lease space from entities affiliated with their physician partners at negotiated rates that management believes were equal to fair market value at the inception of the leases based on relevant market data. Certain surgery centers reimburse their physician partners for salaries and benefits and billing fees related to time spent by employees of their practices on activities of the centers at current market rates. In addition, certain centers compensate at market rates their physician partners for physician advisory services provided to the surgery centers, including medical director and performance improvement services.   

Excluding transactions with investments in unconsolidated affiliates disclosed in Note 5, related party payments for the years ended December 31, 2015, 2014 and 2013 were as follows (in thousands):

	2015		2014		2013
Operating leases	$	27,622	$	27,559	$	29,240
Salaries and benefits	62,590		66,763		72,892
Billing fees	10,873		9,899		11,591
Medical advisory services	2,635		2,811		2,993

The Company also reimburses their physician partners for operating expenses paid by the physician partners to third party providers on the behalf of the surgery center. The Company believes that the foregoing transactions are reasonably expected to benefit the Company and that the amount of reimbursed expenses included in other operating expenses in the accompanying consolidated statements of earnings for each of the years ended December 31, 2015, 2014 and 2013 were not significant.

It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.

(18)  Employee Benefit Programs

The Company maintains multiple qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code. These plans are defined contribution plans covering substantially all employees of the Company and provide for voluntary contributions by employees, subject to certain limits. Company contributions are primarily based on specified percentages of employee compensation. In some instances, the plan may allow for elective or required Company contributions subject to the limits defined by each plan. The Company funds contributions as accrued. The Company’s contributions for the years ended December 31, 2015, 2014 and 2013 were approximately $14.1 million, $1.6 million and $1.1 million, respectively, and vest immediately or incrementally over a period of four to five years, depending on the plan and the tenures of the respective employees for which the contributions were made. During 2014, the Company recorded expenses of approximately $5.6 million related to Sheridan which represented the period July 16, 2014 through December 31, 2014.

The Company maintains the Supplemental Executive and Director Retirement Savings Plan. This plan is a defined contribution plan covering all officers of the Company and provides for voluntary contributions of up to 50% of employee annual compensation.  Company contributions are at the discretion of the Compensation Committee of the Board of Directors and vest incrementally over five years. The employee and employer contributions are placed in a Rabbi Trust and recorded in the accompanying consolidated balance sheets in prepaid and other current assets. Employer contributions to this plan for the years ended December 31, 2015, 2014 and 2013 were approximately $5.2 million, $0.8 million and $2.3 million, respectively. As of December 31, 2015 and 2014, the cash surrender value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets in the accompanying consolidated balance sheets, was $16.6 million and $17.3 million, respectively.

(19)  Commitments and Contingencies

Litigation

From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows.

89

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Insurance Programs

Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.

The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.

The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries.

Redeemable Noncontrolling Interests

Certain of the Company’s wholly-owned subsidiaries are responsible for all debts incurred but unpaid by the Company's less than wholly-owned partnerships as these subsidiaries are the general partner. As manager of the operations of these partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions. In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015. As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Physician Services Headquarters Operating Lease

On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which it intends to be the future headquarters of its physician services operations. The Company took possession of the space in the fourth quarter of 2015 and began tenant improvements on approximately 167,000 square feet of space, which it intends to occupy during the third quarter of 2016. In addition, the Company plans to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which it intends to occupy during the fourth quarter of 2016. Annual rent expense is expected to be approximately $2.9 million. The initial term of this lease agreement expires in February 2029.

(20) Segment Reporting

Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine.

The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

90

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

The following table presents financial information for each reportable segment (in thousands):

	Year ended December 31,
	2015			2014			2013
Net Revenue:
Ambulatory Services	$	1,230,050		$	1,109,935		$	1,057,196
Physician Services (1)	1,336,834			512,014			—
Total	$	2,566,884		$	1,621,949		$	1,057,196
Adjusted Segment EBITDA:
Ambulatory Services	$	226,229		$	197,377		$	187,972
Physician Services (1)	266,031			107,105			—
Total	$	492,260		$	304,482		$	187,972
Adjusted Segment EBITDA:	$	492,260		$	304,482		$	187,972
Earnings from continuing operations attributable to noncontrolling interests	218,181			190,809			183,484
Interest expense, net	(121,586		)	(83,285		)	(29,525		)
Depreciation and amortization	(97,493		)	(60,344		)	(32,400		)
Share-based compensation	(15,009		)	(10,104		)	(8,321		)
Net change in fair value of contingent consideration	(8,804		)	—			—
Transaction costs	(8,324		)	(33,890		)	(300		)
Debt extinguishment costs	—			(16,887		)	—
Net gain on deconsolidations	36,694			3,411			2,237
Earnings from continuing operations before income taxes	$	495,919		$	294,192		$	303,147
Acquisition and Capital Expenditures:
Ambulatory Services (2)	$	168,593		$	81,156		$	102,450
Physician Services	854,401			28,909			—
Total	$	1,022,994		$	110,065		$	102,450

	2015		2014
Assets:
Ambulatory Services	$	2,609,479	$	2,526,625
Physician Services	3,937,003		2,974,437
Total	$	6,546,482	$	5,501,062

(1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

(2) Excludes the purchase price to acquire Sheridan in 2014.

91

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

(21)  Financial Information for the Company and Its Subsidiaries

The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	20,437	$	27,507	$	58,716	$	—		$	106,660
Restricted cash and marketable securities	—		—		13,506		—			13,506
Accounts receivable, net	—		223,434		113,896		—			337,330
Supplies inventory	—		—		21,406		—			21,406
Prepaid and other current assets	28,739		39,046		16,062		(8,076		)	75,771
Total current assets	49,176		289,987		223,586		(8,076		)	554,673
Property and equipment, net	12,515		14,601		162,052		—			189,168
Investments in and receivables from unconsolidated affiliates	4,901,026		1,775,272		—		(6,507,128		)	169,170
Goodwill	—		1,956,741		—		2,013,469			3,970,210
Intangible assets, net	59,928		1,579,537		2,346		—			1,641,811
Other assets	4,653		1,717		17,078		(1,998		)	21,450
Total assets	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	11,677	$	—		$	20,377
Accounts payable	2,816		3,760		29,837		(3,852		)	32,561
Accrued salaries and benefits	31,510		158,705		12,322		—			202,537
Accrued interest	30,463		—		17		—			30,480
Other accrued liabilities	13,962		76,590		32,909		(4,224		)	119,237
Total current liabilities	87,451		239,055		86,762		(8,076		)	405,192
Long-term debt	2,373,251		—		55,275		(23,396		)	2,405,130
Deferred income taxes	268,573		432,923		—		(1,998		)	699,498
Other long-term liabilities	4,560		71,509		20,114		—			96,183
Intercompany payable	—		1,228,157		—		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		63,060		112,672			175,732
Equity:
Total AmSurg Corp. equity	2,293,463		3,646,211		132,267		(3,778,478		)	2,293,463
Noncontrolling interests – non-redeemable	—		—		47,584		423,700			471,284
Total equity	2,293,463		3,646,211		179,851		(3,354,778		)	2,764,747
Total liabilities and equity	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482

92

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	46,097		37,826		13,795		(4,818		)	92,900
Total current assets	180,448		185,370		203,225		(4,818		)	564,225
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	207,500		404,984		—		(1,466		)	611,018
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062

93

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	28,554		$	1,331,042	$	1,245,292		$	(38,004	)	$	2,566,884
Operating expenses:
Salaries and benefits	69,102			937,484		308,313			(507		)	1,314,392
Supply cost	—			2,436		181,866			(80		)	184,222
Other operating expenses	24,682			145,369		265,160			(37,417		)	397,794
Transaction costs	1,762			6,562		—			—			8,324
Depreciation and amortization	3,912			61,658		31,923			—			97,493
Total operating expenses	99,458			1,153,509		787,262			(38,004		)	2,002,225
Gain (loss) on deconsolidations	—			37,350		(656		)	—			36,694
Equity in earnings of unconsolidated affiliates	349,139			251,093		—			(584,080		)	16,152
Operating income	278,235			465,976		457,374			(584,080		)	617,505
Interest expense, net	41,140			77,947		2,499			—			121,586
Earnings from continuing operations before income taxes	237,095			388,029		454,875			(584,080		)	495,919
Income tax expense	73,159			38,891		1,740			—			113,790
Net earnings from continuing operations	163,936			349,138		453,135			(584,080		)	382,129
Net loss from discontinued operations	(989		)	—		(24		)	—			(1,013		)
Net earnings	162,947			349,138		453,111			(584,080		)	381,116
Net earnings attributable to noncontrolling interests	—			—		218,169			—			218,169
Net earnings attributable to AmSurg Corp. shareholders	162,947			349,138		234,942			(584,080		)	162,947
Preferred stock dividends	(9,056		)	—		—			—			(9,056		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	154,880		$	349,138	$	234,954		$	(584,080	)	$	154,892
Loss from discontinued operations, net of income tax	(989		)	—		(12		)	—			(1,001		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891

94

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,773		$	508,572	$	1,112,940		$	(24,336	)	$	1,621,949
Operating expenses:
Salaries and benefits	65,697			350,615		284,050			(5,786		)	694,576
Supply cost	—			1,292		163,004			—			164,296
Other operating expenses	18,667			53,413		231,398			(18,550		)	284,928
Transaction costs	29,004			4,886		—			—			33,890
Depreciation and amortization	4,044			25,610		30,690			—			60,344
Total operating expenses	117,412			435,816		709,142			(24,336		)	1,238,034
Gain on deconsolidation	—			3,411		—			—			3,411
Equity in earnings of unconsolidated affiliates	237,657			211,889		—			(442,508		)	7,038
Operating income	145,018			288,056		403,798			(442,508		)	394,364
Interest expense, net	47,997			33,026		2,262			—			83,285
Debt extinguishment costs	16,887			—		—			—			16,887
Earnings from continuing operations before income taxes	80,134			255,030		401,536			(442,508		)	294,192
Income tax expense	29,166			17,373		1,564			—			48,103
Net earnings from continuing operations	50,968			237,657		399,972			(442,508		)	246,089
Net earnings (loss) from discontinued operations	2,733			—		(4,029		)	—			(1,296		)
Net earnings	53,701			237,657		395,943			(442,508		)	244,793
Net earnings attributable to noncontrolling interests	—			21		191,071			—			191,092
Net earnings attributable to AmSurg Corp. shareholders	53,701			237,636		204,872			(442,508		)	53,701
Preferred stock dividends	(4,503		)	—		—			—			(4,503		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	46,465		$	237,636	$	209,184		$	(442,508	)	$	50,777
Earnings (loss) from discontinued operations, net of income tax	2,733			—		(4,312		)	—			(1,579		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198

95

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,167	$	—	$	1,050,547		$	(17,518	)	$	1,057,196
Operating expenses:
Salaries and benefits	61,038		—		267,014			(467		)	327,585
Supply cost	—		—		153,126			—			153,126
Other operating expenses	22,360		—		211,192			(17,051		)	216,501
Transaction costs	300		—		—			—			300
Depreciation and amortization	3,186		—		29,214			—			32,400
Total operating expenses	86,884		—		660,546			(17,518		)	729,912
Gain on deconsolidation	—		2,237		—			—			2,237
Equity in earnings of unconsolidated affiliates	207,199		204,962		—			(409,010		)	3,151
Operating income	144,482		207,199		390,001			(409,010		)	332,672
Interest expense, net	27,282		—		2,243			—			29,525
Earnings from continuing operations before income taxes	117,200		207,199		387,758			(409,010		)	303,147
Income tax expense	47,139		—		1,515			—			48,654
Net earnings from continuing operations	70,061		207,199		386,243			(409,010		)	254,493
Net earnings from discontinued operations	2,642		—		4,409			—			7,051
Net earnings	72,703		207,199		390,652			(409,010		)	261,544
Net earnings attributable to noncontrolling interests	—		—		188,841			—			188,841
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	70,061	$	207,199	$	202,759		$	(409,010	)	$	71,009
Earnings (loss) from discontinued operations, net of income tax	2,642		—		(948		)	—			1,694
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703

96

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	40,432		$	353,932		$	489,820		$	(346,225	)	$	537,959
Cash flows from investing activities:
Acquisitions and related transactions	(757,775		)	(969,259		)	—			764,345			(962,689		)
Acquisition of property and equipment	(5,876		)	(22,988		)	(31,441		)	—			(60,305		)
Proceeds from sale of interests in surgery centers	—			7,114			—			—			7,114
Purchases of marketable securities	—			—			(3,984		)	—			(3,984		)
Maturities of marketable securities	—			—			4,233			—			4,233
Other	—			(2,927		)	1,733			—			(1,194		)
Net cash flows used in investing activities	(763,651		)	(988,060		)	(29,459		)	764,345			(1,016,825		)
Cash flows from financing activities:
Proceeds from long-term borrowings	546,000			—			14,133			—			560,133
Repayment on long-term borrowings	(379,700		)	—			(12,886		)	—			(392,586		)
Distributions to owners, including noncontrolling interests	—			(109,862		)	(451,262		)	346,225			(214,899		)
Capital contributions	—			757,775			—			(757,775		)	—
Proceeds from common stock offering	466,777			—			—			—			466,777
Payments of equity issuance costs	(19,058		)	—			—			—			(19,058		)
Financing cost incurred	(1,101		)	—			(10		)	—			(1,111		)
Changes in intercompany balances with affiliates, net	5,016			—			(5,016		)	—			—
Other financing activities, net	(8,629		)	(9,749		)	3,139			(6,570		)	(21,809		)
Net cash flows provided by (used in) financing activities	609,305			638,164			(451,902		)	(418,120		)	377,447
Net increase (decrease) in cash and cash equivalents	(113,914		)	4,036			8,459			—			(101,419		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	20,437		$	27,507		$	58,716		$	—		$	106,660

97

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	96,681		$	298,415		$	430,880		$	(413,605	)	$	412,371
Cash flows from investing activities:
Acquisitions and related transactions	(2,124,124		)	(2,188,191		)	1,520			2,126,737			(2,184,058		)
Acquisition of property and equipment	(7,877		)	(9,933		)	(22,407		)	—			(40,217		)
Proceeds from sale of interests in surgery centers	—			7,069			—			—			7,069
Purchases of marketable securities	—			—			(6,474		)	—			(6,474		)
Maturities of marketable securities	—			—			3,486			—			3,486
Other	(3,068		)	(6,594		)	4,721			—			(4,941		)
Net cash flows used in investing activities	(2,135,069		)	(2,197,649		)	(19,154		)	2,126,737			(2,225,135		)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,040,000			—			8,958			—			2,048,958
Repayment on long-term borrowings	(396,493		)	—			(11,982		)	—			(408,475		)
Distributions to owners, including noncontrolling interests	—			(202,247		)	(401,455		)	413,605			(190,097		)
Capital contributions	—			2,124,124			—			(2,124,124		)	—
Proceeds from preferred stock offering	172,500			—			—			—			172,500
Proceeds from common stock offering	439,875			—			—			—			439,875
Payments of equity issuance costs	(24,494		)	—			—			—			(24,494		)
Financing cost incurred	(65,811		)	—			—			—			(65,811		)
Changes in intercompany balances with affiliates, net	2,965			—			(2,965		)	—			—
Other financing activities, net	(2,513		)	828			1,845			(2,613		)	(2,453		)
Net cash flows provided by (used in) financing activities	2,166,029			1,922,705			(405,599		)	(1,713,132		)	1,970,003
Net increase in cash and cash equivalents	127,641			23,471			6,127			—			157,239
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	134,351		$	23,471		$	50,257		$	—		$	208,079

98

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	45,127		$	208,773		$	426,572		$	(347,648	)	$	332,824
Cash flows from investing activities:
Acquisitions and related transactions	—			(74,288		)	—			694			(73,594		)
Acquisition of property and equipment	(3,693		)	—			(25,163		)	—			(28,856		)
Proceeds from sale of interests in surgery centers	—			3,553			—			—			3,553
Other	—			159			—			—			159
Net cash flows used in investing activities	(3,693		)	(70,576		)	(25,163		)	694			(98,738		)
Cash flows from financing activities:
Proceeds from long-term borrowings	152,700			—			9,504			—			162,204
Repayment on long-term borrowings	(188,081		)	—			(14,002		)	—			(202,083		)
Distributions to owners, including noncontrolling interests	—			(138,875		)	(392,922		)	347,648			(184,149		)
Changes in intercompany balances with affiliates, net	88			—			(88		)	—			—
Other financing activities, net	(6,690		)	678			1,090			(694		)	(5,616		)
Net cash flows used in financing activities	(41,983		)	(138,197		)	(396,418		)	346,954			(229,644		)
Net increase (decrease) in cash and cash equivalents	(549		)	—			4,991			—			4,442
Cash and cash equivalents, beginning of period	7,259			—			39,139			—			46,398
Cash and cash equivalents, end of period	$	6,710		$	—		$	44,130		$	—		$	50,840

(22)  Subsequent Events

The Company assessed events occurring subsequent to December 31, 2015 for potential recognition and disclosure in the consolidated financial statements. No events have occurred that would require adjustment to or disclosure in the consolidated financial statements. 

99

Item 8. Financial Statements and Supplementary Data - (continued) Table of Contents

Quarterly Statement of Earnings Data (Unaudited)

The following table presents certain quarterly statement of earnings data for the years ended December 31, 2015 and 2014. The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.

	2015									2014
	Q1		Q2		Q3		Q4			Q1			Q2		Q3 (1)			Q4
	(In thousands, except per share data)
Net revenues	$	570,445	$	641,950	$	650,227	$	704,262		$	259,561		$	278,227	$	502,350		$	581,811
Earnings from continuing operations before income taxes	83,004		115,940		135,797		161,178			73,028			80,487		39,142			101,535
Net earnings from continuing operations	68,755		90,747		98,279		124,348			60,046			67,689		39,120			79,234
Net earnings (loss) from discontinued operations	—		—		—		(1,013		)	68			483		(1,697		)	(150		)
Net earnings	68,755		90,747		98,279		123,335			60,114			68,172		37,423			79,084
Net earnings (loss) attributable to AmSurg Corp. common shareholders:
Continuing	18,774		31,411		40,397		64,310			17,392			18,771		(10,697		)	25,311
Discontinued	—		—		—		(1,001		)	(197		)	190		(1,376		)	(196		)
Net earnings (loss)	$	18,774	$	31,411	$	40,397	$	63,309		$	17,195		$	18,961	$	(12,073	)	$	25,115
Basic net earnings (loss) from continuing operations per share	$	0.39	$	0.66	$	0.85	$	1.31		$	0.55		$	0.59	$	(0.23	)	$	0.53
Basic net earnings (loss) per share	$	0.39	$	0.66	$	0.85	$	1.28		$	0.54		$	0.60	$	(0.26	)	$	0.53
Diluted net earnings (loss) from continuing operations per share	$	0.39	$	0.65	$	0.83	$	1.26		$	0.54		$	0.58	$	(0.23	)	$	0.53
Diluted net earnings (loss) per share	$	0.39	$	0.65	$	0.83	$	1.24		$	0.54		$	0.59	$	(0.26	)	$	0.53

(1)     The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction

costs were incurred during the quarter.

100

Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Management’s Report on Internal Control Over Financial Reporting

We are responsible for the preparation and integrity of the consolidated financial statements appearing in our Annual Report. The consolidated financial statements were prepared in conformity with United States generally accepted accounting principles and include amounts based on management’s estimates and judgments. All other financial information in this report has been presented on a basis consistent with the information included in the consolidated financial statements.

We are also responsible for establishing and maintaining adequate internal controls over financial reporting. We maintain a system of internal controls that is designed to provide reasonable assurance as to the fair and reliable preparation and presentation of the consolidated financial statements, as well as to safeguard assets from unauthorized use or disposition. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

Our control environment is the foundation for our system of internal controls over financial reporting and is embodied in our Code of Conduct. It sets the tone of our organization and includes factors such as integrity and ethical values. Our internal controls over financial reporting are supported by formal policies and procedures which are reviewed, modified and improved as changes occur in business conditions and operations.

We conducted an evaluation of effectiveness of our internal controls over financial reporting based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, effectiveness of controls and a conclusion on this evaluation. Our review excluded acquisitions that occurred in 2015, whose consolidated assets of approximately $1.2 billion and whose net revenues of approximately $179.1 million, were included in the Company’s consolidated balance sheet and statement of earnings as of and for the year ended December 31, 2015. We expect that our internal control system will be fully implemented at the acquired entities during 2016 and correspondingly evaluated by us for effectiveness. Although there are inherent limitations in the effectiveness of any system of internal controls over financial reporting, based on our evaluation, we have concluded that our internal controls over financial reporting were effective as of December 31, 2015.

The effectiveness of the Company’s internal control over financial reporting has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, and they have issued an attestation report on the Company’s internal control over financial reporting which is set forth in the Report of Independent Registered Public Accounting Firm in Part II, Item 9A of this Annual Report on Form 10-K.

/s/ Christopher A. Holden                                                     

Christopher A. Holden

President and Chief Executive Officer

/s/ Claire M. Gulmi                                                                

Claire M. Gulmi

Executive Vice President and Chief Financial Officer

101

Item 9A. Controls and Procedures - (continued) Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

AmSurg Corp.

Nashville, Tennessee

We have audited the internal control over financial reporting of AmSurg Corp. and subsidiaries (the "Company") as of December 31, 2015, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. As described in Management’s Report on Internal Control Over Financial Reporting, management excluded from its assessment the internal control over financial reporting for the Company’s acquisitions occurring during 2015, whose financial statements constitute approximately $1.2 billion of consolidated assets and approximately $179.1 of net revenues of the consolidated financial statement amounts as of and for the year ended December 31, 2015. Accordingly, our audit did not include the internal control over financial reporting of the Company’s 2015 acquisitions. The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed by, or under the supervision of, the company's principal executive and principal financial officers, or persons performing similar functions, and effected by the company's board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements and financial statement schedule as of and for the year ended December 31, 2015 of the Company and our report dated February 25, 2016 expressed an unqualified opinion on those financial statements and financial statement schedule.

/s/  DELOITTE & TOUCHE LLP

Nashville, Tennessee

February 25, 2016

102

Item 9A. Controls and Procedures - (continued) Table of Contents

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our chief executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of December 31, 2015.  Based on that evaluation, our chief executive officer (principal executive officer) and chief financial officer (principal accounting officer) have concluded that our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2015 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Item 9B.     Other Information

Not applicable.

103

Part III

Item 10.      Directors, Executive Officers and Corporate Governance

Information with respect to our directors, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Election of Directors,” is incorporated herein by reference.  Pursuant to General Instruction G(3), information concerning our executive officers is included in Part I of this Annual Report on Form 10-K under the caption “Executive Officers of the Registrant.”

Information with respect to compliance with Section 16(a) of the Securities Exchange Act of 1934, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Section 16(a) Beneficial Ownership Reporting Compliance,” is incorporated herein by reference.

Information with respect to our code of ethics, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the captions “Code of Conduct” and “Code of Ethics,” is incorporated herein by reference.

Information with respect to our audit committee and audit committee financial experts, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Election of Directors,” is incorporated herein by reference.

Item 11.      Executive Compensation

Information required by this caption, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Executive Compensation,” is incorporated herein by reference. 

Item 12.      Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information with respect to security ownership of certain beneficial owners and management and related stockholder matters, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Stock Ownership” and information with respect to our equity compensation plans at December 31, 2015, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Equity Compensation Plan Information,” is incorporated herein by reference.

Item 13.      Certain Relationships and Related Transactions, and Director Independence

Information with respect to certain relationships and related transactions, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Certain Relationships and Related Transactions,” is incorporated herein by reference.

Information with respect to the independence of our directors, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Corporate Governance,” is incorporated herein by reference.

Item 14.      Principal Accounting Fees and Services

Information with respect to the fees paid to and services provided by our principal accountant, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 26, 2016, under the caption “Fees Billed to Us by Deloitte & Touche LLP During 2015 and 2014,” is incorporated herein by reference.

104

Part IV

Item 15.      Exhibits and Financial Statement Schedules

(a)      Financial Statements, Financial Statement Schedules and Exhibits

(1)  Financial Statements:  See Item 8 herein.
(2)  Financial Statement Schedules:
Report of Independent Registered Public Accounting Firm	S-1
Schedule II – Valuation and Qualifying Accounts	S-2
(All other schedules are omitted because they are not applicable or not required, or because the required information is included in the consolidated financial statements or notes thereto.)
(3)  Exhibits:  See the exhibit listing set forth below.

105

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

AmSurg Corp.

Nashville, Tennessee

We have audited the consolidated financial statements of AmSurg Corp. and subsidiaries (the “Company”) as of December 31, 2015 and 2014, and for each of the three years in the period ended December 31, 2015, and the Company’s internal control over financial reporting as of December 31, 2015, and have issued our reports thereon dated February 25, 2016; such consolidated financial statements and reports are included elsewhere in this Form 10-K. Our audits also included the consolidated financial statement schedule of the Company listed in Item 15. This consolidated financial statement schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion based on our audits. In our opinion, such consolidated financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/  DELOITTE & TOUCHE LLP                                                                                                                                        

Nashville, Tennessee

February 25, 2016

S-1

AmSurg Corp.

Schedule II – Valuation and Qualifying Accounts

For the Years Ended December 31, 2015, 2014 and 2013

(In thousands) 

	Balance at		Charged to		Charge-off			Balance
	Beginning		Cost and		Against			at End of
	of Period		Expenses		Allowances			Period
Allowance for uncollectible accounts included under the balance sheet caption “Accounts receivable”:
Year ended December 31, 2015	$	113,357	$	287,427	$	(233,373	)	$	167,411
Year ended December 31, 2014	27,862		139,274		(53,779		)	113,357
Year ended December 31, 2013	22,379		21,983		(16,500		)	27,862

S-2

(3)   Exhibits Table of Contents

Exhibit		Description
2.1		Purchase Agreement and Agreement and Plan of Merger, dated as of May 29, 2014, by and among AmSurg Corp., Arizona Merger Corporation, Arizona II Merger Corporation, Sunbeam GP Holdings, LLC, Sunbeam GP LLC, Sunbeam Holdings, L.P., Sunbeam Primary Holdings, Inc., and HFCP VI Securityholders’ Rep LLC (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K, dated June 2, 2014)
2.2		Amendment No. 1 to Purchase Agreement and Agreement and Plan of Merger, dated as of June 12, 2014, by and among AmSurg Corp., Arizona Merger Corporation, Arizona II Merger Corporation, Sunbeam GP Holdings, LLC, Sunbeam GP LLC, Sunbeam Holdings, L.P., Sunbeam Primary Holdings, Inc., and HFCP VI Securityholders’ Rep LLC (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K, dated June 18, 2014)
2.3		Letter Agreement, dated July 16, 2014, by and among AmSurg Corp., Arizona Merger Corporation, Arizona II Merger Corporation, Sunbeam GP Holdings, LLC, Sunbeam GP, LLC, Sunbeam Holdings, L.P., Sunbeam Primary Holdings, Inc., and HFCP VI Securityholders Rep, LLC (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K, dated July 22, 2014)
3.1		Second Amended and Restated Charter of AmSurg, as amended (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K, dated May 22, 2015)
3.2		Second Amended and Restated Bylaws of AmSurg, as amended (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K, dated May 22, 2012)
4.1		Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form 10/A-4 (filed with the Commission on July 13, 2001))
4.2		Indenture, dated as of November 20, 2012, among AmSurg Corp., the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K, dated November 20, 2012)
4.3		Indenture, dated as of July 16, 2014, among AmSurg Escrow Corp., the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K, dated July 22, 2014)
4.4		First Supplemental Indenture, dated as of July 16, 2014, between AmSurg Corp. and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K, dated July 22, 2014)
4.5		Supplemental Indenture, dated as of July 16, 2014, among AmSurg Corp., the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K, dated July 22, 2014)
4.6		Form of 5.625% Rule 144A Senior Note due 2022 (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K, dated July 22, 2014)
4.7		Form of 5.625% Regulation S Senior Note due 2022 (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K, dated July 22, 2014)
10.1	*	Form of Indemnification Agreement with directors, executive officers and advisors (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (filed with the Commission on February 4, 2014))
10.2	*	Amended and Restated 1997 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)

(3)   Exhibits - (continued) Table of Contents

Exhibit		Description
10.3	*	First Amendment to Amended and Restated 1997 Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K, dated November 21, 2006)
10.4	*	Form of Non-Qualified Stock Option Agreement – 1997 Incentive Plan (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K, dated February 2, 2005)
10.5		Lease Agreement dated February 24, 1999 between Burton Hills III, LLC and AmSurg (incorporated by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q for the quarter ended June 30, 1999)
10.6		First Amendment to Lease Agreement dated June 27, 2001 by and between Burton Hills III, LLC and AmSurg (incorporated by reference to Exhibit 10 of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2002)
10.7		Second Amendment to Lease Agreement dated January 31, 2003 by and between Burton Hills III Partnership and AmSurg (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K for the year ended December 31, 2003)
10.8		Third Amendment to Lease Agreement dated September 1, 2003 by and between Burton Hills III Partnership and AmSurg (incorporated by reference to Exhibit 10.15 to the Annual Report on Form 10-K for the year ended December 31, 2003)
10.9		Fourth Amendment to Lease Agreement dated October 31, 2003 by and between Burton Hills III Partnership and AmSurg (incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K for the year ended December 31, 2003)
10.10		Fifth Amendment to Lease Agreement, dated November 9, 2012, between Burton Hills III Investments and AmSurg Corp. (incorporated by reference to Exhibit 10.22 to the Annual Report on Form 10-K for the year ended December 31, 2012)
10.11		Sixth Amendment to Lease Agreement, dated December 27, 2012, between Burton Hills III Investments and AmSurg Corp. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated January 3, 2013)
10.12		Lease Agreement, dated December 27, 2012, between Burton 6, LLC and AmSurg Corp. (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K, dated January 3, 2013)
10.13		First Amendment to Lease Agreement, dated February 15, 2013, between Burton 6, LLC and AmSurg Corp. (incorporated by reference to Exhibit 10.25 to the Annual Report on Form 10-K for the year ended December 31, 2012)
10.14		Second Amendment to Lease Agreement, dated April 11, 2013, between Burton 6, LLC and AmSurg Corp. (incorporated by reference to Exhibit 10.27 to the Annual Report on Form 10-K for the year ended December 31, 2013)
10.15		Third Amendment to Lease Agreement, dated October 13, 2013, between Burton 6, LLC and AmSurg Corp. (incorporated by reference to Exhibit 10.28 to the Annual Report on Form 10-K for the year ended December 31, 2013)

(3)   Exhibits - (continued) Table of Contents

Exhibit		Description
10.16		Office Lease, By and Between 8000 West Sunrise Lot B, as Landlord and AmSurg Corp., as Tenant (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K dated January 22, 2015)
10.17	*	Amended and Restated AmSurg Corp. Supplemental Executive & Director Retirement Savings Plan (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K dated January 6, 2012)
10.18	*	AmSurg Corp. 2006 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated November 22, 2013)
10.19	*	Form of Restricted Share Award Agreement for Non-Employee Directors – 2006 Incentive Plan (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K, dated February 21, 2007)
10.20	*	Form of Non-Qualified Stock Option Agreement for Executive Officers – 2006 Incentive Plan (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K, dated February 21, 2007)
10.21	*	Form of Restricted Share Award for Employees – 2006 Incentive Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated May 26, 2010)
10.22	*	AmSurg Corp. Long-Term Care Plan (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2005)
10.23	*	Second Amended and Restated Employment Agreement, dated November 21, 2013, between AmSurg and Christopher A. Holden (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated November 22, 2013)
10.24	*	Third Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Claire M. Gulmi (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated February 4, 2014)
10.25	*	Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Kevin D. Eastridge (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K, dated February 4, 2014)
10.26	*	Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Phillip A. Clendenin (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K, dated February 4, 2014)
10.27	*	Employment Agreement dated, July 16, 2014, between the Company and Robert Coward (incorporated by reference to Exhibit 10.2 of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015)
10.28	*	Schedule of Non-employee Director Compensation
10.29		Credit Agreement, dated as of July 16, 2014, among AmSurg Corp., the banks and other financial institutions from time to time party thereto, and Citibank, N.A., in its capacity as Administrative Agent for the lenders (incorporated by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014)
10.30		Incremental Agreement No. 1, dated October 21, 2015, by and among the Company, Citibank, N.A., as administrative agent and the other lenders party thereto (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated October 27, 2015)
10.31	*	AmSurg Corp. 2014 Equity and Incentive Plan (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated May 21, 2014)

(3)   Exhibits - (continued) Table of Contents

Exhibit		Description
10.32	*	Form of Restricted Stock Award Agreement for 2014 Equity and Incentive Plan (incorporated by reference to Exhibit 10.4 of the Quarterly Report on Form 10-Q for the quarter ended June 30, 2014)
10.33	*	Form of Performance Share Unit Award Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K dated February 9, 2015)
12.1		Statement of Computation of Ratios of Earnings to Fixed Charges
21.1		Subsidiaries of AmSurg
23.1		Consent of Independent Registered Public Accounting Firm
24.1		Power of Attorney (included in the signature page hereto)
31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101		Interactive data files pursuant to Rule 405 of Regulation S-T; (i) the Consolidated Balance Sheets at December 31, 2015 and December 31, 2014, (ii) the Consolidated Statements of Earnings for the years ended December 31, 2015, 2014 and 2013, (iii) the Consolidated Statements of Changes in Equity for the years ended December 31, 2015, 2014 and 2013, (v) the Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2014 and 2013, and (vi) the Notes to the Consolidated Financial Statements for the years ended December 31, 2015, 2014 and 2013.
	*	Management contract or compensatory plan, contract or arrangement

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMSURG CORP.
Date: February 25, 2016
	By:	/s/ Christopher A. Holden
		Christopher A. Holden
		(President and Chief Executive Officer)

     KNOW ALL MEN BY THESE PRESENTS, each person whose signature appears below hereby constitutes and appoints Christopher A. Holden and Claire M. Gulmi, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Christopher A. Holden	President, Chief Executive Officer and Director (Principal Executive Officer)	February 25, 2016
Christopher A. Holden
/s/ Claire M. Gulmi	Executive Vice President, Chief Financial Officer, Secretary and Director (Principal Financial and Accounting Officer)	February 25, 2016
Claire M. Gulmi
/s/ Steven I. Geringer	Chairman of the Board	February 25, 2016
Steven I. Geringer
/s/ Thomas G. Cigarran	Director	February 25, 2016
Thomas G. Cigarran
/s/ James A. Deal	Director	February 25, 2016
James A. Deal
/s/ John T. Gawaluck	Director	February 25, 2016
John T. Gawaluck
/s/ Henry D. Herr	Director	February 25, 2016
Henry D. Herr
/s/ Joey A. Jacobs	Director	February 25, 2016
Joey A. Jacobs
/s/ Kevin P. Lavender	Director	February 25, 2016
Kevin P. Lavender
/s/ Cynthia S. Miller	Director	February 25, 2016
Cynthia S. Miller
/s/ John W. Popp, Jr., M.D.	Director	February 25, 2016
John W. Popp, Jr., M.D.

EX-10.28

Exhibit 10.28

Non-Employee Director Compensation

The Chairman of the Board of Directors receives an annual retainer of $160,000 for his services as Chairman and his attendance at meetings of the Board of Directors and committees of the Board. Each other non-employee director (the “non-employee directors”) receives an annual retainer of $90,000 for his or her services as a director. In addition, the Chairman of the Board of Directors receives an annual grant of restricted stock with a value equal to $195,000, and each other non-employee director receives an annual grant of restricted stock with a value equal to $145,000. Chairmen of the Audit, Compensation and Nominating and Governance Committees receive an annual retainer of $45,000, $25,000 and $20,000, respectively. Non-chair members of the Audit Committee receive an annual retainer of $25,000, and non-chair members of the Compensation and Nominating and Governance Committee receive an annual retainer of $15,000 and $8,000, respectively.

From time to time, the Board of Directors of the Company may form ad hoc committees. Each non-employee director who serves on an ad hoc committee receives $1,000 for each meeting of the ad hoc committee that he or she attends, whether in person or via telephone, except that the Chair of any ad hoc committee receives $2,000 for each such meeting that he or she attends.

The Company maintains a supplemental executive and director retirement savings plan pursuant to which non-employee directors may defer up to 100 percent of their cash director fees and make pre-tax contributions to an investment account established in their name. Participants in the supplemental executive and director retirement savings plan are fully vested in their contributions to the plan, and direct the investment of their accounts in investment alternatives that the Company selects. All contributions to the plan are subject to claims of our creditors.

The Company also reimburses each non-employee director for his or her out-of-pocket expenses incurred in attending Board of Directors’ meetings and committee meetings.

EX-12.1

Exhibit 12.1

STATEMENT OF COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
	Year Ended December 31,
(In thousands)	2011		2012		2013		2014		2015
Computation of Earnings:
Pre-tax earnings from continuing operations, excluding equity in earnings of unconsolidated affiliates	$	215,233	$	255,027	$	299,996	$	287,154	$	479,767
Plus: Fixed charges	17,797		19,669		32,529		87,029		125,851
Plus: Amortization of capitalized interest	121		115		91		91		92
Plus: Distributed earning from equity investees	800		1,830		3,073		3,630		6,887
Less: Capitalized interest	85		43		24		—		42
Earnings	$	233,866	$	276,598	$	335,665	$	377,904	$	612,555
Fixed Charges:
Interest expense and amortization of deferred financing costs on all indebtedness	$	15,311	$	16,950	$	29,525	$	83,285	$	121,586
Capitalized interest	85		43		24		—		42
Estimate of interest component of rental expenses	2,401		2,676		2,980		3,744		4,223
Fixed charges	17,797		19,669		32,529		87,029		125,851
Preferred distributions	—		—		—		7,505		15,093
Total combined fixed charges and preferred distributions	$	17,797	$	19,669	$	32,529	$	94,534	$	140,944
Ratio of earnings to fixed charges	13.1x		14.1x		10.3x		4.0x		4.3x

EX-21.1

Exhibit 21.1

Subsidiary List
Wholly-Owned Subsidiaries
Name of Subsidiary	State of Organization
AmSurg KEC, Inc.	TN
AmSurg EC Topeka, Inc.	TN
AmSurg EC St. Thomas, Inc.	TN
AmSurg EC Beaumont, Inc.	TN
AmSurg EC Santa Fe, Inc.	TN
AmSurg EC Washington, Inc.	TN
AmSurg Torrance, Inc.	TN
AmSurg Abilene, Inc.	TN
AmSurg Maryville, Inc.	TN
AmSurg Melbourne, Inc.	TN
AmSurg Hillmont, Inc.	TN
AmSurg Northwest Florida, Inc.	TN
AmSurg Palmetto, Inc.	TN
AmSurg Ocala, Inc.	TN
AmSurg Crystal River, Inc.	TN
AmSurg Abilene Eye, Inc.	TN
AmSurg El Paso, Inc.	TN
AmSurg La Jolla, Inc.	TN
AmSurg Burbank, Inc.	TN
AmSurg Inglewood, Inc.	TN
AmSurg Suncoast, Inc.	TN
AmSurg San Antonio TX, Inc.	TN
AmSurg Temecula CA, Inc.	TN
AmSurg Escondido CA, Inc.	TN
AmSurg San Luis Obispo CA, Inc.	TN
AmSurg Scranton PA, Inc.	TN
AmSurg Arcadia CA, Inc.	TN
AmSurg Main Line PA, LLC	TN
AmSurg Oakland CA, Inc.	TN
AmSurg Lancaster PA, LLC	TN
AmSurg Pottsville PA, LLC	TN
AmSurg Glendora CA, Inc.	TN
AmSurg Holdings, Inc.	DE
AmSurg Anesthesia Management Services, LLC	TN
Long Beach NSC, LLC	TN
Torrance NSC, LLC	TN
Davis NSC, LLC	TN
Fullerton NSC, LLC	TN
San Antonio NSC, LLC	TN
Austin NSC, LLC	TN
Twin Falls NSC, LLC	TN
Kenwood NSC, LLC	TN
Towson NSC, LLC	TN
Wilton NSC, LLC	TN

Subsidiary List
NSC West Palm, LLC	TN
Tampa Bay NSC, LLC	TN
Coral Springs NSC, LLC	TN
Weston NSC, LLC	TN
NSC RBO East, LLC	TN
Illinois NSC, Inc.	TN
NSC Healthcare, Inc.	TN
AmSurg Colton CA, Inc.	TN
AmSurg Fresno Endoscopy, Inc.	TN
AmSurg Temecula II, Inc.	TN
AmSurg Santa Fe Anesthesia, LLC	TN
All Women's Healthcare, Inc.	FL
All Women's Healthcare Holdings, Inc.	DE
All Women's Healthcare of Dade, Inc.	FL
All Women's Healthcare of Sawgrass, Inc.	FL
All Women's Healthcare of West Broward, Inc.	FL
All Women's Healthcare Services, Inc.	FL
Anesthesiologists of Greater Orlando, Inc.	FL
Anesthesiology Associates of Tallahassee, Inc.	FL
Bethesda Anesthesia Associates, Inc.	FL
Boca Anesthesia Service, Inc.	FL
Discovery Clinical Research, Inc.	FL
Drs. Ellis, Rojas, Ross & Debs, Inc. d/b/a Kendall Anesthesia Associates	FL
Flamingo Anesthesia Associates, Inc.	FL
FM Healthcare Services, Inc.	FL
FMO Healthcare Holdings, Inc.	DE
FO Investments, Inc.	FL
FO Investments II, Inc.	FL
FO Investments III, Inc.	FL
Global Surgical Partners, Inc.	FL
Greater Florida Anesthesiologists, LLC	FL
Gynecologic Oncology Associates, Inc.	FL
Jacksonville Beaches Anesthesia Associates, Inc.	FL
Jupiter Anesthesia Associates, LLC	FL
Jupiter Healthcare, LLC	FL
Marblehead Surety & Reinsurance Company, Ltd.	Cayman
New Generations Babee Bag, Inc.	FL
North Florida Perinatal Associates, Inc.	FL
Parity Healthcare, Inc.	FL
Partners in Medical Billing, Inc.	FL
Physician Office Partners, Inc.	KS
Sheridan Anesthesia Services of Alabama, Inc.	FL
Sheridan Anesthesia Services of Louisiana, Inc.	FL
Sheridan Anesthesia Services of Oklahoma, Inc.	FL
Sheridan Anesthesia Services of Southwest Florida, Inc. (Collier)	FL
Sheridan Anesthesia Services of Virginia, Inc.	FL
Sheridan Children's Healthcare Services, Inc.	FL
Sheridan Children's Healthcare Services of Arizona, Inc.	FL

Subsidiary List
Sheridan Children’s Healthcare Services of Kentucky, Inc.	FL
Sheridan Children's Healthcare Services of Louisiana, Inc.	FL
Sheridan Children's Healthcare Services of New Mexico, Inc.	FL
Sheridan Children’s Healthcare Services of Ohio, Inc.	FL
Sheridan Children's Healthcare Services of Virginia, Inc.	FL
Sheridan Clinical Research, Inc.	FL
Sheridan Emergency Physician Services, Inc.	FL
Sheridan Emergency Physician Services of Alabama, Inc.	FL
Sheridan Emergency Physician Services of Mississippi, Inc.	FL
Sheridan Emergency Physician Services of Missouri, Inc.	FL
Sheridan Emergency Physician Services of North Missouri, Inc.	FL
Sheridan Emergency Physician Services of South Florida, Inc.	FL
Sheridan Healthcare, Inc.	DE
Sheridan Healthcare of Louisiana, Inc.	FL
Sheridan Healthcare of Missouri, Inc.	FL
Sheridan Healthcare of Vermont, Inc.	FL
Sheridan Healthcare of Virginia, Inc.	FL
Sheridan Healthcare of West Virginia, Inc.	WV
Sheridan Healthcorp, Inc.	FL
Sheridan Healthcorp of California, Inc.	CA
Sheridan Healthy Hearing Services, Inc.	FL
Sheridan Holdings, Inc.	DE
Sheridan InvestCo, LLC	DE
Sheridan Leadership Academy, Inc.	FL
Sheridan Radiology Services, Inc.	DE
Southeast Perinatal Associates, Inc.	FL
Sunbeam Intermediate Holdings, Inc.	DE
Sunbeam Primary Holdings, Inc	DE
Tennessee Valley Neonatology, Inc.	FL
Tiva Healthcare, Inc.	FL
All Women's Healthcare of South Broward, Inc.	FL
All Women's Healthcare of Southern Florida, Inc.	FL
Pinecrest Anesthesia Associates, Inc.	FL
Sheridan Emergency Physician Services of Virginia, Inc.	FL
Sheridan Radiology Management Services, Inc.	DE
Sheridan Radiology Services of Virginia, Inc.	FL
Surgery Specialists of Broward, Inc.	FL
Medical Anesthesia Consultants Medical Group, Inc.	CA
Comprehensive Teleradiology Solutions, Inc.	FL
Florida United Radiology, L.C.	FL
Jupiter Imaging Associates, Inc.	FL
Sheridan Radiology Services of Central Florida, Inc.	FL
Sheridan Radiology Services of Kentucky, Inc.	FL
Sheridan Radiology Services of Pinellas, Inc.	FL
Sheridan Radiology Services of South Florida, Inc.	FL
Anesthesia Associates of Pinellas County Division, LLC	FL
Brandon Anesthesia Associates Division, LLC	FL
Clearwater Pain Management Associates Division, LLC	FL

Subsidiary List
Global Surgical Partners of Sarasota, L.L.C.	FL
Gulfcoast Anesthesia Partners Division, LLC	FL
LA-NJ, LLC	NJ
PA Services, LLC	NJ
SAPM, LLC	NJ
SAS-NJ, LLC	NJ
South Florida Division of GFA, LLC	FL
Sunbeam Asset LLC	DE
Unicom Anesthesia Associates Division, LLC	FL
Radiology Associates of Hollywood, Inc.	FL
Coastal Anesthesia Consultants, LLC	FL
Coastal Anesthesia Staffing, LLC	FL
Bay Area Anesthesia, L.L.C.	FL
Sheridan ROP Services of Florida, Inc.	FL
Sheridan ROP Services of Virginia, Inc.	FL
Emergency Physician Solutions of North Florida, LLC	FL
Anesthesia Physician Solutions of North Florida, LLC	FL
Sheridan Children’s Services of Alabama, Inc.	FL
Sheridan Perinatal Services of Arizona, Inc.	FL
Emergency Physician Solutions of South Florida Peds, LLC	FL
Valley Anesthesiology Consultants, Inc.	AZ
Medical Information Managements Solutions, LLC	AZ
Chandler Emergency Medical Group, L.L.C. d/b/a Premier Emergency Medical Specialists	AZ
NAC Properties, LLC	GA
Sentinel Healthcare Services, LLC	GA
ASDH I, LLC	TN
AmSurg EC Centennial, Inc.	TN
AmSurg Miami, Inc.	TN
AmSurg Naples, Inc.	TN
AmSurg Kissimmee FL, Inc.	TN
AmSurg Altamonte Springs FL, Inc.	TN
AmSurg New Port Richey FL, Inc.	TN
AmSurg Finance, Inc.	TN
Ardmore NSC, LLF	TN
SHI II, LLC	TN
Ambridge Revenue Management Group, LLC	TN
Majority-Owned Subsidiaries
Name of Subsidiary	State of Organization
Austin NSC, LP	TX
Kenwood ASC, LLC	OH
Towson Surgical Center, LLC	MD
Davis Surgery Center, L.P.	CA
Boston Out-Patient Surgical Suites, L.L.C.	TN
Middlesex Endoscopy Center, LLC	TN
Fullerton Surgical Center, L.P.	CA

Subsidiary List
Coral Springs Ambulatory Surgery Center, LLC	DE
Pioneer Valley Surgicenter, LLC	TN
Surgery Center of Allentown, LLC	TN
Eastern Massachusetts Surgery Center, LLC	TN
Diagnostic Endoscopy Center, LLC	TN
Tampa Bay Specialty Surgery Center, LLC	FL
The Endoscopy Center of St. Thomas, L.P.	TN
The Abilene ASC, L.P.	TN
The Baltimore Endoscopy ASC, LLC	TN
Boston Endoscopy Center, LLC	TN
WB Surgery Center, LLC	TN
Weston Outpatient Surgical Center, Ltd.	FL
Colton CA Multi ASC, L.P.	TN
North Richland Hills Endoscopy Center, LLC	TN
Old Town Endoscopy Center, LLC	TN
Park Ventura Endoscopy Center, LLC	TN
Redbird Square Endoscopy Center, LLC	TN
32nd Street Surgery Center, LLC	TN
Red River Surgery Center, LLC	TN
Premier Ambulatory Surgery of Austin, LLP	DE
Physicians’ Eye Surgery Center, LLC	TN
Bethesda Outpatient Surgery Center, LLC	TN
San Antonio ASC, LP	TX
The San Diego CA Multi-Specialty ASC, LLC	TN
Blaine MN Multi-Specialty ASC, LLC	TN
Central Park Endoscopy Center, LLC	TN
North Valley Orthopedic Surgery Center, L.L.C.	TN
Hillmoor Eye Surgery Center, LLC	TN
Arizona Endoscopy Center, LLC	TN
Hudson Crossing Surgery Center, LLC	TN
Short Hills Surgery Center, LLC	TN
Center for Ambulatory Surgery, LLC	TN
Southern Idaho Ambulatory Surgery Center, LLC	ID
Poway CA Multi-Specialty ASC, LLC	TN
Mount Dora Ophthalmology ASC, LLC	TN
Northeast Surgical Care of Newington, LLC	TN
The Maryville ASC , L.P.	TN
The Torrance CA Multi-Specialty ASC, LLC	TN
West Palm Outpatient Surgery & Laser Center, LTD	FL
MDSINE, LLC	TN
Long Beach Surgery Center, L.P.	CA
The Endoscopy Center of Knoxville, L.P.	TN
The Endoscopy Center of Topeka, L.P.	TN
The Endoscopy Center of Southeast Texas, L.P.	TN
The Endoscopy Center of Santa Fe, L.P.	TN
The Endoscopy Center of Washington D.C., L.P.	TN
Endoscopy Center of the South Bay, L.P.	TN
The Melbourne ASC, L.P.	TN

Subsidiary List
The Hillmont ASC, L.P.	TN
The Northwest Florida ASC, L.P.	TN
The Palmetto ASC, L.P.	TN
The Ocala Endoscopy ASC, L.P.	TN
The Crystal River Endoscopy ASC, L.P.	TN
The Abilene Eye ASC, L.P.	TN
The El Paso ASC, L.P.	TN
The La Jolla Endoscopy Center, L.P.	TN
The Burbank Ophthalmology ASC, L.P.	TN
Los Angeles/Inglewood Endoscopy ASC, L.P.	TN
The Suncoast Endoscopy ASC, L.P.	TN
The San Antonio TX Endoscopy ASC, L.P.	TN
The Temecula CA Endoscopy ASC, L.P.	TN
The Escondido CA Endoscopy ASC, LP	TN
The San Luis Obispo CA Endoscopy ASC, L.P.	TN
The Scranton PA Endoscopy ASC, L.P.	TN
The Arcadia CA Endoscopy ASC, L.P.	TN
The Main Line PA Endoscopy ASC, L.P.	TN
The Oakland CA Endoscopy ASC, L.P.	TN
The Lancaster PA Endoscopy ASC, L.P.	TN
The Pottsville PA Endoscopy ASC, L.P.	TN
Glendora CA Endoscopy ASC, L.P.	TN
The Knoxville Ophthalmology ASC, LLC	TN
Montgomery Eye Surgery Center, LLC	TN
EyeCare Consultants Surgery Center, LLC	TN
The Columbia ASC, LLC	TN
The Wichita Orthopaedic ASC, LLC	TN
The Willoughby ASC, LLC	TN
The Westglen Endoscopy Center, LLC	TN
The Chevy Chase ASC, LLC	TN
The Oklahoma City ASC, LLC	TN
The Cincinnati ASC, LLC	TN
The Fayetteville ASC, LLC	TN
The Independence ASC, LLC	TN
AmSurg Northern Kentucky GI, LLC	TN
AmSurg Louisville GI, LLC	TN
AmSurg Kentucky Ophthalmology, LLC	TN
The Phoenix Ophthalmology ASC, LLC	TN
The Toledo Endoscopy ASC, LLC	TN
The Sun City Ophthalmology ASC, LLC	TN
The Cape Coral/Ft. Myers Endoscopy ASC, LLC	TN
The Boca Raton Ophthalmology ASC, LLC	TN
The Minneapolis Ophthalmology ASC, LLC	TN
Northside Gastroenterology Endoscopy Center, LLC	IN
The Oakhurst Endoscopy ASC, LLC	TN
The Waldorf Endoscopy ASC, LLC	TN
The Sarasota Endoscopy ASC, LLC	TN
The Middletown Endoscopy ASC, LLC	TN

Subsidiary List
The Dover Ophthalmology ASC, LLC	TN
The Surgery Center of Middle Tennessee, LLC	TN
The Kingston Ophthalmology ASC, LLC	TN
The Las Vegas East Ophthalmology ASC, LLC	NV
The Blue Ridge/Clemson Orthopaedic ASC, LLC	TN
The Hutchinson Ophthalmology ASC, LLC	TN
The Metairie Ophthalmology ASC, LLC	TN
The Bel Air Endoscopy ASC, LLC	TN
Bloomfield Eye Surgery Center, LLC	TN
The Newark Endoscopy ASC, LLC	TN
The Southfield Endoscopy ASC, LLC	TN
The Alexandria Ophthalmology ASC, LLC	TN
The Columbia ASC Northwest, LLC	TN
St. George Endoscopy Center, LLC	TN
The Paducah Ophthalmology ASC, LLC	TN
The Greenville ASC, LLC	TN
The Columbia TN Endoscopy ASC, LLC	TN
The Rogers AR Ophthalmology ASC, LLC	TN
The Tulsa OK Ophthalmology ASC, LLC	TN
Banner Arizona ASC, LLC	TN
The Kingsport TN Ophthalmology ASC, LLC	TN
The Lewes DE Endoscopy ASC, LLC	TN
The Winter Haven/Sebring FL Ophthalmology ASC, LLC	TN
The Rockledge FL Endoscopy ASC, LLC	TN
The Tampa FL Endoscopy ASC, LLC	TN
The Pueblo CO Ophthalmology ASC, LLC	TN
Western Washington Endoscopy Centers, LLC	TN
The Lakeland FL Endoscopy ASC, LLC	TN
The Northern NV Endoscopy ASC, LLC	TN
The Edina MN Ophthalmology ASC, LLC	TN
The West Palm Beach FL Endoscopy ASC, LLC	TN
Gainesville FL Orthopaedic ASC, LLC	TN
The Raleigh NC Endoscopy ASC, LLC	TN
The Lake Bluff IL Endoscopy ASC, LLC	TN
The Sun City AZ Endoscopy ASC, LLC	TN
The Overland Park KS Endoscopy ASC, LLC	TN
The Casper WY Endoscopy ASC, LLC	TN
The Rockville MD Endoscopy ASC, LLC	TN
Blue Water ASC, LLC	MI
Greenspring Station Endoscopy ASC, LLC	MD
Maryland Endoscopy Center Limited Liability Company	MD
The Scranton PA GP, LLC	TN
The Orlando FL Endoscopy ASC, LLC	TN
The St. Louis MO Orthopaedic ASC, LLC	TN
The Yuma AZ Endoscopy ASC, LLC	TN
The Greensboro NC Endoscopy ASC, LLC	TN
The Tulsa OK Endoscopy ASC, LLC	TN
The St. Cloud MN Ophthalmology ASC, LLC	TN

Subsidiary List
The Salem OR Ophthalmology ASC, LLC	TN
The El Dorado Multi-Specialty ASC, LLC	TN
The Nashville TN Ophthalmology ASC, LLC	TN
The Laurel MD Endoscopy ASC, LLC	TN
The Shenandoah TX Endoscopy ASC, LLC	TN
The New Orleans LA Uptown/West Bank Endoscopy ASC, LLC	TN
The Metairie LA Endoscopy ASC, LLC	TN
The Rockville, ESC-North MD Endoscopy ASC, LLC	TN
The Silver Spring MD Endoscopy ASC, LLC	TN
Ocean Endosurgery Center	NJ
The South Bend IN Endoscopy ASC, LLC	TN
The Mesquite TX Endoscopy ASC, LLC	TN
The Conroe TX Endoscopy ASC, LLC	TN
The Kissimmee FL Endoscopy ASC, LLC	TN
The Altamonte Springs FL Endoscopy ASC, LLC	TN
The Glendale AZ Endoscopy ASC, LLC	TN
The Baton Rouge LA Endoscopy ASC, LLC	TN
The Pikesville MD Endoscopy ASC, LLC	TN
The Glen Burnie MD Endoscopy ASC, LLC	TN
West Bridgewater MA Endoscopy ASC, LLC	TN
The Orlando/Mills FL Endoscopy ASC, LLC	TN
Miami Kendall FL Endoscopy ASC, LLC	TN
St. Clair Shores MI Ophthalmology ASC, LLC	TN
Marin Endoscopy Center, LLC	TN
Casa Colina Surgery Center, LLC	TN
Digestive Health Center, LLC	TN
Digestive Endoscopy Center, LLC	TN
Phoenix Orthopaedic Ambulatory Center, L.L.C.	TN
Gastroenterology Associates Endoscopy Center, LLC	TN
Phoenix Endoscopy, L.L.C.	TN
Central Texas Endoscopy Center, LLC	TN
Eye Surgery Center, LLC	TN
Carroll County Digestive Disease Center, LLC	TN
Triangle Endoscopy Center, LLC	TN
Elms Endoscopy Center, LLC	TN
TEC North, LLC	TN
Hermitage TN Endoscopy ASC, LLC	TN
Waco Gastroenterology Endoscopy Center, LLC	TN
Surgery Center of Volusia, LLC	TN
COA ASC of Franklin County, LLC	TN
North Valley Endoscopy Center, LLC	TN
East Valley Endoscopy, LLC	TN
Eagle Eye Surgery and Laser Center, LLC	TN
Doctors Park Surgery Center, LLC	TN
AmSurg Tampa Bay Anesthesia, LLC	TN
AmSurg North Valley Anesthesia, LLC	TN
AmSurg Oakland Anesthesia, L.P.	TN
AmSurg St. George Anesthesia, LLC	TN

Subsidiary List
AmSurg Arcadia Anesthesia, L.P.	TN
Mid-Atlantic Endoscopy Center, LLC	TN
Sunrise Ambulatory Surgical Center, LLC	TN
Glen Endoscopy Center, LLC	TN
Cascade Endoscopy Center, LLC	TN
Oak Lawn IL Endoscopy ASC, LLC	TN
St. Charles-AmSurg ASC Partners, LLC	DE
Fresno CA Endoscopy ASC, L.P.	TN
Temecula CA United Surgery Center, L.P.	TN
Eye Surgery Center of Wichita, LLC	TN
AmSurg Fresno CA Anesthesia, L.P.	TN
Bend Surgery Center, LLC	TN
Surgery Center of Northeast Texas, LLC	TN
Manatee Surgical Center, LLC	FL
MSC Anesthesia, Inc.	FL
Meadows Surgery Center, LLC	NJ
South Palm Ambulatory Surgery Center, LLC	FL
Jupiter Medical Specialists, LLC	FL
General Surgery of Jupiter Medical Specialists, LLC	FL
Radiology Services of Jupiter Medical Specialists, LLC	FL
Women’s Health and Wellness of Jupiter Medical Specialists, LLC	FL
HCA-Sheridan Holdings, LLC d/b/a Specialty Physician Solutions	DE
Anesthesia Physician Solutions of South Florida, LLC	FL
Emergency Physician Solutions of South Florida, LLC	FL
Radiology Physician Solutions of Florida, LLC	FL
Radiology Physician Solutions of West Florida, LLC	FL
Anesthesia Physician Solutions of West Florida, LLC	FL
Nephrology Services of Jupiter Medical Specialists, LLC	FL
Campus Surgery Center, LLC	TN
Waverly Surgery Center, LLC	TN
College Heights Endoscopy Center, LLC	TN
Ocala FL Orthopaedic ASC, LLC	TN
Surgical Center at Millburn, LLC	TN
AmSurg San Luis Obispo Anesthesia, LLC	TN
AmSurg Willoughby Anesthesia, LLC	TN
AmSurg Westminster Anesthesia, LLC	TN
AmSurg Lewes Anesthesia, LLC	TN
AmSurg Rockledge FL Anesthesia, LLC	TN
AmSurg Altamonte Springs Anesthesia, LLC	TN
AmSurg Citrus Anesthesia, LLC	TN
AmSurg Port Orange Anesthesia, LLC	TN
AmSurg South Bay Anesthesia, L.P.	TN
AmSurg MDSINE Anesthesia, LLC	TN
AmSurg Stamford Anesthesia, LLC	TN
AmSurg Marin Anesthesia, L.P.	TN
AmSurg Abilene Anesthesia, LLC	TN
AmSurg Hermitage Anesthesia, LLC	TN
AmSurg Oak Lawn IL Anesthesia, LLC	TN

Subsidiary List
Anesthesia Associates of Ocala, LLC	TN
AmSurg Melbourne Anesthesia, LLC	TN
AmSurg MDSINE Anesthesia, LLC	TN
AmSurg Stamford Anesthesia, LLC	TN
AmSurg Indianapolis Anesthesia, LLC	TN
AmSurg Cincinnati Anesthesia, LLC	TN
Surgical Specialty Center of Northeastern Pennsylvania, LLC	TN
Maryland Endoscopy Anesthesia, LLC	TN
Eye Surgery Center of Western Ohio, LLC	TN
AmSurg Springfield Anesthesia, LLC	TN
Anesthesia Associates of Columbia TN, LLC	TN
Anesthesia Associates of Joplin, LLC	TN
South Portland Surgical Center, LLC	TN
Anesthesia Associates of Bryan, LLC	TN
River Drive Surgery Center, L.L.C.	TN
Connecticut Eye Surgery Center South, LLC	TN
Eastern Connecticut Endoscopy Center, LLC	TN
Redding Anesthesia Associates, LP	TN
AmSurg Columbia Anesthesia, LLC	TN
AmSurg Toledo Anesthesia, LLC	TN
The El Paso ASC, L.P.	TN
AmSurg Greenville Anesthesia, LLC	TN
AmSurg Greensboro Anesthesia, LLC	TN
Associated Eye Surgical Center, LLC	TN
Orlando Mills Anesthesia Associates, LLC	TN
Less than Majority-Owned Subsidiaries
Name of Subsidiary	State of Organization
Baycare Surgery Centers, LLC	FL
Austin Endoscopy Center I, LP	TX
Austin Endoscopy Center II, LP	TX
Stamford/NSC Management, LLC	CT
SSPC Building, LP	TX
Torrance Surgery Center, L.P.	CA
Trinity Surgery Center, LLC	FL
Sierra Pacific Surgery Center, LLC	TN
AmSurg Fresno CA, Inc.	TN
Fresno CA Multi ASC, L.P.	TN
Central California Healthcare Holdings, LLC	DE
Fresno Surgery Center, L.P.	CA
The Florham Park Endoscopy ASC, LLC	TN
The Chattanooga Endoscopy ASC, LLC	TN
The Voorhees NJ Endoscopy ASC, LLC	TN
The Hanover NJ Endoscopy ASC, LLC	TN
The West Orange NJ Endoscopy ASC, LLC	TN
Jersey ASC Ventures, LLC	DE

Subsidiary List
West Orange ASC, LLC	DE
Livingston ASC, LLC	DE
Cañon City CO Multi-Specialty ASC, LLC	TN
AmSurg New Port Richey Anesthesia, LLC	TN
May Street Surgi Center, LLC	TN
AmSurg Chattanooga Anesthesia, LLC	TN
Wilton Surgery Center, LLC	CT
Bardmoor Surgery Center, LLC	FL
Torrance Memorial Surgical Center, LLC I	CA
CHIC/AMSURG Surgery Centers, LLC	CO
AmSurg Baptist Network Alliance, LLC	FL
Baptist Surgery and Endoscopy Centers, L.L.C.	FL
Manchester Ambulatory Surgery Center, LP	MO
Voorhees Endoscopy Holding Co., LLC	NJ
Sarasota Physicians Surgical Center, LLC	FL

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement Nos. 333-305776 and 333-196966 on Form S-3 and Registration Statement Nos. 333-41961, 333-33576, 333-56950, 333-65748, 333-81880, 333-90156, 333-107637, 333-118095, 333-134948, 333-149976, 333-151262, 333-170531 and 333-197424 on Form S-8 of our reports dated February 25, 2016, relating to the consolidated financial statements and financial statement schedule of AmSurg Corp. and subsidiaries (the “Company”), and the effectiveness of the Company’s internal control over financial reporting appearing in this Annual Report on Form 10-K of AmSurg Corp. for the year ended December 31, 2015.

/s/ DELOITTE & TOUCHE LLP

Nashville, Tennessee

February 25, 2016

EX-31.1

Exhibit 31.1

Certifications

I, Christopher A. Holden, certify that:

1. I have reviewed this annual report on Form 10-K of AmSurg Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 25, 2016

By:	/s/ Christopher A. Holden
Name:	Christopher A. Holden
Title:	President and Chief Executive Officer

EX-31.2

Exhibit 31.2

Certifications

I, Claire M. Gulmi, certify that:

1. I have reviewed this annual report on Form 10-K of AmSurg Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 25, 2016

By:	/s/ Claire M. Gulmi
Name:	Claire M. Gulmi
Title:	Executive Vice President and
	Chief Financial Officer

EX-32.1

Exhibit 32.1

AMSURG CORP.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of AmSurg Corp. (the “Company”) on Form 10-K for the year ending December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Christopher A. Holden

Christopher A. Holden

President and Chief Executive

Officer of the Company

February 25, 2016

/s/ Claire M. Gulmi

Claire M. Gulmi

Executive Vice President and

Chief Financial Officer of the Company

February 25, 2016

XML

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 24, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	0000895930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		54,720,648
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 3,318,935,487

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 106,660	$ 208,079
Restricted cash and marketable securities	13,506	10,219
Accounts receivable, net of allowance of $167,411 and $113,357, respectively	337,330	233,053
Supplies inventory	21,406	19,974
Prepaid and other current assets	75,771	92,900
Total current assets	554,673	564,225
Property and equipment, net	189,168	180,448
Investments in unconsolidated affiliates	169,170	75,475
Goodwill	3,970,210	3,381,149
Intangible assets, net	1,641,811	1,273,879
Other assets	21,450	25,886
Total assets	6,546,482	5,501,062
Liabilities and Equity
Current portion of long-term debt	20,377	18,826
Accounts payable	32,561	29,585
Accrued salaries and benefits	202,537	140,044
Accrued interest	30,480	29,644
Other accrued liabilities	119,237	67,986
Total current liabilities	405,192	286,085
Long-term debt	2,405,130	2,232,186
Deferred income taxes	699,498	611,018
Other long-term liabilities	$ 96,183	$ 89,443
Commitments and contingencies
Noncontrolling interests – redeemable	$ 175,732	$ 184,099
Equity:
Preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632	166,632
Common stock, no par value, 120,000 and 70,000 shares authorized, respectively, 54,294 and 48,113 shares issued and outstanding, respectively	1,345,418	885,393
Retained earnings	781,413	627,522
Total AmSurg Corp. equity	2,293,463	1,679,547
Noncontrolling interests – non-redeemable	471,284	418,684
Total equity	2,764,747	2,098,231
Total liabilities and equity	$ 6,546,482	$ 5,501,062

XML

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 167,411	$ 113,357
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,725,000	1,725,000
Preferred stock, shares outstanding	1,725,000	1,725,000
Common stock, shares authorized	120,000,000	70,000,000
Common Stock, Shares, Issued	54,294,000	48,113,000
Common stock, shares outstanding	54,294,000	48,113,000

XML

Consolidated Statements Of Earnings - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues	$ 2,832,958	$ 1,738,950	$ 1,057,196
Provision for uncollectibles	(287,427)	(139,274)	(21,947)
Net revenue	2,566,884	1,621,949	1,057,196
Operating expenses:
Salaries and benefits	1,314,392	694,576	327,585
Supply cost	184,222	164,296	153,126
Other operating expenses	397,794	284,928	216,501
Transaction costs	8,324	33,890	300
Depreciation and amortization	97,493	60,344	32,400
Total operating expenses	2,002,225	1,238,034	729,912
Net gain on deconsolidations	36,694	3,411	2,237
Equity in earnings of unconsolidated affiliates	16,152	7,038	3,151
Operating income	617,505	394,364	332,672
Interest expense, net	121,586	83,285	29,525
Debt extinguishment costs	0	16,887	0
Earnings from continuing operations before income taxes	495,919	294,192	303,147
Income tax expense	113,790	48,103	48,654
Net earnings from continuing operations	382,129	246,089	254,493
Net earnings (loss) from discontinued operations	(1,013)	(1,296)	7,051
Net earnings	381,116	244,793	261,544
Less net earnings attributable to noncontrolling interests	218,169	191,092	188,841
Net earnings attributable to AmSurg Corp. shareholders	162,947	53,701	72,703
Preferred stock dividends	(9,056)	(4,503)	0
Net earnings attributable to AmSurg Corp. common shareholders	153,891	49,198	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	154,892	50,777	71,009
Earnings (loss) from discontinued operations, net of income tax	(1,001)	(1,579)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$ 153,891	$ 49,198	$ 72,703
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations (usd per share)	$ 3.22	$ 1.29	$ 2.27
Net earnings from discontinued operations (usd per share)	(0.02)	(0.04)	0.05
Net earnings (usd per share)	3.20	1.25	2.32
Diluted earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations (usd per share)	3.18	1.28	2.22
Net earnings from discontinued operations (usd per share)	(0.02)	(0.04)	0.05
Net earnings (usd per share)	$ 3.16	$ 1.24	$ 2.28
Weighted average number of shares and share equivalents outstanding:
Basic (in shares)	48,058	39,311	31,338
Diluted (in shares)	51,612	39,625	31,954
Physician Services [Member]
Provision for uncollectibles	$ (266,074)	$ (117,001)	$ 0
Net revenue	$ 1,336,834	$ 512,014	$ 0

XML

Consolidated Statements Of Changes In Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Mandatory Convertible Preferred Stock [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
Balance at Dec. 31, 2012		$ 183,867	$ 0	$ 505,621	$ 310,978	$ 1,000,466	$ 175,382
Balance (in shares) at Dec. 31, 2012		31,941,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 261,544			72,703	49,789	122,492	139,052
Issuance of restricted stock (in shares)		292,000
Cancellation of restricted stock (in shares)		(16,000)
Stock options exercised		$ 33,349				33,349
Stock options exercised (in shares)	1,392,366	1,393,000
Stock repurchased		$ (45,964)				(45,964)
Stock repurchased (in shares)		(1,257,000)
Share-based compensation		$ 8,321				8,321
Tax benefit related to exercise of share-based awards		7,247				7,247
Acquisitions and other transactions impacting noncontrolling interests		679			48,115	48,794	(319)
Distributions to noncontrolling interests, net of capital contributions					(49,533)	(49,533)	(134,298)
Disposals and other transactions impacting noncontrolling interests		(1,626)			2,010	384	(2,120)
Balance at Dec. 31, 2013		$ 185,873	$ 0	578,324	361,359	1,125,556	177,697
Balance (in shares) at Dec. 31, 2013		32,353,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 244,793			53,701	56,048	109,749	135,044
Issuance of stock		$ 693,289	$ 166,632			859,921
Issuance of stock (in shares)		15,490,000	1,725,000
Issuance of restricted stock (in shares)		272,000
Cancellation of restricted stock (in shares)		(12,000)
Stock options exercised		$ 2,630				2,630
Stock options exercised (in shares)	111,743	111,000
Stock repurchased		$ (4,615)				(4,615)
Stock repurchased (in shares)		(101,000)
Share-based compensation		$ 10,104				10,104
Tax benefit related to exercise of share-based awards		3,177				3,177
Dividends paid on preferred stock				(4,503)		(4,503)
Acquisitions and other transactions impacting noncontrolling interests		744			54,725	55,469	6,482
Distributions to noncontrolling interests, net of capital contributions					(56,439)	(56,439)	(133,594)
Disposals and other transactions impacting noncontrolling interests		(5,809)			2,991	(2,818)	(1,530)
Balance at Dec. 31, 2014	$ 2,098,231	$ 885,393	$ 166,632	627,522	418,684	2,098,231	184,099
Balance (in shares) at Dec. 31, 2014		48,113,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 381,116			162,947	67,568	230,515	150,601
Issuance of stock		$ 447,720				447,720
Issuance of stock (in shares)		5,835,000
Issuance of restricted stock (in shares)		314,000
Cancellation of restricted stock (in shares)		(14,000)
Stock options exercised		$ 2,584				2,584
Stock options exercised (in shares)	113,220	113,000
Stock repurchased		$ (3,684)				(3,684)
Stock repurchased (in shares)		(67,000)
Share-based compensation		$ 15,009				15,009
Tax benefit related to exercise of share-based awards		4,001				4,001
Dividends paid on preferred stock				(9,056)		(9,056)
Acquisitions and other transactions impacting noncontrolling interests		1,019			81,863	82,882	(725)
Distributions to noncontrolling interests, net of capital contributions					(66,294)	(66,294)	(147,182)
Disposals and other transactions impacting noncontrolling interests		(6,624)			(30,537)	(37,161)	(11,061)
Balance at Dec. 31, 2015	$ 2,764,747	$ 1,345,418	$ 166,632	$ 781,413	$ 471,284	$ 2,764,747	$ 175,732
Balance (in shares) at Dec. 31, 2015		54,294,000	1,725,000

XML

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net earnings	$ 381,116	$ 244,793	$ 261,544
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	97,493	60,344	32,400
Amortization of deferred loan costs	8,362	17,715	1,977
Provision for uncollectibles	287,427	139,274	21,947
Net (gain) loss on sale of long-lived assets	(12)	2,843	(1,468)
Net gain on deconsolidations	(36,694)	(3,411)	(2,237)
Share-based compensation	15,009	10,104	8,321
Excess tax benefit from share-based compensation	(4,001)	(3,177)	(7,247)
Deferred income taxes	19,037	30,780	38,363
Equity in earnings of unconsolidated affiliates	(16,152)	(7,038)	(3,151)
Debt extinguishment costs	0	4,536	0
Net change in fair value of contingent consideration	8,804	0	0
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(326,234)	(137,663)	(23,244)
Supplies inventory	(342)	(206)	132
Prepaid and other current assets	25,880	(9,091)	(5,308)
Accounts payable	3,131	(8,440)	441
Accrued expenses and other liabilities	66,600	66,175	6,693
Other, net	8,535	4,833	3,661
Net cash flows provided by operating activities	537,959	412,371	332,824
Cash flows from investing activities:
Acquisitions and related expenses	(962,689)	(2,184,058)	(73,594)
Acquisition of property and equipment	(60,305)	(40,217)	(28,856)
Proceeds from sale of interests in surgery centers	7,114	7,069	3,553
Purchases of marketable securities	(3,984)	(6,474)	0
Maturities of marketable securities	4,233	3,486	0
Other	(1,194)	(4,941)	159
Net cash flows used in investing activities	(1,016,825)	(2,225,135)	(98,738)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	560,133	2,048,958	162,204
Repayment on long-term borrowings and revolving credit facility	(392,586)	(408,475)	(202,083)
Distributions to noncontrolling interests	(214,899)	(190,097)	(184,149)
Proceeds from preferred stock offering	0	172,500	0
Proceeds from common stock offering	466,777	439,875	0
Proceeds from issuance of common stock upon exercise of stock options	2,584	2,630	33,349
Repurchase of common stock	(3,684)	(4,615)	(45,964)
Payments of equity issuance costs	(19,058)	(24,494)	0
Financing costs incurred	(1,111)	(65,811)	(1,322)
Other	(20,709)	(468)	8,321
Net cash flows provided by (used in) financing activities	377,447	1,970,003	(229,644)
Net increase (decrease) in cash and cash equivalents	(101,419)	157,239	4,442
Cash and cash equivalents, beginning of period	208,079	50,840	46,398
Cash and cash equivalents, end of period	106,660	208,079	50,840
Supplemental cash flow information:
Interest payments	112,678	38,129	28,378
Income tax payments, net of refunds	$ 74,602	$ 19,224	$ 7,756

XML

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Accounting Policies

Below are a summary of the Company's policies that are not otherwise found within other notes.

a.     Principles of Consolidation

Ambulatory Services

AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics. All LLCs and LPs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively. The Company does not have an ownership interest in a partnership greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in 23 partnerships, 2 of which it consolidates as the Company has substantive participation rights and 21 of which it does not consolidate as the Company’s rights are limited to protective rights only. Consolidation of certain less than wholly owned partnerships is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the partnership, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the partnership, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. 

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LLCs or LPs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan has certain management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is generally a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned affiliates. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “Consolidations.”

b.    Cash and Cash Equivalents

Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value.

c.    Restricted Cash and Marketable Securities

As of December 31, 2015 and 2014, the Company had $27.4 million and $30.3 million, respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $13.9 million and $20.1 million as of December 31, 2015 and 2014, respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of December 31, 2015 and 2014, the Company had $2.7 million and $3.0 million, respectively, included in restricted cash and marketable securities at cost, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.

d.    Supplies Inventory

Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.

e.    Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2015 and 2014, with the exception of contingent purchase price payables and the retained interests of investments in unconsolidated affiliates (further discussed in note 4 and note 5, respectively), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2015. The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value.

f.    Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

g.    Reclassifications

Certain amounts in the consolidated financial statements and these notes have been reclassified for the retrospective adoption of the Financial Accounting Standards Board's (FASB) Accounting Standards Update (ASU) 2015-17 “Balance Sheet Classification of Deferred Taxes”. See below for further explanation.

h.    Recent Accounting Pronouncements

In April 2014, the FASB issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted. From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. The guidance in ASU 2014-09 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein.

The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015, including interim periods therein. The Company does not believe this ASU will impact the Company's consolidated financial position, results of operations or cash flows. However, the Company continues to evaluate the disclosures required under this ASU and has not yet determined the impact, if any.

In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. Upon adoption, the Company will reclassify debt issuance costs which are currently presented as a component of intangible assets in the accompanying consolidated balance sheets to long-term debt, except those debt issuance costs associated with the Company's revolving credit facility. The Company expects the adoption of this standard will not have a significant impact on the Company's consolidated financial position and will have no impact on the results of operations or cash flows.

In September 2015, the FASB issued ASU 2015-16 “Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments” which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment, including the effect on earnings of any amounts it would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after December 31, 2015 with early adoption permitted. The Company adopted this standard as of September 2015. The adoption of this ASU did not have a material effect on the Company's consolidated financial position, results of operations or cash flows as of December 31, 2015.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes” which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and non-current. The guidance is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted and companies may adopt the guidance prospectively or retrospectively. The Company adopted this standard retrospectively as of December 31, 2015 and as a result, reclassified $22.5 million from prepaid and other current assets to noncurrent deferred income taxes at December 31, 2014 in the accompanying consolidated balance sheets.

XML

Revenue Recognition

12 Months Ended

Dec. 31, 2015

Revenue Recognition [Abstract]

Revenue Recognition

Revenue Recognition

Ambulatory Services

Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2015, 2014 and 2013, the Company derived approximately 26%, 25% and 25%, respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.

Physician Services

Physician services revenues primarily consist of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors.

The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors.

The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

Net revenue for the physician services segment consists of the following major payors (in thousands):

	Year Ended December 31, 2015					Period from July 16, 2014 - December 31, 2014 (1)
Medicare	$	172,783		12.9	%	$	61,378		12.0	%
Medicaid	69,607			5.2		28,224			5.5
Commercial and managed care	1,007,902			75.4		382,343			74.7
Self-pay	222,830			16.7		102,727			20.1
Net fee for service revenue	1,473,122			110.2		574,672			112.3
Contract and other revenue	129,786			9.7		54,343			10.6
Provision for uncollectibles	(266,074		)	(19.9	)	(117,001		)	(22.9	)
Net revenue for physician services	$	1,336,834		100.0	%	$	512,014		100.0	%

(1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

XML

Accounts Receivable

12 Months Ended

Dec. 31, 2015

Receivables [Abstract]

Accounts Receivable

Accounts Receivable

The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Assessment of actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company routinely tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, for each facility or contract, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company may also supplement its allowance for doubtful accounts policy for its physician services using a hindsight calculation that utilizes write-off data for all payor classes during the previous periods to estimate the allowance for doubtful accounts at a point in time. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, specialty mix, acuity, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.

Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statement of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statement of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statement of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for the ambulatory services segment is included in other operating expenses and was approximately $21.4 million, $21.9 million and $21.7 million for the years ended December 31, 2015, 2014 and 2013, respectively. Bad debt expense related to physician services was $266.1 million for the year ended December 31, 2015 and $117.0 million during the period from July 16, 2014 through December 31, 2014.

At December 31, 2015 and 2014 allowances for doubtful accounts were $167.4 million and $113.4 million, respectively. The increase in the allowance for doubtful accounts is primarily a result of operations from acquisitions completed during the year ended December 31, 2015. At December 31, 2015 and 2014, approximately 80% and 73%, respectively, of the Company’s allowance for doubtful accounts was related to fee for service patient receivables associated with the Company's physician services segment. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors and by the geographic dispersion of the Company’s operations.

XML

Acquisitions

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Acquisitions

Acquisitions

The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Ambulatory Services Acquisitions

During 2015 and 2014, the Company, through a wholly-owned subsidiary, acquired a controlling interest in seven and eight surgery centers, respectively. Of the centers acquired during 2014, three were acquired as part of the Sheridan transaction and five were individually acquired in separate transactions. The aggregate amount paid for the centers and for settlement of purchase price payable obligations during December 31, 2015 and 2014 was approximately $131.3 million and $50.9 million, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility. The acquisitions completed during the year ended December 31, 2015 consist of the following:

Acquired Operations	Location	Date Acquired	Specialty
River Drive Surgery & Laser Center, LLC	Elmwood Park, NJ	February 2015	Ophthalmology
Campus Surgery Center, LLC	Daly City, CA	June 2015	Multi-Specialty
Waverly Surgery Center, LLC	Palo Alto, CA	June 2015	Multi-Specialty
Surgical Center at Millburn, LLC	Millburn-East Willow, NJ	July 2015	Multi-Specialty
Eye Surgery Center of Western Ohio, LLC	Lima, OH	August 2015	Ophthalmology
Surgical Specialty Center of Northeastern PA, LLC	Forty Fort, PA	October 2015	Multi-Specialty
South Portland Surgical Center, LLC	Tualatin, OR	November 2015	Multi-Specialty

Physician Services Acquisitions

The Company completed the acquisition of nine physician practices in 2015 and two physician practices in 2014 following the acquisition of Sheridan. During 2015 and 2014, the total consideration consisted of cash of $831.4 million and $19.0 million, respectively, which was funded at closing through available cash, current year operating cash flow and borrowings through the Company's credit facility. The acquisitions completed during the year ended December 31, 2015 consist of the following:

Acquired Operations	Location	Date Acquired	Specialty
Ambulatory Anesthesia Care, PC	Mountainside, NJ	January 2015	Anesthesia
Sheridan Radiology Management Services, Inc.	Beachwood, OH	January 2015	Radiology
Radiology Associates of Hollywood, P.A.	Pembroke Pines, FL	March 2015	Radiology
Halifax Anesthesiology Associates, P.A.	Daytona Beach, FL	April 2015	Anesthesia
Coastal Anesthesiology Consultants, P.A.	St. Augustine, FL	July 2015	Anesthesia
Bay Area Anesthesia, LLC	Tampa, FL	August 2015	Anesthesia
Valley Anesthesia Consultants, Ltd.	Phoenix, AZ	November 2015	Anesthesia
Chandler Emergency Medical Group, LLC	Phoenix, AZ	December 2015	Emergency
Northside Anesthesiology Consultants, LLC	Atlanta, GA	December 2015	Anesthesia

As a result of certain acquisitions completed during the year ended December 31, 2014, the Company has agreed to pay as additional consideration, amounts which are contingent on the acquired entities achieving future performance metrics. As of December 31, 2015 and December 31, 2014, the Company had accrued $5.5 million and $20.7 million, respectively, as a component of accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets which represents management's estimate of the fair values of the contingent consideration. During the year ended December 31, 2015, the Company made a payment of $28.7 million, of which $15.7 million was to settle the amount recorded at the acquisition date and represents a financing outflow in the consolidated statement of cash flows. As of December 31, 2015, the Company estimates it may have to pay between $5.0 million and $6.0 million in future contingent payments for acquisitions made prior to December 31, 2014 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisitions over each respective measurement period. During the year ended December 31, 2015, the Company recorded a net increase of $10.0 million based on results of operations of the associated acquisitions, of which $8.8 million is included in other operating expenses in the accompanying consolidated statements of earnings. Additionally, the Company recorded an increase in the contingent liability of $3.5 million during the year ended December 31, 2015 as a result of the acquisition accounting associated with the purchase of Sheridan. The acquisitions completed during the year ended December 31, 2015 did not contain provisions for contingent consideration.

The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the payments of the additional consideration varies by agreement but is expected to occur within one to three years from the respective date of acquisition.

Sheridan Acquisition

On July 16, 2014 (the “acquisition date”), the Company completed the acquisition of Sheridan in a cash and stock transaction. At closing, the Company paid approximately $2.1 billion in cash and issued 5,713,909 shares of its common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The shares issued to Sheridan were valued at approximately $272.0 million based on the closing price of the Company's common stock on July 16, 2014. The acquisition of Sheridan enhances the growth profile and diversity of the Company focusing on complementary specialties across the healthcare continuum.

To fund the transaction, the Company completed offerings of common stock and mandatory convertible preferred stock resulting in the issuance of 9,775,000 shares of common stock and 1,725,000 shares of mandatory convertible preferred stock. Proceeds from the common stock offering and mandatory preferred stock offering, net of transaction fees, were approximately $421.3 million and $166.6 million, respectively. In addition, on July 16, 2014, the Company entered into a new senior secured credit facility, which includes an $870.0 million term loan and a $300.0 million revolving credit facility, and completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022.

Fees and expenses associated with the Sheridan transaction, which includes fees incurred related to the Company's equity issuances and debt financings, was approximately $139.1 million during the year ended December 31, 2014. Approximately $53.0 million was capitalized as deferred financing costs, $24.5 million was related to the equity offerings and recorded as a reduction to equity, $31.9 million was expensed as transaction costs, $12.8 million was amortized through interest expense and $16.9 million was recorded as debt extinguishment costs during the year ended December 31, 2014.

Purchase Price Allocations

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2015 and 2014, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 

	2015			2014
	Individual			Individual
	Acquisitions (1)			Acquisitions			Sheridan
Accounts receivable	$	62,216		$	1,816		$	130,260
Other current assets	21,477			1,075			105,757
Property and equipment	15,484			3,294			20,185
Goodwill	682,458			101,865			1,534,656
Intangible assets	420,414			14,207			1,200,028
Other long-term assets	342			—			50,304
Accounts payable	(3,641		)	(2,519		)	(5,862		)
Other accrued liabilities	(45,386		)	(626		)	(118,548		)
Deferred income taxes	(88,728		)	—			(432,792		)
Other long-term liabilities	(4,958		)	(8,588		)	(69,456		)
Long-term debt	(6,046		)	(717		)	(4,594		)
Total fair value	1,053,632			109,807			2,409,938
Less: Fair value attributable to noncontrolling interests	85,443			39,371			24,365
Acquisition date fair value of total consideration transferred	$	968,189		$	70,436		$	2,385,573

(1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2015.

During 2015, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2014. During 2015, factors became known to the Company that resulted in changes to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to Sheridan and resulted in a net decrease to goodwill of $8.3 million, an increase to other accrued expenses, a decrease to other current assets and a decrease to deferred income taxes.

The total fair value of acquisitions completed by the Company include amounts allocated to goodwill, which result from the acquisitions' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. Additionally, the Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests associated with acquisitions completed in the last twelve months. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the amortizable intangible assets recognized. The amount allocated to the deferred income tax liability is subject to change as a result of the final allocation of purchase price to amortizable intangibles. The Company expects to finalize the purchase price allocation for its most recent acquisitions as soon as practical.

During the year ended December 31, 2015, the Company incurred approximately $8.3 million of transaction costs associated with its acquisition of surgery centers and physician practices. During the year ended December 31, 2014, the Company incurred approximately $33.9 million of transaction costs primarily associated with the acquisition of Sheridan. Such costs excluded those amounts that were either capitalized or expensed as part of the financing transactions associated with acquisitions.

Revenues and net earnings included in the years ended December 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands):

	2015		2014
	Individual		Individual
	Acquisitions		Acquisitions		Sheridan
Net revenue	$	179,113	$	20,844	517,213
Net earnings	26,901		5,155		26,776
Less: Net earnings attributable to noncontrolling interests	7,448		2,859		459
Net earnings attributable to AmSurg Corp. common shareholders	$	19,453	$	2,296	$	26,317

The unaudited consolidated pro forma results for the years ended December 31, 2015 and 2014, assuming all 2015 acquisitions had been consummated on January 1, 2014, all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands):

	2015		2014
Net revenue	$	2,858,544	$	2,680,273
Net earnings	401,950		322,653
Amounts attributable to AmSurg Corp. common shareholders:
Net earnings	170,453		104,548
Net earnings per common share:
Basic	$	3.55	$	2.21
Diluted	$	3.48	$	2.20

XML

Investments in Unconsolidated Affiliates

12 Months Ended

Dec. 31, 2015

Equity Method Investments and Joint Ventures [Abstract]

Investments in Unconsolidated Affiliates

Investments in Unconsolidated Affiliates

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination are generally based on a combination of multiple valuation methods which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

As of December 31, 2015 and 2014, the Company has recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $169.2 million and $75.5 million, respectively. The Company's net earnings from these investments during the years ended December 31, 2015, 2014 and 2013 were approximately $16.2 million, $7.0 million and $3.2 million, respectively.

During the year ended December 31, 2015, the Company's ambulatory services segment entered into five separate equity method investments. As a result of these investment transactions, the Company contributed its controlling interest in nine centers and received net cash of $8.5 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and the Company. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, the Company obtained a non-controlling interest in three additional centers and one surgical hospital which were contributed by the health systems.

During the year ended December 31, 2015, the Company's physician services segment contributed three contracts into an entity jointly owned by the Company and a health system.

During the year ended December 31, 2014, the Company's ambulatory services segment entered into four separate equity method investments. As a result of these investment transactions, the Company contributed its controlling interest in four of its centers and received net cash of $1.2 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and the Company. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, the Company obtained a non-controlling interest in one additional centers which was contributed by a health system.

During the year ended December 31, 2013, the Company's ambulatory services segment entered into one equity method investment. As a result of this investment transaction, the Company contributed cash of $0.3 million and its controlling interest in one center in exchange for a noncontrolling interests in the new investment. This investment is jointly owned by a health system and the Company. The newly formed investment (including the contributed center) are controlled by the health system. Also, as part of this transaction, the Company obtained a non-controlling interest in one additional center which was contributed by the health system.

As a result of these transactions, for the years ended December 31, 2015 and 2014, the Company recorded the fair value of the Company's investment in these entities of approximately $83.1 million and $56.4 million, respectively, in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates.

In each of these transactions, the gain or loss on deconsolidation, which is primarily non-cash in nature, is determined based on the difference between the fair value of the Company’s interest, which is based on estimates of the expected future earnings, in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers or contracts immediately prior to each transaction. In certain cases, the Company evaluated likely scenarios which were weighted by a range of expected probabilities of 10% to 50% which were primarily based on third party valuations received by the Company. Accordingly, the Company recognized a net gain on deconsolidations in the accompanying consolidated statements of earnings of approximately $36.7 million, $3.4 million, and $2.2 million during the years ended December 31, 2015, 2014 and 2013.

Included in the Company’s investments in unconsolidated affiliates are certain investments which the Company has determined meet the definition of a variable interest entity. The Company has a variable interest in these investments through its equity interests; however, the Company is not the primary beneficiary of these entities as it only holds 50% of the voting rights and does not have the power to direct the activities that most significantly impact the entities' economic performance as a result of the Company’s shared control. As a result, the Company has accounted for these investments under the equity method of accounting. The Company's investment in these entities was $89.6 million and $53.2 million as of December 31, 2015 and 2014, respectively, and are reflected in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates. During the year ended December 31, 2015, the Company contributed four centers which were previously controlled into an entity deemed by the Company to meet the definition of a variable interest entity which resulted in the Company’s recording the fair value of its retained noncontrolling interest of approximately $27.1 million as a component of investments in unconsolidated affiliates in the accompanying consolidated balance sheets. During the year ended December 31, 2014, as part of the acquisition of Sheridan, the Company acquired an interest in an entity deemed to be a variable interest entity and recorded the estimated fair value of the investment of $49.4 million on the acquisition date. The Company’s ownership interest in these investments ranges from 49% to 51% and under the terms of the operating agreements, the Company earns billing and management fees and receives its share of earnings distributions from each entity. The Company has no other material obligations or guarantees related to these entities.

The Company has recorded its share of the earnings of these investments of $11.0 million and $3.4 million as a component of equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings during 2015 and 2014, respectively. In addition, the Company recognized management and billing fees totaling $14.3 million and $4.7 million during 2015 and 2014, respectively, which are included in net revenue in the accompanying consolidated statement of earnings. Additionally, the Company has recorded receivables from these entities in the amount of $2.3 million and $3.5 million as of December 31, 2015 and 2014, respectively. These receivables are included in other current assets in the accompanying consolidated balance sheets.

XML

Discontinued Operations

12 Months Ended

Dec. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Dispositions

Discontinued Operations

During the years ended December 31, 2014 and 2013, the Company discontinued the operations of certain centers in its ambulatory services segment due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. For centers discontinued in 2014 and prior, the results of operations of those centers have been classified as discontinued operations in all periods presented. As of January 1, 2015, the Company adopted ASU 2014-08 which raised the threshold for a disposal to qualify as a discontinued operation. As a result, the Company expects that any future disposals of its centers will no longer meet the definition to be accounted for as discontinued operations, and any gain or loss from such disposals will be included in continuing operations. The Company did not dispose of any centers during the year ended December 31, 2015, but continues to have operating activity associated with centers previously classified as discontinued operations.

Results of operations and associated gain (loss) on discontinued centers for the years ended December 31, 2015, 2014 and 2013 are as follows (in thousands):

	2015			2014			2013
Revenues	$	—		$	9,545		$	25,373
Earnings before income taxes	—			893			5,607
Results of discontinued operations, net of tax:
Earnings (loss) from operations of discontinued interests in surgery centers	(1,013		)	710			4,449
Gain (loss) on disposal of discontinued interests in surgery centers	—			(2,006		)	2,602
Net earnings (loss) from discontinued operations	(1,013		)	(1,296		)	7,051
Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests	(12		)	283			5,357
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$	(1,001	)	$	(1,579	)	$	1,694

Cash proceeds from centers discontinued for the years ended December 31, 2014 and 2013 were $7.1 million and $3.6 million, respectively. There were no cash proceeds during 2015.

XML

Prepaid and Other Current Assets

12 Months Ended

Dec. 31, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid and Other Current Assets

Prepaid and Other Current Assets

The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Income taxes receivable	$	7,908	$	28,694
Prepaid expenses	18,900		18,682
Deferred compensation plan assets	16,623		17,320
Other	32,340		28,204
Total prepaid and other current assets	$	75,771	$	92,900

XML

Property and Equipment

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and Equipment

Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment is recognized over useful lives of three to ten years.

Property and equipment at December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Building and improvements	$	177,253		$	170,420
Movable equipment	237,312			215,444
Construction in progress	8,676			11,940
	423,241			397,804
Less accumulated depreciation	(234,073		)	(217,356		)
Property and equipment, net	$	189,168		$	180,448

At December 31, 2015, the Company and its partnerships had unfunded construction and equipment purchases of approximately $18.3 million in order to complete construction in progress primarily associated with the construction of the Company's new physician services headquarters. Depreciation expense for continuing and discontinued operations for the years ended December 31, 2015, 2014 and 2013 was $35.4 million, $33.2 million and $29.8 million, respectively.

XML

Goodwill And Intangible Assets

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill And Intangible Assets

Goodwill and Intangible Assets

The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in the Company's physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2015, and determined that its indefinite lived intangibles were not impaired. The Company's finite-lived intangibles includes its customer relationship with hospitals. The Company tests its finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2015, there were no events or circumstances that indicated a potential impairment in the Company's finite-lived intangibles.

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands):

	2015			2014
Balance, beginning of year	$	3,381,149		$	1,758,970
Goodwill acquired, including post acquisition adjustments	674,476			1,636,521
Goodwill disposed, including impact of deconsolidation transactions	(85,415		)	(14,342		)
Balance, end of year	$	3,970,210		$	3,381,149

As of December 31, 2015, the ambulatory services segment and the physician services segment each had approximately $2.0 billion of goodwill compared to $1.9 billion for ambulatory services and $1.5 billion for physician services, respectively, at December 31, 2014. During the year ended December 31, 2015, goodwill increased $123.4 million for the ambulatory services segment primarily due to the acquisition of seven centers, net of nine deconsolidations. During the year ended December 31, 2015, goodwill increased by $465.7 million for the physician services segment primarily due to the acquisition of nine physician practices, net of three deconsolidations. For the years ended December 31, 2015 and 2014 approximately $295.7 million and $64.5 million, respectively, of goodwill recorded was deductible for tax purposes.

Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements. Customer relationships with hospitals are initially recorded at their estimated fair value and amortized on a straight-line basis over 20 years. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years.

Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015							2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,379,977	$	(74,490	)	$	1,305,487	$	971,645	$	(22,145	)	$	949,500
Deferred financing costs	60,664		(13,490		)	47,174		59,574		(5,151		)	54,423
Capitalized software	71,462		(28,125		)	43,337		50,387		(19,197		)	31,190
Agreements, contracts and other	11,267		(2,449		)	8,818		3,523		(2,752		)	771
Total amortizable intangible assets	1,523,370		(118,554		)	1,404,816		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	8,995		—			8,995		9,995		—			9,995
Total non-amortizable intangible assets	236,995		—			236,995		237,995		—			237,995
Total intangible assets	$	1,760,365	$	(118,554	)	$	1,641,811	$	1,323,124	$	(49,245	)	$	1,273,879

Amortization of intangible assets for the years ended December 31, 2015, 2014 and 2013 was $70.5 million, $32.5 million and $2.2 million, respectively. Included in the 2014 amount above is also $12.8 million that was charged to interest expenses related to a write-off of a commitment fee for bridge financing, which the Company had secured in order to complete the acquisition of Sheridan but did not require upon obtaining permanent financing. Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2015 is $90.3 million, $89.1 million, $87.8 million, $84.8 million, $81.6 million and $971.2 million, respectively. The Company expects to recognize amortization of all intangible assets over a weighted average period of 17.8 years with no expected residual values.

XML

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2015

Accrued Liabilities, Current [Abstract]

Other Current Liabilities

Other Accrued Liabilities

The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Accrued professional liabilities	$	14,362	$	11,983
Contingent purchase price payable	5,509		12,213
Current income taxes payable	7,892		—
Refunds payable	48,415		17,752
Other	43,059		26,038
Total other accrued liabilities	$	119,237	$	67,986

XML

Accrued Professional Liabilities

12 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Accounts Professional Liabilities

Accrued Professional Liabilities

The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted.

At December 31, 2015, the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands):

	2015		2014
Estimated losses under self-insured programs	$	30,748	$	25,337
Incurred but not reported losses	36,166		28,448
Total accrued professional liabilities	66,914		53,785
Less estimated losses payable within one year	14,362		11,983
Total	$	52,552	$	41,802

The changes to the Company's estimated losses under self-insured programs as of December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Balance, beginning of year	$	53,785		$	1,171
Assumed liabilities through acquisitions	13,317			53,512
Provision related to current period reserves	15,943			5,423
Payments for current period reserves	(4,475		)	(1,595		)
Benefit related to changes in prior period reserves	(425		)	(661		)
Payments for prior period reserves	(8,863		)	(6,055		)
Other, net	(2,368		)	1,990
Balance, end of year	$	66,914		$	53,785

XML

Long-Term Debt

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Long-Term Debt

Long-term Debt

Long-term debt at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015		2014
Revolving credit agreement	$	175,000	$	—
Term Loan	856,950		865,650
Senior Unsecured Notes due 2020 (5.625%)	250,000		250,000
Senior Unsecured Notes due 2022 (5.625%)	1,100,000		1,100,000
Other debt at an average interest rate of 3.4%, due through 2022	24,944		20,156
Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021	18,613		15,206
	2,425,507		2,251,012
Less current portion	20,377		18,826
Long-term debt	$	2,405,130	$	2,232,186

Principal payments required on the Company’s long-term debt and capital leases in the five years and thereafter subsequent to December 31, 2015 are $20.4 million, $18.0 million, $14.8 million, $187.0 million, $261.0 million, and $1.9 billion. The fair value of the Company's fixed rate long-term debt and variable rate long-term debt approximated its carrying values of $1.4 billion and $1.0 billion at December 31, 2015, respectively.  With the exception of the Company’s 2020 and 2022 Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s 2020 and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

a.     Term Loan and Credit Facility

On July 16, 2014, the Company entered into a credit facility that is comprised of an $870.0 million term loan and a $300.0 million revolving credit facility. On October 21, 2015, the Company exercised the accordion feature of its revolving credit facility and increased the Company's borrowing capacity by $200.0 million to $500.0 million. As of December 31, 2015, the Company had available $325.0 million under the revolving credit facility.

The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on December 31, 2015). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually.

The revolving credit facility matures on July 16, 2019 and permits the Company to borrow at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a combination thereof; and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the senior secured credit facility by an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s less than wholly-owned subsidiaries. As of December 31, 2015, the Company was in compliance with the covenants contained in the term loan and credit facility.

Prior to entering into the Company's credit facility, the Company maintained a revolving credit facility which had a maturity of June 2018. On July 3, 2014, the Company utilized proceeds received from its common and preferred stock offerings to repay its outstanding obligation under the existing revolving credit facility. As a result of the early termination, the Company recognized approximately $4.5 million as debt extinguishment costs in the accompanying statements of earnings during the year ended December 31, 2014 related to the write-off of net deferred loan costs.

b.     Senior Unsecured Notes

2020 Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (2020 Senior Unsecured Notes). On May 31, 2013, the Company completed an offer to exchange the outstanding 2020 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended (Securities Act). The net proceeds from the issuance of the 2020 Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The 2020 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.

The Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:  

Period	Redemption Price
2015	104.219	%
2016	102.813	%
2017	101.406	%
2018 and thereafter	100.000	%

The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at December 31, 2015.

2022 Senior Unsecured Notes

On July 16, 2014, the Company completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (2022 Senior Unsecured Notes). On February 19, 2015, the Company completed an offer to exchange the outstanding 2022 Senior Unsecured Notes, for an equal amount of such notes that are registered under the Securities Act. The 2022 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, beginning on January 15, 2015, and ending on the maturity date of July 15, 2022.

Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:

Period	Redemption Price
2017	104.219	%
2018	102.813	%
2019	101.406	%
2020 and thereafter	100.000	%

The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at December 31, 2015.

c.     Senior Secured Notes

During 2010, the Company issued $75.0 million principal amount of senior secured notes due 2020 (Senior Secured Notes) pursuant to a note purchase agreement. The Senior Secured Notes had a maturity date of May 28, 2020. On July 16, 2014, the Company redeemed the Senior Secured Notes utilizing proceeds received from its common and preferred stock offerings. As a result of the early extinguishment, the Company paid an early termination fee of approximately $12.4 million to the holders of the Senior Secured Notes, which is recognized as a component of debt extinguishment costs during the year ended December 31, 2014 in the accompanying statements of earnings.

d.     Other debt

Certain partnerships included in the Company’s consolidated financial statements have loans with local lending institutions, included above in other debt, which are collateralized by certain assets of the surgery centers with a book value of approximately $41.7 million. The Company and the partners have guaranteed payment of the loans in proportion to the relative partnership interests.

XML

Other Long-term Liabilities

12 Months Ended

Dec. 31, 2015

Other Liabilities Disclosure [Abstract]

Other Long-term Liabilities

Other Long-term Liabilities

The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Accrued professional liabilities	$	52,552	$	41,802
Contingent purchase price payable	—		8,470
Deferred rent	18,958		16,814
Tax-effected unrecognized benefits	3,426		8,353
Other	21,247		14,004
Other long-term liabilities	$	96,183	$	89,443

XML

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012.

Total income taxes expense (benefit) for the years ended December 31, 2015, 2014 and 2013 was included within the following sections of the consolidated financial statements as follows (in thousands):

	2015			2014			2013
Earnings from continuing operations	$	113,790		$	48,103		$	48,654
Discontinued operations	(694		)	(643		)	9
Shareholders’ equity	(2,227		)	(3,177		)	(7,381		)
Total	$	110,869		$	44,283		$	41,282

Income tax expense from continuing operations for the years ended December 31, 2015, 2014 and 2013 was comprised of the following (in thousands):

	2015		2014		2013
Current:
Federal	$	83,228	$	8,640	$	7,895
State	14,268		4,396		3,598
Deferred:
Federal	11,715		27,505		31,509
State	4,579		7,562		5,652
Income tax expense	$	113,790	$	48,103	$	48,654

Income tax expense from continuing operations for the years ended December 31, 2015, 2014 and 2013 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):

	2015			2014			2013
Statutory federal income tax	$	173,572		$	102,967		$	106,101
Less federal income tax assumed directly by noncontrolling interests	(76,364		)	(66,783		)	(64,219		)
State income taxes, net of federal income tax benefit	11,604			6,616			5,539
Increase in valuation allowances	317			4,662			924
Interest related to unrecognized tax benefits	(548		)	(161		)	(155		)
Other	5,209			802			464
Income tax expense	$	113,790		$	48,103		$	48,654

The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Decreases in interest and penalty obligations of $0.2 million, $0.1 million and $0.2 million were recognized in the consolidated statement of earnings for the years ended December 31, 2015, 2014 and 2013, respectively, resulting in a total recognition of interest and penalty obligations of approximately $0.8 million and $1.2 million in the consolidated balance sheet at December 31, 2015 and 2014, respectively.

The Company primarily has unrecognized tax benefits that represent an amortization deduction which is temporary in nature. A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2015, 2014 and 2013 is as follows (in thousands):

	2015			2014			2013
Balance at beginning of year	$	7,336		$	6,330		$	9,235
Additions for tax positions of current year	—			204			46
Increases (decreases) for tax positions taken during a prior period	(1,006		)	1,069			—
Lapse of statute of limitations	(3,178		)	(267		)	(2,951		)
Balance at end of year	$	3,152		$	7,336		$	6,330

The Company believes that the total amount of increases in unrecognized tax benefits within the next 12 months is not considered significant. The total amount of unrecognized tax benefits that would affect the Company’s effective tax rate if recognized is approximately $0.1 million.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Deferred tax assets:
Allowance for uncollectible accounts	$	3,276		$	1,096
Accrued assets and other	36,600			27,537
Share-based compensation	10,710			7,719
Interest on unrecognized tax benefits	113			245
Accrued liabilities and other	4,080			3,931
Medical malpractice	19,035			16,240
Operating and capital loss carryforwards	29,718			22,709
Valuation allowances	(21,814		)	(17,457		)
Total deferred tax assets	81,718			62,020
Deferred tax liabilities:
Prepaid expenses	1,789			2,435
Property and equipment, principally due to differences in depreciation	16,787			15,235
Goodwill, intangible assets and other, principally due to differences in amortization	762,640			655,358
Total deferred tax liabilities	781,216			673,028
Net deferred tax liabilities	$	699,498		$	611,008

The Company has provided valuation allowances on its gross deferred tax assets to the extent that management does not believe that it is more likely than not that such asset will be realized. Capital loss carryforwards began to expire in 2014, and state net operating losses began to expire in 2015.

XML

Shareholders' Equity

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

a. Common Stock

During December 2015, the Company issued 5,835,000 shares of its common stock in a public offering, at $80.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $19.1 million. Proceeds were used to repay a portion of the Company's revolving credit facility, to fund a portion of the acquisitions completed during the year ended 2015 and for general corporate purposes.

On July 2, 2014, the Company issued 9,775,000 shares of its common stock in a public offering, at $45.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $18.5 million. Proceeds from the issuance were used to satisfy certain debt obligations with the remaining amount utilized to fund a portion of the Sheridan acquisition. In addition, on July 16, 2014, the Company issued 5,713,909 shares of its common stock directly to the former owners of Sheridan as part of the total consideration for the Sheridan acquisition. The Company registered these shares with the SEC in October of 2014. The former owners of Sheridan subsequently sold their shares in November of 2014.

During 2013, under a board authorized stock repurchase program, the Company purchased 1,154,378 shares of the Company's common stock for approximately $42.7 million, at an average price of $36.93 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company's stock incentive plans. The stock repurchase program expired during 2014.

In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vested to cover payroll withholding taxes in accordance with the restricted stock agreements. During 2015 and 2014, the Company repurchased 67,000 shares and 100,720 shares, respectively, of common stock for approximately $3.7 million and $4.6 million, respectively.

b. Preferred Stock

On July 2, 2014, the Company issued 1,725,000 shares of its mandatory convertible preferred stock in a public offering, at $100.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $5.9 million.

The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate from the date of issuance and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100, plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount.

During the year ended December 31, 2015, the Company's Board of Directors declared four dividends each totaling $1.3125 per share in cash, or $2.3 million, for the Company's mandatory convertible preferred stock. All dividends declared during 2015 have been paid except those dividends declared on November 19, 2015, which were funded to the paying agent to be paid on January 1, 2016 to the shareholders of record as of December 15, 2015.

On August 29, 2014, the Company's Board of Directors declared its first dividend of $1.2979 per share in cash, or $2.2 million and on November 25, 2014, the Company's Board of Directors declared a dividend for $1.3125 per share, or $2.3 million for the Company's mandatory convertible preferred stock.

c. Stock Incentive Plans

Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards. 

Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $4.0 million, $3.2 million and $7.2 million for the years ended December 31, 2015, 2014 and 2013, respectively.

The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock.

In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan. The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At December 31, 2015, 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 900,039 shares were available for future equity grants. Restricted stock granted to outside directors vests on the first anniversary of the date of grant. Restricted stock granted to employees vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date. Under Company policy, shares held by outside directors and senior management are subject to certain holding requirements and restrictions.

The Company has not issued options subsequent to 2008, and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity for the years ended December 31, 2015, 2014 and 2013 was as follows (in thousands):

	2015		2014		2013
Share-based compensation expense	$	15,009	$	10,104	$	8,321
Fair value of shares vested	13,220		15,126		11,742
Cash received from option exercises	2,584		2,630		33,349
Tax benefit from option exercises	4,001		3,177		7,247

As of December 31, 2015, the Company had total unrecognized compensation cost of approximately $16.6 million related to non-vested awards, which the Company expects to recognize through 2019 and over a weighted average period of 1.1 years. During the years ended December 31, 2015, 2014 and 2013, there were no options that were anti-dilutive.

A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2015, is as follows:

			Weighted
	Number		Average
	of Shares		Grant Price
Non-vested shares at January 1, 2013	828,686		$	22.50
Shares granted	291,863		31.66
Shares vested	(360,337	)	21.55
Shares forfeited	(16,343	)	23.11
Non-vested shares at December 31, 2013	743,869		$	26.54
Shares granted	272,780		43.12
Shares vested	(336,160	)	25.69
Shares forfeited	(12,380	)	38.94
Non-vested shares at December 31, 2014	668,109		$	33.51
Shares granted	313,498		56.19
Shares vested	(233,831	)	28.19
Shares forfeited	(13,675	)	42.15
Non-vested shares at December 31, 2015	734,101		$	44.73

In addition to the non-vested restricted shares, during the year ended December 31, 2015, the Company granted 68,533 performance-based restricted stock units (RSUs) to certain of its officers and physician employees. The fair value of the Company's common stock on the grant date of these RSUs was $55.40. The RSUs will vest ratably over a three year period from the grant date. The conversion of the RSUs to restricted stock is contingent on the Company’s achievement of a specified one-year financial performance goal for the year ended December 31, 2015 and, if achieved, would occur during the first quarter of 2016. If the financial performance goal is not achieved, the RSUs will be forfeited. The number of RSUs that will ultimately be received by the holders range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At December 31, 2015, the financial performance goal was achieved at a level that will result in the conversion of the RSUs to restricted stock at 150%.

A summary of stock option activity for the three years ended December 31, 2015 is summarized as follows:

					Weighted
			Weighted		Average
			Average		Remaining
	Number		Exercise		Contractual
	of Shares		Price		Term (in years)
Outstanding at January 1, 2013	1,662,830		$	23.82	2.9
Options exercised with total intrinsic value of $33.3 million	(1,392,366	)	23.95
Outstanding at December 31, 2013	270,464		$	23.16	2.5
Options exercised with total intrinsic value of $2.6 million	(111,743	)	23.53
Outstanding at December 31, 2014	158,721		$	22.89	1.7
Options exercised with total intrinsic value of $4.9 million	(113,220	)	22.81
Options terminated	(11,750	)	23.42
Outstanding, Vested and Exercisable at December 31, 2015 with an aggregate intrinsic value of $1.8 million	33,751		$	22.98	1.1

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at December 31, 2015 exercised their options at the Company’s closing stock price on December 31, 2015.

d. Earnings per Share

Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

	Earnings		Shares	Per Share
	(Numerator)		(Denominator)	Amount
For the year ended December 31, 2015:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	154,892	48,058	$	3.22
Preferred stock dividends	9,056		—
Effect of dilutive securities, options and non-vested shares	—		3,554
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	163,948	51,612	$	3.18
For the year ended December 31, 2014:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	50,777	39,311	$	1.29
Effect of dilutive securities, options and non-vested shares	—		314
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	50,777	39,625	$	1.28
For the year ended December 31, 2013:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	71,009	31,338	$	2.27
Effect of dilutive securities, options and non-vested shares	—		616
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	71,009	31,954	$	2.22

XML

Leases

12 Months Ended

Dec. 31, 2015

Leases [Abstract]

Leases

Leases

The Company has entered into various building and equipment capital and operating leases in operation and under development and for office space, expiring at various dates through 2037. Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2015 were as follows (in thousands):

Year Ended December 31,	Capital Leases		Operating Leases
2016	$	3,021	$	55,636
2017	2,776		55,857
2018	2,502		53,515
2019	2,068		52,034
2020	1,866		50,378
Thereafter	12,991		331,746
Total minimum rentals	25,224		$	599,166
Less amounts representing interest at rates ranging from 1.7% to 13.4%	6,611
Capital lease obligations	$	18,613

At December 31, 2015, buildings and equipment with a cost of approximately $23.4 million and accumulated depreciation of approximately $5.6 million were held under capital leases. The Company and the partners in the partnerships have guaranteed payment of certain of these leases. Rental expense for operating leases for the years ended December 31, 2015, 2014 and 2013 was approximately $74.6 million, $66.1 million and $52.6 million, respectively.

XML

Related Party Transactions

12 Months Ended

Dec. 31, 2015

Related Party Transactions [Abstract]

Related Party Transactions

Related Party Transactions

Certain surgery centers lease space from entities affiliated with their physician partners at negotiated rates that management believes were equal to fair market value at the inception of the leases based on relevant market data. Certain surgery centers reimburse their physician partners for salaries and benefits and billing fees related to time spent by employees of their practices on activities of the centers at current market rates. In addition, certain centers compensate at market rates their physician partners for physician advisory services provided to the surgery centers, including medical director and performance improvement services.   

Excluding transactions with investments in unconsolidated affiliates disclosed in Note 5, related party payments for the years ended December 31, 2015, 2014 and 2013 were as follows (in thousands):

	2015		2014		2013
Operating leases	$	27,622	$	27,559	$	29,240
Salaries and benefits	62,590		66,763		72,892
Billing fees	10,873		9,899		11,591
Medical advisory services	2,635		2,811		2,993

The Company also reimburses their physician partners for operating expenses paid by the physician partners to third party providers on the behalf of the surgery center. The Company believes that the foregoing transactions are reasonably expected to benefit the Company and that the amount of reimbursed expenses included in other operating expenses in the accompanying consolidated statements of earnings for each of the years ended December 31, 2015, 2014 and 2013 were not significant.

It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.

XML

Employee Benefit Programs

12 Months Ended

Dec. 31, 2015

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plans

Employee Benefit Programs

The Company maintains multiple qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code. These plans are defined contribution plans covering substantially all employees of the Company and provide for voluntary contributions by employees, subject to certain limits. Company contributions are primarily based on specified percentages of employee compensation. In some instances, the plan may allow for elective or required Company contributions subject to the limits defined by each plan. The Company funds contributions as accrued. The Company’s contributions for the years ended December 31, 2015, 2014 and 2013 were approximately $14.1 million, $1.6 million and $1.1 million, respectively, and vest immediately or incrementally over a period of four to five years, depending on the plan and the tenures of the respective employees for which the contributions were made. During 2014, the Company recorded expenses of approximately $5.6 million related to Sheridan which represented the period July 16, 2014 through December 31, 2014.

The Company maintains the Supplemental Executive and Director Retirement Savings Plan. This plan is a defined contribution plan covering all officers of the Company and provides for voluntary contributions of up to 50% of employee annual compensation.  Company contributions are at the discretion of the Compensation Committee of the Board of Directors and vest incrementally over five years. The employee and employer contributions are placed in a Rabbi Trust and recorded in the accompanying consolidated balance sheets in prepaid and other current assets. Employer contributions to this plan for the years ended December 31, 2015, 2014 and 2013 were approximately $5.2 million, $0.8 million and $2.3 million, respectively. As of December 31, 2015 and 2014, the cash surrender value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets in the accompanying consolidated balance sheets, was $16.6 million and $17.3 million, respectively.

XML

Commitments And Contingencies

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies

Commitments and Contingencies

Litigation

From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows.

Insurance Programs

Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.

The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.

The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries.

Redeemable Noncontrolling Interests

Certain of the Company’s wholly-owned subsidiaries are responsible for all debts incurred but unpaid by the Company's less than wholly-owned partnerships as these subsidiaries are the general partner. As manager of the operations of these partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions. In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015. As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Physician Services Headquarters Operating Lease

On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which it intends to be the future headquarters of its physician services operations. The Company took possession of the space in the fourth quarter of 2015 and began tenant improvements on approximately 167,000 square feet of space, which it intends to occupy during the third quarter of 2016. In addition, the Company plans to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which it intends to occupy during the fourth quarter of 2016. Annual rent expense is expected to be approximately $2.9 million. The initial term of this lease agreement expires in February 2029.

XML

Segment Reporting

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine.

The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

The following table presents financial information for each reportable segment (in thousands):

	Year ended December 31,
	2015			2014			2013
Net Revenue:
Ambulatory Services	$	1,230,050		$	1,109,935		$	1,057,196
Physician Services (1)	1,336,834			512,014			—
Total	$	2,566,884		$	1,621,949		$	1,057,196
Adjusted Segment EBITDA:
Ambulatory Services	$	226,229		$	197,377		$	187,972
Physician Services (1)	266,031			107,105			—
Total	$	492,260		$	304,482		$	187,972
Adjusted Segment EBITDA:	$	492,260		$	304,482		$	187,972
Earnings from continuing operations attributable to noncontrolling interests	218,181			190,809			183,484
Interest expense, net	(121,586		)	(83,285		)	(29,525		)
Depreciation and amortization	(97,493		)	(60,344		)	(32,400		)
Share-based compensation	(15,009		)	(10,104		)	(8,321		)
Net change in fair value of contingent consideration	(8,804		)	—			—
Transaction costs	(8,324		)	(33,890		)	(300		)
Debt extinguishment costs	—			(16,887		)	—
Net gain on deconsolidations	36,694			3,411			2,237
Earnings from continuing operations before income taxes	$	495,919		$	294,192		$	303,147
Acquisition and Capital Expenditures:
Ambulatory Services (2)	$	168,593		$	81,156		$	102,450
Physician Services	854,401			28,909			—
Total	$	1,022,994		$	110,065		$	102,450

	2015		2014
Assets:
Ambulatory Services	$	2,609,479	$	2,526,625
Physician Services	3,937,003		2,974,437
Total	$	6,546,482	$	5,501,062

(1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

(2) Excludes the purchase price to acquire Sheridan in 2014.

XML

Financial Information for the Company and Its Subsidiaries

12 Months Ended

Dec. 31, 2015

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Financial Information for the Company and Its Subsidiaries

Financial Information for the Company and Its Subsidiaries

The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	20,437	$	27,507	$	58,716	$	—		$	106,660
Restricted cash and marketable securities	—		—		13,506		—			13,506
Accounts receivable, net	—		223,434		113,896		—			337,330
Supplies inventory	—		—		21,406		—			21,406
Prepaid and other current assets	28,739		39,046		16,062		(8,076		)	75,771
Total current assets	49,176		289,987		223,586		(8,076		)	554,673
Property and equipment, net	12,515		14,601		162,052		—			189,168
Investments in and receivables from unconsolidated affiliates	4,901,026		1,775,272		—		(6,507,128		)	169,170
Goodwill	—		1,956,741		—		2,013,469			3,970,210
Intangible assets, net	59,928		1,579,537		2,346		—			1,641,811
Other assets	4,653		1,717		17,078		(1,998		)	21,450
Total assets	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	11,677	$	—		$	20,377
Accounts payable	2,816		3,760		29,837		(3,852		)	32,561
Accrued salaries and benefits	31,510		158,705		12,322		—			202,537
Accrued interest	30,463		—		17		—			30,480
Other accrued liabilities	13,962		76,590		32,909		(4,224		)	119,237
Total current liabilities	87,451		239,055		86,762		(8,076		)	405,192
Long-term debt	2,373,251		—		55,275		(23,396		)	2,405,130
Deferred income taxes	268,573		432,923		—		(1,998		)	699,498
Other long-term liabilities	4,560		71,509		20,114		—			96,183
Intercompany payable	—		1,228,157		—		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		63,060		112,672			175,732
Equity:
Total AmSurg Corp. equity	2,293,463		3,646,211		132,267		(3,778,478		)	2,293,463
Noncontrolling interests – non-redeemable	—		—		47,584		423,700			471,284
Total equity	2,293,463		3,646,211		179,851		(3,354,778		)	2,764,747
Total liabilities and equity	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	46,097		37,826		13,795		(4,818		)	92,900
Total current assets	180,448		185,370		203,225		(4,818		)	564,225
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	207,500		404,984		—		(1,466		)	611,018
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	28,554		$	1,331,042	$	1,245,292		$	(38,004	)	$	2,566,884
Operating expenses:
Salaries and benefits	69,102			937,484		308,313			(507		)	1,314,392
Supply cost	—			2,436		181,866			(80		)	184,222
Other operating expenses	24,682			145,369		265,160			(37,417		)	397,794
Transaction costs	1,762			6,562		—			—			8,324
Depreciation and amortization	3,912			61,658		31,923			—			97,493
Total operating expenses	99,458			1,153,509		787,262			(38,004		)	2,002,225
Gain (loss) on deconsolidations	—			37,350		(656		)	—			36,694
Equity in earnings of unconsolidated affiliates	349,139			251,093		—			(584,080		)	16,152
Operating income	278,235			465,976		457,374			(584,080		)	617,505
Interest expense, net	41,140			77,947		2,499			—			121,586
Earnings from continuing operations before income taxes	237,095			388,029		454,875			(584,080		)	495,919
Income tax expense	73,159			38,891		1,740			—			113,790
Net earnings from continuing operations	163,936			349,138		453,135			(584,080		)	382,129
Net loss from discontinued operations	(989		)	—		(24		)	—			(1,013		)
Net earnings	162,947			349,138		453,111			(584,080		)	381,116
Net earnings attributable to noncontrolling interests	—			—		218,169			—			218,169
Net earnings attributable to AmSurg Corp. shareholders	162,947			349,138		234,942			(584,080		)	162,947
Preferred stock dividends	(9,056		)	—		—			—			(9,056		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	154,880		$	349,138	$	234,954		$	(584,080	)	$	154,892
Loss from discontinued operations, net of income tax	(989		)	—		(12		)	—			(1,001		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,773		$	508,572	$	1,112,940		$	(24,336	)	$	1,621,949
Operating expenses:
Salaries and benefits	65,697			350,615		284,050			(5,786		)	694,576
Supply cost	—			1,292		163,004			—			164,296
Other operating expenses	18,667			53,413		231,398			(18,550		)	284,928
Transaction costs	29,004			4,886		—			—			33,890
Depreciation and amortization	4,044			25,610		30,690			—			60,344
Total operating expenses	117,412			435,816		709,142			(24,336		)	1,238,034
Gain on deconsolidation	—			3,411		—			—			3,411
Equity in earnings of unconsolidated affiliates	237,657			211,889		—			(442,508		)	7,038
Operating income	145,018			288,056		403,798			(442,508		)	394,364
Interest expense, net	47,997			33,026		2,262			—			83,285
Debt extinguishment costs	16,887			—		—			—			16,887
Earnings from continuing operations before income taxes	80,134			255,030		401,536			(442,508		)	294,192
Income tax expense	29,166			17,373		1,564			—			48,103
Net earnings from continuing operations	50,968			237,657		399,972			(442,508		)	246,089
Net earnings (loss) from discontinued operations	2,733			—		(4,029		)	—			(1,296		)
Net earnings	53,701			237,657		395,943			(442,508		)	244,793
Net earnings attributable to noncontrolling interests	—			21		191,071			—			191,092
Net earnings attributable to AmSurg Corp. shareholders	53,701			237,636		204,872			(442,508		)	53,701
Preferred stock dividends	(4,503		)	—		—			—			(4,503		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	46,465		$	237,636	$	209,184		$	(442,508	)	$	50,777
Earnings (loss) from discontinued operations, net of income tax	2,733			—		(4,312		)	—			(1,579		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,167	$	—	$	1,050,547		$	(17,518	)	$	1,057,196
Operating expenses:
Salaries and benefits	61,038		—		267,014			(467		)	327,585
Supply cost	—		—		153,126			—			153,126
Other operating expenses	22,360		—		211,192			(17,051		)	216,501
Transaction costs	300		—		—			—			300
Depreciation and amortization	3,186		—		29,214			—			32,400
Total operating expenses	86,884		—		660,546			(17,518		)	729,912
Gain on deconsolidation	—		2,237		—			—			2,237
Equity in earnings of unconsolidated affiliates	207,199		204,962		—			(409,010		)	3,151
Operating income	144,482		207,199		390,001			(409,010		)	332,672
Interest expense, net	27,282		—		2,243			—			29,525
Earnings from continuing operations before income taxes	117,200		207,199		387,758			(409,010		)	303,147
Income tax expense	47,139		—		1,515			—			48,654
Net earnings from continuing operations	70,061		207,199		386,243			(409,010		)	254,493
Net earnings from discontinued operations	2,642		—		4,409			—			7,051
Net earnings	72,703		207,199		390,652			(409,010		)	261,544
Net earnings attributable to noncontrolling interests	—		—		188,841			—			188,841
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	70,061	$	207,199	$	202,759		$	(409,010	)	$	71,009
Earnings (loss) from discontinued operations, net of income tax	2,642		—		(948		)	—			1,694
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	40,432		$	353,932		$	489,820		$	(346,225	)	$	537,959
Cash flows from investing activities:
Acquisitions and related transactions	(757,775		)	(969,259		)	—			764,345			(962,689		)
Acquisition of property and equipment	(5,876		)	(22,988		)	(31,441		)	—			(60,305		)
Proceeds from sale of interests in surgery centers	—			7,114			—			—			7,114
Purchases of marketable securities	—			—			(3,984		)	—			(3,984		)
Maturities of marketable securities	—			—			4,233			—			4,233
Other	—			(2,927		)	1,733			—			(1,194		)
Net cash flows used in investing activities	(763,651		)	(988,060		)	(29,459		)	764,345			(1,016,825		)
Cash flows from financing activities:
Proceeds from long-term borrowings	546,000			—			14,133			—			560,133
Repayment on long-term borrowings	(379,700		)	—			(12,886		)	—			(392,586		)
Distributions to owners, including noncontrolling interests	—			(109,862		)	(451,262		)	346,225			(214,899		)
Capital contributions	—			757,775			—			(757,775		)	—
Proceeds from common stock offering	466,777			—			—			—			466,777
Payments of equity issuance costs	(19,058		)	—			—			—			(19,058		)
Financing cost incurred	(1,101		)	—			(10		)	—			(1,111		)
Changes in intercompany balances with affiliates, net	5,016			—			(5,016		)	—			—
Other financing activities, net	(8,629		)	(9,749		)	3,139			(6,570		)	(21,809		)
Net cash flows provided by (used in) financing activities	609,305			638,164			(451,902		)	(418,120		)	377,447
Net increase (decrease) in cash and cash equivalents	(113,914		)	4,036			8,459			—			(101,419		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	20,437		$	27,507		$	58,716		$	—		$	106,660

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	96,681		$	298,415		$	430,880		$	(413,605	)	$	412,371
Cash flows from investing activities:
Acquisitions and related transactions	(2,124,124		)	(2,188,191		)	1,520			2,126,737			(2,184,058		)
Acquisition of property and equipment	(7,877		)	(9,933		)	(22,407		)	—			(40,217		)
Proceeds from sale of interests in surgery centers	—			7,069			—			—			7,069
Purchases of marketable securities	—			—			(6,474		)	—			(6,474		)
Maturities of marketable securities	—			—			3,486			—			3,486
Other	(3,068		)	(6,594		)	4,721			—			(4,941		)
Net cash flows used in investing activities	(2,135,069		)	(2,197,649		)	(19,154		)	2,126,737			(2,225,135		)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,040,000			—			8,958			—			2,048,958
Repayment on long-term borrowings	(396,493		)	—			(11,982		)	—			(408,475		)
Distributions to owners, including noncontrolling interests	—			(202,247		)	(401,455		)	413,605			(190,097		)
Capital contributions	—			2,124,124			—			(2,124,124		)	—
Proceeds from preferred stock offering	172,500			—			—			—			172,500
Proceeds from common stock offering	439,875			—			—			—			439,875
Payments of equity issuance costs	(24,494		)	—			—			—			(24,494		)
Financing cost incurred	(65,811		)	—			—			—			(65,811		)
Changes in intercompany balances with affiliates, net	2,965			—			(2,965		)	—			—
Other financing activities, net	(2,513		)	828			1,845			(2,613		)	(2,453		)
Net cash flows provided by (used in) financing activities	2,166,029			1,922,705			(405,599		)	(1,713,132		)	1,970,003
Net increase in cash and cash equivalents	127,641			23,471			6,127			—			157,239
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	134,351		$	23,471		$	50,257		$	—		$	208,079

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	45,127		$	208,773		$	426,572		$	(347,648	)	$	332,824
Cash flows from investing activities:
Acquisitions and related transactions	—			(74,288		)	—			694			(73,594		)
Acquisition of property and equipment	(3,693		)	—			(25,163		)	—			(28,856		)
Proceeds from sale of interests in surgery centers	—			3,553			—			—			3,553
Other	—			159			—			—			159
Net cash flows used in investing activities	(3,693		)	(70,576		)	(25,163		)	694			(98,738		)
Cash flows from financing activities:
Proceeds from long-term borrowings	152,700			—			9,504			—			162,204
Repayment on long-term borrowings	(188,081		)	—			(14,002		)	—			(202,083		)
Distributions to owners, including noncontrolling interests	—			(138,875		)	(392,922		)	347,648			(184,149		)
Changes in intercompany balances with affiliates, net	88			—			(88		)	—			—
Other financing activities, net	(6,690		)	678			1,090			(694		)	(5,616		)
Net cash flows used in financing activities	(41,983		)	(138,197		)	(396,418		)	346,954			(229,644		)
Net increase (decrease) in cash and cash equivalents	(549		)	—			4,991			—			4,442
Cash and cash equivalents, beginning of period	7,259			—			39,139			—			46,398
Cash and cash equivalents, end of period	$	6,710		$	—		$	44,130		$	—		$	50,840

XML

Subsequent Events

12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

The Company assessed events occurring subsequent to December 31, 2015 for potential recognition and disclosure in the consolidated financial statements. No events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

XML

Quarterly Statement of Earnings Data (Unaudited)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Quarterly Statement of Earnings Data (Unaudited)

Quarterly Statement of Earnings Data (Unaudited)

The following table presents certain quarterly statement of earnings data for the years ended December 31, 2015 and 2014. The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.

	2015									2014
	Q1		Q2		Q3		Q4			Q1			Q2		Q3 (1)			Q4
	(In thousands, except per share data)
Net revenues	$	570,445	$	641,950	$	650,227	$	704,262		$	259,561		$	278,227	$	502,350		$	581,811
Earnings from continuing operations before income taxes	83,004		115,940		135,797		161,178			73,028			80,487		39,142			101,535
Net earnings from continuing operations	68,755		90,747		98,279		124,348			60,046			67,689		39,120			79,234
Net earnings (loss) from discontinued operations	—		—		—		(1,013		)	68			483		(1,697		)	(150		)
Net earnings	68,755		90,747		98,279		123,335			60,114			68,172		37,423			79,084
Net earnings (loss) attributable to AmSurg Corp. common shareholders:
Continuing	18,774		31,411		40,397		64,310			17,392			18,771		(10,697		)	25,311
Discontinued	—		—		—		(1,001		)	(197		)	190		(1,376		)	(196		)
Net earnings (loss)	$	18,774	$	31,411	$	40,397	$	63,309		$	17,195		$	18,961	$	(12,073	)	$	25,115
Basic net earnings (loss) from continuing operations per share	$	0.39	$	0.66	$	0.85	$	1.31		$	0.55		$	0.59	$	(0.23	)	$	0.53
Basic net earnings (loss) per share	$	0.39	$	0.66	$	0.85	$	1.28		$	0.54		$	0.60	$	(0.26	)	$	0.53
Diluted net earnings (loss) from continuing operations per share	$	0.39	$	0.65	$	0.83	$	1.26		$	0.54		$	0.58	$	(0.23	)	$	0.53
Diluted net earnings (loss) per share	$	0.39	$	0.65	$	0.83	$	1.24		$	0.54		$	0.59	$	(0.26	)	$	0.53

(1)     The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction

costs were incurred during the quarter.

XML

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2015

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

AmSurg Corp.

Schedule II – Valuation and Qualifying Accounts

For the Years Ended December 31, 2015, 2014 and 2013

(In thousands) 

	Balance at		Charged to		Charge-off			Balance
	Beginning		Cost and		Against			at End of
	of Period		Expenses		Allowances			Period
Allowance for uncollectible accounts included under the balance sheet caption “Accounts receivable”:
Year ended December 31, 2015	$	113,357	$	287,427	$	(233,373	)	$	167,411
Year ended December 31, 2014	27,862		139,274		(53,779		)	113,357
Year ended December 31, 2013	22,379		21,983		(16,500		)	27,862

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

Ambulatory Services

AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics. All LLCs and LPs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively. The Company does not have an ownership interest in a partnership greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in 23 partnerships, 2 of which it consolidates as the Company has substantive participation rights and 21 of which it does not consolidate as the Company’s rights are limited to protective rights only. Consolidation of certain less than wholly owned partnerships is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the partnership, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the partnership, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. 

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LLCs or LPs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan has certain management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is generally a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned affiliates. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “Consolidations.”

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value.

Restricted Cash

Restricted Cash and Marketable Securities

As of December 31, 2015 and 2014, the Company had $27.4 million and $30.3 million, respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $13.9 million and $20.1 million as of December 31, 2015 and 2014, respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of December 31, 2015 and 2014, the Company had $2.7 million and $3.0 million, respectively, included in restricted cash and marketable securities at cost, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.

Supplies Inventory

Supplies Inventory

Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.

Fair Value Measurements

Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2015 and 2014, with the exception of contingent purchase price payables and the retained interests of investments in unconsolidated affiliates (further discussed in note 4 and note 5, respectively), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2015. The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

Reclassifications

Certain amounts in the consolidated financial statements and these notes have been reclassified for the retrospective adoption of the Financial Accounting Standards Board's (FASB) Accounting Standards Update (ASU) 2015-17

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In April 2014, the FASB issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted. From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. The guidance in ASU 2014-09 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein.

The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015, including interim periods therein. The Company does not believe this ASU will impact the Company's consolidated financial position, results of operations or cash flows. However, the Company continues to evaluate the disclosures required under this ASU and has not yet determined the impact, if any.

In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. Upon adoption, the Company will reclassify debt issuance costs which are currently presented as a component of intangible assets in the accompanying consolidated balance sheets to long-term debt, except those debt issuance costs associated with the Company's revolving credit facility. The Company expects the adoption of this standard will not have a significant impact on the Company's consolidated financial position and will have no impact on the results of operations or cash flows.

In September 2015, the FASB issued ASU 2015-16 “Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments” which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment, including the effect on earnings of any amounts it would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after December 31, 2015 with early adoption permitted. The Company adopted this standard as of September 2015. The adoption of this ASU did not have a material effect on the Company's consolidated financial position, results of operations or cash flows as of December 31, 2015.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes” which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and non-current. The guidance is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted and companies may adopt the guidance prospectively or retrospectively. The Company adopted this standard retrospectively as of December 31, 2015 and as a result, reclassified $22.5 million from prepaid and other current assets to noncurrent deferred income taxes at December 31, 2014 in the accompanying consolidated balance sheets.

Revenue Recognition

Ambulatory Services

Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2015, 2014 and 2013, the Company derived approximately 26%, 25% and 25%, respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.

Physician Services

Physician services revenues primarily consist of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors.

The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors.

The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

Accounts Receivable

Accounts Receivable

The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Assessment of actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company routinely tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, for each facility or contract, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company may also supplement its allowance for doubtful accounts policy for its physician services using a hindsight calculation that utilizes write-off data for all payor classes during the previous periods to estimate the allowance for doubtful accounts at a point in time. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, specialty mix, acuity, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.

Acquisitions

Acquisitions

The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Investments in Unconsolidated Affiliates

Investments in Unconsolidated Affiliates

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination are generally based on a combination of multiple valuation methods which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment is recognized over useful lives of three to ten years.

Goodwill and Intangible Assets

Goodwill and Intangible Assets

The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in the Company's physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2015, and determined that its indefinite lived intangibles were not impaired. The Company's finite-lived intangibles includes its customer relationship with hospitals. The Company tests its finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2015, there were no events or circumstances that indicated a potential impairment in the Company's finite-lived intangibles.

Amortization of Intangible Assets

Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements. Customer relationships with hospitals are initially recorded at their estimated fair value and amortized on a straight-line basis over 20 years. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years.

Insurance Programs

The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted.

Insurance Programs

Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.

Income Taxes

Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012.

Stock Incentive Plans

Stock Incentive Plans

Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards. 

Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $4.0 million, $3.2 million and $7.2 million for the years ended December 31, 2015, 2014 and 2013, respectively.

The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock.

Earnings per Share

Earnings per Share

Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.

Related Party Transactions

It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.

Segment Reporting

Segment Reporting

Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine.

The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

XML

Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2015

Revenue Recognition [Abstract]

Schedule of Revenue and Fees by Segment and Major Payors

Net revenue for the physician services segment consists of the following major payors (in thousands):

	Year Ended December 31, 2015					Period from July 16, 2014 - December 31, 2014 (1)
Medicare	$	172,783		12.9	%	$	61,378		12.0	%
Medicaid	69,607			5.2		28,224			5.5
Commercial and managed care	1,007,902			75.4		382,343			74.7
Self-pay	222,830			16.7		102,727			20.1
Net fee for service revenue	1,473,122			110.2		574,672			112.3
Contract and other revenue	129,786			9.7		54,343			10.6
Provision for uncollectibles	(266,074		)	(19.9	)	(117,001		)	(22.9	)
Net revenue for physician services	$	1,336,834		100.0	%	$	512,014		100.0	%

(1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

XML

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The acquisitions completed during the year ended December 31, 2015 consist of the following:

Acquired Operations	Location	Date Acquired	Specialty
River Drive Surgery & Laser Center, LLC	Elmwood Park, NJ	February 2015	Ophthalmology
Campus Surgery Center, LLC	Daly City, CA	June 2015	Multi-Specialty
Waverly Surgery Center, LLC	Palo Alto, CA	June 2015	Multi-Specialty
Surgical Center at Millburn, LLC	Millburn-East Willow, NJ	July 2015	Multi-Specialty
Eye Surgery Center of Western Ohio, LLC	Lima, OH	August 2015	Ophthalmology
Surgical Specialty Center of Northeastern PA, LLC	Forty Fort, PA	October 2015	Multi-Specialty
South Portland Surgical Center, LLC	Tualatin, OR	November 2015	Multi-Specialty

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2015 and 2014, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 

	2015			2014
	Individual			Individual
	Acquisitions (1)			Acquisitions			Sheridan
Accounts receivable	$	62,216		$	1,816		$	130,260
Other current assets	21,477			1,075			105,757
Property and equipment	15,484			3,294			20,185
Goodwill	682,458			101,865			1,534,656
Intangible assets	420,414			14,207			1,200,028
Other long-term assets	342			—			50,304
Accounts payable	(3,641		)	(2,519		)	(5,862		)
Other accrued liabilities	(45,386		)	(626		)	(118,548		)
Deferred income taxes	(88,728		)	—			(432,792		)
Other long-term liabilities	(4,958		)	(8,588		)	(69,456		)
Long-term debt	(6,046		)	(717		)	(4,594		)
Total fair value	1,053,632			109,807			2,409,938
Less: Fair value attributable to noncontrolling interests	85,443			39,371			24,365
Acquisition date fair value of total consideration transferred	$	968,189		$	70,436		$	2,385,573

(1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2015.

The acquisitions completed during the year ended December 31, 2015 consist of the following:

Acquired Operations	Location	Date Acquired	Specialty
Ambulatory Anesthesia Care, PC	Mountainside, NJ	January 2015	Anesthesia
Sheridan Radiology Management Services, Inc.	Beachwood, OH	January 2015	Radiology
Radiology Associates of Hollywood, P.A.	Pembroke Pines, FL	March 2015	Radiology
Halifax Anesthesiology Associates, P.A.	Daytona Beach, FL	April 2015	Anesthesia
Coastal Anesthesiology Consultants, P.A.	St. Augustine, FL	July 2015	Anesthesia
Bay Area Anesthesia, LLC	Tampa, FL	August 2015	Anesthesia
Valley Anesthesia Consultants, Ltd.	Phoenix, AZ	November 2015	Anesthesia
Chandler Emergency Medical Group, LLC	Phoenix, AZ	December 2015	Emergency
Northside Anesthesiology Consultants, LLC	Atlanta, GA	December 2015	Anesthesia

Revenues And Net Earnings Associated With Acquisitions

Revenues and net earnings included in the years ended December 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands):

	2015		2014
	Individual		Individual
	Acquisitions		Acquisitions		Sheridan
Net revenue	$	179,113	$	20,844	517,213
Net earnings	26,901		5,155		26,776
Less: Net earnings attributable to noncontrolling interests	7,448		2,859		459
Net earnings attributable to AmSurg Corp. common shareholders	$	19,453	$	2,296	$	26,317

Consolidated Pro Forma Results Of Acquisition

The unaudited consolidated pro forma results for the years ended December 31, 2015 and 2014, assuming all 2015 acquisitions had been consummated on January 1, 2014, all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands):

	2015		2014
Net revenue	$	2,858,544	$	2,680,273
Net earnings	401,950		322,653
Amounts attributable to AmSurg Corp. common shareholders:
Net earnings	170,453		104,548
Net earnings per common share:
Basic	$	3.55	$	2.21
Diluted	$	3.48	$	2.20

XML

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Results Of Operations Of Centers Discontinued

Results of operations and associated gain (loss) on discontinued centers for the years ended December 31, 2015, 2014 and 2013 are as follows (in thousands):

	2015			2014			2013
Revenues	$	—		$	9,545		$	25,373
Earnings before income taxes	—			893			5,607
Results of discontinued operations, net of tax:
Earnings (loss) from operations of discontinued interests in surgery centers	(1,013		)	710			4,449
Gain (loss) on disposal of discontinued interests in surgery centers	—			(2,006		)	2,602
Net earnings (loss) from discontinued operations	(1,013		)	(1,296		)	7,051
Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests	(12		)	283			5,357
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$	(1,001	)	$	(1,579	)	$	1,694

XML

Prepaid and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid and Other Current Assets

The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Income taxes receivable	$	7,908	$	28,694
Prepaid expenses	18,900		18,682
Deferred compensation plan assets	16,623		17,320
Other	32,340		28,204
Total prepaid and other current assets	$	75,771	$	92,900

XML

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment at December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Building and improvements	$	177,253		$	170,420
Movable equipment	237,312			215,444
Construction in progress	8,676			11,940
	423,241			397,804
Less accumulated depreciation	(234,073		)	(217,356		)
Property and equipment, net	$	189,168		$	180,448

XML

Goodwill And Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Changes In Carrying Amount Of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands):

	2015			2014
Balance, beginning of year	$	3,381,149		$	1,758,970
Goodwill acquired, including post acquisition adjustments	674,476			1,636,521
Goodwill disposed, including impact of deconsolidation transactions	(85,415		)	(14,342		)
Balance, end of year	$	3,970,210		$	3,381,149

Schedule of Finite-Lived Intangible Assets

Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015							2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,379,977	$	(74,490	)	$	1,305,487	$	971,645	$	(22,145	)	$	949,500
Deferred financing costs	60,664		(13,490		)	47,174		59,574		(5,151		)	54,423
Capitalized software	71,462		(28,125		)	43,337		50,387		(19,197		)	31,190
Agreements, contracts and other	11,267		(2,449		)	8,818		3,523		(2,752		)	771
Total amortizable intangible assets	1,523,370		(118,554		)	1,404,816		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	8,995		—			8,995		9,995		—			9,995
Total non-amortizable intangible assets	236,995		—			236,995		237,995		—			237,995
Total intangible assets	$	1,760,365	$	(118,554	)	$	1,641,811	$	1,323,124	$	(49,245	)	$	1,273,879

Schedule of Indefinite-Lived Intangible Assets

Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015							2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,379,977	$	(74,490	)	$	1,305,487	$	971,645	$	(22,145	)	$	949,500
Deferred financing costs	60,664		(13,490		)	47,174		59,574		(5,151		)	54,423
Capitalized software	71,462		(28,125		)	43,337		50,387		(19,197		)	31,190
Agreements, contracts and other	11,267		(2,449		)	8,818		3,523		(2,752		)	771
Total amortizable intangible assets	1,523,370		(118,554		)	1,404,816		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	8,995		—			8,995		9,995		—			9,995
Total non-amortizable intangible assets	236,995		—			236,995		237,995		—			237,995
Total intangible assets	$	1,760,365	$	(118,554	)	$	1,641,811	$	1,323,124	$	(49,245	)	$	1,273,879

XML

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Accrued Liabilities, Current [Abstract]

Schedule of Other Accrued Liabilities

The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Accrued professional liabilities	$	14,362	$	11,983
Contingent purchase price payable	5,509		12,213
Current income taxes payable	7,892		—
Refunds payable	48,415		17,752
Other	43,059		26,038
Total other accrued liabilities	$	119,237	$	67,986

XML

Accrued Professional Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Professional Liabilities

At December 31, 2015, the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands):

	2015		2014
Estimated losses under self-insured programs	$	30,748	$	25,337
Incurred but not reported losses	36,166		28,448
Total accrued professional liabilities	66,914		53,785
Less estimated losses payable within one year	14,362		11,983
Total	$	52,552	$	41,802

Schedule of Self Insurance Reserve Roll Forward

The changes to the Company's estimated losses under self-insured programs as of December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Balance, beginning of year	$	53,785		$	1,171
Assumed liabilities through acquisitions	13,317			53,512
Provision related to current period reserves	15,943			5,423
Payments for current period reserves	(4,475		)	(1,595		)
Benefit related to changes in prior period reserves	(425		)	(661		)
Payments for prior period reserves	(8,863		)	(6,055		)
Other, net	(2,368		)	1,990
Balance, end of year	$	66,914		$	53,785

XML

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Components Of Long-Term Debt

Long-term debt at December 31, 2015 and 2014 consisted of the following (in thousands):

	2015		2014
Revolving credit agreement	$	175,000	$	—
Term Loan	856,950		865,650
Senior Unsecured Notes due 2020 (5.625%)	250,000		250,000
Senior Unsecured Notes due 2022 (5.625%)	1,100,000		1,100,000
Other debt at an average interest rate of 3.4%, due through 2022	24,944		20,156
Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021	18,613		15,206
	2,425,507		2,251,012
Less current portion	20,377		18,826
Long-term debt	$	2,405,130	$	2,232,186

Redemption Price Percentage

The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:  

Period	Redemption Price
2015	104.219	%
2016	102.813	%
2017	101.406	%
2018 and thereafter	100.000	%

The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:

Period	Redemption Price
2017	104.219	%
2018	102.813	%
2019	101.406	%
2020 and thereafter	100.000	%

XML

Other Long-term Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Other Liabilities Disclosure [Abstract]

Other Long-term Liabilities

The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands):

	2015		2014
Accrued professional liabilities	$	52,552	$	41,802
Contingent purchase price payable	—		8,470
Deferred rent	18,958		16,814
Tax-effected unrecognized benefits	3,426		8,353
Other	21,247		14,004
Other long-term liabilities	$	96,183	$	89,443

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Schedule Of Total Income Tax Expense

Total income taxes expense (benefit) for the years ended December 31, 2015, 2014 and 2013 was included within the following sections of the consolidated financial statements as follows (in thousands):

	2015			2014			2013
Earnings from continuing operations	$	113,790		$	48,103		$	48,654
Discontinued operations	(694		)	(643		)	9
Shareholders’ equity	(2,227		)	(3,177		)	(7,381		)
Total	$	110,869		$	44,283		$	41,282

Schedule of Components of Income Tax Expense (Benefit)

Income tax expense from continuing operations for the years ended December 31, 2015, 2014 and 2013 was comprised of the following (in thousands):

	2015		2014		2013
Current:
Federal	$	83,228	$	8,640	$	7,895
State	14,268		4,396		3,598
Deferred:
Federal	11,715		27,505		31,509
State	4,579		7,562		5,652
Income tax expense	$	113,790	$	48,103	$	48,654

Schedule of Effective Income Tax Rate Reconciliation

Income tax expense from continuing operations for the years ended December 31, 2015, 2014 and 2013 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):

	2015			2014			2013
Statutory federal income tax	$	173,572		$	102,967		$	106,101
Less federal income tax assumed directly by noncontrolling interests	(76,364		)	(66,783		)	(64,219		)
State income taxes, net of federal income tax benefit	11,604			6,616			5,539
Increase in valuation allowances	317			4,662			924
Interest related to unrecognized tax benefits	(548		)	(161		)	(155		)
Other	5,209			802			464
Income tax expense	$	113,790		$	48,103		$	48,654

Summary of Income Tax Contingencies

A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2015, 2014 and 2013 is as follows (in thousands):

	2015			2014			2013
Balance at beginning of year	$	7,336		$	6,330		$	9,235
Additions for tax positions of current year	—			204			46
Increases (decreases) for tax positions taken during a prior period	(1,006		)	1,069			—
Lapse of statute of limitations	(3,178		)	(267		)	(2,951		)
Balance at end of year	$	3,152		$	7,336		$	6,330

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2015 and 2014 were as follows (in thousands):

	2015			2014
Deferred tax assets:
Allowance for uncollectible accounts	$	3,276		$	1,096
Accrued assets and other	36,600			27,537
Share-based compensation	10,710			7,719
Interest on unrecognized tax benefits	113			245
Accrued liabilities and other	4,080			3,931
Medical malpractice	19,035			16,240
Operating and capital loss carryforwards	29,718			22,709
Valuation allowances	(21,814		)	(17,457		)
Total deferred tax assets	81,718			62,020
Deferred tax liabilities:
Prepaid expenses	1,789			2,435
Property and equipment, principally due to differences in depreciation	16,787			15,235
Goodwill, intangible assets and other, principally due to differences in amortization	762,640			655,358
Total deferred tax liabilities	781,216			673,028
Net deferred tax liabilities	$	699,498		$	611,008

XML

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

Share-Based Activity

Other information pertaining to share-based activity for the years ended December 31, 2015, 2014 and 2013 was as follows (in thousands):

	2015		2014		2013
Share-based compensation expense	$	15,009	$	10,104	$	8,321
Fair value of shares vested	13,220		15,126		11,742
Cash received from option exercises	2,584		2,630		33,349
Tax benefit from option exercises	4,001		3,177		7,247

Schedule Of Changes In Non-Vested Restricted Shares

A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2015, is as follows:

			Weighted
	Number		Average
	of Shares		Grant Price
Non-vested shares at January 1, 2013	828,686		$	22.50
Shares granted	291,863		31.66
Shares vested	(360,337	)	21.55
Shares forfeited	(16,343	)	23.11
Non-vested shares at December 31, 2013	743,869		$	26.54
Shares granted	272,780		43.12
Shares vested	(336,160	)	25.69
Shares forfeited	(12,380	)	38.94
Non-vested shares at December 31, 2014	668,109		$	33.51
Shares granted	313,498		56.19
Shares vested	(233,831	)	28.19
Shares forfeited	(13,675	)	42.15
Non-vested shares at December 31, 2015	734,101		$	44.73

Schedule Of Stock Option Activity

A summary of stock option activity for the three years ended December 31, 2015 is summarized as follows:

					Weighted
			Weighted		Average
			Average		Remaining
	Number		Exercise		Contractual
	of Shares		Price		Term (in years)
Outstanding at January 1, 2013	1,662,830		$	23.82	2.9
Options exercised with total intrinsic value of $33.3 million	(1,392,366	)	23.95
Outstanding at December 31, 2013	270,464		$	23.16	2.5
Options exercised with total intrinsic value of $2.6 million	(111,743	)	23.53
Outstanding at December 31, 2014	158,721		$	22.89	1.7
Options exercised with total intrinsic value of $4.9 million	(113,220	)	22.81
Options terminated	(11,750	)	23.42
Outstanding, Vested and Exercisable at December 31, 2015 with an aggregate intrinsic value of $1.8 million	33,751		$	22.98	1.1

Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

	Earnings		Shares	Per Share
	(Numerator)		(Denominator)	Amount
For the year ended December 31, 2015:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	154,892	48,058	$	3.22
Preferred stock dividends	9,056		—
Effect of dilutive securities, options and non-vested shares	—		3,554
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	163,948	51,612	$	3.18
For the year ended December 31, 2014:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	50,777	39,311	$	1.29
Effect of dilutive securities, options and non-vested shares	—		314
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	50,777	39,625	$	1.28
For the year ended December 31, 2013:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	71,009	31,338	$	2.27
Effect of dilutive securities, options and non-vested shares	—		616
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	71,009	31,954	$	2.22

XML

Leases (Tables)

12 Months Ended

Dec. 31, 2015

Leases [Abstract]

Future Minimum Lease Payment Schedule

Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2015 were as follows (in thousands):

Year Ended December 31,	Capital Leases		Operating Leases
2016	$	3,021	$	55,636
2017	2,776		55,857
2018	2,502		53,515
2019	2,068		52,034
2020	1,866		50,378
Thereafter	12,991		331,746
Total minimum rentals	25,224		$	599,166
Less amounts representing interest at rates ranging from 1.7% to 13.4%	6,611
Capital lease obligations	$	18,613

XML

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2015

Related Party Transactions [Abstract]

Schedule of Related Party Payments

elated party payments for the years ended December 31, 2015, 2014 and 2013 were as follows (in thousands):

	2015		2014		2013
Operating leases	$	27,622	$	27,559	$	29,240
Salaries and benefits	62,590		66,763		72,892
Billing fees	10,873		9,899		11,591
Medical advisory services	2,635		2,811		2,993

XML

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table presents financial information for each reportable segment (in thousands):

	Year ended December 31,
	2015			2014			2013
Net Revenue:
Ambulatory Services	$	1,230,050		$	1,109,935		$	1,057,196
Physician Services (1)	1,336,834			512,014			—
Total	$	2,566,884		$	1,621,949		$	1,057,196
Adjusted Segment EBITDA:
Ambulatory Services	$	226,229		$	197,377		$	187,972
Physician Services (1)	266,031			107,105			—
Total	$	492,260		$	304,482		$	187,972
Adjusted Segment EBITDA:	$	492,260		$	304,482		$	187,972
Earnings from continuing operations attributable to noncontrolling interests	218,181			190,809			183,484
Interest expense, net	(121,586		)	(83,285		)	(29,525		)
Depreciation and amortization	(97,493		)	(60,344		)	(32,400		)
Share-based compensation	(15,009		)	(10,104		)	(8,321		)
Net change in fair value of contingent consideration	(8,804		)	—			—
Transaction costs	(8,324		)	(33,890		)	(300		)
Debt extinguishment costs	—			(16,887		)	—
Net gain on deconsolidations	36,694			3,411			2,237
Earnings from continuing operations before income taxes	$	495,919		$	294,192		$	303,147
Acquisition and Capital Expenditures:
Ambulatory Services (2)	$	168,593		$	81,156		$	102,450
Physician Services	854,401			28,909			—
Total	$	1,022,994		$	110,065		$	102,450

	2015		2014
Assets:
Ambulatory Services	$	2,609,479	$	2,526,625
Physician Services	3,937,003		2,974,437
Total	$	6,546,482	$	5,501,062

(1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

(2) Excludes the purchase price to acquire Sheridan in 2014.

XML

Financial Information for the Company and Its Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2015

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	20,437	$	27,507	$	58,716	$	—		$	106,660
Restricted cash and marketable securities	—		—		13,506		—			13,506
Accounts receivable, net	—		223,434		113,896		—			337,330
Supplies inventory	—		—		21,406		—			21,406
Prepaid and other current assets	28,739		39,046		16,062		(8,076		)	75,771
Total current assets	49,176		289,987		223,586		(8,076		)	554,673
Property and equipment, net	12,515		14,601		162,052		—			189,168
Investments in and receivables from unconsolidated affiliates	4,901,026		1,775,272		—		(6,507,128		)	169,170
Goodwill	—		1,956,741		—		2,013,469			3,970,210
Intangible assets, net	59,928		1,579,537		2,346		—			1,641,811
Other assets	4,653		1,717		17,078		(1,998		)	21,450
Total assets	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	11,677	$	—		$	20,377
Accounts payable	2,816		3,760		29,837		(3,852		)	32,561
Accrued salaries and benefits	31,510		158,705		12,322		—			202,537
Accrued interest	30,463		—		17		—			30,480
Other accrued liabilities	13,962		76,590		32,909		(4,224		)	119,237
Total current liabilities	87,451		239,055		86,762		(8,076		)	405,192
Long-term debt	2,373,251		—		55,275		(23,396		)	2,405,130
Deferred income taxes	268,573		432,923		—		(1,998		)	699,498
Other long-term liabilities	4,560		71,509		20,114		—			96,183
Intercompany payable	—		1,228,157		—		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		63,060		112,672			175,732
Equity:
Total AmSurg Corp. equity	2,293,463		3,646,211		132,267		(3,778,478		)	2,293,463
Noncontrolling interests – non-redeemable	—		—		47,584		423,700			471,284
Total equity	2,293,463		3,646,211		179,851		(3,354,778		)	2,764,747
Total liabilities and equity	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	46,097		37,826		13,795		(4,818		)	92,900
Total current assets	180,448		185,370		203,225		(4,818		)	564,225
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	207,500		404,984		—		(1,466		)	611,018
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062

Condensed Consolidating Statement of Earnings

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	28,554		$	1,331,042	$	1,245,292		$	(38,004	)	$	2,566,884
Operating expenses:
Salaries and benefits	69,102			937,484		308,313			(507		)	1,314,392
Supply cost	—			2,436		181,866			(80		)	184,222
Other operating expenses	24,682			145,369		265,160			(37,417		)	397,794
Transaction costs	1,762			6,562		—			—			8,324
Depreciation and amortization	3,912			61,658		31,923			—			97,493
Total operating expenses	99,458			1,153,509		787,262			(38,004		)	2,002,225
Gain (loss) on deconsolidations	—			37,350		(656		)	—			36,694
Equity in earnings of unconsolidated affiliates	349,139			251,093		—			(584,080		)	16,152
Operating income	278,235			465,976		457,374			(584,080		)	617,505
Interest expense, net	41,140			77,947		2,499			—			121,586
Earnings from continuing operations before income taxes	237,095			388,029		454,875			(584,080		)	495,919
Income tax expense	73,159			38,891		1,740			—			113,790
Net earnings from continuing operations	163,936			349,138		453,135			(584,080		)	382,129
Net loss from discontinued operations	(989		)	—		(24		)	—			(1,013		)
Net earnings	162,947			349,138		453,111			(584,080		)	381,116
Net earnings attributable to noncontrolling interests	—			—		218,169			—			218,169
Net earnings attributable to AmSurg Corp. shareholders	162,947			349,138		234,942			(584,080		)	162,947
Preferred stock dividends	(9,056		)	—		—			—			(9,056		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	154,880		$	349,138	$	234,954		$	(584,080	)	$	154,892
Loss from discontinued operations, net of income tax	(989		)	—		(12		)	—			(1,001		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,773		$	508,572	$	1,112,940		$	(24,336	)	$	1,621,949
Operating expenses:
Salaries and benefits	65,697			350,615		284,050			(5,786		)	694,576
Supply cost	—			1,292		163,004			—			164,296
Other operating expenses	18,667			53,413		231,398			(18,550		)	284,928
Transaction costs	29,004			4,886		—			—			33,890
Depreciation and amortization	4,044			25,610		30,690			—			60,344
Total operating expenses	117,412			435,816		709,142			(24,336		)	1,238,034
Gain on deconsolidation	—			3,411		—			—			3,411
Equity in earnings of unconsolidated affiliates	237,657			211,889		—			(442,508		)	7,038
Operating income	145,018			288,056		403,798			(442,508		)	394,364
Interest expense, net	47,997			33,026		2,262			—			83,285
Debt extinguishment costs	16,887			—		—			—			16,887
Earnings from continuing operations before income taxes	80,134			255,030		401,536			(442,508		)	294,192
Income tax expense	29,166			17,373		1,564			—			48,103
Net earnings from continuing operations	50,968			237,657		399,972			(442,508		)	246,089
Net earnings (loss) from discontinued operations	2,733			—		(4,029		)	—			(1,296		)
Net earnings	53,701			237,657		395,943			(442,508		)	244,793
Net earnings attributable to noncontrolling interests	—			21		191,071			—			191,092
Net earnings attributable to AmSurg Corp. shareholders	53,701			237,636		204,872			(442,508		)	53,701
Preferred stock dividends	(4,503		)	—		—			—			(4,503		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	46,465		$	237,636	$	209,184		$	(442,508	)	$	50,777
Earnings (loss) from discontinued operations, net of income tax	2,733			—		(4,312		)	—			(1,579		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,167	$	—	$	1,050,547		$	(17,518	)	$	1,057,196
Operating expenses:
Salaries and benefits	61,038		—		267,014			(467		)	327,585
Supply cost	—		—		153,126			—			153,126
Other operating expenses	22,360		—		211,192			(17,051		)	216,501
Transaction costs	300		—		—			—			300
Depreciation and amortization	3,186		—		29,214			—			32,400
Total operating expenses	86,884		—		660,546			(17,518		)	729,912
Gain on deconsolidation	—		2,237		—			—			2,237
Equity in earnings of unconsolidated affiliates	207,199		204,962		—			(409,010		)	3,151
Operating income	144,482		207,199		390,001			(409,010		)	332,672
Interest expense, net	27,282		—		2,243			—			29,525
Earnings from continuing operations before income taxes	117,200		207,199		387,758			(409,010		)	303,147
Income tax expense	47,139		—		1,515			—			48,654
Net earnings from continuing operations	70,061		207,199		386,243			(409,010		)	254,493
Net earnings from discontinued operations	2,642		—		4,409			—			7,051
Net earnings	72,703		207,199		390,652			(409,010		)	261,544
Net earnings attributable to noncontrolling interests	—		—		188,841			—			188,841
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	70,061	$	207,199	$	202,759		$	(409,010	)	$	71,009
Earnings (loss) from discontinued operations, net of income tax	2,642		—		(948		)	—			1,694
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703

Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	40,432		$	353,932		$	489,820		$	(346,225	)	$	537,959
Cash flows from investing activities:
Acquisitions and related transactions	(757,775		)	(969,259		)	—			764,345			(962,689		)
Acquisition of property and equipment	(5,876		)	(22,988		)	(31,441		)	—			(60,305		)
Proceeds from sale of interests in surgery centers	—			7,114			—			—			7,114
Purchases of marketable securities	—			—			(3,984		)	—			(3,984		)
Maturities of marketable securities	—			—			4,233			—			4,233
Other	—			(2,927		)	1,733			—			(1,194		)
Net cash flows used in investing activities	(763,651		)	(988,060		)	(29,459		)	764,345			(1,016,825		)
Cash flows from financing activities:
Proceeds from long-term borrowings	546,000			—			14,133			—			560,133
Repayment on long-term borrowings	(379,700		)	—			(12,886		)	—			(392,586		)
Distributions to owners, including noncontrolling interests	—			(109,862		)	(451,262		)	346,225			(214,899		)
Capital contributions	—			757,775			—			(757,775		)	—
Proceeds from common stock offering	466,777			—			—			—			466,777
Payments of equity issuance costs	(19,058		)	—			—			—			(19,058		)
Financing cost incurred	(1,101		)	—			(10		)	—			(1,111		)
Changes in intercompany balances with affiliates, net	5,016			—			(5,016		)	—			—
Other financing activities, net	(8,629		)	(9,749		)	3,139			(6,570		)	(21,809		)
Net cash flows provided by (used in) financing activities	609,305			638,164			(451,902		)	(418,120		)	377,447
Net increase (decrease) in cash and cash equivalents	(113,914		)	4,036			8,459			—			(101,419		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	20,437		$	27,507		$	58,716		$	—		$	106,660

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	96,681		$	298,415		$	430,880		$	(413,605	)	$	412,371
Cash flows from investing activities:
Acquisitions and related transactions	(2,124,124		)	(2,188,191		)	1,520			2,126,737			(2,184,058		)
Acquisition of property and equipment	(7,877		)	(9,933		)	(22,407		)	—			(40,217		)
Proceeds from sale of interests in surgery centers	—			7,069			—			—			7,069
Purchases of marketable securities	—			—			(6,474		)	—			(6,474		)
Maturities of marketable securities	—			—			3,486			—			3,486
Other	(3,068		)	(6,594		)	4,721			—			(4,941		)
Net cash flows used in investing activities	(2,135,069		)	(2,197,649		)	(19,154		)	2,126,737			(2,225,135		)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,040,000			—			8,958			—			2,048,958
Repayment on long-term borrowings	(396,493		)	—			(11,982		)	—			(408,475		)
Distributions to owners, including noncontrolling interests	—			(202,247		)	(401,455		)	413,605			(190,097		)
Capital contributions	—			2,124,124			—			(2,124,124		)	—
Proceeds from preferred stock offering	172,500			—			—			—			172,500
Proceeds from common stock offering	439,875			—			—			—			439,875
Payments of equity issuance costs	(24,494		)	—			—			—			(24,494		)
Financing cost incurred	(65,811		)	—			—			—			(65,811		)
Changes in intercompany balances with affiliates, net	2,965			—			(2,965		)	—			—
Other financing activities, net	(2,513		)	828			1,845			(2,613		)	(2,453		)
Net cash flows provided by (used in) financing activities	2,166,029			1,922,705			(405,599		)	(1,713,132		)	1,970,003
Net increase in cash and cash equivalents	127,641			23,471			6,127			—			157,239
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	134,351		$	23,471		$	50,257		$	—		$	208,079

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	45,127		$	208,773		$	426,572		$	(347,648	)	$	332,824
Cash flows from investing activities:
Acquisitions and related transactions	—			(74,288		)	—			694			(73,594		)
Acquisition of property and equipment	(3,693		)	—			(25,163		)	—			(28,856		)
Proceeds from sale of interests in surgery centers	—			3,553			—			—			3,553
Other	—			159			—			—			159
Net cash flows used in investing activities	(3,693		)	(70,576		)	(25,163		)	694			(98,738		)
Cash flows from financing activities:
Proceeds from long-term borrowings	152,700			—			9,504			—			162,204
Repayment on long-term borrowings	(188,081		)	—			(14,002		)	—			(202,083		)
Distributions to owners, including noncontrolling interests	—			(138,875		)	(392,922		)	347,648			(184,149		)
Changes in intercompany balances with affiliates, net	88			—			(88		)	—			—
Other financing activities, net	(6,690		)	678			1,090			(694		)	(5,616		)
Net cash flows used in financing activities	(41,983		)	(138,197		)	(396,418		)	346,954			(229,644		)
Net increase (decrease) in cash and cash equivalents	(549		)	—			4,991			—			4,442
Cash and cash equivalents, beginning of period	7,259			—			39,139			—			46,398
Cash and cash equivalents, end of period	$	6,710		$	—		$	44,130		$	—		$	50,840

XML

Quarterly Statement of Earnings Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

The following table presents certain quarterly statement of earnings data for the years ended December 31, 2015 and 2014. The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.

	2015									2014
	Q1		Q2		Q3		Q4			Q1			Q2		Q3 (1)			Q4
	(In thousands, except per share data)
Net revenues	$	570,445	$	641,950	$	650,227	$	704,262		$	259,561		$	278,227	$	502,350		$	581,811
Earnings from continuing operations before income taxes	83,004		115,940		135,797		161,178			73,028			80,487		39,142			101,535
Net earnings from continuing operations	68,755		90,747		98,279		124,348			60,046			67,689		39,120			79,234
Net earnings (loss) from discontinued operations	—		—		—		(1,013		)	68			483		(1,697		)	(150		)
Net earnings	68,755		90,747		98,279		123,335			60,114			68,172		37,423			79,084
Net earnings (loss) attributable to AmSurg Corp. common shareholders:
Continuing	18,774		31,411		40,397		64,310			17,392			18,771		(10,697		)	25,311
Discontinued	—		—		—		(1,001		)	(197		)	190		(1,376		)	(196		)
Net earnings (loss)	$	18,774	$	31,411	$	40,397	$	63,309		$	17,195		$	18,961	$	(12,073	)	$	25,115
Basic net earnings (loss) from continuing operations per share	$	0.39	$	0.66	$	0.85	$	1.31		$	0.55		$	0.59	$	(0.23	)	$	0.53
Basic net earnings (loss) per share	$	0.39	$	0.66	$	0.85	$	1.28		$	0.54		$	0.60	$	(0.26	)	$	0.53
Diluted net earnings (loss) from continuing operations per share	$	0.39	$	0.65	$	0.83	$	1.26		$	0.54		$	0.58	$	(0.23	)	$	0.53
Diluted net earnings (loss) per share	$	0.39	$	0.65	$	0.83	$	1.24		$	0.54		$	0.59	$	(0.26	)	$	0.53

(1)     The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction

costs were incurred during the quarter.

XML

Summary of Significant Accounting Policies (Details) $ in Millions	Dec. 31, 2015 USD ($) center	Dec. 31, 2014 USD ($)
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51% | center	23
Restricted Cash and Marketable Securities
Restricted cash and marketable securities, total	$ 27.4	$ 30.3
Restricted cash and marketable securities, noncurrent	13.9	20.1
Restricted marketable securities	$ 2.7	3.0
Consolidated [Member]
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51% | center	2
Nonconsolidated [Member]
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51% | center	21
New Accounting Pronouncement, Early Adoption, Effect [Member]
Ownership Interests [Line Items]
Deferred tax assets, net, current		$ 22.5

XML

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue, Major Customer [Line Items]
Provision for uncollectibles										$ (287,427)	$ (139,274)	$ (21,947)
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561		2,566,884	1,621,949	1,057,196
Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									$ 574,672	1,473,122
Contract and other revenue									54,343	129,786
Provision for uncollectibles									(117,001)	(266,074)	(117,001)	0
Net revenue									512,014	$ 1,336,834	$ 512,014	$ 0
Ambulatory Services [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues from governmental healthcare programs										26.00%	25.00%	25.00%
Net revenue										$ 1,230,050	$ 1,109,935	$ 1,057,196
Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									61,378	172,783
Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									28,224	69,607
Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									382,343	1,007,902
Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									$ 102,727	$ 222,830
Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									100.00%	100.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									112.30%	110.20%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									12.00%	12.90%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									5.50%	5.20%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									74.70%	75.40%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									20.10%	16.70%
Contract and Other Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									10.60%	9.70%
Provision for Uncollectibles [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									22.90%	19.90%

XML

Accounts Receivable (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense		$ 287,427	$ 139,274	$ 21,947
Allowances for accounts receivable	$ 113,357	$ 167,411	$ 113,357
Product Concentration Risk [Member] | Allowance for Doubtful Accounts [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts related to fee for service patient visits		80.00%	73.00%
Ambulatory Services [Member] | Other Operating Expenses [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense		$ 21,400	$ 21,900	21,700
Physician Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 117,001	$ 266,074	$ 117,001	$ 0

XML

Acquisitions (Narrative) (Details)			1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 16, 2014 USD ($) shares	Jul. 02, 2014 shares	Dec. 31, 2015 USD ($) shares	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($) physician_practice	Dec. 31, 2015 USD ($) physician_practice center	Dec. 31, 2014 USD ($) center	Dec. 31, 2013 USD ($) center	Oct. 21, 2015 USD ($)
Business Acquisition [Line Items]
Acquisitions and related expenses, net						$ 962,689,000	$ 2,184,058,000	$ 73,594,000
Acquisition accounting, change in the contingent consideration						8,804,000	0	0
Proceeds from common stock offering						466,777,000	439,875,000	0
Proceeds from preferred stock offering						0	172,500,000	0
Payments of equity issuance costs						(19,058,000)	(24,494,000)	0
Transaction costs				$ 25,100,000		8,324,000	33,890,000	300,000
Debt extinguishment costs						0	(16,887,000)	$ 0
Contingent purchase price payable			$ 0		$ 8,470,000	0	8,470,000
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Cash paid to acquire business	$ 2,100,000,000
Value of common stock issued for acquisition	272,000,000
Fees and expenses associated with acquisition					139,100,000		139,100,000
Deferred financing costs					$ 53,000,000		53,000,000
Goodwill, Purchase Accounting Adjustments						8,300,000
Transaction costs							31,900,000
Common Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares) | shares		9,775,000	5,835,000
Proceeds from common stock offering	$ 421,300,000
Common Stock [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Shares of common stock issued for acquisition | shares	5,713,909
Mandatory Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares) | shares		1,725,000
Proceeds from preferred stock offering	$ 166,600,000
Senior Secured Credit Facility - Term Loan [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	870,000,000.0
Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	300,000,000.0								$ 500,000,000
Debt extinguishment costs						4,500,000
Senior Notes [Member] | 2022 Senior Unsecured Notes [Member]
Business Acquisition [Line Items]
Face amount	$ 1,100,000,000.0
Interest rate	5.625%
Bridge Loan [Member] | Interest Expense [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Fees paid to obtain a commitment for financing							12,800,000
Ambulatory Services [Member]
Business Acquisition [Line Items]
Acquisitions and related expenses, net						$ 131,300,000	$ 50,900,000
Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center						7	8
Ambulatory Services [Member] | Sheridan Healthcare [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center							3
Ambulatory Services [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center							5
Physician Services [Member]
Business Acquisition [Line Items]
Acquisition accounting, change in the contingent consideration						$ 10,000,000
Physician Services [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Acquisition accounting, change in the contingent consideration						$ 3,500,000
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Number of business acquisitions | physician_practice					2	9
Cash paid to acquire business					$ 19,000,000	$ 831,400,000
Estimate of fair values of the contingent consideration			$ 5,500,000		$ 20,700,000	5,500,000	$ 20,700,000
Payments for contingent consideration						28,700,000
Payment to settle amount recorded at the acquisition date						15,700,000
Estimate contingent consideration payment, low			5,000,000			5,000,000
Estimate contingent consideration payment, high			$ 6,000,000			$ 6,000,000
Joint Venture [Member] | Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center						9	4	1
Joint Venture [Member] | Physician Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center						3

XML

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill	$ 3,970,210	$ 3,381,149	$ 1,758,970
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable	62,216	1,816
Other current assets	21,477	1,075
Property and equipment	15,484	3,294
Goodwill	682,458	101,865
Intangible assets	420,414	14,207
Other long-term assets	342	0
Accounts payable	(3,641)	(2,519)
Other accrued liabilities	(45,386)	(626)
Deferred income taxes	(88,728)	0
Other long-term liabilities	(4,958)	(8,588)
Long-term debt	(6,046)	(717)
Total fair value	1,053,632	109,807
Less: Fair value attributable to noncontrolling interests	85,443	39,371
Acquisition date fair value of total consideration transferred	968,189	70,436
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Accounts receivable		130,260
Other current assets		105,757
Property and equipment		20,185
Goodwill		1,534,656
Intangible assets		1,200,028
Other long-term assets		50,304
Accounts payable		(5,862)
Other accrued liabilities		(118,548)
Deferred income taxes		(432,792)
Other long-term liabilities		(69,456)
Long-term debt		(4,594)
Total fair value		2,409,938
Less: Fair value attributable to noncontrolling interests		24,365
Acquisition date fair value of total consideration transferred		2,385,573
Physician Services [Member]
Business Acquisition [Line Items]
Goodwill	$ 2,000,000	$ 1,500,000

XML

Acquisitions (Revs and Earnings) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Revenues	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561	$ 2,566,884	$ 1,621,949	$ 1,057,196
Net earnings	123,335	98,279	90,747	68,755	79,084	37,423	68,172	60,114	381,116	244,793	261,544
Less: Net earnings attributable to noncontrolling interests									218,169	191,092	188,841
Net earnings attributable to AmSurg Corp. common shareholders	$ 63,309	$ 40,397	$ 31,411	$ 18,774	$ 25,115	$ (12,073)	$ 18,961	$ 17,195	153,891	49,198	$ 72,703
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Revenues									179,113	20,844
Net earnings									26,901	5,155
Less: Net earnings attributable to noncontrolling interests									7,448	2,859
Net earnings attributable to AmSurg Corp. common shareholders									$ 19,453	2,296
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Revenues										517,213
Net earnings										26,776
Less: Net earnings attributable to noncontrolling interests										459
Net earnings attributable to AmSurg Corp. common shareholders										$ 26,317

XML

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Business Combinations [Abstract]
Net revenue	$ 2,858,544	$ 2,680,273
Net earnings	401,950	322,653
Net earnings attributable to AmSurg Corp. common shareholders	$ 170,453	$ 104,548
Net earnings per common share, Basic (usd per share)	$ 3.55	$ 2.21
Net earnings per common share, Diluted (usd per share)	$ 3.48	$ 2.20

XML

Investments in Unconsolidated Affiliates (Details) $ in Thousands	3 Months Ended								6 Months Ended	12 Months Ended
	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) entity equity_method_investment center	Dec. 31, 2014 USD ($) equity_method_investment center	Dec. 31, 2013 USD ($) equity_method_investment center
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 169,170				$ 75,475				$ 75,475	$ 169,170	$ 75,475
Equity in earnings of unconsolidated affiliates										16,152	7,038	$ 3,151
Net gain on deconsolidations										36,694	3,411	2,237
Management and billing fees included in net revenue	704,262	$ 650,227	$ 641,950	$ 570,445	581,811	$ 502,350	$ 278,227	$ 259,561		2,566,884	1,621,949	1,057,196
Receivables from VIEs included in other current assets	75,771				92,900				92,900	75,771	92,900
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	89,600				53,200				53,200	89,600	53,200
Equity in earnings of unconsolidated affiliates										$ 11,000	3,400
Ownership percentage										50.00%
Management and billing fees included in net revenue										$ 14,300	4,700
Receivables from VIEs included in other current assets	2,300				3,500				3,500	$ 2,300	3,500
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage										49.00%
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage										51.00%
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Increase in equity method investments										$ 83,100	56,400
Joint Venture [Member] | Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 27,100									$ 27,100
Number consolidated centers contributed to joint venture | center										4
Sheridan Healthcare [Member] | Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates					$ 49,400				49,400		49,400
Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Management and billing fees included in net revenue										$ 1,230,050	$ 1,109,935	$ 1,057,196
Ambulatory Services [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Estimated probability of fair value variables range										10.00%
Ambulatory Services [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Estimated probability of fair value variables range										50.00%
Ambulatory Services [Member] | Controlling Interest [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number consolidated centers contributed to joint venture | center										9	4	1
Ambulatory Services [Member] | Noncontrolling Interest In Centers [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number of equity investments acquired in the period | equity_method_investment										5	4	1
Number of joint venture entities acquired | center										3	1	1
Ambulatory Services [Member] | Noncontrolling Interest In Surgical Hospital [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number of joint venture entities acquired | entity										1
Physician Services [Member]
Schedule of Equity Method Investments [Line Items]
Management and billing fees included in net revenue									$ 512,014	$ 1,336,834	$ 512,014	$ 0
Physician Services [Member] | Controlling Interest [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number consolidated centers contributed to joint venture | center										3
Deconsolidation [Member] | Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Net cash received in exchange for noncontrolling interests in new investments										$ 8,500	$ 1,200
Cash contributed from divestiture of interest in consolidated subsidiaries												$ 300

XML

Discontinued Operations (Results Of Operations Of Centers Discontinued) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Results of discontinued operations, net of tax:
Net earnings (loss) from discontinued operations	$ (1,013)	$ 0	$ 0	$ 0	$ (150)	$ (1,697)	$ 483	$ 68	$ (1,013)	$ (1,296)	$ 7,051
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$ (1,001)	$ 0	$ 0	$ 0	$ (196)	$ (1,376)	$ 190	$ (197)	(1,001)	(1,579)	1,694
Cash proceeds from disposal									7,114	7,069	3,553
Discontinued Operations, Disposed Of By Sale Or Abandonment [Member]
Disposal Groups, Including Discontinued Operations [Line Items]
Revenues									0	9,545	25,373
Earnings before income taxes									0	893	5,607
Results of discontinued operations, net of tax:
Earnings (loss) from operations of discontinued interests in surgery centers									(1,013)	710	4,449
Gain (loss) on disposal of discontinued interests in surgery centers									0	(2,006)	2,602
Net earnings (loss) from discontinued operations									(1,013)	(1,296)	7,051
Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests									(12)	283	5,357
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders									(1,001)	(1,579)	1,694
Cash proceeds from disposal									$ 0	$ 7,100	$ 3,600

XML

Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Income taxes receivable	$ 7,908	$ 28,694
Prepaid expenses	18,900	18,682
Deferred compensation plan assets	16,623	17,320
Other	32,340	28,204
Total prepaid and other current assets	$ 75,771	$ 92,900

XML

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Unfunded construction and equipment purchases	$ 18.3
Depreciation expense	$ 35.4	$ 33.2	$ 29.8
Building and Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	20 years
Building and Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	40 years
Movable Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Movable Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	10 years

XML

Property and Equipment (PPE Schedule) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Building and improvements	$ 177,253	$ 170,420
Movable equipment	237,312	215,444
Construction in progress	8,676	11,940
Property and equipment, gross	423,241	397,804
Less accumulated depreciation	(234,073)	(217,356)
Property and equipment, net	$ 189,168	$ 180,448

XML

Goodwill And Intangible Assets (Narrative) (Details) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2014 USD ($) physician_practice	Dec. 31, 2015 USD ($) physician_practice center	Dec. 31, 2014 USD ($) center	Dec. 31, 2013 USD ($) center
Segment Reporting Information [Line Items]
Goodwill	$ 3,381,149	$ 3,970,210	$ 3,381,149	$ 1,758,970
Increase in goodwill		674,476	1,636,521
Goodwill deductible for tax purposes	64,500	$ 295,700	64,500
Amortization period		17 years 292 days
Debt extinguishment costs		$ 0	4,536	0
Amortization of Intangible Assets		70,500	32,500	$ 2,200
Estimated amortization of intangible assets, 2016		90,300
Estimated amortization of intangible assets, 2017		89,100
Estimated amortization of intangible assets, 2018		87,800
Estimated amortization of intangible assets, 2019		84,800
Estimated amortization of intangible assets, 2020		81,600
Estimated amortization of intangible assets, 2021 and thereafter		971,200
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,900,000	2,000,000	1,900,000
Increase in goodwill		123,400
Physician Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,500,000	2,000,000	1,500,000
Increase in goodwill		465,700
Sheridan Healthcare [Member]
Segment Reporting Information [Line Items]
Goodwill	1,534,656		1,534,656
Deferred financing costs	53,000		53,000
Intangible assets	1,200,028		1,200,028
Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Goodwill	101,865	682,458	101,865
Intangible assets	$ 14,207	$ 420,414	14,207
Series of Individually Immaterial Business Acquisitions [Member] | Physician Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | physician_practice	2	9
Interest Expense [Member] | Bridge Loan [Member] | Sheridan Healthcare [Member]
Segment Reporting Information [Line Items]
Fees paid to obtain a commitment for financing			$ 12,800
Customer Relationships [Member]
Segment Reporting Information [Line Items]
Amortization period		20 years
Deferred Financing Costs, Amortizable Non-Compete Agreements, and Customer Agreements [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Amortization period		5 years
Deferred Financing Costs, Amortizable Non-Compete Agreements, and Customer Agreements [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Amortization period		10 years
Capitalized software [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Amortization period		3 years
Capitalized software [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Amortization period		8 years
Controlling Interest [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | center		7	8
Controlling Interest [Member] | Sheridan Healthcare [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | center			3
Controlling Interest [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | center			5
Joint Venture [Member] | Controlling Interest [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center		9	4	1
Joint Venture [Member] | Controlling Interest [Member] | Physician Services [Member]
Segment Reporting Information [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center		3

XML

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Balance, beginning of year	$ 3,381,149	$ 1,758,970
Goodwill acquired, including post acquisition adjustments	674,476	1,636,521
Goodwill disposed, including impact of deconsolidation transactions	(85,415)	(14,342)
Balance, end of year	$ 3,970,210	$ 3,381,149

XML

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$ 236,995	$ 237,995
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,523,370	1,085,129
Accumulated Amortization	(118,554)	(49,245)
Net	1,404,816	1,035,884
Total intangible assets, gross carrying amount	1,760,365	1,323,124
Total intangible assets, net	1,641,811	1,273,879
Trade name [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	228,000	228,000
Restrictive covenant arrangements [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	8,995	9,995
Customer relationships with hospitals [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,379,977	971,645
Accumulated Amortization	(74,490)	(22,145)
Net	1,305,487	949,500
Deferred financing cost [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	60,664	59,574
Accumulated Amortization	(13,490)	(5,151)
Net	47,174	54,423
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	71,462	50,387
Accumulated Amortization	(28,125)	(19,197)
Net	43,337	31,190
Agreements, contracts, and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,267	3,523
Accumulated Amortization	(2,449)	(2,752)
Net	$ 8,818	$ 771

XML

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accrued professional liabilities	$ 14,362	$ 11,983
Contingent purchase price payable	5,509	12,213
Current income taxes payable	7,892	0
Refunds payable	48,415	17,752
Other	43,059	26,038
Total other accrued liabilities	$ 119,237	$ 67,986

XML

Accrued Professional Liabilities - Components of Reserves (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Estimated losses under self-insured programs	$ 30,748	$ 25,337
Incurred but not reported losses	36,166	28,448
Total accrued professional liabilities	66,914	53,785	$ 1,171
Less estimated losses payable within one year	14,362	11,983
Total	$ 52,552	$ 41,802

XML

Accrued Professional Liabilities - Rollforward of Reserves (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Self Insurance Reserve [Roll Forward]
Beginning balance	$ 53,785	$ 1,171
Assumed liabilities through acquisitions	13,317	53,512
Provision related to current period reserves	15,943	5,423
Payments for current period reserves	(4,475)	(1,595)
Benefit related to changes in prior period reserves	(425)	(661)
Payments for prior period reserves	(8,863)	(6,055)
Other, net	(2,368)	1,990
Ending balance	$ 66,914	$ 53,785

XML

Long-Term Debt (Narrative) (Details) - USD ($)		12 Months Ended
	Jul. 16, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 21, 2015	Nov. 20, 2012	May. 28, 2010
Payments required on Company's long-term debt and capital leases
2016		$ 20,400,000
2017		18,000,000
2018		14,800,000
2019		187,000,000
2020		261,000,000
Thereafter		1,900,000,000
Term Loan and Credit Facility
Debt extinguishment costs		0	$ (16,887,000)	$ 0
Revolving Credit Facility [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		175,000,000	0
Term Loan and Credit Facility
Remaining carrying value under revolving credit facility		325,000,000
Loans Payable [Member]
Other Debt
Book value of certain assets of surgery centers pledged as collateral		41,700,000
Fixed Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		1,400,000,000
Long-term debt, fair value		1,400,000,000
Variable Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		1,000,000,000
Long-term debt, fair value		1,000,000,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		250,000,000	250,000,000
Senior Unsecured Debt
Face amount						$ 250,000,000.0
Interest rate						5.625%
Senior Secured Debt
Face amount						$ 250,000,000.0
Interest rate						5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		$ 1,100,000,000	$ 1,100,000,000
Senior Unsecured Debt
Face amount	$ 1,100,000,000.0
Interest rate	5.625%
Redeemable principal percentage		35.00%
Senior Secured Debt
Face amount	$ 1,100,000,000.0
Interest rate	5.625%
8.04% Senior Secured Notes due 2020 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Face amount							$ 75,000,000.0
Senior Secured Debt
Face amount							$ 75,000,000.0
Early termination fee		$ 12,400,000
Period Prior to July 15, 2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount		105.625%
Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 870,000,000.0
Quarterly principal payment as a percent of face amount	0.25%
Annual principal payment	$ 8,700,000
Revolving Credit Facility [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 300,000,000.0				$ 500,000,000
Line of Credit Facility, Accordion Feature, Increase To Maximum Borrowing Capacity					$ 200,000,000
Unused commitment fee as a percent	0.375%
Debt extinguishment costs		$ 4,500,000
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
Base Rate [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Base Rate [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Floor rate	0.75%
Current variable rate		3.75%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%
LIBOR [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
LIBOR [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%

XML

Long-Term Debt (Components Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Other debt at an average interest rate of 3.4%, due through 2022	$ 24,944	$ 20,156
Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021	18,613	15,206
Long-term debt and capitalized lease arrangements	2,425,507	2,251,012
Less current portion	20,377	18,826
Long-term debt	$ 2,405,130	2,232,186
Other debt, average rate	3.40%
Capitalized lease arrangements, average rate	5.40%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 175,000	0
Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt	856,950	865,650
Fixed Interest Rate [Member]
Debt Instrument [Line Items]
Long-term debt	1,400,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	250,000	250,000
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	1,100,000	$ 1,100,000
Variable Interest Rate [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,000,000

XML

Long-Term Debt (Redemption Price) (Details) - Senior Notes [Member]	12 Months Ended
	Dec. 31, 2015
2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	104.219%
2016 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	102.813%
2017 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	101.406%
2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	104.219%
2018 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	100.00%
2018 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	102.813%
2019 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	101.406%
2020 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	100.00%

XML

Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Accrued professional liabilities	$ 52,552	$ 41,802
Contingent purchase price payable	0	8,470
Deferred rent	18,958	16,814
Tax-effected unrecognized benefits	3,426	8,353
Other	21,247	14,004
Other long-term liabilities	$ 96,183	$ 89,443

XML

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U.S. federal income tax rate	35.00%	35.00%	35.00%
Decreases in interest and penalty obligations	$ 0.2	$ 0.1	$ 0.2
Interest obligations	0.8	$ 1.2
Tax-effected unrecognized benefits	$ 0.1

XML

Income Taxes (Total Income Tax Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Earnings from continuing operations	$ 113,790	$ 48,103	$ 48,654
Discontinued operations	(694)	(643)	9
Shareholders’ equity	(2,227)	(3,177)	(7,381)
Total	$ 110,869	$ 44,283	$ 41,282

XML

Income Taxes (Income Tax Expense from Cont. Ops) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$ 83,228	$ 8,640	$ 7,895
State	14,268	4,396	3,598
Deferred:
Federal	11,715	27,505	31,509
State	4,579	7,562	5,652
Income tax expense	$ 113,790	$ 48,103	$ 48,654

XML

Income Taxes (Income Tax Expense Reconciliation to Federal Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax	$ 173,572	$ 102,967	$ 106,101
Less federal income tax assumed directly by noncontrolling interests	(76,364)	(66,783)	(64,219)
State income taxes, net of federal income tax benefit	11,604	6,616	5,539
Increase in valuation allowances	317	4,662	924
Interest related to unrecognized tax benefits	(548)	(161)	(155)
Other	5,209	802	464
Income tax expense	$ 113,790	$ 48,103	$ 48,654

XML

Income Taxes (Unrecognized Tax Liability Rec) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 7,336	$ 6,330	$ 9,235
Additions for tax positions of current year	0	204	46
Increases (decreases) for tax positions taken during a prior period	(1,006)	1,069	0
Lapse of statute of limitations	(3,178)	(267)	(2,951)
Balance at end of year	$ 3,152	$ 7,336	$ 6,330

XML

Income Taxes (Deferred Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Allowance for uncollectible accounts	$ 3,276	$ 1,096
Accrued assets and other	36,600	27,537
Share-based compensation	10,710	7,719
Interest on unrecognized tax benefits	113	245
Accrued liabilities and other	4,080	3,931
Medical malpractice	19,035	16,240
Operating and capital loss carryforwards	29,718	22,709
Valuation allowances	(21,814)	(17,457)
Total deferred tax assets	81,718	62,020
Deferred tax liabilities:
Prepaid expenses	1,789	2,435
Property and equipment, principally due to differences in depreciation	16,787	15,235
Goodwill, intangible assets and other, principally due to differences in amortization	762,640	655,358
Total deferred tax liabilities	781,216	673,028
Net deferred tax liabilities	$ 699,498	$ 611,008

XML

Shareholder's Equity (Narrative) (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended				12 Months Ended
	Nov. 25, 2014 USD ($) $ / shares	Aug. 29, 2014 USD ($) $ / shares	Jul. 16, 2014 shares	Jul. 02, 2014 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares	Jun. 30, 2015 USD ($) $ / shares	Mar. 31, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($) installment $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares
Preferred Stock
Preferred stock dividends | $										$ 9,056	$ 4,503	$ 0
Stock Incentive Plans:
Excess tax benefit from share-based compensation | $										$ 4,001	$ 3,177	$ 7,247
Number of shares authorized for grant under share incentive plan					1,200,000	1,200,000				1,200,000
Shares available for future grants/issuance under stock incentive plan					900,039	900,039				900,039
Unrecognized compensation cost on non vested awards | $					$ 16,600	$ 16,600				$ 16,600
Weighted average period										1 year 1 month 12 days
Shares granted, Number of Shares										313,498	272,780	291,863
Shares granted, Weighted Average Grant Price (usd per share) | $ / shares										$ 56.19	$ 43.12	$ 31.66
Stock Repurchased Under Repurchase Program [Member]
Common Stock:
Repurchase of common stock, shares												1,154,378
Repurchase of common stock | $												$ 42,700
Average price per share | $ / shares												$ 36.93
Stock Repurchased To Cover Employee Tax Withholdings [Member]
Common Stock:
Repurchase of common stock, shares										67,000	100,720
Repurchase of common stock | $										$ 3,700	$ 4,600
Stock Options [Member]
Stock Incentive Plans:
Award vesting period										4 years
Options term										10 years
Employees [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Award vesting period										4 years
Number of installments in restricted stock granted. | installment										3
Stock Options [Member]
Stock Incentive Plans:
Number of anti-dilutive options										0	0	0
Common Stock [Member]
Common Stock:
Issuance of stock (in shares)				9,775,000	5,835,000
Issuance of stock, price per share | $ / shares				$ 45.00	$ 80.00
Stock offering expenses | $				$ 18,500	$ 19,100
Mandatory Convertible Preferred Stock [Member]
Common Stock:
Issuance of stock (in shares)				1,725,000
Issuance of stock, price per share | $ / shares				$ 100.00
Stock offering expenses | $				$ 5,900
Preferred Stock
Dividend rate										5.25%
Initial liquidation preference (usd per share) | $ / shares					$ 100	$ 100				$ 100
Consecutive trading day										20 days
Dividends declared (usd per share) | $ / shares	$ 1.3125	$ 1.2979				$ 1.3125	$ 1.3125	$ 1.3125	$ 1.3125
Preferred stock dividends | $	$ 2,300	$ 2,200				$ 2,300	$ 2,300	$ 2,300	$ 2,300
Sheridan Healthcare [Member] | Common Stock [Member]
Common Stock:
Shares of common stock issued for acquisition			5,713,909
Minimum [Member] | Mandatory Convertible Preferred Stock [Member]
Preferred Stock
Conversion rate (shares)					1.8141	1.8141				1.8141
Maximum [Member] | Mandatory Convertible Preferred Stock [Member]
Preferred Stock
Conversion rate (shares)					2.2222	2.2222				2.2222
Restricted Stock Units (RSUs) [Member]
Stock Incentive Plans:
Award vesting period										3 years
Shares granted, Number of Shares										68,533
Shares granted, Weighted Average Grant Price (usd per share) | $ / shares										$ 55.40
Financial performance goal term										1 year
Percent of units granted										150.00%
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Stock Incentive Plans:
Percent of units granted										0.00%
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Stock Incentive Plans:
Percent of units granted										150.00%

XML

Shareholders' Equity (Share-Based Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Share-based compensation expense	$ 15,009	$ 10,104	$ 8,321
Fair value of shares vested	13,220	15,126	11,742
Cash received from option exercises	2,584	2,630	33,349
Tax benefit from option exercises	$ 4,001	$ 3,177	$ 7,247

XML

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares at beginning of period, Number of Shares	668,109	743,869	828,686
Shares granted, Number of Shares	313,498	272,780	291,863
Shares vested, Number of Shares	(233,831)	(336,160)	(360,337)
Shares forfeited, Number of Shares	(13,675)	(12,380)	(16,343)
Non-vested shares at end of period, Number of Shares	734,101	668,109	743,869
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares at beginning of period, Weighted Average Grant Price (usd per share)	$ 33.51	$ 26.54	$ 22.50
Shares granted, Weighted Average Grant Price (usd per share)	56.19	43.12	31.66
Shares vested, Weighted Average Grant Price (usd per share)	28.19	25.69	21.55
Shares forfeited, Weighted Average Grant Price (usd per share)	42.15	38.94	23.11
Non-vested shares at end of period, Weighted Average Grant Price (usd per share)	$ 44.73	$ 33.51	$ 26.54

XML

Shareholder's Equity (Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of Shares	158,721	270,464	1,662,830
Options exercised, Number of Shares	(113,220)	(111,743)	(1,392,366)
Options terminated, Number of Shares	(11,750)
Outstanding at end of period, Number of Shares	33,751	158,721	270,464	1,662,830
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period, Weighted Average Exercise Price (usd per share)	$ 22.89	$ 23.16	$ 23.82
Options exercised, Weighted Average Exercise Price (usd per share)	22.81	23.53	23.95
Options terminated, Weighted Average Exercise Price (usd per share)	23.42
Outstanding at end of period, Weighted Average Exercise Price (usd per share)	$ 22.98	$ 22.89	$ 23.16	$ 23.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days	1 year 256 days	2 years 182 days	2 years 328 days
Outstanding at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days	1 year 256 days	2 years 182 days	2 years 328 days

XML

Shareholder's Equity (Schedule of Stock Option Activity - Additional) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Total intrinsic value with options exercised	$ 4.9	$ 2.6	$ 33.3
Aggregate intrinsic value of options outstanding	1.8
Total intrinsic value of options vested or expected to vest	$ 1.8
Vested or expected to vest at end of period, Number of Shares	33,751
Vested or expected to vest at end of period, weighted average exercise price (usd per share)	$ 22.98
Vested or expected to vest at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days
Total Intrinsic value of options exercisable	$ 1.8
Exercisable at end of period, Number of Shares	33,751
Exercisable at end of period, Weighted Average Exercise Price (usd per share)	$ 22.98
Exercisable at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days

XML

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (Numerator)	$ 64,310	$ 40,397	$ 31,411	$ 18,774	$ 25,311	$ (10,697)	$ 18,771	$ 17,392	$ 154,892	$ 50,777	$ 71,009
Convertible Preferred Dividends, Net of Tax									9,056
Net Income (Loss) Attributable to Parent, Diluted									$ 163,948
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic), shares (Numerator)									48,058	39,311	31,338
Effect of dilutive securities options and non-vested shares, shares									3,554	314	616
Net earnings from continuing operations attributable to AmSurg Corp. (diluted), shares (Denominator)									51,612	39,625	31,954
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) (usd per share)	$ 1.31	$ 0.85	$ 0.66	$ 0.39	$ 0.53	$ (0.23)	$ 0.59	$ 0.55	$ 3.22	$ 1.29	$ 2.27
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) (usd per share)	$ 1.26	$ 0.83	$ 0.65	$ 0.39	$ 0.53	$ (0.23)	$ 0.58	$ 0.54	$ 3.18	$ 1.28	$ 2.22

XML

Leases (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
Lease Expiration Date	Apr. 30, 2037
Capital lease assets	$ 23.4
Capital lease assets, accumulated depreciation	5.6
Operating leases, rental expense	$ 74.6	$ 66.1	$ 52.6

XML

Leases (Future Min Schedule) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2016	$ 3,021
2017	2,776
2018	2,502
2019	2,068
2020	1,866
Thereafter	12,991
Total minimum rentals	25,224
Less amounts representing interest at rates ranging from 1.7% to 13.4%	6,611
Capital lease obligations	18,613	$ 15,206
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2016	55,636
2017	55,857
2018	53,515
2019	52,034
2020	50,378
Thereafter	331,746
Total minimum rentals	$ 599,166

XML

Leases (Future Min Schedule - Additional) (Details)	12 Months Ended
	Dec. 31, 2015
Minimum [Member]
Capital Lease Interest Rate Range [Line Items]
Capital lease interest rates	1.70%
Maximum [Member]
Capital Lease Interest Rate Range [Line Items]
Capital lease interest rates	13.40%

XML

Related Party Transactions (Related Party Payments) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Operating leases	$ 27,622	$ 27,559	$ 29,240
Salaries and benefits	62,590	66,763	72,892
Billing fees	10,873	9,899	11,591
Medical advisory services	$ 2,635	$ 2,811	$ 2,993

XML

Employee Benefit Programs (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Contribution Plan Disclosure [Line Items]
Cash surrender value	$ 17,320	$ 16,623	$ 17,320
AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions		14,100	1,600	$ 1,100
401(k) as Part of Sheridan Acquisition [Member]
Defined Contribution Plan Disclosure [Line Items]
Plan expense	5,600
Supplemental Executive And Director Retirement Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions		$ 5,200	800	$ 2,300
Maximum voluntary contribution as a percent of annual compensation		50.00%
Supplemental Executive And Director Retirement Savings Plan [Member] | Prepaid Expenses and Other Current Assets [Member]
Defined Contribution Plan Disclosure [Line Items]
Cash surrender value	$ 17,320	$ 16,623	$ 17,320
Minimum [Member] | AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Requisite service period		4 years
Maximum [Member] | AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Requisite service period		5 years

XML

Commitments and Contingencies (Details) ft² in Thousands, $ in Millions		3 Months Ended
	Jan. 16, 2015 USD ($) ft²	Sep. 30, 2016 ft²	Dec. 31, 2015 ft²
Schedule Of Operating Leases Square Footage [Line Items]
Operating Leases, Area Of Office Space	222		167
Operating Leases, Rent Expense, Per Year | $	$ 2.9
Scenario, Forecast [Member]
Schedule Of Operating Leases Square Footage [Line Items]
Operating Leases, Area Of Office Space		55

XML

Segment Reporting (Details) $ in Thousands	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2014 USD ($) segment	Jul. 15, 2014 segment	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment									2	1
Segment Reporting Information [Line Items]
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561			$ 2,566,884	$ 1,621,949	$ 1,057,196
Adjusted EBITDA											492,260	304,482	187,972
Earnings from continuing operations attributable to noncontrolling interests											218,181	190,809	183,484
Interest expense, net											(121,586)	(83,285)	(29,525)
Depreciation and amortization											(97,493)	(60,344)	(32,400)
Share-based compensation											(15,009)	(10,104)	(8,321)
Net change in fair value of contingent consideration											(8,804)	0	0
Transaction costs						(25,100)					(8,324)	(33,890)	(300)
Debt extinguishment costs											0	(16,887)	0
Net gain on deconsolidations											36,694	3,411	2,237
Earnings from continuing operations before income taxes	161,178	$ 135,797	$ 115,940	$ 83,004	101,535	$ 39,142	$ 80,487	$ 73,028			495,919	294,192	303,147
Acquisition and Capital Expenditures											1,022,994	110,065	102,450
Assets	6,546,482				5,501,062				$ 5,501,062		6,546,482	5,501,062
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Net revenue											1,230,050	1,109,935	1,057,196
Adjusted EBITDA											226,229	197,377	187,972
Acquisition and Capital Expenditures											168,593	81,156	102,450
Assets	2,609,479				2,526,625				2,526,625		2,609,479	2,526,625
Physician Services [Member]
Segment Reporting Information [Line Items]
Net revenue									512,014		1,336,834	512,014	0
Adjusted EBITDA											266,031	107,105	0
Net change in fair value of contingent consideration											(10,000)
Acquisition and Capital Expenditures											854,401	28,909	$ 0
Assets	$ 3,937,003				$ 2,974,437				$ 2,974,437		$ 3,937,003	$ 2,974,437

XML

Financial Information for the Company and Its Subsidiaries (Balance Sheets) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Assets
Cash and cash equivalents	$ 106,660	$ 208,079	$ 50,840	$ 46,398
Restricted cash and marketable securities	13,506	10,219
Accounts receivable, net	337,330	233,053
Supplies inventory	21,406	19,974
Prepaid and other current assets	75,771	92,900
Total current assets	554,673	564,225
Property and equipment, net	189,168	180,448
Investments in and receivables from unconsolidated affiliates	169,170	75,475
Goodwill	3,970,210	3,381,149	1,758,970
Intangible assets, net	1,641,811	1,273,879
Other assets	21,450	25,886
Total assets	6,546,482	5,501,062
Liabilities and Equity
Current portion of long-term debt	20,377	18,826
Accounts payable	32,561	29,585
Accrued salaries and benefits	202,537	140,044
Accrued interest	30,480	29,644
Other accrued liabilities	119,237	67,986
Total current liabilities	405,192	286,085
Long-term debt	2,405,130	2,232,186
Deferred income taxes	699,498	611,018
Other long-term liabilities	96,183	89,443
Intercompany payable	0	0
Noncontrolling interests – redeemable	175,732	184,099
Equity:
Total AmSurg Corp. equity	2,293,463	1,679,547
Noncontrolling interests – non-redeemable	471,284	418,684
Total equity	2,764,747	2,098,231
Total liabilities and equity	6,546,482	5,501,062
Consolidating Adjustments [Member]
Assets
Cash and cash equivalents	0	0	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	(8,076)	(4,818)
Total current assets	(8,076)	(4,818)
Property and equipment, net	0	0
Investments in and receivables from unconsolidated affiliates	(6,507,128)	(5,425,210)
Goodwill	2,013,469	1,890,168
Intangible assets, net	0	0
Other assets	(1,998)	(1,466)
Total assets	(4,503,733)	(3,541,326)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(3,852)	(4,080)
Accrued salaries and benefits	0	0
Accrued interest	0	0
Other accrued liabilities	(4,224)	(738)
Total current liabilities	(8,076)	(4,818)
Long-term debt	(23,396)	(28,412)
Deferred income taxes	(1,998)	(1,466)
Other long-term liabilities	0	0
Intercompany payable	(1,228,157)	(1,227,989)
Noncontrolling interests – redeemable	112,672	120,555
Equity:
Total AmSurg Corp. equity	(3,778,478)	(2,774,257)
Noncontrolling interests – non-redeemable	423,700	375,061
Total equity	(3,354,778)	(2,399,196)
Total liabilities and equity	(4,503,733)	(3,541,326)
Parent Company [Member]
Assets
Cash and cash equivalents	20,437	134,351	6,710	7,259
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	28,739	46,097
Total current assets	49,176	180,448
Property and equipment, net	12,515	10,391
Investments in and receivables from unconsolidated affiliates	4,901,026	3,912,804
Goodwill	0	0
Intangible assets, net	59,928	67,678
Other assets	4,653	3,323
Total assets	5,027,298	4,174,644
Liabilities and Equity
Current portion of long-term debt	8,700	8,700
Accounts payable	2,816	1,849
Accrued salaries and benefits	31,510	25,035
Accrued interest	30,463	29,621
Other accrued liabilities	13,962	8,051
Total current liabilities	87,451	73,256
Long-term debt	2,373,251	2,206,950
Deferred income taxes	268,573	207,500
Other long-term liabilities	4,560	7,391
Intercompany payable	0	0
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	2,293,463	1,679,547
Noncontrolling interests – non-redeemable	0	0
Total equity	2,293,463	1,679,547
Total liabilities and equity	5,027,298	4,174,644
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	27,507	23,471	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	223,434	123,772
Supplies inventory	0	301
Prepaid and other current assets	39,046	37,826
Total current assets	289,987	185,370
Property and equipment, net	14,601	9,972
Investments in and receivables from unconsolidated affiliates	1,775,272	1,587,881
Goodwill	1,956,741	1,490,981
Intangible assets, net	1,579,537	1,203,218
Other assets	1,717	943
Total assets	5,617,855	4,478,365
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	3,760	35
Accrued salaries and benefits	158,705	101,395
Accrued interest	0	0
Other accrued liabilities	76,590	44,305
Total current liabilities	239,055	145,735
Long-term debt	0	0
Deferred income taxes	432,923	404,984
Other long-term liabilities	71,509	63,616
Intercompany payable	1,228,157	1,219,979
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	3,646,211	2,644,051
Noncontrolling interests – non-redeemable	0	0
Total equity	3,646,211	2,644,051
Total liabilities and equity	5,617,855	4,478,365
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	58,716	50,257	$ 44,130	$ 39,139
Restricted cash and marketable securities	13,506	10,219
Accounts receivable, net	113,896	109,281
Supplies inventory	21,406	19,673
Prepaid and other current assets	16,062	13,795
Total current assets	223,586	203,225
Property and equipment, net	162,052	160,085
Investments in and receivables from unconsolidated affiliates	0	0
Goodwill	0	0
Intangible assets, net	2,346	2,983
Other assets	17,078	23,086
Total assets	405,062	389,379
Liabilities and Equity
Current portion of long-term debt	11,677	10,126
Accounts payable	29,837	31,781
Accrued salaries and benefits	12,322	13,614
Accrued interest	17	23
Other accrued liabilities	32,909	16,368
Total current liabilities	86,762	71,912
Long-term debt	55,275	53,648
Deferred income taxes	0	0
Other long-term liabilities	20,114	18,436
Intercompany payable	0	8,010
Noncontrolling interests – redeemable	63,060	63,544
Equity:
Total AmSurg Corp. equity	132,267	130,206
Noncontrolling interests – non-redeemable	47,584	43,623
Total equity	179,851	173,829
Total liabilities and equity	$ 405,062	$ 389,379

XML

Financial Information for the Company and Its Subsidiaries (Income Statements) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Financial Statements, Captions [Line Items]
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561	$ 2,566,884	$ 1,621,949	$ 1,057,196
Operating expenses:
Salaries and benefits									1,314,392	694,576	327,585
Supply cost									184,222	164,296	153,126
Other operating expenses									397,794	284,928	216,501
Transaction costs						25,100			8,324	33,890	300
Depreciation and amortization									97,493	60,344	32,400
Total operating expenses									2,002,225	1,238,034	729,912
Net gain on deconsolidations									36,694	3,411	2,237
Equity in earnings of unconsolidated affiliates									16,152	7,038	3,151
Operating income									617,505	394,364	332,672
Interest expense, net									121,586	83,285	29,525
Debt extinguishment costs									0	16,887	0
Earnings from continuing operations before income taxes	161,178	135,797	115,940	83,004	101,535	39,142	80,487	73,028	495,919	294,192	303,147
Income tax expense									113,790	48,103	48,654
Net earnings from continuing operations	124,348	98,279	90,747	68,755	79,234	39,120	67,689	60,046	382,129	246,089	254,493
Net earnings (loss) from discontinued operations	(1,013)	0	0	0	(150)	(1,697)	483	68	(1,013)	(1,296)	7,051
Net earnings	123,335	98,279	90,747	68,755	79,084	37,423	68,172	60,114	381,116	244,793	261,544
Less net earnings attributable to noncontrolling interests									218,169	191,092	188,841
Net earnings attributable to AmSurg Corp. shareholders									162,947	53,701	72,703
Preferred stock dividends									(9,056)	(4,503)	0
Net earnings attributable to AmSurg Corp. common shareholders	63,309	40,397	31,411	18,774	25,115	(12,073)	18,961	17,195	153,891	49,198	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	64,310	40,397	31,411	18,774	25,311	(10,697)	18,771	17,392	154,892	50,777	71,009
Earnings (loss) from discontinued operations, net of income tax	(1,001)	0	0	0	(196)	(1,376)	190	(197)	(1,001)	(1,579)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$ 63,309	$ 40,397	$ 31,411	$ 18,774	$ 25,115	$ (12,073)	$ 18,961	$ 17,195	153,891	49,198	72,703
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									(38,004)	(24,336)	(17,518)
Operating expenses:
Salaries and benefits									(507)	(5,786)	(467)
Supply cost									(80)	0	0
Other operating expenses									(37,417)	(18,550)	(17,051)
Transaction costs									0	0	0
Depreciation and amortization									0	0	0
Total operating expenses									(38,004)	(24,336)	(17,518)
Net gain on deconsolidations									0	0	0
Equity in earnings of unconsolidated affiliates									(584,080)	(442,508)	(409,010)
Operating income									(584,080)	(442,508)	(409,010)
Interest expense, net									0	0	0
Debt extinguishment costs										0
Earnings from continuing operations before income taxes									(584,080)	(442,508)	(409,010)
Income tax expense									0	0	0
Net earnings from continuing operations									(584,080)	(442,508)	(409,010)
Net earnings (loss) from discontinued operations									0	0	0
Net earnings									(584,080)	(442,508)	(409,010)
Less net earnings attributable to noncontrolling interests									0	0	0
Net earnings attributable to AmSurg Corp. shareholders									(584,080)	(442,508)
Preferred stock dividends									0	0
Net earnings attributable to AmSurg Corp. common shareholders									(584,080)	(442,508)	(409,010)
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									(584,080)	(442,508)	(409,010)
Earnings (loss) from discontinued operations, net of income tax									0	0	0
Net earnings attributable to AmSurg Corp. common shareholders									(584,080)	(442,508)	(409,010)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									28,554	24,773	24,167
Operating expenses:
Salaries and benefits									69,102	65,697	61,038
Supply cost									0	0	0
Other operating expenses									24,682	18,667	22,360
Transaction costs									1,762	29,004	300
Depreciation and amortization									3,912	4,044	3,186
Total operating expenses									99,458	117,412	86,884
Net gain on deconsolidations									0	0	0
Equity in earnings of unconsolidated affiliates									349,139	237,657	207,199
Operating income									278,235	145,018	144,482
Interest expense, net									41,140	47,997	27,282
Debt extinguishment costs										16,887
Earnings from continuing operations before income taxes									237,095	80,134	117,200
Income tax expense									73,159	29,166	47,139
Net earnings from continuing operations									163,936	50,968	70,061
Net earnings (loss) from discontinued operations									(989)	2,733	2,642
Net earnings									162,947	53,701	72,703
Less net earnings attributable to noncontrolling interests									0	0	0
Net earnings attributable to AmSurg Corp. shareholders									162,947	53,701
Preferred stock dividends									(9,056)	(4,503)
Net earnings attributable to AmSurg Corp. common shareholders									153,891	49,198	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									154,880	46,465	70,061
Earnings (loss) from discontinued operations, net of income tax									(989)	2,733	2,642
Net earnings attributable to AmSurg Corp. common shareholders									153,891	49,198	72,703
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									1,331,042	508,572	0
Operating expenses:
Salaries and benefits									937,484	350,615	0
Supply cost									2,436	1,292	0
Other operating expenses									145,369	53,413	0
Transaction costs									6,562	4,886	0
Depreciation and amortization									61,658	25,610	0
Total operating expenses									1,153,509	435,816	0
Net gain on deconsolidations									37,350	3,411	2,237
Equity in earnings of unconsolidated affiliates									251,093	211,889	204,962
Operating income									465,976	288,056	207,199
Interest expense, net									77,947	33,026	0
Debt extinguishment costs										0
Earnings from continuing operations before income taxes									388,029	255,030	207,199
Income tax expense									38,891	17,373	0
Net earnings from continuing operations									349,138	237,657	207,199
Net earnings (loss) from discontinued operations									0	0	0
Net earnings									349,138	237,657	207,199
Less net earnings attributable to noncontrolling interests									0	21	0
Net earnings attributable to AmSurg Corp. shareholders									349,138	237,636
Preferred stock dividends									0	0
Net earnings attributable to AmSurg Corp. common shareholders									349,138	237,636	207,199
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									349,138	237,636	207,199
Earnings (loss) from discontinued operations, net of income tax									0	0	0
Net earnings attributable to AmSurg Corp. common shareholders									349,138	237,636	207,199
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									1,245,292	1,112,940	1,050,547
Operating expenses:
Salaries and benefits									308,313	284,050	267,014
Supply cost									181,866	163,004	153,126
Other operating expenses									265,160	231,398	211,192
Transaction costs									0	0	0
Depreciation and amortization									31,923	30,690	29,214
Total operating expenses									787,262	709,142	660,546
Net gain on deconsolidations									(656)	0	0
Equity in earnings of unconsolidated affiliates									0	0	0
Operating income									457,374	403,798	390,001
Interest expense, net									2,499	2,262	2,243
Debt extinguishment costs										0
Earnings from continuing operations before income taxes									454,875	401,536	387,758
Income tax expense									1,740	1,564	1,515
Net earnings from continuing operations									453,135	399,972	386,243
Net earnings (loss) from discontinued operations									(24)	(4,029)	4,409
Net earnings									453,111	395,943	390,652
Less net earnings attributable to noncontrolling interests									218,169	191,071	188,841
Net earnings attributable to AmSurg Corp. shareholders									234,942	204,872
Preferred stock dividends									0	0
Net earnings attributable to AmSurg Corp. common shareholders									234,942	204,872	201,811
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									234,954	209,184	202,759
Earnings (loss) from discontinued operations, net of income tax									(12)	(4,312)	(948)
Net earnings attributable to AmSurg Corp. common shareholders									$ 234,942	$ 204,872	$ 201,811

XML

Financial Information for the Company and Its Subsidiaries (Cash Flow Statements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net cash flows provided by operating activities	$ 537,959	$ 412,371	$ 332,824
Cash flows from investing activities:
Acquisitions and related transactions	(962,689)	(2,184,058)	(73,594)
Acquisition of property and equipment	(60,305)	(40,217)	(28,856)
Proceeds from sale of interests in surgery centers	7,114	7,069	3,553
Purchases of marketable securities	(3,984)	(6,474)	0
Maturities of marketable securities	4,233	3,486	0
Other	(1,194)	(4,941)	159
Net cash flows used in investing activities	(1,016,825)	(2,225,135)	(98,738)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	560,133	2,048,958	162,204
Repayment on long-term borrowings and revolving credit facility	(392,586)	(408,475)	(202,083)
Distributions to owners, including noncontrolling interests	(214,899)	(190,097)	(184,149)
Capital contributions	0	0
Proceeds from preferred stock offering	0	172,500	0
Proceeds from common stock offering	466,777	439,875	0
Payments of equity issuance costs	(19,058)	(24,494)	0
Financing costs incurred	(1,111)	(65,811)	(1,322)
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	(21,809)	(2,453)	(5,616)
Net cash flows provided by (used in) financing activities	377,447	1,970,003	(229,644)
Net increase (decrease) in cash and cash equivalents	(101,419)	157,239	4,442
Cash and cash equivalents, beginning of period	208,079	50,840	46,398
Cash and cash equivalents, end of period	106,660	208,079	50,840
Consolidating Adjustments [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	(346,225)	(413,605)	(347,648)
Cash flows from investing activities:
Acquisitions and related transactions	764,345	2,126,737	694
Acquisition of property and equipment	0	0	0
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	0	0	0
Net cash flows used in investing activities	764,345	2,126,737	694
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0	0
Repayment on long-term borrowings and revolving credit facility	0	0	0
Distributions to owners, including noncontrolling interests	346,225	413,605	347,648
Capital contributions	(757,775)	(2,124,124)
Proceeds from preferred stock offering		0
Proceeds from common stock offering	0	0
Payments of equity issuance costs	0	0
Financing costs incurred	0	0
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	(6,570)	(2,613)	(694)
Net cash flows provided by (used in) financing activities	(418,120)	(1,713,132)	346,954
Net increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents, beginning of period	0	0	0
Cash and cash equivalents, end of period	0	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	40,432	96,681	45,127
Cash flows from investing activities:
Acquisitions and related transactions	(757,775)	(2,124,124)	0
Acquisition of property and equipment	(5,876)	(7,877)	(3,693)
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	0	(3,068)	0
Net cash flows used in investing activities	(763,651)	(2,135,069)	(3,693)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	546,000	2,040,000	152,700
Repayment on long-term borrowings and revolving credit facility	(379,700)	(396,493)	(188,081)
Distributions to owners, including noncontrolling interests	0	0	0
Capital contributions	0	0
Proceeds from preferred stock offering		172,500
Proceeds from common stock offering	466,777	439,875
Payments of equity issuance costs	(19,058)	(24,494)
Financing costs incurred	(1,101)	(65,811)
Changes in intercompany balances with affiliates, net	5,016	2,965	88
Other financing activities, net	(8,629)	(2,513)	(6,690)
Net cash flows provided by (used in) financing activities	609,305	2,166,029	(41,983)
Net increase (decrease) in cash and cash equivalents	(113,914)	127,641	(549)
Cash and cash equivalents, beginning of period	134,351	6,710	7,259
Cash and cash equivalents, end of period	20,437	134,351	6,710
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	353,932	298,415	208,773
Cash flows from investing activities:
Acquisitions and related transactions	(969,259)	(2,188,191)	(74,288)
Acquisition of property and equipment	(22,988)	(9,933)	0
Proceeds from sale of interests in surgery centers	7,114	7,069	3,553
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	(2,927)	(6,594)	159
Net cash flows used in investing activities	(988,060)	(2,197,649)	(70,576)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0	0
Repayment on long-term borrowings and revolving credit facility	0	0	0
Distributions to owners, including noncontrolling interests	(109,862)	(202,247)	(138,875)
Capital contributions	757,775	2,124,124
Proceeds from preferred stock offering		0
Proceeds from common stock offering	0	0
Payments of equity issuance costs	0	0
Financing costs incurred	0	0
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	(9,749)	828	678
Net cash flows provided by (used in) financing activities	638,164	1,922,705	(138,197)
Net increase (decrease) in cash and cash equivalents	4,036	23,471	0
Cash and cash equivalents, beginning of period	23,471	0	0
Cash and cash equivalents, end of period	27,507	23,471	0
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	489,820	430,880	426,572
Cash flows from investing activities:
Acquisitions and related transactions	0	1,520	0
Acquisition of property and equipment	(31,441)	(22,407)	(25,163)
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	(3,984)	(6,474)
Maturities of marketable securities	4,233	3,486
Other	1,733	4,721	0
Net cash flows used in investing activities	(29,459)	(19,154)	(25,163)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	14,133	8,958	9,504
Repayment on long-term borrowings and revolving credit facility	(12,886)	(11,982)	(14,002)
Distributions to owners, including noncontrolling interests	(451,262)	(401,455)	(392,922)
Capital contributions	0	0
Proceeds from preferred stock offering		0
Proceeds from common stock offering	0	0
Payments of equity issuance costs	0	0
Financing costs incurred	(10)	0
Changes in intercompany balances with affiliates, net	(5,016)	(2,965)	(88)
Other financing activities, net	3,139	1,845	1,090
Net cash flows provided by (used in) financing activities	(451,902)	(405,599)	(396,418)
Net increase (decrease) in cash and cash equivalents	8,459	6,127	4,991
Cash and cash equivalents, beginning of period	50,257	44,130	39,139
Cash and cash equivalents, end of period	$ 58,716	$ 50,257	$ 44,130

XML

Quarterly Statement of Earnings Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561	$ 2,566,884	$ 1,621,949	$ 1,057,196
Earnings from continuing operations before income taxes	161,178	135,797	115,940	83,004	101,535	39,142	80,487	73,028	495,919	294,192	303,147
Net earnings from continuing operations	124,348	98,279	90,747	68,755	79,234	39,120	67,689	60,046	382,129	246,089	254,493
Net earnings (loss) from discontinued operations	(1,013)	0	0	0	(150)	(1,697)	483	68	(1,013)	(1,296)	7,051
Net earnings	123,335	98,279	90,747	68,755	79,084	37,423	68,172	60,114	381,116	244,793	261,544
Net earnings (loss) attributable to AmSurg Corp. common shareholders:
Continuing	64,310	40,397	31,411	18,774	25,311	(10,697)	18,771	17,392	154,892	50,777	71,009
Discontinued	(1,001)	0	0	0	(196)	(1,376)	190	(197)	(1,001)	(1,579)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$ 63,309	$ 40,397	$ 31,411	$ 18,774	$ 25,115	$ (12,073)	$ 18,961	$ 17,195	$ 153,891	$ 49,198	$ 72,703
Basic net earnings (loss) from continuing operations per share	$ 1.31	$ 0.85	$ 0.66	$ 0.39	$ 0.53	$ (0.23)	$ 0.59	$ 0.55	$ 3.22	$ 1.29	$ 2.27
Basic net earnings (loss) per share	1.28	0.85	0.66	0.39	0.53	(0.26)	0.60	0.54	3.20	1.25	2.32
Diluted net earnings (loss) from continuing operations per share	1.26	0.83	0.65	0.39	0.53	(0.23)	0.58	0.54	3.18	1.28	2.22
Diluted net earnings (loss) per share	$ 1.24	$ 0.83	$ 0.65	$ 0.39	$ 0.53	$ (0.26)	$ 0.59	$ 0.54	$ 3.16	$ 1.24	$ 2.28
Debt extinguishment costs									$ 0	$ (16,887)	$ 0
Transaction costs						$ 25,100			$ 8,324	$ 33,890	$ 300

XML

Schedule II - Valuation and Qualifying Accounts (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance, Beginning Balance	$ 113,357	$ 27,862	$ 22,379
Charged to Cost and Expenses	287,427	139,274	21,983
Charge-off Against Allowances	(233,373)	(53,779)	(16,500)
Valuation Allowances and Reserves, Balance, Ending Balance	$ 167,411	$ 113,357	$ 27,862